Thienopyrrole compounds

ABSTRACT

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 63/176,109, filed on Apr. 16, 2021, U.S. Provisional Application No. 63/216,418, filed on Jun. 29, 2021, and U.S. Provisional Application No. 63/305,610, filed on Feb. 1, 2022, each of which is incorporated herein in its entirety for all purposes.

FIELD

This disclosure relates generally to novel thienopyrrole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. In some embodiments, the novel thienopyrrole compounds provided herein may be used in the treatment of certain diseases and disorders, including, but not limited to, an inflammatory condition, systemic lupus erythematosus, cutaneous lupus erythematosus, or lupus nephritis.

BACKGROUND

Toll-like receptors (TLRs) are a family of transmembrane immune receptors that sense pathogens, trigger innate immune responses, and prime adaptive immunity. TLR7/8/9 are endosomally localized TLRs that respond to single-stranded RNAs (TLR7/8) or unmethylated DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). Activation of TLR7/8/9 leads to inflammatory responses including the production of Type I interferons and proinflammatory cytokines, activation of B cells and antibody production, and neutrophil NETosis. Aberrant activation of TLR7/8/9 contributes to elevated Type I interferon response, increased pro-inflammatory cytokines, and sustained autoantibody production that may fuel the chronic progression of a variety of autoimmune disease and inflammatory conditions leading to broad inflammation and tissue damage. (Kawai et al., 2010, Nat Immunol 11, 373; Joosten et al., 2016, Nat Rev Rheomatol 12, 344; Crow et al., 2019, Lupus Sci Med 6, e000336; Garcia-Romo et al., 2011, Sci Transl Med 3, 73ra20; Kono et al., 2009, PNAS 106, 12061; Koh et al., 2013, J Immunol 190, 4982). Therefore, there is a need for compounds that are potent TLR7, and/or TLR8, and/or TLR9 antagonists that are stable and exhibit effective pharmacokinetic and/or pharmacodynamic profiles.

SUMMARY

In one embodiment, provided herein is a compound of Formula I,

or a pharmaceutically acceptable salt thereof. wherein

-   R¹ is 8-10 membered fused bicyclic heterocyclyl or 8-10 membered     fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic     heterocyclyl and 8-10 membered fused bicyclic heteroaryl are each     independently optionally substituted with 1-4 R^(a) groups; -   R² is H, C₁₋₆ alkyl, or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy,     -   wherein the C₁₋₆ alkoxy is optionally substituted with 1-3         halogen groups; -   R³ is H, halogen, —CN, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or     4-7 membered monocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, and 4-7         membered monocyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl,         —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇         monocyclic cycloalkoxy, and 4-7 membered monocyclic         heterocycloxy,         -   wherein the C₁₋₄ alkoxy is optionally substituted with 1-3             halogen groups; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is C₁₋₆ alkyl, C₂₋₆ alkenyl, —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇     monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl,     phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl and C₂₋₆ alkenyl are each independently         optionally substituted with 1-4 R^(b) groups;     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-2 R⁸ groups and are each independently         optionally substituted with 1-3 R^(a) groups; -   R⁶ is C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered     monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered     monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl,     6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused     bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   R¹³ is C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl,     C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   R⁷ is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or 4-6 membered     monocyclic heterocyclyl, wherein the C₁₋₆ alkyl, C₃₋₇ monocyclic     cycloalkyl, and 4-6 membered monocyclic heterocyclyl are each     independently optionally substituted with 1-4 groups independently     selected from —OH, halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is halogen, —C(O)R⁹, —NR¹⁰R¹⁰, C₁₋₆ alkyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl,     phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered     spirocyclic heterocyclyl, —OR⁵, —C(O)OR⁵, —C(O)N(R⁵)(R⁵),     —N(R⁵)₂(R⁵)⁺, —N(R⁵)C(O)R⁵, —N(R⁵)C(O)OR⁵, —N(R⁵)C(O)N(R⁵)(R⁵),     —N(R⁵)S(O)₂(R^(5a)) —NR⁵S(O)₂N(R⁵)(R⁵), —NR⁵S(O)₂O(R^(5a)),     —OC(O)R⁵, —OC(O)OR⁵, —OC(O)N(R⁵)(R⁵), —SR⁵, —S(O)R^(5a) —S(O)(NH)R⁵,     —S(O)₂R^(5a), —S(O)₂N(R⁵)(R⁵), or —N═S(R^(5a))(R^(5a))═O,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups, wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused         bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7         membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6         membered monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   each R⁹ independently is C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused     bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,     naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered     monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl,     6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused     bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   each R⁵ and R¹⁰ independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆     alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   each R^(5a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl,     -   herein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   each R^(a) independently is oxo, imino, halogen, —NO₂, —N₃, —CN,     C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl,     C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl,     phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6     membered monocyclic heteroaryl, 8-10 membered fused bicyclic     heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10     membered fused bicyclic heteroaryl, 7-10 membered spirocyclic     heterocyclyl, —OR¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹),     —NR¹¹R¹¹, —N(R¹¹)₂(R¹¹)⁺, —N(R¹¹)C(O)R¹¹, —N(R¹¹)C(O)OR¹¹,     —N(R¹¹)C(O)N(R¹¹)(R¹¹), —N(R¹¹)S(O)₂(R^(11a)) —NR¹¹S(O)₂N(R¹¹)(R¹¹),     —NR¹¹S(O)₂O(R^(11a)), —OC(O)R¹¹, —OC(O)OR¹¹, —OC(O)N(R¹¹)(R¹¹),     —SR¹¹, —S(O)R^(11a), —S(O)(NH)R¹¹, —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹),     or —N═S(R^(11a))(R^(11a))═O,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-3 R^(c) groups,         wherein the C₅₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-3 R^(d) groups, -   each R^(b) independently is oxo, imino, halogen, —NO₂, —N₃, —CN,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic     heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10     membered fused bicyclic heteroaryl, 7-10 membered spirocyclic     heterocyclyl, —OR¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹),     —NR¹¹R¹¹, —N(R¹¹)₂(R¹¹)⁺, —N(R¹¹)C(O)R¹¹, —N(R¹¹)C(O)OR¹¹,     —N(R¹¹)C(O)N(R¹¹)(R¹¹), —N(R¹¹)S(O)₂(R^(11a)),     —NR¹¹S(O)₂N(R¹¹)(R¹¹), —NR¹¹S(O)₂O(R^(11a)) —OC(O)R¹¹, —OC(O)OR¹¹,     —OC(O)N(R¹¹)(R¹¹), —SR¹¹, —S(O)R^(11a), —S(O)(NH)R¹¹, —S(O)₂R^(11a),     —S(O)₂N(R¹¹)(R¹¹), or —N═S(R^(11a))(R^(11a))═O     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-3 R^(d) groups; -   each R^(c) independently is halogen, —CN, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹², —C(O)R¹²,     —C(O)OR¹², —C(O)N(R¹²)(R¹²), —NR¹²R¹², —N(R¹²)₂(R¹²)⁺—N(R¹²)C(O)R¹²,     —N(R¹²)C(O)OR¹², —N(R¹²)C(O)N(R¹²)(R¹²), —N(R¹²)S(O)₂(R^(12a))     —NR¹²S(O)₂N(R¹²)(R¹²), —NR¹²S(O)₂O(R^(12a)), —OC(O)R¹², —OC(O)OR¹²,     —OC(O)N(R¹²)(R¹²), —SR¹², —S(O)R^(12a), —S(O)(NH)R¹², —S(O)₂R^(12a)     —S(O)₂N(R¹²)(R¹²), or —N═S(R^(12a))(R^(12a))═O; -   each R^(d) independently is oxo, halogen, —CN, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹², —C(O)R¹²,     —C(O)OR¹², —C(O)N(R¹²)(R¹²), —NR¹²R¹², —N(R¹²)₂(R¹²)⁺,     —N(R¹²)C(O)R¹², —N(R¹²)C(O)OR¹², —N(R¹²)C(O)N(R¹²)(R¹²),     —N(R¹²)S(O)₂(R^(12a)) —NR¹²S(O)₂N(R¹²)(R¹²), —NR¹²S(O)₂O(R^(12a)),     —OC(O)R¹², —OC(O)OR¹², —OC(O)N(R¹²)(R¹²), —SR¹², —S(O)R^(12a),     —S(O)(NH)R¹², —S(O)₂R^(12a) —S(O)₂N(R¹²)(R¹²), or     —N═S(R^(12a))(R^(12a))═O; -   each R¹¹ independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇         monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀         bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered         monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl,         8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged         bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl,         and 7-10 membered spirocyclic heterocyclyl are each         independently optionally substituted with 1-3 R^(c) groups; -   each R^(11a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆     alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇         monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀         bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered         monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl,         8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged         bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl,         and 7-10 membered spirocyclic heterocyclyl are each         independently optionally substituted with 1-3 R^(c) groups; -   each R¹² independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl; -   each R^(12a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆     alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered     fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10     membered spirocyclic heterocyclyl independently have 1-4 ring     heteroatoms independently selected from N, O, and S.

In one embodiment, provided herein is a pharmaceutical composition comprising a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

In one embodiment, provided herein is a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating systemic lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating cutaneous lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a method of treating lupus nephritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in therapy.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of treating systemic lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of treating cutaneous lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in a method of treating lupus nephritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

DETAILED DESCRIPTION I. Definitions

The description below is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the appended claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. It must be noted that as used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, e.g., reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art, and so forth.

As used in the present disclosure, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —CONH₂ is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named. A solid line coming out of the center of a ring (including a fused, bridged or spirocyclic ring system) indicates that the point of attachment for a substituent on the ring can be at any ring atom. For example, R^(aa) in the below structure can be attached to any of the five carbon ring atoms or R^(aa) can replace the hydrogen attached to the nitrogen ring atom:

As another example, R^(aa) in the below structure:

R^(aa) can be attached to any of the numbered positions shown below:

A solid line coming out of the center of a ring (including a fused, bridged, or spirocyclic ring system) indicates that the point of attachment for the ring system to the rest of the compound can be at any ring atom of the fused, bridged, or spirocyclic ring system. For example, in the below structure:

the monocyclic heterocyclyl can be attached to the rest of the compound at any of the numbered positions shown below:

As another example, in the below fused bicyclic heterocyclic structure,

the fused bicyclic heterocyclyl can be attached to the rest of the compound at any of the eight numbered positions shown below:

The prefix “C_(u-v)” indicates that the following group has from u to v carbon atoms. For example, “C₁₋₆ alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms. Likewise, the term “x-y membered” rings, wherein x and y are numerical ranges, such as “3 to 12-membered heterocyclyl”, refers to a ring containing x-y atoms (i.e., 3-12), of which up to 80% may be heteroatoms, such as N, O, S, P, and the remaining atoms are carbon.

Also, certain commonly used alternative chemical names may or may not be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, or alkylyl group, an “arylene” group or an “arylenyl” group, or arylyl group, respectively.

“A compound disclosed herein” or “a compound of the present disclosure” or “a compound provided herein” or “a compound described herein” refers to the compounds of Formula I. Also included are the specific compounds of Examples 1 to 68.

Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term “about” includes the indicated amount ±10%. In other embodiments, the term “about” includes the indicated amount ±5%. In certain other embodiments, the term “about” includes the indicated amount ±1%. Also, the term “about X” includes description of “X”.

“Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C₁₋₂₀ alkyl), 1 to 12 carbon atoms (i.e., C₁₋₁₂ alkyl), 1 to 8 carbon atoms (i.e., C₁₋₈ alkyl), 1 to 6 carbon atoms (i.e., C₁₋₆ alkyl), 1 to 4 carbon atoms (i.e., C₁₋₄ alkyl), 1 to 3 carbon atoms (i.e., C₁₋₃ alkyl), or 1 to 2 carbon atoms (i.e., C₁₋₂ alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e. —(CH₂)₃CH₃), sec-butyl (i.e. —CH(CH₃)CH₂CH₃), isobutyl (i.e. —CH₂CH(CH₃)₂) and tert-butyl (i.e. —C(CH₃)₃); and “propyl” includes n-propyl (i.e. —(CH₂)₂CH₃) and isopropyl (i.e. —CH(CH₃)₂).

“Alkenyl” refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C₂₋₂₀ alkenyl), 2 to 8 carbon atoms (i.e., C_(2-s) alkenyl), 2 to 6 carbon atoms (i.e., C₂₋₆ alkenyl), or 2 to 4 carbon atoms (i.e., C₂₋₄ alkenyl). Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

“Alkynyl” refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C₂₋₂₀ alkynyl), 2 to 8 carbon atoms (i.e., C₂₋₈ alkynyl), 2 to 6 carbon atoms (i.e., C₂₋₆ alkynyl), or 2 to 4 carbon atoms (i.e., C₂₋₄ alkynyl). The term “alkynyl” also includes those groups having one triple bond and one double bond.

“Alkylene” refers to a divalent and unbranched saturated hydrocarbon chain. As used herein, alkylene has 1 to 20 carbon atoms (i.e., C₁₋₂₀ alkylene), 1 to 12 carbon atoms (i.e., C₁₋₁₂ alkylene), 1 to 8 carbon atoms (i.e., C₁₋₈ alkylene), 1 to 6 carbon atoms (i.e., C₁₋₆ alkylene), 1 to 4 carbon atoms (i.e., C₁₋₄ alkylene), 1 to 3 carbon atoms (i.e., C₁₋₃ alkylene), or 1 to 2 carbon atoms (i.e., C₁₋₂ alkylene). Examples of alkylene groups include methylene, ethylene, propylene, butylene, pentylene, and hexylene. In some embodiments, an alkylene is optionally substituted with an alkyl group. Examples of substituted alkylene groups include —CH(CH₃)CH₂—, —CH₂CH(CH₃)—, —CH₂CH(CH₂CH₃)—, —CH₂C(CH₃)₂—, —C(CH₃)₂CH₂—, —CH(CH₃)CH(CH₃)—, —CH₂C(CH₂CH₃)(CH₃)—, and —CH₂C(CH₂CH₃)₂.

“Alkoxy” refers to the group “alkyl-O-”. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. “Haloalkoxy” refers to an alkoxy group as defined above, wherein one or more hydrogen atoms are replaced by a halogen.

“Acyl” refers to a group —C(═O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

“Amido” refers to both a “C-amido” group which refers to the group —C(═O)NR^(Y)R^(z) and an “N-amido” group which refers to the group —NR^(Y)C(═O)R^(z), wherein R^(y) and R^(z) are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, heteroaryl, cycloalkyl, or heterocyclyl; each of which may be optionally substituted.

“Amino” refers to the group —NR^(Y)R^(z) wherein R^(y) and R^(z) are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; each of which may be optionally substituted.

“Aryl” refers to an aromatic carbocyclic group having a single ring (e.g. monocyclic) or multiple rings (e.g. bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., C₆₋₂₀ aryl), 6 to 12 carbon ring atoms (i.e., C₆₋₁₂ aryl), or 6 to 10 carbon ring atoms (i.e., C₆₋₁₀ aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.

“Cyano” or “carbonitrile” refers to the group —CN.

“Cycloalkyl” refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e. the cyclic group having at least one double bond). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C₃₋₂₀ cycloalkyl), 3 to 12 ring carbon atoms (i.e., C₃₋₁₂ cycloalkyl), 3 to 10 ring carbon atoms (i.e., C₃₋₁₀ cycloalkyl), 3 to 8 ring carbon atoms (i.e., C₃₋₈ cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C₃₋₆ cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

“Cycloalkoxy” refers to the group “cycloalkyl-O-”. Examples of cycloalkoxy groups include but are not limited to:

“Bridged” refers to a ring fusion wherein different atoms on a ring are joined by a divalent substituent, such as an alkylenyl group, an alkylenyl group containing one or two heteroatoms, or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems.

The term “fused” refers to a ring which is bound to an adjacent ring.

“Spiro” refers to a ring substituent which is joined by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents.

“Halogen” or “halo” includes fluoro, chloro, bromo, and iodo.

“Haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (—CHF₂) and trifluoromethyl (—CF₃).

“Heteroalkylene” refers to a divalent and unbranched saturated hydrocarbon chain having one, two, or three heteroatoms selected from NH, O, or S. As used herein, a heteroalkylene has 1 to 20 carbon atoms and one, two, or three heteroatoms selected from NH, O, and S (i.e., C₁₋₂₀ heteroalkylene); 1 to 8 carbon atoms and one, two, or three heteroatoms selected from NH, O, and S (i.e., C₁₋₈ heteroalkylene); 1 to 6 carbon atoms and one, two, or three heteroatoms selected from NH, O, and S S (i.e., C₁₋₆ heteroalkylene); 1 to 4 carbon atoms and one, two, or three heteroatoms selected from NH, O, and S (i.e., C₁₋₄ heteroalkylene); 1 to 3 carbon atoms and one, two, or three heteroatoms selected from NH, O, and S (i.e., C₁₋₃ heteroalkylene); or 1 to 2 carbon atoms and one, two, or three heteroatoms selected from NH, O, and S (i.e., C₁₋₃ heteroalkylene). For example, —CH₂O— is a C₁ heteroalkylene and —CH₂SCH₂— is a C₂ heteroalkylene. Examples of heteroalkylene groups include —CH₂CH₂OCH₂—, —CH₂SCH₂OCH₂—, —CH₂O—, and —CH₂NHCH₂—. In some embodiments, a heteroalkylene is optionally substituted with an alkyl group. Examples of substituted heteroalkylene groups include —CH(CH₃)N(CH₃)CH₂—, —CH₂OCH(CH₃)—, —CH₂CH(CH₂CH₃)S—, —CH₂NHC(CH₃)₂—, —C(CH₃)₂SCH₂—, —CH(CH₃)N(CH₃)CH(CH₃)O—, —CH₂SC(CH₂CH₃)(CH₃)—, and —CH₂C(CH₂CH₃)₂NH—.

“Heteroaryl” refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl includes 1 to 20 carbon ring atoms (i.e., C₁₋₂₀ heteroaryl), 3 to 12 carbon ring atoms (i.e., C₃₋₁₂ heteroaryl), or 3 to 8 carbon ring atoms (i.e., C₃₋₈ heteroaryl); and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass or overlap with aryl as defined above.

“Heterocyclyl” or “heterocyclic ring” or “heterocycle” refers to a non-aromatic cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. As used herein, “heterocyclyl” or “heterocyclic ring” or “heterocycle” refer to rings that are saturated or partially saturated unless otherwise indicated, e.g., in some embodiments “heterocyclyl” or “heterocyclic ring” or “heterocycle” refers to rings that are partially saturated where specified. The term “heterocyclyl” or “heterocyclic ring” or “heterocycle” includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond). A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro. As used herein, heterocyclyl has 2 to 20 carbon ring atoms (i.e., C₂₋₂₀ heterocyclyl), 2 to 12 carbon ring atoms (i.e., C₂₋₁₂ heterocyclyl), 2 to 10 carbon ring atoms (i.e., C₂₋₁₀ heterocyclyl), 2 to 8 carbon ring atoms (i.e., C_(2-s) heterocyclyl), 3 to 12 carbon ring atoms (i.e., C₃₋₁₂ heterocyclyl), 3 to 8 carbon ring atoms (i.e., C₃₋₈ heterocyclyl), or 3 to 6 carbon ring atoms (i.e., C₃₋₆ heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl. As used herein, the term “bridged-heterocyclyl” refers to a four- to ten-membered cyclic moiety connected at two non-adjacent atoms of the heterocyclyl with one or more (e.g., 1 or 2) four- to ten-membered cyclic moiety having at least one heteroatom where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. As used herein, “bridged-heterocyclyl” includes bicyclic and tricyclic ring systems. Also as used herein, the term “spiro-heterocyclyl” refers to a ring system in which a three- to ten-membered heterocyclyl has one or more additional ring, wherein the one or more additional ring is three- to ten-membered cycloalkyl or three- to ten-membered heterocyclyl, where a single atom of the one or more additional ring is also an atom of the three- to ten-membered heterocyclyl. Examples of the spiro-heterocyclyl include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. As used herein, the terms “heterocycle”, “heterocyclyl”, and “heterocyclic ring” are used interchangeably. In some embodiments, a heterocyclyl is substituted with an oxo group.

“Heterocycloxy” refers to the group “—O(heterocyclyl)”. Examples of heterocycloxy groups include but are not limited to —O(pyrrolidinyl), —O(tetrahydrofuranyl), —O(piperidinyl), —O(morpholinyl), —O(oxetanyl), and —O(2-oxa-7-azaspiro[3.5]nonanyl).

“Hydroxy” or “hydroxyl” refers to the group —OH.

“Oxo” refers to the group (═O) or (O).

“Sulfonyl” refers to the group —S(O)₂R^(bb), where R^(bb) is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

Whenever the graphical representation of a group terminates in a singly bonded nitrogen atom, that group represents an —NH group unless otherwise indicated. Similarly, unless otherwise expressed, hydrogen atom(s) are implied and deemed present where necessary in view of the knowledge of one of skill in the art to complete valency or provide stability.

The terms “optional” or “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term “optionally substituted” means that any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.

The term “substituted” means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof. Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term “substituted” may describe other chemical groups defined herein. For example, the term “substituted aryl” includes, but is not limited to, “alkylaryl.” Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

In some embodiments, a substituted cycloalkyl, a substituted heterocyclyl, a substituted aryl, and/or a substituted heteroaryl includes a cycloalkyl, a heterocyclyl, an aryl, and/or a heteroaryl that has a substituent on the ring atom to which the cycloalkyl, heterocyclyl, aryl, and/or heteroaryl is attached to the rest of the compound. For example, in the below moiety, the cyclopropyl is substituted with a methyl group:

The compounds of the embodiments disclosed herein, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. Where compounds are represented in their chiral form, it is understood that the embodiment encompasses, but is not limited to, the specific diastereomerically or enantiomerically enriched form. Where chirality is not specified but is present, it is understood that the embodiment is directed to either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound(s). As used herein, “scalemic mixture” is a mixture of stereoisomers at a ratio other than 1:1.

A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.

“Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. A mixture of enantiomers at a ratio other than 1:1 is a “scalemic” mixture.

“Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

A “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any compounds provided herein.

Some of the compounds provided herein exist as tautomeric isomers. Tautomeric isomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.

A “solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds provided herein are also provided. Hydrates of the compounds provided herein are also provided.

Any formula or structure provided herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to ²H (deuterium, D), ³H (tritium), ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸F, ³¹P, ³²P ³⁵S, ³⁶Cl and ¹²⁵I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as ²H, ³H, ¹³C and ¹⁴C are incorporated, are also provided herein. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.

The present disclosure also includes compounds of Formula I or II, in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound of Formula I or II when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.

Deuterium labelled or substituted therapeutic compounds of the present disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to absorption, distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index. An ¹⁸F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound of Formula I or II.

The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure, any atom specifically designated as a deuterium (D) is meant to represent deuterium.

In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

The term “pharmaceutically acceptable salt” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, mono, di or tri cycloalkyl amines, mono, di or tri arylamines or mixed amines, and the like. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.

As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

“Treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (i.e., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (i.e., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (i.e., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (i.e., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival).

“Prevention” or “preventing” means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.

“Subject” refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.

The term “therapeutically effective amount” or “effective amount” of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to improve a symptom of a disease or condition responsive to inhibition of toll-like receptor 7, 8, and/or 9. The therapeutically effective amount may vary depending on the subject, and the disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one of ordinary skill in the art.

II. Compounds

In one embodiment, provided herein is a compound of Formula I,

or a pharmaceutically acceptable salt thereof, wherein

-   R¹ is 8-10 membered fused bicyclic heterocyclyl or 8-10 membered     fused bicyclic heteroaryl,     -   wherein the 8-10 membered fused bicyclic heterocyclyl and 8-10         membered fused bicyclic heteroaryl are each independently         optionally substituted with 1-4 R^(a) groups; -   R² is H, C₁₋₆ alkyl, or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy,     -   wherein the C₁₋₆ alkoxy is optionally substituted with 1-3         halogen groups; -   R³ is H, halogen, —CN, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or     4-7 membered monocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, and 4-7         membered monocyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl,         —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇         monocyclic cycloalkoxy, and 4-7 membered monocyclic         heterocycloxy,         -   wherein the C₁₋₄ alkoxy is optionally substituted with 1-3             halogen groups; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is C₁₋₆ alkyl, C₂₋₆ alkenyl, —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇     monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl,     phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl, wherein the C₁₋₆ alkyl and C₂₋₆     alkenyl are each independently optionally substituted with 1-4 R^(b)     groups, wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered     monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered     monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl,     6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused     bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are     each independently optionally substituted with 1-2 R⁸ groups and are     each independently optionally substituted with 1-3 R^(a) groups; -   R⁶ is C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered     monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered     monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl,     6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused     bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   R¹³ is C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl,     C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   R⁷ is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or 4-6 membered     monocyclic heterocyclyl, wherein the C₁₋₆ alkyl, C₃₋₇ monocyclic     cycloalkyl, and 4-6 membered monocyclic heterocyclyl are each     independently optionally substituted with 1-4 groups independently     selected from —OH, halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is halogen, —C(O)R⁹, —NR¹⁰R¹⁰, C₁₋₆ alkyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl,     phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered     spirocyclic heterocyclyl, —OR⁵, —C(O)OR⁵, —C(O)N(R⁵)(R⁵),     —N(R⁵)₂(R⁵)⁺, —N(R⁵)C(O)R⁵, —N(R⁵)C(O)OR⁵, —N(R⁵)C(O)N(R⁵)(R⁵),     —N(R⁵)S(O)₂(R^(5a)) —NR⁵S(O)₂N(R⁵)(R⁵), —NR⁵S(O)₂O(R^(5a)),     —OC(O)R⁵, —OC(O)OR⁵, —OC(O)N(R⁵)(R⁵), —SR⁵, —S(O)R^(5a) S(O)(NH)R⁵,     —S(O)₂R^(5a), —S(O)₂N(R⁵)(R⁵), or —N═S(R^(5a))(R^(5a))═O,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups;     -   each R⁹ independently is C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused         bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic         heterocyclyl, wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀         fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl,         phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6         membered monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   each R⁵ and R¹⁰ independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆     alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   each R^(5a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups; -   each R^(a) independently is oxo, imino, halogen, —NO₂, —N₃, —CN,     C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl,     C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl,     phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6     membered monocyclic heteroaryl, 8-10 membered fused bicyclic     heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10     membered fused bicyclic heteroaryl, 7-10 membered spirocyclic     heterocyclyl, —OR¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹),     —NR¹¹R¹¹, —N(R¹¹)₂(R¹¹)⁺, —N(R¹¹)C(O)R¹¹, —N(R¹¹)C(O)OR¹¹,     —N(R¹¹)C(O)N(R¹¹)(R¹¹), —N(R¹¹)S(O)₂(R^(11a)) —NR¹¹S(O)₂N(R¹¹)(R¹¹),     —NR¹¹S(O)₂O(R^(11a)) —OC(O)R¹¹, —OC(O)OR¹¹, —OC(O)N(R¹¹)(R¹¹),     —SR¹¹, —S(O)R^(11a), —S(O)(NH)R¹¹, —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹),     or —N═S(R^(11a))(R^(11a))═O,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-3 R^(c) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-3 R^(d) groups, -   each R^(b) independently is oxo, imino, halogen, —NO₂, —N₃, —CN,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic     heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10     membered fused bicyclic heteroaryl, 7-10 membered spirocyclic     heterocyclyl, —OR¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹),     —NR¹¹R¹¹, —N(R¹¹)₂(R¹¹)⁺, —N(R¹¹)C(O)R¹¹, —N(R¹¹)C(O)OR¹¹,     —N(R¹¹)C(O)N(R¹¹)(R¹¹), —N(R¹¹)S(O)₂(R^(11a)),     —NR¹¹S(O)₂N(R¹¹)(R¹¹), —NR¹¹S(O)₂O(R^(11a)) —OC(O)R¹¹, —OC(O)OR¹¹,     —OC(O)N(R¹¹)(R¹¹), —SR¹¹, —S(O)R^(11a), —S(O)(NH)R¹¹, —S(O)₂R^(11a),     —S(O)₂N(R¹¹)(R¹¹), or —N═S(R^(11a))(R^(11a))═O     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-3 R^(d) groups; -   each R independently is halogen, —CN, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹², —C(O)R¹²,     —C(O)OR¹², —C(O)N(R¹²)(R¹²), —NR¹²R¹², —N(R¹²)₂(R¹²)⁺—N(R¹²)C(O)R¹²,     —N(R¹²)C(O)OR¹², —N(R¹²)C(O)N(R¹²)(R¹²), —N(R¹²)S(O)₂(R^(12a))     —NR¹²S(O)₂N(R¹²)(R¹²), —NR¹²S(O)₂O(R^(12a)), —OC(O)R¹², —OC(O)OR¹²,     —OC(O)N(R¹²)(R¹²), —SR¹², —S(O)R^(12a), —S(O)(NH)R¹², —S(O)₂R^(12a)     —S(O)²N(R¹²)(R¹²), or —N═S(R^(12a))(R^(12a))═O; -   each R^(d) independently is oxo, halogen, —CN, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹², —C(O)R¹²,     —C(O)OR¹², —C(O)N(R¹²)(R¹²), —NR¹²R¹², —N(R¹²)₂(R¹²)⁺,     —N(R¹²)C(O)R¹², —N(R¹²)C(O)OR¹², —N(R¹²)C(O)N(R¹²)(R¹²),     —N(R¹²)S(O)₂(R^(12a)) —NR¹²S(O)₂N(R¹²)(R¹²), —NR¹²S(O)₂O(R^(12a)),     —OC(O)R¹², —OC(O)OR¹², —OC(O)N(R¹²)(R¹²), —SR¹², —S(O)R^(12a),     —S(O)(NH)R¹², —S(O)₂R^(12a) —S(O)₂N(R¹²)(R¹²), or     —N═S(R^(12a))(R^(12a))═O; -   each R¹¹ independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇         monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀         bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered         monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl,         8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged         bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl,         and 7-10 membered spirocyclic heterocyclyl are each         independently optionally substituted with 1-3 R^(c) groups; -   each R^(11a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆     alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇         monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀         bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered         monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl,         8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged         bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl,         and 7-10 membered spirocyclic heterocyclyl are each         independently optionally substituted with 1-3 R^(c) groups; -   each R¹² independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,     C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀     bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered     monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10     membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10     membered spirocyclic heterocyclyl; -   each R^(12a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆     alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic     cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl,     4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered     fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic     heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10     membered spirocyclic heterocyclyl independently have 1-4 ring     heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-4 R^(a) groups; -   R² is C₁₋₆ alkyl or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇ monocyclic cycloalkyl,     C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic         cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 R^(a) groups; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-4 R^(a)     groups; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-4     R^(a) groups; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, —NR¹⁰R¹⁰, —S(O)₂R^(5a), C₁₋₆     alkyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10     membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 6-10 membered bridged bicyclic         heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are         each independently optionally substituted with 1-4 R^(a) groups; -   each R⁹ independently is C₃₋₇ monocyclic cycloalkyl, 4-7 membered     monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl,     6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered     spirocyclic heterocyclyl, wherein the C₃₋₇ monocyclic cycloalkyl,     4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic     heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, and 7-10     membered spirocyclic heterocyclyl are each independently optionally     substituted with 1-4 R^(a) groups; -   each R¹⁰ independently is H or 4-7 membered monocyclic heterocyclyl,     wherein the 4-7 membered monocyclic heterocyclyl is optionally     substituted with 1-4 R^(a) groups; -   each R^(5a) independently is 4-7 membered monocyclic heterocyclyl,     wherein the 4-7 membered monocyclic heterocyclyl is optionally     substituted with 1-4 R^(a) groups; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-4 R^(a) groups; -   R² is C₁₋₆ alkyl or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 R^(a) groups; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-4 R^(a)     groups; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-4     R^(a) groups; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered     monocyclic heterocyclyl, or 6-10 membered bridged bicyclic     heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups, wherein the 4-7 membered monocyclic heterocyclyl and         6-10 membered bridged bicyclic heterocyclyl are each         independently optionally substituted with 1-4 R^(a) groups; -   each R⁹ independently is 4-7 membered monocyclic heterocyclyl, 6-10     membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic     heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl, 6-10     membered bridged bicyclic heterocyclyl, and 7-10 membered     spirocyclic heterocyclyl are each independently optionally     substituted with 1-4 R^(a) groups; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-3 groups independently selected from —OH, halogen, —CN, oxo,     —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₆ alkyl, and C₃₋₇ monocyclic cycloalkyl,     -   wherein the C₁₋₆ alkyl and C₁₋₄ alkoxy are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, and —NR¹²R¹²; -   R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇ monocyclic cycloalkyl,     C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic         cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄     alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are     each independently optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, and —NR¹²R¹²; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-3     groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,     C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, —NR¹⁰R¹⁰, —S(O)₂R^(5a), C₁₋₆     alkyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic     heteroaryl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10     membered spirocyclic heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         —C(O)R¹¹, —C(O)OR¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a),         —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(8a),     -   wherein the 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 6-10 membered bridged bicyclic         heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are         each independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b); -   each R^(8a) independently is 4-7 membered monocyclic heterocyclyl or     5-6 membered monocyclic heteroaryl; -   each R^(8b) independently is 4-7 membered monocyclic heterocyclyl; -   each R⁹ independently is C₃₋₇ monocyclic cycloalkyl, 4-7 membered     monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl,     6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered     spirocyclic heterocyclyl, wherein the C₃₋₇ monocyclic cycloalkyl,     4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic     heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, and 7-10     membered spirocyclic heterocyclyl are each independently optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a); -   each R^(9a) independently is 4-7 membered monocyclic heterocyclyl; -   each R¹⁰ independently is H or 4-7 membered monocyclic heterocyclyl; -   each R^(5a) independently is 4-7 membered monocyclic heterocyclyl; -   each R¹¹ independently is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl,     or 4-7 membered monocyclic heterocyclyl; -   each R^(11a) independently is C₁₋₄ alkyl; -   each R¹² independently is H or C₁₋₄ alkyl; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-3 groups independently selected from —OH, halogen, —CN, oxo,     —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₆ alkyl, and C₃₋₇ monocyclic cycloalkyl,     -   wherein the C₁₋₆ alkyl and C₁₋₄ alkoxy are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, and —NR¹²R¹²; -   R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄     alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are     each independently optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, and —NR¹²R¹²; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-3     groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,     C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered     monocyclic heterocyclyl, or 6-10 membered bridged bicyclic     heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), C₁₋₄ alkoxy, and R^(8a),     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl; -   R^(8a) is 4-7 membered monocyclic heterocyclyl; -   each R⁹ independently is 4-7 membered monocyclic heterocyclyl, 6-10     membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic     heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl, 6-10     membered bridged bicyclic heterocyclyl, and 7-10 membered     spirocyclic heterocyclyl are each optionally substituted with 1-3     groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,     C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   each R¹¹ independently is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl,     or 4-7 membered monocyclic heterocyclyl; -   each R^(11a) independently is C₁₋₄ alkyl; -   each R¹² independently is H or C₁₋₄ alkyl; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-4 R^(a) groups; -   R² is C₁₋₆ alkyl or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 R^(a) groups; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-4 R^(a)     groups; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-4     R^(a) groups; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered     monocyclic heterocyclyl, or 6-10 membered bridged bicyclic     heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-4 R^(a) groups; -   R⁹ is 4-7 membered monocyclic heterocyclyl or 6-10 membered bridged     bicyclic heterocyclyl, wherein the 4-7 membered monocyclic     heterocyclyl and 6-10 membered bridged bicyclic heterocyclyl are     each independently optionally substituted with 1-4 R^(a) groups; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-3 groups independently selected from —OH, halogen, —CN, oxo,     —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₆ alkyl, and C₃₋₇ monocyclic cycloalkyl,     -   wherein the C₁₋₆ alkyl and C₁₋₄ alkoxy are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, and —NR¹²R¹²; -   R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered     bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic     heteroaryl, or 7-10 membered spirocyclic heterocyclyl,     -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄     alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are     each independently optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, and —NR¹²R¹²; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-3     groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,     C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered     monocyclic heterocyclyl, or 6-10 membered bridged bicyclic     heterocyclyl, wherein the C₁₋₆ alkyl is optionally substituted with     1-3 groups independently selected from —OH, halogen, —CN, oxo,     —NR¹¹R¹¹, —C(O)NR¹¹R¹¹, C₁₋₄ alkoxy, and R^(8a),     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl; -   R^(8a) is 4-7 membered monocyclic heterocyclyl; -   R⁹ is 4-7 membered monocyclic heterocyclyl or 6-10 membered bridged     bicyclic heterocyclyl, wherein the 4-7 membered monocyclic     heterocyclyl and 6-10 membered bridged bicyclic heterocyclyl are     each optionally substituted with 1-3 groups independently selected     from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   each R¹¹ independently is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl,     or 4-7 membered monocyclic heterocyclyl; -   each R¹² independently is H or C₁₋₄ alkyl; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-4 R^(a) groups; -   R² is C₁₋₆ alkyl or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, or 8-10     membered fused bicyclic heteroaryl,     -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, and 8-10 membered fused bicyclic         heteroaryl are each independently optionally substituted with         1-2 R⁸ groups and are each independently optionally substituted         with 1-3 R^(a) groups; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-4 R^(a)     groups; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-4     R^(a) groups; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered     monocyclic heterocyclyl, or 6-10 membered bridged bicyclic     heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-4 R^(a) groups; -   R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-4 R^(a)     groups; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof,

-   R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10     membered fused bicyclic heteroaryl is optionally substituted with     1-3 groups independently selected from —OH, —CN, oxo, halogen, C₁₋₆     alkyl, C₁₋₄ alkoxy, C₃₋₇ monocyclic cycloalkyl, and —NR¹¹R¹¹,     -   wherein the C₁₋₆ alkyl and C₁₋₄ alkoxy are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, and —NR¹²R¹²; -   R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆     alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently     optionally substituted with 1-4 groups independently selected from     halogen and C₁₋₆ alkoxy; -   R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-3 groups independently selected from —OH,     halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂; -   each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with     the nitrogen to which they are attached, form a 4-7 membered     monocyclic heterocyclyl; -   Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic     heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic     heteroaryl, 8-10 membered fused bicyclic heterocyclyl, or 8-10     membered fused bicyclic heteroaryl,     -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, and 8-10 membered fused bicyclic         heteroaryl are each independently optionally substituted with         1-2 R⁸ groups and are each independently optionally substituted         with 1-3 groups independently selected from —OH, halogen, —CN,         oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄     alkoxy, and C₁₋₅ alkyl,     -   wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, and —NR¹²R¹²; -   R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7     membered monocyclic heterocyclyl is optionally substituted with 1-3     groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,     C₁₋₄ alkoxy, and C₁₋₅ alkyl; -   R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally     substituted with 1-4 groups independently selected from —OH,     halogen, —CN, and C₁₋₆ alkoxy; -   each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered     monocyclic heterocyclyl, or 6-10 membered bridged bicyclic     heterocyclyl,     -   wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         —C(O)NR¹¹R¹¹, C₁₋₄ alkoxy, and R^(8a),     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl; -   each R^(8a) independently is 4-7 membered monocyclic heterocyclyl; -   R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered     monocyclic heterocyclyl is optionally substituted with 1-3 groups     independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄     alkoxy, and C₁₋₅ alkyl; -   each R¹¹ independently is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl,     or 4-7 membered monocyclic heterocyclyl; -   each R¹² independently is H or C₁₋₄ alkyl; -   wherein each 4-membered monocyclic heterocyclyl independently has 1     ring heteroatom selected from N, O, and S; -   wherein each 5-7 membered monocyclic heterocyclyl independently has     1-2 ring heteroatoms independently selected from N, O, and S; -   wherein each 6-membered bridged bicyclic heterocyclyl independently     has 1 ring heteroatom selected from N, O, and S; -   wherein each 7-membered bridged bicyclic heterocyclyl independently     has 1-2 ring heteroatoms independently selected from N, O, and S;     and -   wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused     bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl,     and 8-10 membered fused bicyclic heteroaryl independently have 1-4     ring heteroatoms independently selected from N, O, and S.

Unless specified otherwise, each 4-membered monocyclic heterocyclyl as used herein has 1 ring heteroatom selected from N, O, and S. Unless specified otherwise, each 5-7 membered monocyclic heterocyclyl as used herein has 1-2 ring heteroatoms independently selected from N, O, and S. Unless specified otherwise, each 6-membered bridged bicyclic heterocyclyl as used herein has 1 ring heteroatom selected from N, O, and S. Unless specified otherwise, each 7-membered bridged bicyclic heterocyclyl as used herein has 1-2 ring heteroatoms independently selected from N, O, and S. Unless specified otherwise, each 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl as used herein independently have 1-4 ring heteroatoms independently selected from N, O, and S.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl or 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heterocyclyl and 8-10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₆ alkyl.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₆ alkyl.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heterocyclyl.

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₆ alkyl, and C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and C₁₋₄ alkoxy are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹².

In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, R¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₆ alkyl, and C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and C₁₋₄ alkoxy are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹².

In some embodiments of a compound of Formula I, the compound is a compound of Formula II,

or a pharmaceutically acceptable salt thereof, wherein

-   -   X¹ and X² are each independently CR^(1a) or N;     -   R^(1a), R^(1b), and R^(1c) are each independently H, halogen,         C₁₋₆ alkyl, C₁₋₄ alkoxy, C₃₋₇ monocyclic cycloalkyl, or         —N(R¹⁴)(R¹⁴), wherein the C₁₋₆ alkyl and the C₁₋₄ alkoxy are         each independently optionally substituted with 1-3 halogen         groups; and     -   each R¹⁴ independently is H, C₁₋₆ alkyl, C₃₋₇ monocyclic         cycloalkyl, or 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X¹ is CR^(1a) or N. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X¹ is CR^(1a). In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X¹ is CR^(1a) and R^(1a) is H. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X¹ is N.

In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X² is CR^(1a) or N. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X² is CR^(1a). In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X² is CR^(1a) and R^(1a) is H. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, X² is N.

In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1a), R^(1b), and R^(1c) are each independently H, halogen, C₁₋₆ alkyl, C₁₋₄ alkoxy, C₃₋₇ monocyclic cycloalkyl, or —N(R¹⁴)(R¹⁴), wherein the C₁₋₆ alkyl and the C₁₋₄ alkoxy are each independently optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1a), R^(1b), and R^(1c) are each independently H, halogen, methyl, methoxy, —CF₃, or CHF₂.

In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, each R^(1a) independently is H, halogen, C₁₋₆ alkyl, C₁₋₄ alkoxy, C₃₋₇ monocyclic cycloalkyl, or —N(R¹⁴)(R¹⁴), wherein the C₁₋₆ alkyl and the C₁₋₄ alkoxy are each independently optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, each R^(1a) independently is H, halogen, methyl, methoxy, —CF₃, or CHF₂. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is H. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is halogen. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is methyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is —CF₃. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is CHF₂. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is C₁₋₄ alkoxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is methoxy. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is C₃₋₇ monocyclic cycloalkyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R^(1a) is —N(R¹⁴)(R¹⁴).

In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is H, halogen, C₁₋₆ alkyl, C₁₋₄ alkoxy, C₃₋₇ monocyclic cycloalkyl, or —N(R¹⁴)(R¹⁴), wherein the C₁₋₆ alkyl and the C₁₋₄ alkoxy are each independently optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is H, halogen, methyl, methoxy, —CF₃, or CHF₂. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is H. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is halogen. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is methyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is —CF₃. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is CHF₂. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is C₁₋₄ alkoxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is methoxy. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is C₃₋₇ monocyclic cycloalkyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1b) is —N(R¹⁴)(R¹⁴).

In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is H, halogen, C₁₋₆ alkyl, C₁₋₄ alkoxy, C₃₋₇ monocyclic cycloalkyl, or —N(R¹⁴)(R¹⁴), wherein the C₁₋₆ alkyl and the C₁₋₄ alkoxy are each independently optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is H, halogen, methyl, methoxy, —CF₃, or CHF₂. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is H. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is halogen. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is methyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is —CF₃. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is CHF₂. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is C₁₋₄ alkoxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is methoxy. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is C₃₋₇ monocyclic cycloalkyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, R^(1c) is —N(R¹⁴)(R¹⁴).

In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, each R¹⁴ independently is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R¹⁴ is H. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R¹⁴ is C₁₋₆ alkyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R¹⁴ is C₃₋₇ monocyclic cycloalkyl. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both R¹⁴ is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹ is

each of which is optionally substituted with 1-3 groups independently selected from halogen, C₁. 3 alkyl, and C₁₋₃ alkoxy, wherein the C₁₋₃ alkyl is optionally substituted with 1-3 halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹ is

which is optionally substituted with 1-3 groups independently selected from halogen, C₁₋₃ alkyl, and C₁₋₃ alkoxy, wherein the C₁₋₃ alkyl is optionally substituted with 1-3 halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹ is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹ is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹ is

each of which is optionally substituted with 1-3 groups independently selected from halogen, —CN, C₁₋₃ alkyl, and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹ is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is H, C₁₋₆ alkyl, or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is H, C₁₋₆ alkyl, or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is H, C₁₋₆ alkyl, or C₃₋₇ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₇ monocyclic cycloalkyl are each independently optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl or C₃₋₅ monocyclic cycloalkyl, wherein the C₁₋₆ alkyl and the C₃₋₅ monocyclic cycloalkyl are each independently optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₆ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₄ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II or II, or a pharmaceutically acceptable salt thereof, R² is ethyl or isopropyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is methyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is ethyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is propyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is isopropyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 groups independently selected from halogen and C₁. 6 alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁. 3 alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is optionally substituted with 1-4 groups independently selected from halogen and C₁. 6 alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy, wherein the C₁₋₆ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy, wherein the C₁₋₃ alkoxy is optionally substituted with 1-3 halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is optionally substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is substituted with 1-4 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from halogen and C₁₋₃ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is C₃₋₅ monocyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is cyclopropyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R² is isopropyl or cyclopropyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is H, halogen, —CN, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or 4-7 membered monocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, and 4-7         membered monocyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl,         —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇         monocyclic cycloalkoxy, and 4-7 membered monocyclic         heterocycloxy,         -   wherein the C₁₋₄ alkoxy is optionally substituted with 1-3             halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is H or C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is H or methyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is halogen. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is —CN.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇ monocyclic cycloalkoxy, and 4-7 membered monocyclic heterocycloxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇ monocyclic cycloalkoxy, and 4-7 membered monocyclic heterocycloxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇ monocyclic cycloalkoxy, and 4-7 membered monocyclic heterocycloxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇ monocyclic cycloalkoxy, and 4-7 membered monocyclic heterocycloxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇ monocyclic cycloalkoxy, and 4-7 membered monocyclic heterocycloxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, —C(O)N(R⁴)₂, 4-7 membered monocyclic heterocyclyl, C₃₋₇ monocyclic cycloalkoxy, and 4-7 membered monocyclic heterocycloxy, wherein the C₁₋₄ alkoxy is optionally substituted with 1-3 halogen groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, C₁₋₄ alkoxy, —C(O)C₁₋₆ alkyl, and —C(O)N(R⁴)₂.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₄ alkyl optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C₁₋₃ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is methyl substituted with 1-3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is —CHF₂.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₄ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is methyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R³ is H, methyl, —CHF₂, —CH₂OH, —CH₂OCH₃, or ethyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁴ independently is H or C₁₋₆ alkyl, or both R⁴, together with the nitrogen to which they are attached, form a 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁴ is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁴ is C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, both R⁴, together with the nitrogen to which they are attached, form a 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₁₋₆ alkyl, C₂₋₆ alkenyl, —C(O)R¹³, —C(O)NR⁶R⁷,—S(O)₂R⁶, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl and C₂₋₆ alkenyl are each independently         optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-2 R⁸ groups and are each independently         optionally substituted with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic         cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic         cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇ monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₃₋₇ monocyclic cycloalkyl, 4-7 membered monocyclic         heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic         heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10         membered bridged bicyclic heterocyclyl, 8-10 membered fused         bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl         are each independently optionally substituted with 1-2 R⁸ groups         and are each independently optionally substituted with 1-3 R^(a)         groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, or 8-10 membered fused bicyclic heteroaryl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, and 8-10 membered fused bicyclic         heteroaryl are each independently optionally substituted with         1-2 R⁸ groups and are each independently optionally substituted         with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₃₋₇ monocyclic cycloalkyl, C₅₋₁₀ bridged bicyclic         cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10         membered spirocyclic heterocyclyl are each independently         optionally substituted with 1-2 R⁸ groups and are each         independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³, —C(O)NR⁶R⁷, —S(O)₂R⁶, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, or 8-10 membered fused bicyclic heteroaryl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, and 8-10 membered fused bicyclic         heteroaryl are each independently optionally substituted with         1-2 R⁸ groups and are each independently optionally substituted         with 1-3 groups independently selected from —OH, halogen, —CN,         oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 8-10 membered fused bicyclic heteroaryl,

-   -   wherein the C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged         bicyclic cycloalkyl, 8-10 membered fused bicyclic heterocyclyl,         6-10 membered bridged bicyclic heterocyclyl, and 8-10 membered         fused bicyclic heteroaryl are each independently optionally         substituted with 1-2 R⁸ groups and are each independently         optionally substituted with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 8-10 membered fused bicyclic heteroaryl,

-   -   wherein the C₇₋₁₀ fused bicyclic cycloalkyl, 8-10 membered fused         bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, and 8-10 membered fused bicyclic heteroaryl are         each independently optionally substituted with 1-2 R⁸ groups and         are each independently optionally substituted with 1-3 R^(a)         groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₁₋₆ alkyl, wherein the C₁₋₁₀ alkyl is substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₁₋₆ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is substituted with 1-4 R^(b)groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is substituted with 1-3 R^(b)groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₂₋₆ alkenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is optionally substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₇₋₁₀ fused bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

which is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

which is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, wherein the phenyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups and is substituted with 1-3R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl, wherein the 6 membered monocyclic heteroaryl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8membered bridged bicyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-2 R⁸ groups and is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-2 R⁸ groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, or 8-10 membered fused bicyclic heteroaryl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, and 8-10 membered fused bicyclic         heteroaryl are each independently optionally substituted with         1-2 R⁸ groups and are each independently optionally substituted         with 1-3 groups independently selected from —OH, halogen, —CN,         oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, or 8-10 membered fused bicyclic heteroaryl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, phenyl,         naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered         fused bicyclic heterocyclyl, and 8-10 membered fused bicyclic         heteroaryl are each independently optionally substituted with         1-2 R⁸ groups and are each independently optionally substituted         with 1-3 groups independently selected from —OH, halogen, —CN,         oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, and     -   wherein the 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, and 8-10 membered fused bicyclic heteroaryl each         independently have one or two ring heteroatoms that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl,

-   -   wherein the 5-6 membered monocyclic heterocyclyl is optionally         substituted with 1-2 R⁸ groups and is optionally substituted         with 1-2 groups independently selected from —OH, halogen, —CN,         oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, and     -   wherein the 5-6 membered monocyclic heterocyclyl has one or two         ring heteroatoms that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is pyrrolidinyl or piperidinyl, each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is piperidinyl, wherein the piperidinyl is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is azetidinyl optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is azepanyl, wherein the azepanyl is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, naphthalenyl, or 6-membered monocyclic heteroaryl, each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, pyridinyl, or pyrimidinyl, each of which is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl or pyridinyl, each of which is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 8-10 membered fused bicyclic heterocyclyl or 8-10 membered fused bicyclic heteroaryl, each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 6-10 membered bridged bicyclic heterocyclyl optionally substituted with 1-2 R⁸ groups and optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-8 membered bridged bicyclic heterocyclyl optionally substituted with 1-2 R⁸ groups and optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the 7-8 membered bridged bicyclic heterocyclyl has one or two ring heteroatoms that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl optionally substituted with 1-2 R⁸ groups and optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is 7-10 membered spirocyclic heterocyclyl optionally substituted with 1-2 R⁸ groups and optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the 7-10 membered spirocyclic heterocyclyl has one or two ring heteroatoms that is independently selected from N and O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with 1-2 R⁸ groups and is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is

each of which is optionally substituted with one R⁸ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z substituted with one R⁸ group is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is halogen, —C(O)R⁹, —NR¹⁰R¹⁰, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR⁵, —C(O)OR⁵, —C(O)N(R⁵)(R⁵), —N(R⁵)₂(R⁵)⁺, —N(R⁵)C(O)R⁵, —N(R⁵)C(O)OR⁵, —N(R⁵)C(O)N(R⁵)(R⁵), —N(R⁵)S(O)₂(R^(5a)) —NR⁵S(O)₂N(R⁵)(R⁵), —NR⁵S(O)₂O(R^(5a)), —OC(O)R⁵, —OC(O)OR⁵, —OC(O)N(R⁵)(R⁵), —SR⁵, —S(O)R^(5a), —S(O)(NH)R⁵, —S(O)₂R^(5a), —S(O)₂N(R⁵)(R⁵), or —N═S(R^(5a))(R^(5a))═O,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is —C(O)R⁹, —NR¹⁰R¹⁰, —S(O)₂R^(5a), C₁₋₆ alkyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 6-10 membered bridged bicyclic         heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are         each independently optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered monocyclic heterocyclyl, or 6-10 membered bridged bicyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is —C(O)R⁹, —NR¹⁰R¹⁰, —S(O)₂R^(5a), C₁₋₆ alkyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         —C(O)R¹¹, —C(O)OR¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a),         —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(8a),     -   wherein the 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 6-10 membered bridged bicyclic         heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are         each independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered monocyclic heterocyclyl, or 6-10 membered bridged bicyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), C₁₋₄ alkoxy, and R^(8a),     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is —C(O)R⁹, C₁₋₆ alkyl, 4-7 membered monocyclic heterocyclyl, or 6-10 membered bridged bicyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         —C(O)NR¹¹R¹¹, C₁₋₄ alkoxy, and R^(8a),     -   wherein the 4-7 membered monocyclic heterocyclyl and 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(8a) independently is 4-7 membered monocyclic heterocyclyl or 5-6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R^(8a) is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R^(8a) is 5-6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(8b) independently is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R^(8b) is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is halogen. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —OR⁵. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —C(O)OR⁵. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —C(O)N(R⁵)(R⁵). In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —N(R⁵)₂(R⁵)⁺. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —N(R⁵)C(O)R⁵. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —N(R⁵)C(O)OR⁵. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —N(R⁵)C(O)N(R⁵)(R⁵). In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —N(R⁵)S(O)₂(R^(5a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —NR⁵S(O)₂N(R⁵)(R⁵). In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —NR⁵S(O)₂O(R^(5a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —OC(O)R⁵. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —OC(O)OR⁵. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —OC(O)N(R⁵)(R⁵). In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —SR⁵. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —S(O)R^(sa). In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —S(O)(NH)R⁵. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —S(O)₂R^(5a). In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —S(O)₂N(R⁵)(R⁵). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —N═S(R^(5a))(R^(5a))═O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), C₁₋₄ alkoxy, and 4-5 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)NR¹¹R¹¹, C₁₋₄ alkoxy, and 4-5 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-2 groups independently selected from —OH, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-2 groups independently selected from —OH, oxo, —NR¹¹R¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), and 4-5 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, —CN, oxo, —NH₂, —N(CH₃)₂, —C(O)(azetidinyl), —C(O)OH, —C(O)OCH(CH₃)₃, —C(O)NH₂, —C(O)NH₂, —C(O)NH(CH₃), —C(O)NH(CH₂CH₃), —C(O)NH(CH(CH₃)₂), —C(O)NH(cyclopropyl), —C(O)NH(oxetanyl), —C(O)N(CH₃)₂, —S(O)₂CH₃, —S(O)₂NH₂, —S(O)₂NH(CH₃), —S(O)₂N(CH₃)₂, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, —S(O)₂CH₃, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, —S(O)₂CH₃, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂,—C(O)NH₂, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with one group independently selected from —C(O)NH₂ and —C(O)NHCH₃. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is methyl substituted with one —C(O)NH₂ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, —C(O)NHCH₃, —S(O)₂CH₃, oxetanyl, and pyrrolidinyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, —C(O)NHCH₃, oxetanyl, and pyrrolidinyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, —S(O)₂CH₃, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, —S(O)₂CH₃, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, —S(O)₂CH₃, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, and oxetanyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with 1-2 groups independently selected from oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with one group independently selected from —C(O)NH₂ and —C(O)NHCH₃. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is methyl optionally substituted with one —C(O)NH₂ group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-2 groups independently selected from —OH, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-2 groups independently selected from —OH, oxo, —NR¹¹R¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), and 4-5 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, —CN, oxo, —NH₂, —N(CH₃)₂, —C(O)(azetidinyl), —C(O)OH, —C(O)OCH(CH₃)₃, —C(O)NH₂, —C(O)NH₂, —C(O)NH(CH₃), —C(O)NH(CH₂CH₃), —C(O)NH(CH(CH₃)₂), —C(O)NH(cyclopropyl), —C(O)NH(oxetanyl), —C(O)N(CH₃)₂, —S(O)₂CH₃, —S(O)₂NH₂, —S(O)₂NH(CH₃), —S(O)₂N(CH₃)₂, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁. 6 alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, —S(O)₂CH₃, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —NH₂, —N(CH₃)₂, —C(O)NH₂, —C(O)N(CH₃)₂, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, —S(O)₂CH₃, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, and oxetanyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), C₁₋₄ alkoxy, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), —S(O)₂R^(11a), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), C₁₋₄ alkoxy, and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-2 groups independently selected from —OH, —CN, oxo, —NR¹¹R¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-2 groups independently selected from —OH, oxo, —NR¹¹R¹¹, —C(O)NR¹¹R¹¹, —S(O)₂R^(11a), and 4-5 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-2 groups independently selected from oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), and 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-3 groups independently selected from —OH, —CN, oxo, —NH₂, —N(CH₃)₂, —C(O)(azetidinyl), —C(O)OH, —C(O)OCH(CH₃)₃, —C(O)NH₂, —C(O)NH₂, —C(O)NH(CH₃), —C(O)NH(CH₂CH₃), —C(O)NH(CH(CH₃)₂), —C(O)NH(cyclopropyl), —C(O)NH(oxetanyl), —C(O)N(CH₃)₂, —S(O)₂CH₃, —S(O)₂NH₂, —S(O)₂NH(CH₃), —S(O)₂N(CH₃)₂, 4-5 membered monocyclic heterocyclyl, and 5 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with 1-3 groups independently selected from —OH, —CN, oxo, pyrrolidinyl,

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with one group independently selected from —C(O)NH₂ and —C(O)NHCH₃. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is methyl substituted with one —C(O)NH₂ group. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, —C(O)NHCH₃, —S(O)₂CH₃, oxetanyl, and pyrrolidinyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, oxo, —N(CH₃)₂, —C(O)NH₂, —C(O)NHCH₃, oxetanyl, and pyrrolidinyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₇₋₁₀ fused bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is C₅₋₁₀ bridged bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is phenyl, wherein the phenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is phenyl, wherein the phenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is phenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is naphthalenyl, wherein the naphthalenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is naphthalenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 5-6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 8-10 membered fused bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 6-10 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-8 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is 4-7 membered monocyclic heterocyclyl or 6-10 membered bridged bicyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl and the 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is 4-7 membered monocyclic heterocyclyl or 6-10 membered bridged bicyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl and the 6-10         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl, and     -   wherein the 4-7 membered monocyclic heterocyclyl and the 6-10         membered bridged bicyclic heterocyclyl each independently have         one or two ring heteroatoms independently selected from N and S.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is 5-6 membered monocyclic heterocyclyl or 7-8 membered bridged bicyclic heterocyclyl,

-   -   wherein the 5-6 membered monocyclic heterocyclyl and the 7-8         membered bridged bicyclic heterocyclyl are each independently         optionally substituted with 1-2 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,

each of which is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,

each of which is optionally substituted with 1-3 groups independently selected from halogen and oxo.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is piperazinyl,

each of which is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is

each of which is substituted with 1-2 oxo groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is

each of which is substituted with 1-2 oxo groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 oxo groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with one R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is

each of which is optionally substituted with one R^(8b).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(8b) independently is 6-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(8b) independently is 6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(8b) independently is morpholinyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁸ is —C(O)R⁹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —C(O)R⁹.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is C₃₋₇ monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl, wherein the C₃₋₇ monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is 4-7 membered monocyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is 4-7 membered monocyclic heterocyclyl or 6-10 membered bridged bicyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl and 6-10 membered bridged bicyclic heterocyclyl are each optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is C₃₋₇ monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl, wherein the C₃₋₇ monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R⁹.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(9a) independently is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is 4-7 membered monocyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is 4-7 membered monocyclic heterocyclyl or 6-10 membered bridged bicyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl and 6-10 membered bridged bicyclic heterocyclyl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₇. 10 fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₇₋₁₀ fused bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is C₅₋₁₀ bridged bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is phenyl, wherein the phenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is phenyl, wherein the phenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is phenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is naphthalenyl, wherein the naphthalenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is naphthalenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 8-10 membered fused bicyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-7 membered monocyclic heterocyclyl, wherein the 5-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-7 membered monocyclic heterocyclyl, wherein the 5-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-7 membered monocyclic heterocyclyl, wherein the 5-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-7 membered monocyclic heterocyclyl, wherein the 5-7 membered monocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-7 membered monocyclic heterocyclyl, wherein the 5-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-7 membered monocyclic heterocyclyl, wherein the 5-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 5-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is substituted with 1-2 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 4-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and R^(9a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁹ is 6-10 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is C₃₋₅ monocyclic cycloalkyl, wherein the C₃₋₅ monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₁₋₅ alkyl, and 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is cyclopropyl, wherein the cyclopropyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, C₁₋₃ alkoxy, C₁₋₃ alkyl, and 5-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is cyclopropyl, wherein the cyclopropyl is substituted with morpholinyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is 4-7 membered monocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl is optionally         substituted with 1-3 groups independently selected from —OH,         halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, and     -   wherein the 4-7 membered monocyclic heterocyclyl has one or two         ring heteroatoms that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —NH₂, C₁₋₃ alkoxy, and C₁₋₃ alkyl, and wherein the 4-6 membered monocyclic heterocyclyl has one ring heteroatom that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl, and wherein the 4-6 membered monocyclic heterocyclyl has one ring heteroatom that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is azetidinyl or pyrrolidinyl, each of which is optionally substituted with 1-2 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is

each of which is optionally substituted with one methyl group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is oxetanyl, pyrrolidinyl, piperazinyl, or morpholinyl, each of which is optionally substituted with 1-3 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is pyrrolidinyl, piperazinyl, or morpholinyl, each of which is optionally substituted with 1-3 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is 8-10 membered fused bicyclic heterocyclyl,

-   -   wherein the 8-10 membered fused bicyclic heterocyclyl is         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅         alkyl, and     -   wherein the 8-10 membered fused bicyclic heterocyclyl has 1-3         ring heteroatoms independently selected from N and O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁹ independently is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is 6-10 membered bridged bicyclic heterocyclyl optionally substituted with 1-2 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl, and wherein the 6-10 membered bridged bicyclic heterocyclyl has one ring heteroatom that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is

each of which is optionally substituted with 1-3 groups independently selected from fluoro, methoxy, and methyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is a 7-10 membered spirocyclic heterocyclyl optionally substituted with 1-2 groups independently selected from —OH, halogen, C₁₋₃ alkoxy, and C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is a 9 membered spirocyclic heterocyclyl having 1-2 ring heteroatoms independently selected from N and O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁹ is

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁸ independently is —NR¹⁰R¹⁰ or —S(O)₂R^(5a).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —NR^(1O)R¹⁰. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R⁸ is —S(O)₂R^(5a).

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)NR⁶R⁷ or —S(O)₂R⁶.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —S(O)₂R⁶.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)NR⁶R⁷. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)N(H)R⁶. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)N(CH₃)R⁶.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b)         groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl or 4-7 membered monocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^(b)         groups,     -   wherein the 4-7 membered monocyclic heterocyclyl is optionally         substituted with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl or 4-7 membered monocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl is optionally substituted with 1-2 groups         independently selected from —OH, halogen, —NR¹¹R¹¹, and C₁₋₃         alkoxy,     -   wherein the 4-7 membered monocyclic heterocyclyl is optionally         substituted with 1-3 groups independently selected from —OH,         halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, and wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹².

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₄ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₄ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₆ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₄ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted with 1-3 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₄ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, and C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl optionally substituted with one —NR¹¹R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl substituted with one group independently selected from —NH₂, NH(CH₃), and N(CH₃)₂.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₁₋₄ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₇₋₁₀ fused bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is C₅₋₁₀ bridged bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁. 3 alkoxy, and C₁₋₃ alkyl, wherein the C₁₋₃ alkoxy and C₁₋₃ alkyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl, wherein the C₁₋₃ alkoxy and C₁₋₃ alkyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹².

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl, wherein the C₁₋₃ alkoxy and C₁₋₃ alkyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, —NR¹¹R¹¹, C₁₋₃ alkoxy, and C₁₋₃ alkyl, wherein the C₁₋₃ alkoxy and C₁₋₃ alkyl are each independently optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and —NR¹²R¹².

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 5-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 4-7 membered monocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl is optionally         substituted with 1-3 groups independently selected from —OH,         halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl,         wherein the C₁₋₄ alkoxy and C₁₋₅ alkyl are each independently         optionally substituted with 1-3 groups independently selected         from —OH, halogen, —CN, and —NR¹²R¹², and     -   wherein the 4-7 membered monocyclic heterocyclyl has one or two         ring heteroatoms that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 5-6 membered monocyclic heterocyclyl,

-   -   wherein the 5-6 membered heterocyclyl is optionally substituted         with 1-2 groups independently selected from —OH, halogen, —CN,         and C₁₋₅ alkyl, and     -   wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups         independently selected from —OH and halogen.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH and halogen.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one C₁₋₃ alkyl group, wherein the C₁₋₃ alkyl is optionally substituted with 1-2 groups independently selected from —OH and halogen.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is

each of which is optionally substituted with C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is substituted with one —OH group.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is phenyl, wherein the phenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is phenyl, wherein the phenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is phenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is naphthalenyl, wherein the naphthalenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is naphthalenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 5-6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 8-10 membered fused bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 6-10 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁶ is 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or 4-6 membered monocyclic heterocyclyl, wherein the C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, and 4-6 membered monocyclic heterocyclyl are each independently optionally substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is H or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is H or C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is H or methyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is H.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is methyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is 4-6 membered monocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl is substituted with 1-4 groups independently selected from —OH, halogen, —CN, and C₁₋₆ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is 4-6 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R⁷ is oxetanyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R¹³.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, 4-7 membered         monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are         each independently optionally substituted with 1-3 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are         each independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, and C₁₋₅ alkyl,         -   wherein the C₁₋₅ alkyl is optionally substituted with 1-3             groups independently selected from —OH, halogen, —CN, oxo,             and —NR¹²R¹².

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl, 8-10 membered         fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic         heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are         each independently optionally substituted with 1-3 groups         independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹,         C₁₋₄ alkoxy, and C₁₋₅ alkyl,         -   wherein the C₁₋₅ alkyl is optionally substituted with 1-2             groups independently selected from —OH, halogen, —CN, and             —NR¹²R¹², and         -   wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₃₋₇ monocyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₇₋₁₀ fused bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is C₅₋₁₀ bridged bicyclic cycloalkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl,

-   -   wherein the 4-7 membered monocyclic heterocyclyl is optionally         substituted with 1-3 groups independently selected from —OH,         halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, and     -   wherein the 4-7 membered monocyclic heterocyclyl has one or two         ring heteroatoms that is N.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 5-6 membered monocyclic heterocyclyl, wherein the 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 5-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is piperazinyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is phenyl, wherein the phenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is phenyl, wherein the phenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is phenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is naphthalenyl, wherein the naphthalenyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is naphthalenyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 5-6 membered monocyclic heteroaryl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 8-10 membered fused bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 6-10 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 groups independently selected from —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, and C₁₋₅ alkyl, wherein the C₁₋₅ alkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, oxo, and —NR¹²R¹², and wherein each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹³ is 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R⁵ independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is C₂₋₆ alkynyl, wherein the C₂₋₆ alkynyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is phenyl, wherein the phenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁵ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹⁰ independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹⁰ independently is H or 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹⁰ is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R¹⁰ is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹⁰ independently is H or C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹⁰ independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₂₋₆ alkynyl, wherein the C₂₋₆ alkynyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is phenyl, wherein the phenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R¹⁰ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹⁰ independently is H or 4-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹⁰ independently is H or oxetanyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(5a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-4 R^(b) groups,     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(5a) independently is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(5a) independently is 4-7 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is C₂₋₆ alkynyl, wherein the C₂₋₆ alkynyl is optionally substituted with 1-4 R^(b) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is phenyl, wherein the phenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-4 R^(a) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(5a) is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-4 R^(a) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R^(5a) is 4-6 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R^(5a) is piperazinyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(a) independently is oxo, imino, halogen, —NO₂, —N₃, —CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —NR¹¹R¹¹, —N(R¹¹)₂(R¹¹)⁺, —N(R¹¹)C(O)R¹¹, —N(R¹¹)C(O)OR¹¹, —N(R¹¹)C(O)N(R¹¹)(R¹¹), —N(R¹¹)S(O)₂(R^(11a)) —NR¹¹S(O)₂N(R¹¹)(R¹¹) —NR¹¹S(O)₂O(R^(11a)) —OC(O)R¹¹, —OC(O)OR¹¹, —OC(O)N(R¹¹)(R¹), —SR¹¹, —S(O)R^(11a), —S(O)(NH)R¹¹, —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), or —N═S(R^(11a))(R^(11a))═O,

-   -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         independently optionally substituted with 1-3 R^(c) groups, and     -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-3 R^(d) groups.

In some embodiments of a compound of Formula I or II or II, or a pharmaceutically acceptable salt thereof, each R^(a) independently is —OH, halogen, —CN, oxo, —NR¹¹R¹, C₁₋₄ alkoxy, or C₁₋₅ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(a) independently is —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₃ alkoxy, or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is oxo. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is imino. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is halogen. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —NO₂. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —N₃. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —CN. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —C(O)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —C(O)OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —C(O)N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —NR¹¹R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —N(R¹¹)₂(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —N(R¹¹)C(O)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —N(R¹¹)C(O)OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —N(R¹¹)C(O)N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —N(R¹¹)S(O)₂(R^(11a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —NR¹¹S(O)₂N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —NR¹¹S(O)₂O(R^(11a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —OC(O)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —OC(O)OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —OC(O)N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —SR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —S(O)R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —S(O)(NH)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —S(O)₂R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —S(O)₂N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is —N═S(R^(11a))(R^(11a))═O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is C₂₋₆ alkynyl, wherein the C₂₋₆ alkynyl is optionally substituted with 1-3 R^(c) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is phenyl, wherein the phenyl is optionally substituted with 1-3 R^(d)groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(a) is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 Rd groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(b) independently is oxo, imino, halogen, —NO₂, —N₃, —CN, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹¹, —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)(R¹¹), —NR¹¹R¹¹, —N(R¹¹)₂(R¹¹)⁺, —N(R¹¹)C(O)R¹¹, —N(R¹¹)C(O)OR¹¹, —N(R¹¹)C(O)N(R¹¹)(R¹¹), —N(R¹¹)S(O)₂(R^(11a)) —NR¹¹S(O)₂N(R¹¹)(R¹¹), —NR¹¹S(O)₂O(R^(11a)) —OC(O)R¹¹, —OC(O)OR¹¹, —OC(O)N(R¹¹)(R¹¹), —SR¹¹, —S(O)R^(11a), —S(O)(NH)R¹¹, —S(O)₂R^(11a), —S(O)₂N(R¹¹)(R¹¹), or —N═S(R^(11a))(R^(11a))═O,

-   -   wherein the C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic         cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl,         naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered         monocyclic heteroaryl, 8-10 membered fused bicyclic         heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10         membered fused bicyclic heteroaryl, and 7-10 membered         spirocyclic heterocyclyl are each independently optionally         substituted with 1-3 R^(d) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(b) independently is —OH, halogen, —CN, oxo, —NR¹¹R¹¹, C₁₋₄ alkoxy, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(b) independently is —OH, halogen, —CN, oxo, —NR¹¹R¹¹, —C(O)N(R¹¹)(R¹¹), C₁₋₄ alkoxy, or 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(b) independently is —OH, halogen, —CN, oxo, —NR¹¹R¹¹, or C₁₋₄ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(b) independently is —OH, halogen, —CN, oxo, —NR¹¹R¹¹, or C₁₋₃ alkoxy. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(b) independently is halogen or C₁₋₃ alkoxy.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(b) independently is 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, or 6-10 membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 5-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 8-10 membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 6-10 membered bridged bicyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is oxo. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is imino. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is halogen. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —NO₂. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —N₃. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —CN. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —C(O)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —C(O)OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —C(O)N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —NR¹¹R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —N(R¹¹)₂(R¹¹)⁺. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —N(R¹¹)C(O)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —N(R¹¹)C(O)OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —N(R¹¹)C(O)N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —N(R¹¹)S(O)₂(R^(11a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —NR¹¹S(O)₂N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —NR¹¹S(O)₂O(R^(11a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —OC(O)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —OC(O)OR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —OC(O)N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —SR¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —S(O)R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —S(O)(NH)R¹¹. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —S(O)₂R^(11a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —S(O)₂N(R¹¹)(R¹¹). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is —N═S(R^(11a))(R^(11a))═O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is phenyl, wherein the phenyl is optionally substituted with 1-3 R^(d)groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 R^(d) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(b) is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 Rd groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R independently is halogen, —CN, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹², —C(O)R¹², —C(O)OR¹², —C(O)N(R¹²)(R¹²), —NR¹²R¹² —N(R¹²)₂(R¹²)⁺, —N(R¹²)C(O)R¹², —N(R¹²)C(O)OR¹², —N(R¹²)C(O)N(R¹²)(R¹²), —N(R¹²)S(O)₂(R^(12a)) —NR¹²S(O)₂N(R¹²)(R¹²), —NR¹²S(O)₂O(R^(12a)), —OC(O)R¹², —OC(O)OR¹², —OC(O)N(R¹²)(R¹²), —SR¹², —S(O)R^(12a), —S(O)(NH)R¹², —S(O)₂R^(12a), —S(O)₂N(R¹²)(R¹²), or —N═S(R^(12a))(R^(12a))═O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is halogen. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —CN. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁸ is C₇₋₁₀ fused bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is C₅₋₁₀ bridged bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is phenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is naphthalenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁸ is 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is 8-10 membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is 6-10 membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is 8-10 membered fused bicyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁸ is 7-10 membered spirocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —C(O)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —C(O)OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —C(O)N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —N(R¹²)₂(R¹²)⁺. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —N(R¹²)C(O)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —N(R¹²)C(O)OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —N(R¹²)C(O)N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —N(R²)S(O)₂(R^(12a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —NR¹²S(O)₂N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —NR¹²S(O)₂O(R^(12a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —OC(O)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —OC(O)OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —OC(O)N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R⁸ is —SR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —S(O)R^(12a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R is —S(O)(NH)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —S(O)₂R^(12a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R is —S(O)₂N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R is —N═S(R^(12a))(R^(12a))═O.

In some embodiments of a compound of Formula I or II or II, or a pharmaceutically acceptable salt thereof, each R^(c) independently is —OH, halogen, —CN, oxo, or —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R independently is —OH, halogen, —CN, or —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is —OH. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(c) is halogen.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(d) independently is oxo, halogen, —CN, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, —OR¹², —C(O)R¹², —C(O)OR¹², —C(O)N(R¹²)(R¹²), —NR¹²R¹² —N(R¹²)₂(R¹²)⁺, —N(R¹²)C(O)R¹², —N(R¹²)C(O)OR¹², —N(R¹²)C(O)N(R¹²)(R¹²), —N(R¹²)S(O)₂(R^(12a)) —NR¹²S(O)₂N(R¹²)(R¹²), —NR¹²S(O)₂O(R^(12a)), —OC(O)R¹², —OC(O)OR¹², —OC(O)N(R¹²)(R¹²), —SR¹², —S(O)R^(12a), —S(O)(NH)R¹², —S(O)₂R^(12a), —S(O)₂N(R¹²)(R¹²), or —N═S(R^(12a))(R^(12a))═O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is oxo. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is halogen. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —CN. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is C₇₋₁₀ fused bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is C₅₋₁₀ bridged bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is phenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is naphthalenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is 8-10 membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is 6-10 membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is 8-10 membered fused bicyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is 7-10 membered spirocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —C(O)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —C(O)OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —C(O)N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —N(R¹²)₂(R¹²)⁺. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —N(R¹²)C(O)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —N(R¹²)C(O)OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —N(R¹²)C(O)N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —N(R¹²)S(O)₂(R^(12a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —NR¹²S(O)₂N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —NR¹²S(O)₂O(R^(12a)). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —OC(O)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d)is —OC(O)OR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —OC(O)N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —SR¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —S(O)R^(12a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —S(O)(NH)R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —S(O)₂R^(12a). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(d) is —S(O)₂N(R¹²)(R¹²). In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more Rd is —N═S(R^(12a))(R^(12a))═O.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇         monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀         bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered         monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl,         8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged         bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl,         and 7-10 membered spirocyclic heterocyclyl are each         independently optionally substituted with 1-3 R^(c) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ independently is H, C₁₋₆ alkyl, C₃₋₇ monocyclic cycloalkyl, or 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ independently is H or C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with one group selected from —OH and —NR¹²R¹². In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ independently is H or C₁₋₄ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ independently is H or C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ independently is H or methyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ independently is H, C₁₋₄ alkyl, C₃₋₅ monocyclic cycloalkyl, or 4-6 membered monocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹¹ of —NR¹¹R¹¹ and —C(O)NR¹¹R¹¹ independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is methyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is C₂₋₆ alkynyl, wherein the C₂₋₆ alkynyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is phenyl, wherein the phenyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(11a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

-   -   wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇         monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀         bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered         monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl,         8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged         bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl,         and 7-10 membered spirocyclic heterocyclyl are each         independently optionally substituted with 1-3 R^(c) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(11a) independently is C₁₋₄ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R^(11a) is C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is C₂₋₆ alkenyl, wherein the C₂₋₆ alkenyl is optionally substituted with 1-3 R groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is C₂₋₆ alkynyl, wherein the C₂₋₆ alkynyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is C₃₋₇ monocyclic cycloalkyl, wherein the C₃₋₇ monocyclic cycloalkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is C₇₋₁₀ fused bicyclic cycloalkyl, wherein the C₇₋₁₀ fused bicyclic cycloalkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is C₅₋₁₀ bridged bicyclic cycloalkyl, wherein the C₅₋₁₀ bridged bicyclic cycloalkyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is phenyl, wherein the phenyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is naphthalenyl, wherein the naphthalenyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is 8-10 membered fused bicyclic heterocyclyl, wherein the 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is 6-10 membered bridged bicyclic heterocyclyl, wherein the 6-10 membered bridged bicyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(11a) is 8-10 membered fused bicyclic heteroaryl, wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 R^(c) groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹¹ is 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is optionally substituted with 1-3 R^(c) groups.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹² independently is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R¹² independently is H or C₁₋₄ alkyl. In some embodiments of a compound of Formula I or II or II, or a pharmaceutically acceptable salt thereof, each R¹² independently is H or C₁₋₃ alkyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₁₋₄ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₁₋₃ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₂₋₆ alkenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₂₋₆ alkynyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₃₋₇ monocyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₇-1o fused bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is C₅₋₁₀ bridged bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is phenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is naphthalenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is 8-10 membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is 6-10 membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is 8-10 membered fused bicyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R¹² is 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R^(12a) independently is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ monocyclic cycloalkyl, C₇₋₁₀ fused bicyclic cycloalkyl, C₅₋₁₀ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl.

In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is C₁₋₆ alkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is C₂₋₆ alkenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is C₂₋₆ alkynyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is C₃₋₇ monocyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is C₇₋₁₀ fused bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is C₅₋₁₀ bridged bicyclic cycloalkyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is phenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is naphthalenyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is 4-7 membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12′) is 5-6 membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is 8-10 membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is 6-10 membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is 8-10 membered fused bicyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or more R^(12a) is 7-10 membered spirocyclic heterocyclyl.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consist mg of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound that is:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound that is:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound that is:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound that is:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound that is:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound that is:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound that is:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

III. Compositions and Kits

Compounds provided herein, or pharmaceutically acceptable salts thereof, are usually administered in the form of pharmaceutical compositions. Thus, provided herein are also pharmaceutical compositions that comprise one or more of the compounds provided herein or pharmaceutically acceptable salts, isomer, or a mixture thereof and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. The compounds provided herein, or pharmaceutically acceptable salts thereof, may be the sole active ingredient or one of the active ingredients of the pharmaceutical compositions. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.).

In one embodiment, provided herein are pharmaceutical compositions comprising a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In some embodiments, the pharmaceutical compositions comprise a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

In some embodiments, the pharmaceutical compositions provided herein further comprise one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions further comprise a therapeutically effective amount of the one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents, or a pharmaceutically acceptable salt thereof.

In some embodiments, the one or more additional therapeutic agents comprises an anti-malarial agent. In some embodiments, the anti-malarial agent is selected from chloroquine and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.

In some embodiments, the one or more additional therapeutic agents include agents that are therapeutic for an inflammatory condition. In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of: veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, theralizumab, daxdilimab, TAK-079, felzartamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacotuzumab, vobarilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, rozibafusp alfa, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, atacicept, telitacicept, BMS-986256, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, valziflocept, LA-1, cenerimod, prednisone, corticotropin, deucravacitinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, julemic acid, iberdomide, TAM-01, BML-258, brepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, dalazatide, GSK-2646264, SKI-O-703, lanraplenib (GS-9876), GNS-1653, HIMPL-523, RSLV-132, interleukin-2 follow-on biologic, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, elsubrutinib, orelabrutinib, DWP-213388, INV-103, R-salbutamol sulphate, anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, as mometasone, betamethasone, forigerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSCs), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combinations thereof.

The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical compositions may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes. In some embodiments, the pharmaceutical compositions may be administered by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

One mode for administration is parenteral, for example, by injection. The forms in which the pharmaceutical compositions described herein may be incorporated for administration by injection include, for example, aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. In some embodiments, the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions disclosed herein are administered by subcutaneous injection.

The pharmaceutical compositions of the present disclosure may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

In some embodiments, the sterile injectable preparation disclosed herein may also be a sterile injectable solution or suspension prepared from a reconstituted lyophilized powder in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. In certain embodiments the suspension is a microsuspension. In certain embodiments the suspension is a nanosuspension.

In some embodiments, formulations suitable for parenteral administration (e.g., intramuscular (IM) and subcutaneous (SC) administration) will include one or more excipients. Excipients should be compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof. Examples of suitable excipients are well known to the person skilled in the art of parenteral formulation and may be found e.g., in Handbook of Pharmaceutical Excipients (eds. Rowe, Sheskey & Quinn), 6th edition 2009. Examples of solubilizing excipients in a parenteral formulation (e.g., an SC or IM formulation) include, but are not limited to, polysorbates (such as polysorbate 20 or 80) and poloxamers (such as poloxamer 338, 188, or 207).

In some embodiments, the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions disclosed herein are administered with implants.

Oral administration may be another route for administration of the compounds provided herein or pharmaceutically acceptable salts thereof. Administration may be via, for example, capsule or enteric coated tablets. In making the pharmaceutical compositions that include at least one compound provided herein or pharmaceutically acceptable salts, isomer, or a mixture thereof, the active ingredient (such as a compound provided herein) is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the pharmaceutical compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose or any combinations thereof. The pharmaceutical compositions can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents; or any combinations thereof.

The pharmaceutical compositions that include at least one compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof can be formulated so as to provide quick, sustained or delayed release of the active ingredient (such as a compound provided herein) after administration to the subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another formulation for use in the methods of the present disclosure employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds provided herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof. When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.

The tablets or pills of the compounds provided herein or pharmaceutically acceptable salts thereof may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

Pharmaceutical compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In other embodiments, compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tert, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.

In one embodiment, provided herein are kits that comprise a compound provided herein, (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt, stereoisomer, prodrug, or solvate thereof, and suitable packaging. In some embodiments, the kit further comprises instructions for use. In some embodiments, the kit comprises a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt, stereoisomer, prodrug, or solvate thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.

In some embodiments, the kits further comprise one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents, or a pharmaceutically acceptable salt thereof.

In one embodiment, provided herein are articles of manufacture that comprise a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof in a suitable container. In some embodiments, the container may be a vial, jar, ampoule, preloaded syringe, or intravenous bag.

IV. Methods

The methods provided herein may be applied to cell populations in vivo or ex vivo. “In vivo” means within a living individual, as within an animal or human. In this context, the methods provided herein may be used therapeutically in an individual. “Ex vivo” means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the present disclosure may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the present disclosure may be used ex vivo to determine the optimal schedule and/or dosing of administration of a TLR 7, 8, and/or 9 inhibitor as disclosed herein for a given cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the present disclosure may be suited are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.

In one embodiment, the present disclosure provides a method of inhibiting toll-like receptor 7, 8, and/or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 7, 8, and 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 7, 8, or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 7 and 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 7 or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7, 8, and/or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7, 8, and 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7, 8, or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7 and 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7 or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

Non-limiting examples of an inflammatory condition include, without limitation, acne, acid-induced lung injury, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, adult-onset Still's disease, adult respiratory distress syndrome (ARDS), age-related macular degeneration, aging, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, allergic conjunctivitis, allergic contact dermatitis, allergies, allergic encephalomyelitis, allergic neuritis, allograft rejection, alopecia, alopecia areata, Alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, angina pectoris, angioedema, angiofibroma, anhidrotic ectodermal dysplasia-ill, anti-glomerular basement membrane disease, antigen-antibody complex mediated diseases, ankylosing spondylitis, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, ascites, aspergillosis, asthma, atherosclerosis, atherosclerotic plaques, atopic dermatitis, atrophic thyroiditis, autoimmune diseases, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune polyendocrinopathies, autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), autoimmune hepatitis, autoimmune thyroid disorders, autoinflammatory diseases, back pain, Bacillus anthracis infection, Bechet's disease, bee sting-induced inflammation, Behget's syndrome, Bell's palsy, berylliosis, Blau syndrome, bone pain, bronchiolitis, bullous pemphigoid (BP) asthma, burns, bursitis, cardiac hypertrophy, carpal tunnel syndrome, Castleman's disease, catabolic disorders, cataracts, Celiac disease, cerebral aneurysm, chemical irritant-induced inflammation, chorioretinitis, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, chronic heart failure, chronic lung disease of prematurity, chronic obstructive pulmonary disease (COPD), chronic pancreatitis, chronic prostatitis, chronic recurrent multifocal osteomyelitis, cicatricial alopecia, colitis, complex regional pain syndrome, complications of organ transplantation, conjunctivitis, connective tissue disease, contact dermatitis, corneal graft neovascularization, corneal ulcer, Crohn's disease, cryopyrin-associated periodic syndromes, cutaneous lupus erythematosus (CLE), cryptococcosis, cystic fibrosis, deficiency of the interleukin-1 receptor antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diabetic macular edema, diverticulitis, eczema, encephalitis, endometriosis, endotoxemia, eosinophilic pneumonias, epicondylitis, epidermolysis bullosa, erythema multiforme, erythroblastopenia, esophagitis, familial amyloidotic polyneuropathy, familial cold urticarial, familial Mediterranean fever, fetal growth retardation, fibromyalgia, fistulizing Crohn's disease, food allergies, giant cell arteritis, glaucoma, glioblastoma, glomerular disease, glomerular nephritis, glomerulonephritis, gluten-sensitive enteropathy, gout, gouty arthritis, graft-versus-host disease (GVHD), granulomatous hepatitis, Graves' disease, growth plate injuries, Guillain-Barre syndrome, gut diseases, hair loss, Hashimoto's thyroiditis, head injury, headache, hearing loss, heart disease, hemangioma, hemolytic anemia, hemophilic joints, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, heritable disorders of connective tissue, herpes zoster and simplex, hidradenitis suppurativa (HS), hip replacement, Hodgkin's disease, Huntington's disease, hyaline membrane disease, hyperactive inflammatory response, hyperammonemia, hypercalcemia, hypercholesterolemia, hypereosinophilic syndrome (HES), hyperimmunoglobulinemia D with recurrent fever (HIDS), hypersensitivity pneumonitis, hypertropic bone formation, hypoplastic and other anemias, hypoplastic anemia, ichthyosis, idiopathic demyelinating polyneuropathy, Idiopathic inflammatory myopathies (dermatomyositis, polymyositis), idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, immunoglobulin nephropathies, immune complex nephritis, immune thrombocytopenic purpura (ITP), incontinentia pigmenti (IP, Bloch-Siemens syndrome), infectious mononucleosis, infectious diseases including viral diseases such as AIDS (HIV infection), hepatitis A, B, C, D, and E, herpes; inflammation, inflammation of the CNS, inflammatory bowel disease (IBD), inflammatory disease of the lower respiratory tract including bronchitis or chronic obstructive pulmonary diseases, inflammatory disease of the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis, inflammatory diseases of the respiratory tract, inflammatory ischemic event such as stroke or cardiac arrest, inflammatory lung disease, inflammatory myopathy such as myocarditis, inflammatory liver disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, interstitial cystitis, interstitial lung disease, iritis, irritant-induced inflammation, ischemia/reperfusion, joint replacement, juvenile arthritis, juvenile rheumatoid arthritis, keratitis, kidney injury caused by parasitic infections, kidney transplant rejection, leptospirosis, leukocyte adhesion deficiency, lichen sclerosus (LS), Lambert-Eaton myasthenic syndrome, Loeffler's syndrome, lupus, lupus nephritis, Lyme disease, Marfan syndrome (MFS), mast cell activation syndrome, mastocytosis, meningitis, meningioma, mesothelioma, mixed connective tissue disease, Muckle-Wells syndrome (urticaria deafness amyloidosis), mucositis, multiple organ injury syndrome, multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis (MG), myelodysplastic syndrome, myocarditis, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), neovascular glaucoma, nephrotic syndrome, neuritis, neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant rejection, Osier-Weber syndrome, osteoarthritis, osteogenesis imperfecta, osteonecrosis, osteoporosis, osterarthritis, otitis, pachyonychia congenita, Paget's disease, Paget's disease of bone, pancreatitis, Parkinson's disease, pediatric rheumatology, pelvic inflammatory disease, pemphigus, pemphigus vulgaris (PV), bullous pemphigoid (BP), pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pernicious anemia (Addison's disease), pertussis, PFAPA (periodic fever aphthous pharyngitis and cervical adenopathy), pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumocystis infection, pneumonia, pneumonitis, poison ivy/urushiol oil-induced inflammation, polyarthritis nodosa, polychondritis, polycystic kidney disease, polymyalgia rheumatic, giant cell arteritis, polymyositis, pouchitis, reperfusion injury and transplant rejection, primary biliary cirrhosis, primary pulmonary hypertension, primary sclerosing cholangitis (PSC), proctitis, psoriasis, psoriasis vulgaris, psoriatic arthritis, psoriatic epidermis, psychosocial stress diseases, pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, pyogenic granuloma retrolental fibroplasias, pyogenic sterile arthritis, Raynaud's syndrome, Reiter's disease, reactive arthritis, renal disease, renal graft rejection, reperfusion injury, respiratory distress syndrome, retinal disease, retrolental fibroplasia, Reynaud's syndrome, rheumatic carditis, rheumatic diseases, rheumatic fever, rheumatoid arthritis, rhinitis, rhinitis psoriasis, rosacea, sarcoidosis, Schnitzler syndrome, scleritis, sclerosis, scleroderma, scoliosis, seborrhea, sepsis, septic shock, severe pain, Sezary syndrome, sickle cell anemia, silica-induced disease (Silicosis), Sjögren's syndrome, skin diseases, skin irritation, skin rash, skin sensitization (contact dermatitis or allergic contact dermatitis), sleep apnea, spinal cord injury, spinal stenosis, spondyloarthropathies, sports injuries, sprains and strains, Stevens-Johnson syndrome (SJS), stroke, subarachnoid hemorrhage, sunburn, synovial inflammation, systemic inflammatory response syndrome (SIRS), systemic lupus erythematosus (SLE), systemic mast cell disease (SMCD), systemic vasculitis, systemic-onset juvenile idiopathic arthritis, temporal arteritis, tendinitis, tenosynovitis, thrombocytopenia, thyroditis, thyroiditis, tissue transplant, toxoplasmosis, trachoma, transplantation rejection, traumatic brain injury, tuberculosis, tubulointerstitial nephritis, tumor necrosis factor (TNF) receptor associated periodic syndrome (TRAPS), type 1 diabetes, type 2 diabetes, complications from type 1 or type 2 diabetes, ulcerative colitis, urticaria, uterine fibroids, uveitis, uveoretinitis, vascular restenosis, vasculitis, vasculitis (NHLBI), vitiligo, Wegener's granulomatosis, and Whipple's disease.

In some embodiments, the inflammatory condition is selected from inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed connective tissue disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, antineutrophil cytoplasmic antibody-associated vasculitis, anti-phospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome driven inflammatory anemia, IgA nephropathy, type I diabetes, non-alcoholic steatohepatitis, and Sjögren's syndrome. In some embodiments, the inflammatory condition is inflammatory bowel disease. In some embodiments, the inflammatory condition is psoriasis. In some embodiments, the inflammatory condition is psoriatic arthritis. In some embodiments, the inflammatory condition is rheumatoid arthritis. In some embodiments, the inflammatory condition is glomerulonephritis. In some embodiments, the inflammatory condition is mixed connective tissue disease (MCTD). In some embodiments, the inflammatory condition is dermatomyositis. In some embodiments, the inflammatory condition is polymyositis. In some embodiments, the inflammatory condition is systemic sclerosis. In some embodiments, the inflammatory condition is antineutrophil cytoplasmic antibody-associated vasculitis. In some embodiments, the inflammatory condition is anti-phospholipid syndrome. In some embodiments, the inflammatory condition is autoimmune hemolytic anemia. In some embodiments, the inflammatory condition is macrophage activation syndrome driven inflammatory anemia. In some embodiments, the inflammatory condition is IgA nephropathy. In some embodiments, the inflammatory condition is type I diabetes. In some embodiments, the inflammatory condition is non-alcoholic steatohepatitis. In some embodiments, the inflammatory condition is Sjögren's syndrome.

The compounds provided herein, or pharmaceutically acceptable salts thereof, or the pharmaceutical composition provided herein may treat or ameliorate systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, lupus-related, symptom of SLE, symptom of CLE, or other autoimmune disorder. Symptoms of systemic lupus erythematosus include joint pain, joint swelling, arthritis, fatigue, hair loss, mouth sores, swollen lymph nodes, sensitivity to sunlight, skin rash, headaches, numbness, tingling, seizures, vision problems, personality changes, abdominal pain, nausea, vomiting, abnormal heart rhythms, coughing up blood and difficulty breathing, patchy skin color and Raynaud's phenomenon.

In one embodiment, the present disclosure provides a method of treating systemic lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating cutaneous lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a method of treating lupus nephritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In some embodiments, the methods provided herein further comprise administering a therapeutically effective amount of one or more additional therapeutic agents, or a pharmaceutically acceptable salt thereof.

In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, theralizumab, daxdilimab, TAK-079, felzartamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacotuzumab, vobarilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, rozibafusp alfa, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256 (afimetoran), NKTR-35, atacicept, telitacicept, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, valziflocept, LA-1, cenerimod, prednisone, corticotropin, deucravacitinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, julemic acid, iberdomide, TAM-01, BML-258, brepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, dalazatide, GSK-2646264, SKI-O-703, lanraplenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 follow-on biologic, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, elsubrutinib, orelabrutinib, DWP-213388, INV-103, R-salbutamol sulphate, anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, as mometasone, betamethasone, forigerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSCs), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, corticosteroids, azathioprine, mycophenolate mofetil, methotrexate, cyclophosamide, rituximab, nonsteroidal anti-inflammaotry drugs, belimumab, voclosporin, and AMG-592, or a pharmaceutically acceptable salt thereof.

In some embodiments, corticosteroids include but are not limited to prednisone and other drugs that suppress the immune system. In some embodiments, nonsteroidal anti-inflammatory drugs include but are not limited to ibuprofen and naproxen.

In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, theralizumab, daxdilimab, TAK-079, felzartamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacotuzumab, vobarilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, rozibafusp alfa, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, atacicept, telitacicept, BMS-986256, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, valziflocept, LA-1, cenerimod, prednisone, corticotropin, deucravacitinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, julemic acid, iberdomide, TAM-01, BML-258, brepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, dalazatide, GSK-2646264, SKI-O-703, lanraplenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 follow-on biologic, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, elsubrutinib, orelabrutinib, DWP-213388, INV-103, R-salbutamol sulphate, anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, as mometasone, betamethasone, forigerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSCs), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

In some embodiments, the one or more additional therapeutic agents is selected from chloroquine and hydroxychloroquine, or a pharmaceutically acceptable salt thereof. In some embodiments, the one or more additional therapeutic agents is chloroquine. In some embodiments, the one or more additional therapeutic agents is hydroxychloroquine. In some embodiments, the one or more additional therapeutic agent is a pharmaceutically acceptable salt of hydroxychloroquine. In some embodiments, the one or more additional therapeutic agent is hydroxychloroquine sulfate.

In some embodiments of the methods provided herein, the subject is a human.

In some embodiments, the methods provided herein comprise administering a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof. In some embodiments, the methods provided herein comprise administering a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein for use in therapy.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting toll-like receptor 7, 8, and/or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of inhibiting toll-like receptor 7, 8, and 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of inhibiting toll-like receptor 7, 8, or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of inhibiting toll-like receptor 7 and 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of inhibiting toll-like receptor 7 or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of inhibiting toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7, 8, and/or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7, 8, and 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7, 8, or 9 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 and/or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 and 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 or 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. In some embodiments, the compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided herein is for use in a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

Non-limiting examples of an inflammatory condition include, without limitation, acne, acid-induced lung injury, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, adult-onset Still's disease, adult respiratory distress syndrome (ARDS), age-related macular degeneration, aging, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, allergic conjunctivitis, allergic contact dermatitis, allergies, allergic encephalomyelitis, allergic neuritis, allograft rejection, alopecia, alopecia areata, Alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, angina pectoris, angioedema, angiofibroma, anhidrotic ectodermal dysplasia-ill, anti-glomerular basement membrane disease, antigen-antibody complex mediated diseases, ankylosing spondylitis, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, ascites, aspergillosis, asthma, atherosclerosis, atherosclerotic plaques, atopic dermatitis, atrophic thyroiditis, autoimmune diseases, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune polyendocrinopathies, autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), autoimmune hepatitis, autoimmune thyroid disorders, autoinflammatory diseases, back pain, Bacillus anthracis infection, Bechet's disease, bee sting-induced inflammation, Behget's syndrome, Bell's palsy, berylliosis, Blau syndrome, bone pain, bronchiolitis, bullous pemphigoid (BP) asthma, burns, bursitis, cardiac hypertrophy, carpal tunnel syndrome, Castleman's disease, catabolic disorders, cataracts, Celiac disease, cerebral aneurysm, chemical irritant-induced inflammation, chorioretinitis, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, chronic heart failure, chronic lung disease of prematurity, chronic obstructive pulmonary disease (COPD), chronic pancreatitis, chronic prostatitis, chronic recurrent multifocal osteomyelitis, cicatricial alopecia, colitis, complex regional pain syndrome, complications of organ transplantation, conjunctivitis, connective tissue disease, contact dermatitis, corneal graft neovascularization, corneal ulcer, Crohn's disease, cryopyrin-associated periodic syndromes, cutaneous lupus erythematosus (CLE), cryptococcosis, cystic fibrosis, deficiency of the interleukin-1 receptor antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diabetic macular edema, diverticulitis, eczema, encephalitis, endometriosis, endotoxemia, eosinophilic pneumonias, epicondylitis, epidermolysis bullosa, erythema multiforme, erythroblastopenia, esophagitis, familial amyloidotic polyneuropathy, familial cold urticarial, familial Mediterranean fever, fetal growth retardation, fibromyalgia, fistulizing Crohn's disease, food allergies, giant cell arteritis, glaucoma, glioblastoma, glomerular disease, glomerular nephritis, glomerulonephritis, gluten-sensitive enteropathy, gout, gouty arthritis, graft-versus-host disease (GVHD), granulomatous hepatitis, Graves' disease, growth plate injuries, Guillain-Barre syndrome, gut diseases, hair loss, Hashimoto's thyroiditis, head injury, headache, hearing loss, heart disease, hemangioma, hemolytic anemia, hemophilic joints, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, heritable disorders of connective tissue, herpes zoster and simplex, hidradenitis suppurativa (HS), hip replacement, Hodgkin's disease, Huntington's disease, hyaline membrane disease, hyperactive inflammatory response, hyperammonemia, hypercalcemia, hypercholesterolemia, hypereosinophilic syndrome (HES), hyperimmunoglobulinemia D with recurrent fever (HIDS), hypersensitivity pneumonitis, hypertropic bone formation, hypoplastic and other anemias, hypoplastic anemia, ichthyosis, idiopathic demyelinating polyneuropathy, Idiopathic inflammatory myopathies (dermatomyositis, polymyositis), idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, immunoglobulin nephropathies, immune complex nephritis, immune thrombocytopenic purpura (ITP), incontinentia pigmenti (IP, Bloch-Siemens syndrome), infectious mononucleosis, infectious diseases including viral diseases such as AIDS (HIV infection), hepatitis A, B, C, D, and E, herpes; inflammation, inflammation of the CNS, inflammatory bowel disease (IBD), inflammatory disease of the lower respiratory tract including bronchitis or chronic obstructive pulmonary diseases, inflammatory disease of the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis, inflammatory diseases of the respiratory tract, inflammatory ischemic event such as stroke or cardiac arrest, inflammatory lung disease, inflammatory myopathy such as myocarditis, inflammatory liver disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, interstitial cystitis, interstitial lung disease, iritis, irritant-induced inflammation, ischemia/reperfusion, joint replacement, juvenile arthritis, juvenile rheumatoid arthritis, keratitis, kidney injury caused by parasitic infections, kidney transplant rejection, leptospirosis, leukocyte adhesion deficiency, lichen sclerosus (LS), Lambert-Eaton myasthenic syndrome, Loeffler's syndrome, lupus, lupus nephritis, Lyme disease, Marfan syndrome (MFS), mast cell activation syndrome, mastocytosis, meningitis, meningioma, mesothelioma, mixed connective tissue disease, Muckle-Wells syndrome (urticaria deafness amyloidosis), mucositis, multiple organ injury syndrome, multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis (MG), myelodysplastic syndrome, myocarditis, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), neovascular glaucoma, nephrotic syndrome, neuritis, neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant rejection, Osier-Weber syndrome, osteoarthritis, osteogenesis imperfecta, osteonecrosis, osteoporosis, osterarthritis, otitis, pachyonychia congenita, Paget's disease, Paget's disease of bone, pancreatitis, Parkinson's disease, pediatric rheumatology, pelvic inflammatory disease, pemphigus, pemphigus vulgaris (PV), bullous pemphigoid (BP), pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pernicious anemia (Addison's disease), pertussis, PFAPA (periodic fever aphthous pharyngitis and cervical adenopathy), pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumocystis infection, pneumonia, pneumonitis, poison ivy/urushiol oil-induced inflammation, polyarthritis nodosa, polychondritis, polycystic kidney disease, polymyalgia rheumatic, giant cell arteritis, polymyositis, pouchitis, reperfusion injury and transplant rejection, primary biliary cirrhosis, primary pulmonary hypertension, primary sclerosing cholangitis (PSC), proctitis, psoriasis, psoriasis vulgaris, psoriatic arthritis, psoriatic epidermis, psychosocial stress diseases, pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, pyogenic granuloma retrolental fibroplasias, pyogenic sterile arthritis, Raynaud's syndrome, Reiter's disease, reactive arthritis, renal disease, renal graft rejection, reperfusion injury, respiratory distress syndrome, retinal disease, retrolental fibroplasia, Reynaud's syndrome, rheumatic carditis, rheumatic diseases, rheumatic fever, rheumatoid arthritis, rhinitis, rhinitis psoriasis, rosacea, sarcoidosis, Schnitzler syndrome, scleritis, sclerosis, scleroderma, scoliosis, seborrhea, sepsis, septic shock, severe pain, Sezary syndrome, sickle cell anemia, silica-induced disease (Silicosis), Sjögren's syndrome, skin diseases, skin irritation, skin rash, skin sensitization (contact dermatitis or allergic contact dermatitis), sleep apnea, spinal cord injury, spinal stenosis, spondyloarthropathies, sports injuries, sprains and strains, Stevens-Johnson syndrome (SJS), stroke, subarachnoid hemorrhage, sunburn, synovial inflammation, systemic inflammatory response syndrome (SIRS), systemic lupus erythematosus (SLE), systemic mast cell disease (SMCD), systemic vasculitis, systemic-onset juvenile idiopathic arthritis, temporal arteritis, tendinitis, tenosynovitis, thrombocytopenia, thyroditis, thyroiditis, tissue transplant, toxoplasmosis, trachoma, transplantation rejection, traumatic brain injury, tuberculosis, tubulointerstitial nephritis, tumor necrosis factor (TNF) receptor associated periodic syndrome (TRAPS), type 1 diabetes, type 2 diabetes, complications from type 1 or type 2 diabetes, ulcerative colitis, urticaria, uterine fibroids, uveitis, uveoretinitis, vascular restenosis, vasculitis, vasculitis (NHLBI), vitiligo, Wegener's granulomatosis, and Whipple's disease.

In some embodiments, the inflammatory condition is selected from inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed connective tissue disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, antineutrophil cytoplasmic antibody-associated vasculitis, anti-phospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome driven inflammatory anemia, IgA nephropathy, type I diabetes, non-alcoholic steatohepatitis, and Sjögren's syndrome. In some embodiments, the inflammatory condition is inflammatory bowel disease. In some embodiments, the inflammatory condition is psoriasis. In some embodiments, the inflammatory condition is psoriatic arthritis. In some embodiments, the inflammatory condition is rheumatoid arthritis. In some embodiments, the inflammatory condition is glomerulonephritis. In some embodiments, the inflammatory condition is mixed connective tissue disease (MCTD). In some embodiments, the inflammatory condition is dermatomyositis. In some embodiments, the inflammatory condition is polymyositis. In some embodiments, the inflammatory condition is systemic sclerosis. In some embodiments, the inflammatory condition is antineutrophil cytoplasmic antibody-associated vasculitis. In some embodiments, the inflammatory condition is anti-phospholipid syndrome. In some embodiments, the inflammatory condition is autoimmune hemolytic anemia. In some embodiments, the inflammatory condition is macrophage activation syndrome driven inflammatory anemia. In some embodiments, the inflammatory condition is IgA nephropathy. In some embodiments, the inflammatory condition is type I diabetes. In some embodiments, the inflammatory condition is non-alcoholic steatohepatitis. In some embodiments, the inflammatory condition is Sjögren's syndrome.

The compounds provided herein, or pharmaceutically acceptable salts thereof, or the pharmaceutical composition provided herein may treat or ameliorate systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, lupus-related, symptom of SLE, symptom of CLE, or other autoimmune disorder. Symptoms of systemic lupus erythematosus include joint pain, joint swelling, arthritis, fatigue, hair loss, mouth sores, swollen lymph nodes, sensitivity to sunlight, skin rash, headaches, numbness, tingling, seizures, vision problems, personality changes, abdominal pain, nausea, vomiting, abnormal heart rhythms, coughing up blood and difficulty breathing, patchy skin color and Raynaud's phenomenon.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating systemic lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In one embodiment, the present disclosure provides a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating cutaneous lupus erythematosus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

In some embodiments, the uses provided herein further comprise administering a therapeutically effective amount of one or more additional therapeutic agents, or a pharmaceutically acceptable salt thereof.

In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, theralizumab, daxdilimab, TAK-079, felzartamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacotuzumab, vobarilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, rozibafusp alfa, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256 (afimetoran), NKTR-35, atacicept, telitacicept, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, valziflocept, LA-1, cenerimod, prednisone, corticotropin, deucravacitinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, julemic acid, iberdomide, TAM-01, BML-258, brepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, dalazatide, GSK-2646264, SKI-O-703, lanraplenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 follow-on biologic, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, elsubrutinib, orelabrutinib, DWP-213388, INV-103, R-salbutamol sulphate, anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, as mometasone, betamethasone, forigerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSCs), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, corticosteroids, azathioprine, mycophenolate mofetil, methotrexate, cyclophosamide, rituximab, nonsteroidal anti-inflammaotry drugs, belimumab, voclosporin, and AMG-592, or a pharmaceutically acceptable salt thereof.

In some embodiments, corticosteroids include but are not limited to prednisone and other drugs that suppress the immune system. In some embodiments, nonsteroidal anti-inflammatory drugs include but are not limited to ibuprofen and naproxen.

In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, theralizumab, daxdilimab, TAK-079, felzartamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacotuzumab, vobarilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, rozibafusp alfa, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, atacicept, telitacicept, BMS-986256, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, valziflocept, LA-1, cenerimod, prednisone, corticotropin, deucravacitinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, julemic acid, iberdomide, TAM-01, BML-258, brepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, dalazatide, GSK-2646264, SKI-O-703, lanraplenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 follow-on biologic, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, elsubrutinib, orelabrutinib, DWP-213388, INV-103, R-salbutamol sulphate, anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, as mometasone, betamethasone, forigerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSCs), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

In some embodiments, the one or more additional therapeutic agents is selected from chloroquine and hydroxychloroquine, or a pharmaceutically acceptable salt thereof. In some embodiments, the one or more additional therapeutic agents is chloroquine. In some embodiments, the one or more additional therapeutic agents is hydroxychloroquine. In some embodiments, the one or more additional therapeutic agent is a pharmaceutically acceptable salt of hydroxychloroquine. In some embodiments, the one or more additional therapeutic agent is hydroxychloroquine sulfate.

In some embodiments of the uses provided herein, the subject is a human.

In some embodiments, the uses provided herein comprise administering a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula I or II), or a pharmaceutically acceptable salt thereof. In some embodiments, the methods provided herein comprise administering a therapeutically effective amount of a pharmaceutical composition provided herein.

V. Administration

The compounds of the present disclosure or pharmaceutically acceptable salts thereof (also referred to herein as the active ingredients) can be administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with, for example, the condition of the recipient. An advantage of certain compounds disclosed herein, or pharmaceutically acceptable salts thereof, is that they are orally bioavailable and can be dosed orally.

A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In some embodiments, the compound, or a pharmaceutically acceptable salt thereof, is administered on a daily or intermittent schedule for the duration of the individual's life.

The specific dose level of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of milligrams of a compound provided herein, or a pharmaceutically acceptable salt thereof, per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.1 and 150 mg/kg may be appropriate. In some embodiments, about 0.1 and 100 mg/kg may be appropriate. In other embodiments a dosage of between 0.5 and 60 mg/kg may be appropriate. Normalizing according to the subject's body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.

The daily dosage may also be described as a total amount of a compound described herein, or a pharmaceutically acceptable salt thereof, administered per dose or per day. Daily dosage of a compound of Formula I or II, or a pharmaceutically acceptable salt or pharmaceutically acceptable tautomer thereof, may be between about 1 mg and 4,000 mg, between about 2,000 to 4,000 mg/day, between about 1 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 10 to 500 mg/day, between about 20 to 500 mg/day, between about 50 to 300 mg/day, between about 75 to 200 mg/day, or between about 15 to 150 mg/day.

The dosage or dosing frequency of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, may be adjusted over the course of the treatment, based on the judgment of the administering physician.

The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, may be administered to an individual (e.g., a human) in a therapeutically effective amount. In some embodiments, the compound, or a pharmaceutically acceptable salt thereof, is administered once daily.

The compounds provided herein, or pharmaceutically acceptable salts thereof, can be administered by any useful route and means, such as by oral or parenteral (e.g., intravenous) administration. Therapeutically effective amounts of the compound, or a pharmaceutically acceptable salt thereof, may include from about 0.00001 mg/kg body weight per day to about 10 mg/kg body weight per day, such as from about 0.0001 mg/kg body weight per day to about 10 mg/kg body weight per day, or such as from about 0.001 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.01 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.05 mg/kg body weight per day to about 0.5 mg/kg body weight per day. In some embodiments, a therapeutically effective amount of the compounds provided herein, or pharmaceutically acceptable salts thereof, include from about 0.3 mg to about 30 mg per day, or from about 30 mg to about 300 mg per day, or from about 0.3 μg to about 30 mg per day, or from about 30 μg to about 300 μg per day.

A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, may be combined with one or more additional therapeutic agents in any dosage amount of the compound of the present disclosure or a pharmaceutically acceptable salt thereof (e.g., from 1 mg to 1000 mg of compound). Therapeutically effective amounts may include from about 0.1 mg per dose to about 1000 mg per dose, such as from about 50 mg per dose to about 500 mg per dose, or such as from about 100 mg per dose to about 400 mg per dose, or such as from about 150 mg per dose to about 350 mg per dose, or such as from about 200 mg per dose to about 300 mg per dose, or such as from about 0.01 mg per dose to about 1000 mg per dose, or such as from about 0.01 mg per dose to about 100 mg per dose, or such as from about 0.1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 10 mg per dose, or such as from about 1 mg per dose to about 1000 mg per dose. Other therapeutically effective amounts of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, are about 1 mg per dose, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or about 100 mg per dose. Other therapeutically effective amounts of the compound of the present disclosure, or pharmaceutically acceptable salts thereof, are about 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or about 1000 mg per dose.

In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 600 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 500 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 400 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 300 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 200 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 100 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 75 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 50 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 25 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 20 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 15 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 10 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg to about 5 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, or about 25 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 5 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 10 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 15 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 20 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 25 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 30 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 35 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 40 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 45 mg. In some embodiments, a therapeutically effective amount of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is about 50 mg.

In some embodiments, the methods described herein comprise administering to the subject an initial daily dose of about 1 to 500 mg of a compound provided herein, or a pharmaceutically acceptable salt thereof, and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, once per week, once every two weeks, once every three weeks, or once a month.

When administered orally, the total daily dosage for a human subject may be between about 1 mg and 1,000 mg, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day. In some embodiments, the total daily dosage for a human subject may be about 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 200, 300, 400, 500, 600, 700, or 800 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 300, 400, 500, or 600 mg/day administered in a single dose.

In some embodiments, the total daily dosage for a human subject may be about 100 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 150 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 200 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 250 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 300 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 350 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 400 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 450 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 500 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 550 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 600 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 650 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 700 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 750 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 800 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 850 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 900 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 950 mg/day administered in a single dose. In some embodiments, the total daily dosage for a human subject may be about 1000 mg/day administered in a single dose.

A single dose can be administered hourly, daily, weekly, or monthly. For example, a single dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or once every 24 hours. A single dose can also be administered once every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can also be administered once every 1 week, 2, 3, or once every 4 weeks. In certain embodiments, a single dose can be administered once every week. A single dose can also be administered once every month. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once daily in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered twice daily in a method disclosed herein.

The frequency of dosage of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, will be determined by the needs of the individual patient and can be, for example, once per day or twice, or more times, per day. Administration of the compound, or a pharmaceutically acceptable salt thereof, continues for as long as necessary to treat the inflammatory condition, or any other indication described herein. For example, a compound, or a pharmaceutically acceptable salt thereof, can be administered to a human suffering from an inflammatory condition for a period of from 20 days to 180 days or, for example, for a period of from 20 days to 90 days or, for example, for a period of from 30 days to 60 days.

Administration can be intermittent, with a period of several or more days during which a patient receives a daily dose of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, followed by a period of several or more days during which a patient does not receive a daily dose of the compound or a pharmaceutically acceptable salt thereof. For example, a patient can receive a dose of the compound, or a pharmaceutically acceptable salt thereof, every other day, or three times per week. Again by way of example, a patient can receive a dose of the compound, or a pharmaceutically acceptable salt thereof, each day for a period of from 1 to 14 days, followed by a period of 7 to 21 days during which the patient does not receive a dose of the compound, or a pharmaceutically acceptable salt thereof, followed by a subsequent period (e.g., from 1 to 14 days) during which the patient again receives a daily dose of the compound, or a pharmaceutically acceptable salt thereof. Alternating periods of administration of the compound, or a pharmaceutically acceptable salt thereof, followed by non-administration of the compound, or a pharmaceutically acceptable salt thereof, can be repeated as clinically required to treat the patient.

The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions of the present disclosure may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds, or pharmaceutically acceptable salts thereof, may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are well known for inflammatory conditions and other indications described herein. In some embodiments, treatment cycles are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.

VI. Combination Therapy

Patients being treated by administration of the compounds provided herein, or pharmaceutically acceptable salts thereof, often exhibit diseases or conditions that benefit from treatment with other therapeutic agents. These diseases or conditions can be of an inflammatory nature or can be related to cancer, metabolic disorders, gastrointestinal disorders and the like. Thus, one embodiment of the disclosure is a method of treating an inflammation related disease or condition, or a metabolic disorder, gastrointestinal disorder, or cancer and the like comprising administering a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more compounds useful for the treatment of such diseases to a subject, particularly a human subject, in need thereof.

In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.

In some embodiments, when a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one or more additional therapeutic agents as described herein, the components of the composition are administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.

In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.

In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more additional therapeutic agents.

Co-administration includes administration of unit dosages of the compounds provided herein, or pharmaceutically acceptable salts thereof, before or after administration of unit dosages of one or more additional therapeutic agents. The compounds provided herein, or pharmaceutically acceptable salts thereof, may be administered within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, within seconds or minutes. In some embodiments, a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered first, followed, after a period of hours (i.e., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (i.e., 1-12 hours), by administration of a unit dose of a compound provided herein or a pharmaceutically acceptable salt thereof.

In some embodiments, a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, is formulated as a tablet, which may optionally contain one or more other compounds useful for treating the disease being treated. In certain embodiments, the tablet can contain another active ingredient for treating an inflammatory condition or other indication described herein. In some embodiments, such tablets are suitable for once daily dosing.

Also provided herein are methods of treatment in which a compound of Formula I or II, or a tautomer or pharmaceutically acceptable salt thereof, is given to a patient in combination with one or more additional therapeutic agents or therapy. In some embodiments, the total daily dosage of a compound of Formula I or II, or a tautomer, or a pharmaceutically acceptable salt thereof, may be about 1 to about 500 mg/day administered in a single dose for a human subject.

Inflammatory Condition or Disease Combination Therapy

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one or more additional therapeutic agents that treat or ameliorate an inflammatory condition. Non-limiting examples of an inflammatory condition include, without limitation, acne, acid-induced lung injury, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, adult-onset Still's disease, adult respiratory distress syndrome (ARDS), age-related macular degeneration, aging, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, allergic conjunctivitis, allergic contact dermatitis, allergies, allergic encephalomyelitis, allergic neuritis, allograft rejection, alopecia, alopecia areata, Alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, angina pectoris, angioedema, angiofibroma, anhidrotic ectodermal dysplasia-ill, anti-glomerular basement membrane disease, antigen-antibody complex mediated diseases, ankylosing spondylitis, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, ascites, aspergillosis, asthma, atherosclerosis, atherosclerotic plaques, atopic dermatitis, atrophic thyroiditis, autoimmune diseases, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune polyendocrinopathies, autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), autoimmune hepatitis, autoimmune thyroid disorders, autoinflammatory diseases, back pain, Bacillus anthracis infection, Bechet's disease, bee sting-induced inflammation, Behget's syndrome, Bell's palsy, berylliosis, Blau syndrome, bone pain, bronchiolitis, bullous pemphigoid (BP) asthma, burns, bursitis, cardiac hypertrophy, carpal tunnel syndrome, Castleman's disease, catabolic disorders, cataracts, Celiac disease, cerebral aneurysm, chemical irritant-induced inflammation, chorioretinitis, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, chronic heart failure, chronic lung disease of prematurity, chronic obstructive pulmonary disease (COPD), chronic pancreatitis, chronic prostatitis, chronic recurrent multifocal osteomyelitis, cicatricial alopecia, colitis, complex regional pain syndrome, complications of organ transplantation, conjunctivitis, connective tissue disease, contact dermatitis, corneal graft neovascularization, corneal ulcer, Crohn's disease, cryopyrin-associated periodic syndromes, cutaneous lupus erythematosus (CLE), cryptococcosis, cystic fibrosis, deficiency of the interleukin-1 receptor antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diabetic macular edema, diverticulitis, eczema, encephalitis, endometriosis, endotoxemia, eosinophilic pneumonias, epicondylitis, epidermolysis bullosa, erythema multiforme, erythroblastopenia, esophagitis, familial amyloidotic polyneuropathy, familial cold urticarial, familial Mediterranean fever, fetal growth retardation, fibromyalgia, fistulizing Crohn's disease, food allergies, giant cell arteritis, glaucoma, glioblastoma, glomerular disease, glomerular nephritis, glomerulonephritis, gluten-sensitive enteropathy, gout, gouty arthritis, graft-versus-host disease (GVHD), granulomatous hepatitis, Graves' disease, growth plate injuries, Guillain-Barre syndrome, gut diseases, hair loss, Hashimoto's thyroiditis, head injury, headache, hearing loss, heart disease, hemangioma, hemolytic anemia, hemophilic joints, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, heritable disorders of connective tissue, herpes zoster and simplex, hidradenitis suppurativa (HS), hip replacement, Hodgkin's disease, Huntington's disease, hyaline membrane disease, hyperactive inflammatory response, hyperammonemia, hypercalcemia, hypercholesterolemia, hypereosinophilic syndrome (HES), hyperimmunoglobulinemia D with recurrent fever (HIDS), hypersensitivity pneumonitis, hypertropic bone formation, hypoplastic and other anemias, hypoplastic anemia, ichthyosis, idiopathic demyelinating polyneuropathy, Idiopathic inflammatory myopathies (dermatomyositis, polymyositis), idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, immunoglobulin nephropathies, immune complex nephritis, immune thrombocytopenic purpura (ITP), incontinentia pigmenti (IP, Bloch-Siemens syndrome), infectious mononucleosis, infectious diseases including viral diseases such as AIDS (HIV infection), hepatitis A, B, C, D, and E, herpes; inflammation, inflammation of the CNS, inflammatory bowel disease (IBD), inflammatory disease of the lower respiratory tract including bronchitis or chronic obstructive pulmonary diseases, inflammatory disease of the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis, inflammatory diseases of the respiratory tract, inflammatory ischemic event such as stroke or cardiac arrest, inflammatory lung disease, inflammatory myopathy such as myocarditis, inflammatory liver disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, interstitial cystitis, interstitial lung disease, iritis, irritant-induced inflammation, ischemia/reperfusion, joint replacement, juvenile arthritis, juvenile rheumatoid arthritis, keratitis, kidney injury caused by parasitic infections, kidney transplant rejection, leptospirosis, leukocyte adhesion deficiency, lichen sclerosus (LS), Lambert-Eaton myasthenic syndrome, Loeffler's syndrome, lupus, lupus nephritis, Lyme disease, Marfan syndrome (MFS), mast cell activation syndrome, mastocytosis, meningitis, meningioma, mesothelioma, mixed connective tissue disease, Muckle-Wells syndrome (urticaria deafness amyloidosis), mucositis, multiple organ injury syndrome, multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis (MG), myelodysplastic syndrome, myocarditis, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), neovascular glaucoma, nephrotic syndrome, neuritis, neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant rejection, Osier-Weber syndrome, osteoarthritis, osteogenesis imperfecta, osteonecrosis, osteoporosis, osterarthritis, otitis, pachyonychia congenita, Paget's disease, Paget's disease of bone, pancreatitis, Parkinson's disease, pediatric rheumatology, pelvic inflammatory disease, pemphigus, pemphigus vulgaris (PV), bullous pemphigoid (BP), pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pernicious anemia (Addison's disease), pertussis, PFAPA (periodic fever aphthous pharyngitis and cervical adenopathy), pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumocystis infection, pneumonia, pneumonitis, poison ivy/urushiol oil-induced inflammation, polyarthritis nodosa, polychondritis, polycystic kidney disease, polymyalgia rheumatic, giant cell arteritis, polymyositis, pouchitis, reperfusion injury and transplant rejection, primary biliary cirrhosis, primary pulmonary hypertension, primary sclerosing cholangitis (PSC), proctitis, psoriasis, psoriasis vulgaris, psoriatic arthritis, psoriatic epidermis, psychosocial stress diseases, pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, pyogenic granuloma retrolental fibroplasias, pyogenic sterile arthritis, Raynaud's syndrome, Reiter's disease, reactive arthritis, renal disease, renal graft rejection, reperfusion injury, respiratory distress syndrome, retinal disease, retrolental fibroplasia, Reynaud's syndrome, rheumatic carditis, rheumatic diseases, rheumatic fever, rheumatoid arthritis, rhinitis, rhinitis psoriasis, rosacea, sarcoidosis, Schnitzler syndrome, scleritis, sclerosis, scleroderma, scoliosis, seborrhea, sepsis, septic shock, severe pain, Sezary syndrome, sickle cell anemia, silica-induced disease (Silicosis), Sjögren's syndrome, skin diseases, skin irritation, skin rash, skin sensitization (contact dermatitis or allergic contact dermatitis), sleep apnea, spinal cord injury, spinal stenosis, spondyloarthropathies, sports injuries, sprains and strains, Stevens-Johnson syndrome (SJS), stroke, subarachnoid hemorrhage, sunburn, synovial inflammation, systemic inflammatory response syndrome (SIRS), systemic lupus erythematosus (SLE), systemic mast cell disease (SMCD), systemic vasculitis, systemic-onset juvenile idiopathic arthritis, temporal arteritis, tendinitis, tenosynovitis, thrombocytopenia, thyroditis, thyroiditis, tissue transplant, toxoplasmosis, trachoma, transplantation rejection, traumatic brain injury, tuberculosis, tubulointerstitial nephritis, tumor necrosis factor (TNF) receptor associated periodic syndrome (TRAPS), type 1 diabetes, type 2 diabetes, complications from type 1 or type 2 diabetes, ulcerative colitis, urticaria, uterine fibroids, uveitis, uveoretinitis, vascular restenosis, vasculitis, vasculitis (NHLBI), vitiligo, Wegener's granulomatosis, and Whipple's disease.

Non-limiting examples of therapeutic agents for treatment of an inflammatory disease or condition that can be used in combination with the compounds provided herein, or pharmaceutically acceptable salts thereof, include alpha-fetoprotein modulators; adenosine A3 receptor antagonist; adrenomedullin ligands; AKT1 gene inhibitors; antibiotics; antifungals; ASK1 inhibitors; ATPase inhibitors; beta adrenoceptor antagonists; BTK inhibitors; calcineurin inhibitors; carbohydrate metabolism modulators; cathepsin S inhibitors; CCR9 chemokine antagonists; CD233 modulators; CD29 modulators; CD3 antagonists; CD40 ligand inhibitors; CD40 ligand receptor antagonists; chemokine CXC ligand inhibitors; CHST15 gene inhibitors; collagen modulators; COT protein kinase inhibitors; CSF-1 agonist; CSF-1 antagonists; CX3CR1 chemokine modulators DYRK-1 alpha protein kinase inhibitor, eotaxin ligand inhibitors; EP4 prostanoid receptor agonists; FIFO ATP synthase modulators; farnesoid X receptor (FXR, NR1H4) agonists or modulators; fecal microbiota transplantation (FMT), fractalkine ligand inhibitors; free fatty acid receptor 2 antagonists; GATA 3 transcription factor inhibitors; glucagon-like peptide 2 agonists; glucocorticoid agonists; Glucocorticoid receptor modulators; guanylate cyclase receptor agonists; HIF prolyl hydroxylase inhibitors; histone deacetylase inhibitors; HLA class II antigen modulators; hypoxia inducible factor-1 stimulator; ICAM1 gene inhibitors; IL-1 beta ligand modulators; IL-12 antagonists; IL-13 antagonists; IL-18 antagonists; IL-18 receptor accessory protein antagonist, IL-22 agonists; IL-23 antagonists; IL-23A inhibitors; IL-6 antagonists; IL-7 receptor antagonists; IL-8 receptor antagonists; IL-36 inhibitors, integrin alpha-4/beta-1 antagonists; integrin alpha-4/beta-7 antagonists; integrin antagonists; interleukin ligand inhibitors; interleukin receptor 17A antagonists; interleukin-1 beta ligands; interleukin 1 like receptor 2 inhibitors; IL-6 receptor modulators; JAK tyrosine kinase inhibitors; Jak1 tyrosine kinase inhibitors; Jak3 tyrosine kinase inhibitors; lactoferrin stimulators; LanC like protein 2 modulators; leukocyte elastate inhibitors; leukocyte proteinase-3 inhibitors; MAdCAM inhibitors; melanin concentrating hormone (MCH-1) antagonist; melanocortin agonists; metalloprotease-9 inhibitors; microbiome-targeting therapeutics; natriuretic peptide receptor C agonists; neuregulin-4 ligands; NLRP3 inhibitors; NKG2 D activating NK receptor antagonists; NR1H4 receptor (FXR) agonists or modulators(deleted); nuclear factor kappa B inhibitors; opioid receptor antagonists; OX40 ligand inhibitors; oxidoreductase inhibitors; P2X7 purinoceptor modulators; PDE 4 inhibitors; Pellino homolog 1 inhibitors; PPAR alpha/delta agonists; PPAR gamma agonists; Protein arginine deiminase IV inhibitor, protein fimH inhibitors; P-selectin glycoprotein ligand-1 inhibitors; Ret tyrosine kinase receptor inhibitors; RIP-1 kinase inhibitors; RIP-2 kinase inhibitors; RNA polymerase inhibitors; sphingosine 1 phosphate phosphatase 1 stimulators; sphingosine-1-phosphate receptor-1 agonists; sphingosine-1-phosphate receptor-5 agonists; sphingosine-1-phosphate receptor-1 antagonists; sphingosine-1-phosphate receptor-1 modulators; stem cell antigen-1 inhibitors; superoxide dismutase modulators; SYK inhibitors; tissue transglutaminase inhibitor; TLR-3 antagonists; TLR-4 antagonists; Toll-like receptor 8 (TLR8) inhibitors; TNF alpha ligand inhibitors; TNF ligand inhibitors; TNF alpha ligand modulators; TNF antagonists; TPL-2 inhibitors; tumor necrosis factor 14 ligand modulators; tumor necrosis factor 15 ligand inhibitors; Tyk2 tyrosine kinase inhibitors; type I IL-1 receptor antagonists; vanilloid VR1 agonists; and zonulin inhibitors; or any combination thereof.

Adenosine A3 receptor antagonists include but are not limited to PBF-677.

Adrenomedullin ligands include but are not limited to adrenomedullin.

Antibiotics include but are not limited to ciprofloxacin, clarithromycin, metronidazole, vancomycin, rifamycin, rifaximin, and tosufloxacin.

ASK1 inhibitors include but are not limited to GS-4997.

Alpha-fetoprotein modulators include but are not limited to ACT-101.

Anti-CD28 inhibitors include but are not limited to JNJ-3133 and abatacept.

Beta adrenoceptor antagonists include but are not limited to NM-001.

BTK inhibitors include but are not limited to GS-4059.

Calcineurin inhibitors include but are not limited to tacrolimus and ciclosporin.

Carbohydrate metabolism modulators include but are not limited to ASD-003.

Cathepsin S inhibitors include but are not limited to VBY-129.

CCR9 chemokine antagonists include but are not limited to CCX-507.

CD233 modulators include but are not limited to GSK-2831781.

CD29 modulators include but are not limited to PF-06687234.

CD3 antagonists include but are not limited to NI-0401, muromonab-CD3, and teplizumab.

CD4 antagonists include but are not limited to IT-1208.

CD40 ligand inhibitors include but are not limited to SAR-441344 and letolizumab.

CD40 gene inhibitors include but are not limited to NJA-730.

CD40 ligand receptor antagonists include but are not limited to FFP-104, BI-655064, ABBV-323, and VIB-4920.

Chaperonin binding immunoglobulin protein include but are not limited to IRL-201805.

Chemokine CXC ligand inhibitors include but are not limited to LY-3041658.

CHST15 gene inhibitors include but are not limited to STNM-01.

Collagen modulators include but are not limited to ECCS-50 (DCCT-10).

COT protein kinase inhibitors include but are not limited to GS-4875.

CSF-1 antagonists include but are not limited to JNJ-40346527 (PRV-6527) and SNDX-6352.

CX3CR1 chemokine modulators include but are not limited to E-6130.

DYRK-1 alpha protein kinase inhibitor include but are not limited to VRN-02.

Microbiome-targeting therapeutics include but are not limited to SER-287, SER-301, and SER-155.

Eotaxin ligand inhibitors include but are not limited to bertilimumab.

EP4 prostanoid receptor agonists include but are not limited to KAG-308.

FiFO ATP synthase modulators include but are not limited to LYC-30937 EC.

Fractalkine ligand inhibitors include but are not limited to quetmolimab (E-6011).

Free fatty acid receptor 2 antagonists include but are not limited to GLPG-0974.

GATA 3 transcription factor inhibitors include but are not limited to SB-012.

Glucagon-like peptide 2 agonists include but are not limited to teduglutide and apraglutide.

Glucocorticoid receptor agonists include but are not limited to budesonide, beclomethasone dipropionate, and dexamethasone sodium phosphate.

Glucocorticoid receptor modulators/TNF ligand inhibitors include but are not limited to ABBV-3373.

Guanylate cyclase receptor agonists include but are not limited to dolcanatide.

HIF prolyl hydroxylase inhibitors include but are not limited to DS-1093 and AKB-4924.

HIF prolyl hydroxylase-2 inhibitors/hypoxia inducible factor-1 stimulators include but are not limited to GB-004.

Histone deacetylase inhibitors include but are not limited to givinostat and NIPEP-CARE.

Histone deacetylase-6 inhibitors include but are not limited to CKD-506.

HLA class II antigen modulators include but are not limited to HLA class II protein modulators.

ICAM1 gene inhibitors include but are not limited to alicaforsen.

IL-12 antagonists include but are not limited to ustekinumab (IL12/IL23).

IL-13 antagonists include but are not limited to tralokinumab.

IL-18 antagonists include but are not limited to GSK-1070806.

IL-18 receptor accessory protein antagonist include but are not limited to anti-IL-1R⁷ canonical antibody.

IL-22 agonists include but are not limited to AMT-126 and RG-7880.

IL-23 antagonists include but are not limited to tildrakizumab, risankizumab (BI-655066), mirikizumab (LY-3074828), brazikumab (AMG-139), IBI-112, and PTG-200.

IL-23A inhibitors include but are not limited to guselkumab.

IL-6 antagonists include but are not limited to olokizumab.

IL-7 receptor antagonists include but are not limited to OSE-127.

IL-8 receptor antagonists include but are not limited to clotrimazole.

Integrin alpha-4/beta-1 antagonists include but are not limited to natalizumab.

Integrin alpha-4/beta-7 antagonists include but are not limited to etrolizumab (a4b7/aEb7), vedolizumab, carotegrast methyl, TRK-170 (a4b7/a4b 1), PTG-100, and PN-10943.

Integrin antagonists include but are not limited to E-6007.

Interleukin ligand inhibitors include but are not limited to bimekizumab (IL-17A/IL-17F).

Interleukin receptor 17A antagonists include but are not limited to brodalumab.

Interleukin-1 beta ligands include but are not limited to K(D)PT.

Interleukin 1 like receptor 2 inhibitors include but are not limited to BI-655130.

IL-6 receptor modulators include but are not limited to Amilo-SMER and olamkicept.

JAK tyrosine kinase inhibitors include but are not limited to tofacitinib (1/3), peficitinib (1/3), TD-3504, and TD-1473.

Jak1 tyrosine kinase inhibitors include but are not limited to a compound disclosed in U.S. Pat. No. 9,238,628.

Jak3 tyrosine kinase inhibitors include but are not limited to OST-122 and PF-06651600.

Jak3 tyrosine kinase inhibitor/TrkA receptor antagonist include but are not limited to SNA-125.

Examples of other JAK inhibitors include but are not limited to AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110, lestaurtinib, momelotinib (CYT0387), NS-018, pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly tasocitinib), XL019, upadacitinib (ABT-494), LPG-0555, SHR-0302, and brepocitinib (PF-06700841) (JAK1/Tyk2).

Lactoferrin stimulators include but are not limited to recombinant human lactoferrin (VEN-100).

LanC like protein 2 modulators include but are not limited to BT-11 and BT-104.

Leukocyte elastase inhibitors/Leukocyte proteinase-3 inhibitors include but are not limited to tiprelestat.

MAdCAM inhibitors include but are not limited to SHP-647 (PF-547659).

Melanin concentrating hormone (MCH-1) antagonists include but are not limited to CSTI-100.

Melanocortin MC1 receptor agonists include but are not limited to ASP-3291 and PL-8177.

Metalloprotease-9 inhibitors include but are not limited to GS-5745.

Microbiome modulators include but are not limited to ABI-M201.

Natriuretic peptide receptor C agonists include but are not limited to plecanatide.

Neuregulin-4 ligands include but are not limited to NRG-4.

NKG2 D activating NK receptor antagonists include but are not limited to JNJ-4500.

NLRP3 inhibitors include but are not limited to dapansutrile, BMS-986299, SB-414, MCC-950, IFM-514, JT-194, PELA-167, and NBC-6.

Farnesoid X receptor (FXR, NR1H4) agonists or modulators include but are not limited to AGN-242266, cilofexor tromethamine (GS-9674), EDP-305, EYP-001, GNF-5120, MET-409, MET-642, nidufexor (LMB-763), obeticholic acid, TERN-101, and tropifexor.

Nuclear factor kappa B inhibitors include but are not limited to Thetanix.

Opioid receptor antagonists include but are not limited to naltrexone and IRT-103.

OX40 ligand inhibitors include but are not limited to KHK-4083.

Oxidoreductase inhibitors include but are not limited to olsalazine.

Pellino homolog 1 inhibitors include but are not limited to BBT-401.

P2X7 purinoceptor modulators include but are not limited to SGM-1019.

PDE 4 inhibitors include but are not limited to apremilast.

PPAR alpha/delta agonists include but are not limited to elafibranor (GFT-1007).

PPAR gamma agonists include but are not limited to GED-0507-34-Levo.

Protein fimH inhibitors include but are not limited to sibofimloc (EB-8018).

P-selectin glycoprotein ligand-1 inhibitors include but are not limited to SEL-K2, AbGn-168H, and neihulizumab.

Ret tyrosine kinase receptor inhibitors include but are not limited to GSK-3179106.

RIP-1 kinase inhibitors include but are not limited to GSK-2982772 and VRN-04.

RIP-2 kinase inhibitors include but are not limited to GSK-2983559.

Sphingosine 1 phosphate phosphatase 1 stimulators include but are not limited to etrasimod.

Sphingosine-1-phosphate receptor-1 agonists include but are not limited to mocravimod (KRP-203) and BMS-986166.

Sphingosine-1-phosphate receptor-1 agonists/Sphingosine-1-phosphate receptor-5 agonists include but are not limited to ozanimod.

Sphingosine-1-phosphate receptor-1 antagonists include but are not limited to amiselimod (MT-1303).

Sphingosine-1-phosphate receptor-1 modulators include but are not limited to OPL-002, SKi-1.

Stem cell antigen-1 inhibitors include but are not limited to Ampion (DMI-9523).

Superoxide dismutase modulators include but are not limited to midismase.

Syk inhibitors include but are not limited to GS-9876.

tissue transglutaminase inhibitor include but are not limited to zampilimab.

TLR-3 antagonists include but are not limited to PRV-300.

TLR-4 antagonists include but are not limited to JKB-122.

Toll-like receptor 8 (TLR8) inhibitors include but are not limited to E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, VTX-1463, and VTX-763.

TNF alpha ligand inhibitors include but are not limited to adalimumab, certolizumab pegol, infliximab, golimumab, DLX-105, Debio-0512, HMPL-004, CYT-020-TNFQb, Hemay-007, and V-565.

TNF alpha ligand modulators/IL-1 beta ligand modulators include but are not limited to PUR-0110.

TNF antagonists include but are not limited to AVX-470, tulinercept, and etanercept.

Tumor necrosis factor 14 ligand modulators include but are not limited to AEVI-002.

Tumor necrosis factor 15 ligand inhibitors include but are not limited to PF-06480605.

Tyk2 tyrosine kinase inhibitors include but are not limited to PF-06826647 and BMS-986165.

Type I IL-1 receptor antagonists include but are not limited to anakinra.

Zonulin inhibitors include but are not limited to larazotide acetate.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one or more anti-inflammatory agents. Anti-inflammatory agents include but are not limited to non-steroidal anti-inflammatory drugs (NSAIDs), non-specific and COX-2 specific cyclooxgenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, and immunosuppressants.

Examples of NSAIDs include, but are not limited to ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine. Additional examples of NSAIDs also include but are not limited to COX-2 specific inhibitors (i.e., a compound that inhibits COX-2 with an IC₅₀ that is at least 50-fold lower than the IC₅₀ for COX-1), such as celecoxib, valdecoxib, lumiracoxib, etoricoxib and/or rofecoxib.

In some embodiments, the anti-inflammatory agent is a salicylate. Salicylates include but are not limited to acetylsalicylic acid or aspirin, sodium salicylate, choline, and magnesium salicylates.

In some embodiments, the anti-inflammatory agent is a corticosteroid. Non-limiting examples of a corticosteroid include cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, and prednisone.

In some embodiments, the anti-inflammatory agent is a gold compound, e.g., gold sodium thiomalate or auranofin.

In some embodiments, the anti-inflammatory agent is a metabolic inhibitor. Non-limiting examples of a metabolic inhibitor include a dihydrofolate reductase inhibitor, such as methotrexate, or a dihydroorotate dehydrogenase (DHODH) inhibitor, such as leflunomide.

In some embodiments, the anti-inflammatory agent is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist (such as entanercept), or infliximab, which is an anti-TNF alpha monoclonal antibody.

In some embodiments, the anti-inflammatory agent is an immunosuppressant. Non-limiting examples of an immunosuppressant include methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, mycophenolate sodium, mercaptopurine, and mycophenolate mofetil.

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of osteoarthritis (OA). Non-limiting examples of such agents include nonsteroidal antiinflammatory drugs (NSAIDs), topical capsaicin, intraarticular glucocorticoid injections, acetaminophen, duloxetine, tramadol, and injectable corticosteroids such as methylprednisolone acetate, triamcinolone acetate, betamethasone acetate and betamethasone sodium phosphate, triamcinolone hexacetonide, and dexamethasone.

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of a pulmonologic condition, such as idiopathic pulmonary fibrosis (IPF) or interstitial lung disease (ILD). Non-limiting examples of such agents include nitendanib, pirfenidone, corticosteroids such as prednisone, other rheumatologic drugs, including mycophenolate (e.g., CellCept®), azathioprine (e.g., Imuran®), leflunomide (e.g., ARAVA®), rituximab (e.g., RITUXAN®), cyclophosphamide (e.g., CYTOXAN®), tacrolimus (e.g., PROGRAF®), medications that reduce stomach acid, such as H-2-receptor antagonists or proton pump inhibitors such as lansoprazole (e.g., PREVACID®24HR), omeprazole (e.g., Prilosec OTC) and pantoprazole (e.g., PROTONIX®).

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of a heptatologic or nephrologic condition, such as NAFLD, NASH, DKD, or CKD. Non-limiting examples of such agents include metformin, sodium-glucose cotransporter-2 inhibitor (SGLT2i), drug therapy for glycemic control, DPP-4 inhibitor, insulin, sulfonylurea, TZD (thiazolidinedione), alpha-glucosidase inhibitor, SGLT2 inhibitor (e.g., empagliflozin, canagliflozin, dapaglifloz), glucagon-like peptide-1 receptor agonist (GLP-1 RA) (e.g., lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide), DPP-4 inhibitors (e.g., saxagliptin, alogliptin, sitagliptin, linagliptin), one or more agents used to treat high blood pressure such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin 2 receptor blockers (ARBs), agents supportive of weight loss or for control of blood sugar, cholesterol-lowering drugs (e.g., statins), finerenone, and agents for treatment of diabetes mellitus, such as alpha-glucosidase inhibitors (e.g., acarbose, miglitol, voglibose).

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of a dermatologic condition, such as atopic dermatitis (AD). Non-limiting examples of such agents include topical corticosteroids (TCS) (e.g., desonid, hydrocortisone, fluocinolone, triamcinolone, betamethasone diproprionate), topical calcineurin inhibitors (TCI) (e.g., tacrolimus, pimecrolimus), topical antimicrobials and antiseptics, cyclosporine, methotrexate, mycophenolate mofetil, interferon gamma, phosphodiesterase 4 (PDE4) inhibitor such as crisaborole, JAK inhibitor (e.g., ruxolitinib, upadacitinib, abrocitinib), systemic glucocorticoids (e.g., prednisone), dupilumab, and anti-IL-13 antibody (e.g., tralokinumab).

Lupus Combination Therapy

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, is combined with one or more additional therapeutic agents that target adenosylhomocysteinase, ADP ribosyl cyclase-1 (CD38), adrenocorticotrophic hormone ligands, AIMP multisynthetase complex protein 1, annexin A1 modulators, B and T lymphocyte attenuator (BTLA), BDCA2, beta 2 adrenoceptor, B-lymphocyte antigen CD19, B-lymphocyte antigen CD20, B-lymphocyte cell adhesion molecule (CD22), B-lymphocyte stimulator ligand (BAFF), btk tyrosine kinase, cannabinoid CB2 receptor, CD11b agonists, CD38 Activation-inducible TNF receptor, CD40 (CD154) ligand, CD74, CD79b modulators, CDwl23, Collagen VII (Col VII), Complement C5 factor, C-type lectin domain protein 4C, CXCR5 chemokine modulators, deoxyribonuclease modulators, DNA binding protein Ikaros, DYRK-1 alpha protein kinase, dndoplasmin, Exportin 1, FK506 binding protein, glucocorticoid receptor, HLA antigen, IL-10, IL-23m IL-12 receptors, IL-2 receptor, IL-2 receptor alpha subunit, IL-21 modulators, IL-6R, immunoglobulin gamma Fc receptor II modulators, immunoglobulin gamma Fc receptor IIB, inducible T-cell co-stimulator, interferon alpha ligand (INF-alpha), interferon omega ligand (INF omega), interferon type I receptor, interleukin-2 ligand, Itk tyrosine kinase, JAK tyrosine kinase, Jak1 tyrosine kinase, Jak2 tyrosine kinase, Jak3 tyrosine kinase, KCNA voltage-gated potassium channel-3, leukocyte Ig like receptor A4 modulators, mitochondrial 10 kDa heat shock protein, mTOR, non receptor tyrosine kinase TYK2, nuclear export, nuclear factor kappa B inducing kinase, nuclease stimulators, OX-40 receptors, PARP modulators, proteasome modulators, protein arginine deiminase IV (PAD4), protein cereblon modulators, protein MB21D1, retinoid Z receptor gamma inverse, rho associated protein kinase 1, rho associated protein kinase 2, serine threonine protein kinase TBK1 (TBK1), sphingosine kinase 1, sphingosine-1-phosphate receptor-1 modulators, stimulator of interferon genes protein, Syk tyrosine kinase, T cell surface glycoprotein CD28, T-cell differentiation antigen CD6, TLR-7 modulators, TLR-8 modulators, TLR-9 modulators, transcription factor modulators, tumor necrosis factor ligand 13 (APRIL), Tyk2 tyrosine kinase, ubiquitin ligase modulators, and/or zinc finger binding protein Aiolos.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from:

-   -   activation-inducible TNF receptor agonists, including but not         limited to BMS-986256;     -   adenosylhomocysteinase inhibitors, including but not limited to         DZ-2002;     -   adrenocorticotrophic hormone ligands, including but not limited         to corticotropin;     -   AIMP multisynthetase complex protein 1 stimulator/Endoplasmin         inhibitors, including but not limited to anchorins;     -   aniti-CDwl23 antibodies, including but not limited to         talacotuzumab;     -   annexin A1 modulators, including but not limited to         annexuzlimab;     -   anti-IL-12/IL23 antibodies, including but not limited to AK-101;     -   anti-BAFF-R antibodies, including but not limited to lanalumab;     -   anti-BDCA2 antibodies, including but not limited to BIIB-059;     -   anti-BLys antibodies, including but not limited to belimumab and         UBP-1213;     -   anti-BTLA modulator antibodies, including but not limited to         LY-3361237;     -   anti-C5 antibodies, including but not limited to eculizumab;     -   anti-CD154 antibodies, including but not limited to TNX-1500;     -   anti-CD19/CD32b antibodies, including but not limited to         obexelimab;     -   anti-CD20 antibodies, including but not limited to veltuzumab;     -   anti-CD22 antibodies, including but not limited to SM-06, SM-03;     -   anti-CD28 antibodies, including but not limited to theralizumab;     -   anti-CD38 antibodies, including but not limited to TAK-079 and         felzartamab;     -   anti-CD40 antibodies, including but not limited to iscalimab and         dapirolizumab pegol;     -   anti-CD6 antibodies, including but not limited to itolizumab;     -   anti-CD74 antibodies, including but not limited to milatuzumab;     -   anti-CXCR5 antibodies, including but not limited to PF-06835375;     -   anti-IFN-alpha antibodies, including but not limited to         QX-006-N;     -   anti-IFN-alpha/omega antibodies, including but not limited to         JNJ-55920839;     -   anti-IL-10 antibodies, including but not limited to BT-063;     -   anti-IL-21 antibodies, including but not limited to BOS-161721;     -   anti-IL-6R nanobodies, including but not limited to         vobarilizumab;     -   anti-ILT7 antibodies, including but not limited to daxdilimab;     -   anti-interferon alpha vaccines, including but not limited to         CKD-971;     -   anti-interferon receptor type I antibodies, including but not         limited to anifrolumab;     -   anti-PAD4 antibodies, including but not limited to PFI-102;     -   anti-TLR-7 antibodies, including but not limited to DS-7011;     -   BAFF/APRIL inhibitors, including but not limited to ALPN-303;     -   Beta 2 adrenoceptor agonists, including but not limited to         R-salbutamol sulphate;     -   bi-specific antibodies targeting BAFF/ICOSL, including but not         limited to rozibafusp alfa;     -   bi-specific antibodies targeting CD32B/CD79B, including but not         limited to PRV-3279;     -   bi-specific antibodies targeting Col VII/BAFF, including but not         limited to TE-2324;     -   B-lymphocyte stimulator ligand inhibitors, including but not         limited to atacicept and telitacicept;     -   Btk tyrosine kinase inhibitors, including but not limited to         AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride,         branebrutinib, elsubrutinib, and orelabrutinib;     -   Btk/itk tyrosine kinase inhibitors, including but not limited to         DWP-213388;     -   Btk/Jak3 tyrosine kinase inhibitors, including but not limited         to DWP-212525;     -   cannabinoid CB2 receptor agonists, including but not limited to         julemic acid;     -   CD11b agonists, including but not limited to LA-1;     -   deoxyribonuclease gamma stimulators, including but not limited         to NTR-441;     -   deoxyribonuclease modulators, including but not limited to         Oshadi D;     -   DYRK-1 alpha protein kinase inhibitors, including but not         limited to VRN-02;     -   exportin 1 inhibitors, including but not limited to SINE         compounds;     -   glucocorticoid receptor agonists, including but not limited to         prednisone;     -   HLA antigen modulators, including but not limited to PEGylated         HLA-x (SLE);     -   IL-2 receptor alpha subunit stimulators, including but not         limited to NKTR-35;     -   imunoglobulin gamma Fc receptor 113 modulators, including but         not limited to valziflocept;     -   inducible T-cell co-stimulator inhibitor (ICOS)/T cell surface         glycoprotein CD28 inhibitors, including but not limited to         ALPN-101;     -   interferon alpha ligand modulator/TLR-7/TLR-9 modulators,         including but not limited to DV-1079;     -   interleukin-2 ligands, including but not limited to         interleukin-2 Anteluke, interking recombinant human         interleukin-2, ILT-101, and CUG-252;     -   interleukin-2 ligands/IL-2 receptor agonists, including but not         limited to interleukin-2 follow-on biologic;     -   JAK 1/2/3 and ROCK 1/2 inhibitors, including but not limited to         CPL-409116;     -   JAK tyrosine kinase inhibitors, including but not limited to         delgocitinib;     -   Jak1/Jak2 tyrosine kinase inhibitors, including but not limited         to baricitinib;     -   Jak1 tyrosine kinase inhibitors, including but not limited to         upadacitinib, filgotinib, itacitinib, and INCB-54707;     -   Jak1/Tyk2 tyrosine kinase inhibitors, including but not limited         to brepocitinib, SDC-1801, and SDC-1802;     -   JAK3/1 and TBK1 kinase inhibitors, including but not limited to         CS-12192;     -   JAK3/JAK1 tyrosine kinase inhibitors, including but not limited         to tofacitinib citrate;     -   KCNA voltage-gated potassium channel-3 inhibitors, including but         not limited to dalazatide;     -   mitochondrial 10 kDa heat shock protein stimulators, including         but not limited to INV-103;     -   mTOR inhibitors, including but not limited to TAM-01;     -   non-receptor tyrosine kinase TYK2 antagonists, including but not         limited to ICP-330;     -   nuclear export inhibitors, including but not limited to         verdinexor;     -   nuclear factor kappa B inducing kinase inhibitors, including but         not limited to NIK-SMI1;     -   nuclease stimulators, including but not limited to RSLV-132;     -   OX-40 receptor antagonists, including but not limited to         ISB-830;     -   PARP modulators, including but not limited to bendamustine         hydrochloride;     -   PD-L1 CAR-expressing NK-92 cell therapy;     -   proteasome inhibitors, including but not limited to KZR-616;     -   protein cereblon modulators, including but not limited to         iberdomide;     -   protein MB21D1 inhibitors, including but not limited to X-6;     -   retinoid Z receptor gamma inverse agonists, including but not         limited to INV-17;     -   sphingosine kinase 1 inhibitors, including but not limited to         BML-258;     -   sphingosine-1-phosphate receptor-1 modulator, including but not         limited to cenerimod;     -   Syk tyrosine kinase inhibitors, including but not limited to         GSK-2646264, SKI-O-703, lanraplenib (GS-9876), GNS-1653, and         HMPL-523;     -   TLR-9 antagonists, including but not limited to chloroquine,         hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064;         GNKS-356, and AVO-101;     -   TLR7/8 antagonists, including but not limited to M-5049, E-6887,         and BMS-986256;     -   TLR-8 antagonists, including but not limited to ZG-170607;     -   TLR7/8/9 antagonists, including but not limited to IMO-8400 and         IMO-9200;     -   Tyk2 tyrosine kinase inhibitors, including but not limited to         deucravacitinib;     -   ubiquitin ligase modulators, including but not limited to         KPG-818; and     -   other drugs for lupus, including but not limited to mometasone,         betamethasone, forigerimod, anandamide, DCB-SLE1, arsenic         trioxide, tairuimide, TV-4710 (edratide), allogeneic human         umbilical cord-derived mesenchymal stem cell therapy (hUC-MSCs),         LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013,         MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, AMG-592,         phosphatidylserine-liposome-based immunotherapy, and         CD4+CD1271o/-CD25+polyclonal regulatory T cells.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, theralizumab, daxdilimab, TAK-079, felzartamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacotuzumab, vobarilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064; GNKS-356, AVO-101, rozibafusp alfa, VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, atacicept, telitacicept, BMS-986256, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, valziflocept, LA-1, cenerimod, prednisone, corticotropin, deucravacitinib, CPL-409116, CS-12192, tofacitinib citrate, ISB-830, DV-1079, julemic acid, iberdomide, TAM-01, BML-258, brepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, dalazatide, GSK-2646264, SKI-O-703, lanraplenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 follow-on biologic, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, elsubrutinib, orelabrutinib, DWP-213388, INV-103, R-salbutamol sulphate, anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, as mometasone, betamethasone, forigerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSCs), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of systemic lupus erythematosus (SLE) or lupus nephritis (LN). Non-limiting examples of such agents include immunosuppressive drugs that inhibit activity of the immune system and agents approved for treatment of SLE, such as hydroxychloroquine, steroids and corticosteroids (e.g., prednisone, methylprednisolone), belimumab, azathioprine, methotrexate, cyclophosphamide, mycophenolate and mycophenolate mofetil, cyclosporine, leflunomide, voclosporin, abatacept, anifrolumab, rituximab, NSAIDS, such as naproxen sodium and ibuprofen, antimalarial drugs, such as hydroxychloroquine, calcineurin inhibitors, and tacrolimus.

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with two or more agents useful for the treatment of LN, such as prednisone+mycophenolic acid analogs, prednisone+mycophenolic acid sodium prednisone+cyclophosphamide, prednisone+tacrolimus, prednisone+voclosporin, prednisone+belimumab+mycophenolic acid analogs, prednisone+belimumab+cyclophosphamide, prednisone+rituximab.

In further embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with two or more agents useful for the treatment of LN, such as prednisone+mycophenolic acid analogs, prednisone+mycophenolic acid sodium, prednisone+Azathioprine, prednisone+Tacrolimus, prednisone+cyclosporine, prednisone+mizoribine.

Psoriasis Combination Therapy

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents that are useful for treating or ameliorating psoriasis. In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from acetaldehyde dehydrogenase inhibitor, adenosine A1 receptor antagonist, adenosine A3 receptor antagonist, adenosine A3 receptor agonists, ADP ribosyl cyclase-1 inhibitors, alpha 2 adrenoceptor modulator, apolipoprotein A antagonist, aryl hydrocarbon receptor agonist, Bcl-xL Bcl-2 associated death promotor modulators, beta amyloid antagonist, beta-catenin inhibitors, bromodomain containing protein inhibitor, Ca2+release activated Ca2+channel 1 inhibitors, calcineurin inhibitors, calcium channel inhibitors, cannabinoid CB1 receptor antagonist, cathepsin S inhibitors, CCR3 chemokine antagonists, CXCR2 chemokine antagonist, CXCR1/2 chemokine, CCR6 chemokine antagonist, CD223 modulators, CD40 ligand receptor antagonists, cell adhesion molecule inhibitors, cell surface glycoprotein MUC18 inhibitors, CREB binding protein inhibitors, CXCR4 chemokine modulators, cytokine receptor antagonist, cytosolic phospholipase A2 inhibitors, DHFR inhibitors, DYRK-1 alpha protein kinase inhibitor, EGFR family tyrosine kinase receptor inhibitors, enolase 1 inhibitor, eotaxin ligand inhibitors, FiFO ATP synthase modulator, free fatty acid receptor 2 agonist, free fatty acid receptor 3 agonist, galectin-3 inhibitors, glucocorticoid agonists, GM-CSF ligand inhibitors, GNRH receptor modulators, 5-HT 1a receptor antagonist, FGF receptor antagonist, GroEL protein 2 inhibitor, histamine H1 receptor antagonists, histamine H4 receptor antagonists, histone deacetylase-1 inhibitors, histone deacetylase-2 inhibitors, histone deacetylase-3 inhibitors, histone deacetylase-6 inhibitors, Hsp 90 inhibitor, IL-1 receptor antagonist, interleukin 1 like receptor 2 inhibitor, IL-2 receptor alpha subunit stimulator, IL-2 modulator, IL-10 antagonists, IL-12 antagonists, IL-17 agonist, IL17RA gene inhibitor, IL-17 antagonists, IL-23 antagonists, IL-8 antagonists, immunoglobulin like domain receptor 2 antagonist, insulin receptor substrate-1 inhibitors, interferon gamma receptor antagonists, interleukin 17 ligand inhibitors, interleukin 17A ligand inhibitors, interleukin 17A ligand modulators, interleukin 17F ligand inhibitors, interleukin 23A inhibitors, interleukin receptor 17A antagonists, interleukin receptor 17A modulators, interleukin-1 alpha ligand inhibitors, interleukin-1 beta ligand modulators, IRAK-4 protein kinase inhibitor, Itk tyrosine kinase inhibitor, JAK tyrosine kinase inhibitors, Jak1 tyrosine kinase inhibitors, Jak2 tyrosine kinase inhibitors, Jak3 tyrosine kinase inhibitors, KCNA voltage-gated potassium channel-3 inhibitors, Lck tyrosine kinase inhibitors, lysophosphatidate-1 receptor antagonists, MALT protein 1 inhibitors, MAP kinase inhibitors, membrane copper amine oxidase inhibitors, metalloprotease-1 inhibitors, mitochondrial 10 kDa heat shock protein stimulators, mTOR complex 1 inhibitor, mTOR complex 2 inhibitor, non receptor tyrosine kinase TYK2 antagonists, nuclear erythroid 2-related factor 2 stimulators, nuclear factor kappa B inhibitors, nucleoside reverse transcriptase inhibitors, oncostatin M receptor subunit beta inhibitor, opioid receptor delta antagonists, OX40 ligand inhibitor, parathyroid hormone ligand inhibitors, PDE 4 inhibitors, PDE 4b inhibitor, P2Y6 purinoceptor modulator; P-glycoprotein inhibitors, phosphoinositide-3 kinase delta inhibitors, phosphoinositide-3 kinase gamma inhibitors, phospholipase A2 inhibitors, programmed cell death ligand 1 modulators, programmed cell death protein 1 stimulator, P-selectin glycoprotein ligand-1 stimulators, retinoic acid receptor agonists, retinoic acid receptor gamma antagonists, retinoic acid receptor gamma inverse agonists, retinoid receptor agonists, retinoid X receptor agonists, retinoid X receptor modulators, retinoid Z receptor gamma agonists, retinoid Z receptor gamma inverse agonists, retinoid Z receptor gamma antagonist, rho associated protein kinase 2 inhibitors, ribonuclease P inhibitors, RIP-1 kinase inhibitor, sphingosine-1-phosphate receptor-1 antagonists, sphingosine-1-phosphate receptor-1 modulators, Src tyrosine kinase inhibitors, STAT-3 inhibitors, Syk tyrosine kinase inhibitor, T-box transcription factor TBX21 modulators, T-cell differentiation antigen CD6 inhibitors, T-cell surface glycoprotein CD8 inhibitors, T cell surface glycoprotein CD28 stimulator, TGF beta agonists, TLR-7 antagonists, TLR-8 antagonists, TLR-9 antagonists, TNF alpha ligand inhibitors, TNF alpha ligand modulators, TNF antagonists, TNF binding agents, TNF gene inhibitor, topoisomerase II inhibitors, TrkA receptor antagonists, tubulin binding agents, Tyk2 tyrosine kinase inhibitor, type II TNF receptor modulators, unspecified cytokine receptor antagonists, vitamin D3 receptor agonists, vitamin D3 receptor modulators, Wnt ligand inhibitor, and Wnt 5A ligand inhibitor.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from AP-005, 18C3 (anti-IL-1 alpha true human antibody), ABX-464, acitretin, adalimumab, adipocell, AFB-035, aganirsen, AKP-11, alefacept, alitretinoin, Amilo-5mer, aminopterin, amiselimod, apremilast, ASKP-1240, AST-005, ATI-2138, AVX-001, baricitinib, belapectin (GR-MD-02), bertilimumab, betamethasone, BI-655066, BI-730357, BI-730460, BI-730460, bimekizumab, BMS-986165, BMX-010, briakinumab, brodalumab, BTT-1023, C-82, calcipotriol, calcitriol, CC-90005, CCL-20LD, CD-10367, certolizumab pegol, CF-101, ciclosporin, CJM-112, CKBA, clobetasol propionate+tretinoin, CM-2489, CPL-409116, crisaborole, CS-12192, CT-327, CTX-101, dalazatide, DFD-06, dimethyl fumarate, dithranol, DLX-105, DSXS-1411, DSXS-1535, DUR-928, EDP-1815, etanercept, fluocinonide, FPP-003, GK-664-S, GLG-801, GLPG-3121, GLPG-3667, GLPG-3970, GLY-2028, GMDP, GSK-2800528, GSK-2831781, GSK-2981278A, guselkumab, halomethasone, HAT-1, IMO-3100, IMO-8400, inecalcitol, infliximab, INV-103, IR-444, IR-502, itolizumab, ixekizumab, JN-2528, KBL-697, KD-025, LAS-41004, LEO-124249, LEO-29102, LEO-32731, LEO-35299, lithium succinate, LNP-1955, LP-0200, M-1095, maxacalcitol, MDX-018, methotrexate, MOL-4249, mometasone, MP-1032, MSB-03, myristyl nicotinate, namilumab, neihulizumab, niclosamide, NLP-91, NP-000888, NVN-1000, olopatadine, orilotimod, P-3072, P-3073, PAT-1657, Pc4, pefcalcitol, PF-06700841, Prurisol, PRX-003, PRX-167700, PUR-0110, recombinant human LFA-3/antibody fusion protein, RON-2315, RTU-1096, S-414114, secukinumab, SHP-141, SMET-D1, SNK-01, SP-14019, SSS-07, tacalcitol, tazarotene, tildrakizumab, tirbanibulin (KX-01), tofacitinib, toreforant, tregalizumab, TU-2100, UCB-5857, UHE-105, ulobetasol, ustekinumab, VBY-891, voclosporin, VTP-43742, WBI-1001, and ZPL-389, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from:

-   -   acetaldehyde dehydrogenase inhibitor, including but not limited         to ADX-629;     -   adenosine A3 receptor agonists, including but not limited to         piclidenoson (CF-101);     -   adenosine A3 receptor antagonist, including but not limited to         PBF-1650;     -   ADP ribosyl cyclase-1 inhibitors, including but not limited to         IMO-3100;     -   5-HT la receptor antagonist, including but not limited to         AX-1602;     -   apolipoprotein A antagonist, including but not limited to         orticumab;     -   cytokine receptor antagonist, including but not limited to         tapinarof;     -   aryl hydrocarbon receptor modulator, including but not limited         to NTI-528 and RLV-102;     -   Bcl-xL Bcl-2 associated death promotor modulators, including but         not limited to Pc4;     -   beta-catenin inhibitors, including but not limited to C-82;     -   bromodomain containing protein inhibitor, including but not         limited to BOS-475;     -   Ca2+release activated Ca2+channel 1 inhibitors, including but         not limited to CM-2489 and PRCL-02;     -   calcineurin inhibitors, including but not limited to         voclosporin, pimecrolimus, tacrolimus, ciclosporin, HS-378,         oxeclosporin, OLO-400, ADV-P3, and CTX-006;     -   calcium channel inhibitors, including but not limited to         RP-3128;     -   cathepsin S inhibitors, including but not limited to VBY-129,         VBY-891, RWJ-445380, and CRA-028129;     -   CCR3 chemokine antagonists, including but not limited to         bertilimumab;     -   CXCR2 chemokine antagonist, including but not limited to         CCX-624;     -   CD223 modulators, including but not limited to GSK-2831781;     -   CD40 ligand receptor antagonists, including but not limited to         ASKP-1240, lucatumumab, and toralizumab;     -   cell adhesion molecule inhibitors, including but not limited to         BIRT-2584, PC-114, alicaforsen, IC-747, ICM-3, and ISIS-2302;     -   cell surface glycoprotein MUC18 inhibitors, including but not         limited to PRX-003 and imaprelimab;     -   CREB binding protein inhibitors, including but not limited to         C-82;     -   CXCR1/2 chemokine, including but not limited to LY-3041658;     -   CXCR4 chemokine modulators, including but not limited to         CD184-FK506 ADC;     -   cytosolic phospholipase A2 inhibitors, including but not limited         to AVX-001;     -   DHFR inhibitors, including but not limited to methotrexate,         CH-4051, CePep, CH-1504, MQX-5902, and MPI-2505;     -   DYRK-1 alpha protein kinase inhibitor, including but not limited         to VRN-02;     -   EGFR family tyrosine kinase receptor inhibitors, including but         not limited to erlotinib, icotinib hydrochloride, and SGT-210;     -   Enolase 1 inhibitor, including but not limited to HuL-001;     -   Eotaxin ligand inhibitors, including but not limited to         bertilimumab;     -   FIFO ATP synthase modulator, including but not limited to         LYC-30937;     -   FGF receptor antagonist, including but not limited to potassium         dobesilate;     -   free fatty acid receptor 2, 3 agonist, including but not limited         to SFA-002;     -   galectin-3 inhibitors, including but not limited to belapectin         (GR-MD-02);     -   glucocorticoid agonists, including but not limited to         betamethasone, clobetasol, auranofin, NM-135, DSXS-1538b, and         SEGRA;     -   GM-CSF ligand inhibitors, including but not limited to         namilumab;     -   GNRH receptor modulators, including but not limited to NL-001;     -   GroEL protein 2 inhibitor, including but not limited to         prozumab;     -   histamine H1 receptor antagonists, including but not limited to         olopatadine and loratadine+nortriptyline;     -   histamine H4 receptor antagonists, including but not limited to         toreforant and ZPL-389;     -   histone deacetylase-2 inhibitors, including but not limited to         KAR-1880;     -   histone deacetylase 1, 6, 2, 3 inhibitors, including but not         limited to remetinostat (SHP-141);     -   Hsp 90 inhibitor, including but not limited to CTXT-102;     -   TL-2 receptor alpha subunit stimulator, including but not         limited to NKTR-358;     -   TL-2 modulator; including but not limited to CC-92252;     -   IL-10 antagonists, including but not limited to pimecrolimus;     -   IL-12 antagonists, including but not limited to BOW-090,         briakinumab, FM-202, and apilimod;     -   IL-17 antagonists, including but not limited to ixekizumab,         secukinumab, AFB-035, KD-025, DLX-3003, EBI-028, M-1095,         IMO-3100, GR-1501, 608, vunakizumab, sonelokimab, AK-111,         HB-0017, and SIM-335;     -   IL-17 agonist, including but not limited to ZL-1102;     -   IL17RA gene inhibitor, including but not limited to XCUR-17;     -   TL-23 antagonists, including but not limited to tildrakizumab,         BI-655066, AMG-139, briakinumab, mirikizumab         (LY-3074828),FM-202, apilimod, LY-2525623, risankizumab, and         IBI-112;     -   TL-23 antagonist, including but not limited to ustekinumab and         AK-101;     -   TL-8 antagonists, including but not limited to BMS-986253         (MDX-018), AS-101, ABX-IL8, LI-312, SB-332235, and LF-216;     -   immunoglobulin like domain receptor 2 antagonist, including but         not limited to CGEN-15001;     -   insulin receptor substrate-1 inhibitors, including but not         limited to aganirsen;     -   interferon gamma receptor antagonists, including but not limited         to pimecrolimus, AMG-811, OA-1, AGT-1, mometasone+nortriptyline,         and fontolizumab;     -   interleukin 17 ligand inhibitors, including but not limited to         CJM-112, netakimab, and AFB-035;     -   interleukin 17A ligand inhibitors, including but not limited to         COVA-322, JS-005, and ABY-035/AFO2;     -   interleukin 17A ligand modulators, including but not limited to         QX-002-N;     -   interleukin 17A/17F ligand inhibitors, including but not limited         to bimekizumab;     -   interleukin 23A inhibitors, including but not limited to         guselkumab and QX-004-N;     -   interleukin receptor 17A antagonists, including but not limited         to brodalumab and LZM-012;     -   interleukin 1 like receptor 2 inhibitor, including but not         limited to spesolimab and imsidolimab;     -   interleukin-1 alpha ligand inhibitors, including but not limited         to bermekimab (CA-18C3);     -   interleukin-1 beta ligand modulators, including but not limited         to PUR-0110 and AR-100;     -   IRAK-4 protein kinase inhibitor, including but not limited to         BAY-1834845;     -   Itk tyrosine kinase inhibitor, including but not limited to         JTE-051;     -   JAK tyrosine kinase inhibitors, including but not limited to         CS-17380;     -   Jak1 tyrosine kinase inhibitors, including but not limited to         itacitinib, abrocitinib (PF-04965842), solcitinib, SHR-0302, and         filgotinib;     -   JAK1,2,3 tyrosine kinase inhibitor, including but not limited to         jaktinib;     -   JAkl,2 tyrosine kinase inhibitor, including but not limited to         baricitinib and ruxolitinib;     -   TYk2 tyrosine kinase inhibitor, including but not limited to         brepocitinib;     -   Jak1 tyrosine kinase inhibitor, including but not limited to         PF-06263276;     -   JAk 1, 3 tyrosine kinase inhibitor, including but not limited to         CS-944X, tofacitinib, and peficitinib;     -   KCNA voltage-gated potassium channel-3 inhibitors, including but         not limited to KPI-150, dalazatide, BNC-164, and SPS-4251;     -   Lck tyrosine kinase inhibitors, including but not limited to         BMS-350751 and NTRC-0625-0;     -   lysophosphatidate-1 receptor antagonists, including but not         limited to BMS-986202;     -   MAP kinase inhibitors, including but not limited to AIK-33 and         KIN-3032;     -   membrane copper amine oxidase inhibitors, including but not         limited to vepalimomab, BTT-1023, RTU-1096, and PRX-167700;     -   metalloprotease-1 inhibitors, including but not limited to         KIN-3032 and HMR-1571;     -   mitochondrial 10 kDa heat shock protein stimulators, including         but not limited to INV-103;     -   Non receptor tyrosine kinase TYK2 antagonists, including but not         limited to SAR-20347, ICP-332, and SDC-1801;     -   nuclear erythroid 2-related factor 2 stimulators, including but         not limited to dimethyl fumarate and XP-23829;     -   nuclear factor kappa B inhibitors, including but not limited to         S-414114, VGX-1027, AKBA, SP-100030, and YP-008;     -   nucleoside reverse transcriptase inhibitors, including but not         limited to Prurisol;     -   oncostatin M receptor subunit beta inhibitor, including but not         limited to vixarelimab;     -   Opioid receptor delta antagonists, including but not limited to         HS-378;     -   OX40 ligand inhibitor, including but not limited to KY-1005;     -   P38 MAP kinase inhibitor, including but not limited to AMG-101,         AIK-3, VGX-1027, AIK-al, BMS-582949, doramapimod, semapimod,         TA-5493, HEP-689, and RWJ-68354;     -   parathyroid hormone ligand inhibitors, including but not limited         to inecalcitol;     -   PDE 4 inhibitors, including but not limited to apremilast,         roflumilast, orismilast, MK-0873, Ro-20-1724, HMR-1571,         RPR-122818, HPP-737, crisaborole, and DC-591042;     -   PDE 4b inhibitor, including but not limited to GRT-6015;     -   TNF alpha ligand inhibitor, including but not limited to         Hemay-005;     -   P-Glycoprotein inhibitors, including but not limited to         boningmycin;     -   Beta amyloid antagonist, including but not limited to GC-021109;     -   phosphoinositide-3 kinase delta inhibitors, including but not         limited to seletalisib (UCB-5857);     -   mTOR complex 2 inhibitor, including but not limited to         bimiralisib;     -   phosphoinositide-3 kinase gamma inhibitors, including but not         limited to TAT-N25 peptide;     -   phospholipase A2 inhibitor, including but not limited to         ZPL-521, Project P-0229, BMS-181162, and BMS-188184;     -   programmed cell death ligand 1 modulators, including but not         limited to GX-P2;     -   programmed cell death protein 1 stimulator, including but not         limited to LY-3462817 and CC-90006;     -   P-selectin glycoprotein ligand-1 stimulators, including but not         limited toneihulizumab;     -   P-selectin glycoprotein ligand-1, including but not limited to         AbGn-168H;     -   retinoic acid receptor agonists, including but not limited to         acitretin, tazarotene, tretinoin, tazarotene arotinoid         trometamol, CD-1599, AM-580, BMS-181163, and CPR-2005;     -   retinoic acid receptor gamma antagonists, including but not         limited to VTP-43742 and BBI-6000;     -   retinoic acid receptor gamma inverse agonists, including but not         limited to GSK-2981278A and JNJ-3534;     -   retinoid receptor agonists, including but not limited to RASP;     -   retinoid X receptor agonists, including but not limited to         LGD-1550;     -   retinoid X receptor modulators, including but not limited to         bexarotene, alitretinoin, ALRT-1069, LGD-1069, and Net-41B;     -   retinoid Z receptor gamma agonists, including but not limited to         NCE-407;     -   retinoid Z receptor gamma inverse agonists, including but not         limited to ARN-6039, IMU-935, BOS-172767, SAR-441169, and         INV-17;     -   retinoid Z receptor gamma antagonist, including but not limited         to AUR-101, JTE-451, ESR-114, ABBV-157, and AZD-0284;     -   rho associated protein kinase 2 inhibitors, including but not         limited to KD-025;     -   RIP-1 kinase inhibitor, including but not limited to         GSK-2982772, DNL-758, and VRN-04;     -   ribonuclease P inhibitors, including but not limited to RASP;     -   sphingosine-1-phosphate receptor-1 modulators, including but not         limited to amiselimod, AKP-11, FP-253, and CS-0777;     -   sphingosine-1-phosphate receptor-1 agonist, including but not         limited to AK-119, SCD-044, and SYL-927;     -   sphingosine-1-phosphate receptor-5 modulator, including but not         limited to CBP-307;     -   Src tyrosine kinase inhibitors, including but not limited to         tirbanibulin (KX-01);     -   STAT-3 inhibitors, including but not limited to TAK-114,         GLG-801, and MOL-4249;     -   Syk tyrosine kinase inhibitor, including but not limited to         HMPL-523;     -   T-box transcription factor TBX21 modulators, including but not         limited to SB-020;     -   T-cell differentiation antigen CD6 inhibitors, including but not         limited to itolizumab;     -   T-cell surface glycoprotein CD8 inhibitors, including but not         limited to tregalizumab;     -   T cell surface glycoprotein CD28 stimulator, including but not         limited to theralizumab;     -   TGF beta agonists, including but not limited to tregalizumab;     -   TLR-7 antagonists, including but not limited to IMO-3100;     -   TLR-9 antagonists, including but not limited to IMO-3100 and         GNKS-356;     -   TLR 7,8,9 antagonist, including but not limited to IMO-8400;     -   TNF alpha ligand inhibitors, including but not limited to         adalimumab, CHS-1420, BAX-2923, MSB-11022, ABP-501, MYL-1401A,         infliximab, certolizumab pegol, AST-005, etanercept, opinercept,         ISIS-104838, DLX-105, SSS-07, DLX-2751, DLX-105, Debio-0512,         TAQ-588, adalimumab, placulumab, PMI-001, CYT-020-TNFQb,         AN-0128, CYT-007-TNFQb, SYI-2074, YP-008, SCT-640A, SBT-104, and         T-1649;     -   TNF alpha ligand modulators, including but not limited to         PUR-0110, CDP-571, and ACU-D2;     -   TNF antagonists, including but not limited to certolizumab         pegol, SCB-808, BAX-2200, CT-P05, SCB-131, GSK-2800528,         onercept, and ALS-00T2-0501;     -   TNF binding agents, including but not limited to adalimumab,         certolizumab pegol SCB-131, onercept, CT-P17, SBC-808, ABP-501,         MYL-1401A, MSB-11022, BAX-2923, CHS-1420, and BCD-057;     -   TNF gene inhibitor, including but not limited to AST-005;     -   topoisomerase II inhibitors, including but not limited to         GPX-150;     -   TrkA receptor antagonists, including but not limited to VM-902A,         CT-327, K-252a, and lestaurtinib;     -   tubulin binding agents, including but not limited to KX-01 and         paclitaxel;     -   Tyk2 tyrosine kinase inhibitor, including but not limited to         deucravacitinib, PF-06826647, ABBV-712, and CS-43001;     -   type II TNF receptor modulators, including but not limited to         TNR-001, BAX-2200, and SCB-131;     -   unspecified cytokine receptor antagonists, including but not         limited to tetrathiomolybdate, JD-4000, X-083-NAB, SPHD-400,         pimecrolimus, and HMPL-010;     -   vitamin D3 receptor agonists, including but not limited to         inecalcitol, maxacalcitol, calcipotriol, falecalcitriol,         maxacalcitol, calcitriol NS-78, tacalcitol, calcipotriol,         calcithiazol, ecalcidene, lexacalcitol, atocalcitol, and         Ro-65-2299;     -   vitamin D, D3 receptor modulators, including but not limited to         VS-320 and VS-105;     -   Wnt ligand inhibitor, including but not limited to SM-04755; and     -   Wnt 5A ligand inhibitor, including but not limited to Box-5.

Rheumatoid Arthritis Combination Therapy

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents that are useful for treating or ameliorating rheumatoid arthritis. In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from 14-3-3 protein eta inhibitors, 5-lipoxygenase inhibitors, ab1 tyrosine kinase inhibitors, ACTH receptor agonists, adenosine A3 receptor agonists, adenosine deaminase inhibitors, ADP ribosyl cyclase-1 inhibitors, ADP ribosyl cyclase-1 modulators, ADP ribosylation factor 6 inhibitors, adrenocorticotrophic hormone ligands, aggrecanase-2 inhibitors, albumin modulators, anti-TNF steroid conjugate, adenosine A1 receptor antagonist, annexin A1 modulator, AP1 transcription factor inhibitors, apolipoprotein B modulator, aryl hydrocarbon receptor agonist plus autoantigen, basigin inhibitors, bcr protein inhibitors, B-lymphocyte antigen CD19 inhibitors, B-lymphocyte antigen CD20 inhibitors, B-lymphocyte antigen CD20 modulators, B-lymphocyte cell adhesion molecule inhibitor, B-lymphocyte stimulator ligand inhibitors, bradykinin receptor modulators, BRAF gene inhibitors, branched amino acid aminotransferase 1 inhibitors, bromodomain containing protein inhibitors, Btk tyrosine kinase inhibitors, cadherin-11 antagonists, calcineurin inhibitors, calcium channel inhibitors, calreticulin inhibitor, carbonic anhydrase inhibitors, cathepsin K inhibitors, cathepsin S inhibitors, CCR1 chemokine antagonists, CCR2 chemokine antagonists, CCR3 gene modulators, CCR5 chemokine antagonists, CD126 antagonists, CD29 modulators, CD3 modulators, CD39 agonists, CD4 agonists, CD4 antagonists, CD40 ligand inhibitors, CD40 ligand receptor antagonists, CD40 ligand receptor modulators, CD52 antagonists, CD73 agonists, CD79b modulators, CD80 antagonists, CD86 antagonists, CD95 antagonists, cell adhesion molecule inhibitors, chaperonin modulator, choline kinase inhibitors, clusterin stimulators, complement C5 factor inhibitors, complement factor stimulators, C-reactive protein inhibitors, CSF-1 antagonists, CXC10 chemokine ligand inhibitors, CXCR4 chemokine antagonists, cyclin-dependent kinase inhibitor 1 inhibitors, cyclin-dependent kinase-2 inhibitors, cyclin-dependent kinase-4 inhibitors, cyclin-dependent kinase-5 inhibitors, cyclin-dependent kinase-6 inhibitors, cyclin-dependent kinase-7 inhibitors, cyclin-dependent kinase-9 inhibitors, cyclooxygenase 2 inhibitors, cyclooxygenase 2 modulators, cyclooxygenase inhibitors, cytosolic phospholipase A2 inhibitors, cytotoxic T-lymphocyte protein-4 modulators, cytotoxic T-lymphocyte protein-4 stimulators, deoxyribonuclease gamma stimulator, DHFR inhibitors, diamine acetyltransferase inhibitors, dihydroorotate dehydrogenase inhibitors, DYRK-1 alpha protein kinase inhibitor, elongation factor 2 inhibitors, enolase 1 inhibitor, eotaxin 2 ligand inhibitors, EP4 prostanoid receptor antagonists, erythropoietin receptor agonists, factor XIIa antagonist, Fas ligands, FGF-2 ligand inhibitors, FK506 binding protein-12 modulators, folate antagonists, folate receptor agonists, folate receptor beta antagonists, folate receptor modulators, fractalkine ligand inhibitors, fyn tyrosine kinase inhibitors, G protein coupled receptor 15 antagonists, GABA A receptor modulators, glucocorticoid agonists, glucocorticoid antagonists, glucocorticoid induced leucine zipper stimulators, GM-CSF ligand inhibitors, GM-CSF receptor antagonists, GM-CSF receptor modulators, growth regulated protein alpha ligand inhibitors, H+K+ATPase inhibitors, histamine H4 receptor antagonists, histone deacetylase inhibitors, histone deacetylase-6 inhibitors, HIV-1 gp120 protein inhibitors, HLA class II antigen DQ-2 alpha modulators, HLA class II antigen inhibitors, HLA class II antigen modulators, Hsp 70 family inhibitors, hypoxia inducible factor-1 inhibitors, IFNB gene stimulators, I-kappa B kinase beta inhibitors, I-kappa B kinase inhibitors, IL-1 antagonists, IL-10 agonists, IL-11 agonists, IL-12 antagonists, IL-15 antagonists, IL-17 antagonists, IL-17 receptor modulators, IL-18 receptor accessory protein antagonist, IL-8 ligand inhibitors, IL-2 agonists, IL-2 antagonists, IL-21 antagonists, IL-23 antagonists, IL-3 antagonists, IL-4 agonists, IL-6 antagonists, IL-6 receptor modulators, IL-6 neutralizing human antibodies, anti-IL6 antibody, immunoglobulin antagonists, immunoglobulin Gi agonists, immunoglobulin G1 antagonists, immunoglobulin G1 modulators, immunoglobulin G2 antagonists, immunoglobulin G2 modulators, immunoglobulin gamma Fc receptor II modulators, immunoglobulin gamma Fc receptor IIB antagonists, immunoglobulin kappa modulators, immunoglobulin M antagonists, inducible nitric oxide synthase inhibitors (iNOS inhibitors), inosine monophosphate dehydrogenase inhibitors, insulin sensitizers, integrin alpha-1/beta-1 antagonists, integrin alpha-4/beta-1 antagonists, integrin alpha-9 antagonist, integrin antagonists, interferon beta ligands, interferon gamma ligands, interleukin 17A ligand inhibitors, interleukin 17F ligand inhibitors, interleukin 23A inhibitors, interleukin ligands, interleukin receptor 17A antagonists, interleukin-1 beta ligand inhibitors, interleukin-10 ligands, interleukin-2 ligands, interleukin-4 ligands, Interleukin-6 ligand inhibitors, Itk tyrosine kinase inhibitors, JAK tyrosine kinase inhibitors, Jak1 tyrosine kinase inhibitors, Jak2 tyrosine kinase inhibitors, JAK3 gene inhibitors, Jak3 tyrosine kinase inhibitors, Jun N terminal kinase inhibitors, KCNA voltage-gated potassium channel-3 modulators, kelch like ECH associated protein 1 modulators, kit tyrosine kinase inhibitors, LanC like protein 2 modulators, leukotriene BLT receptor antagonist, LITAF gene inhibitors, lymphocyte function antigen-3 receptor antagonists, Lyn tyrosine kinase inhibitors, macrophage-drug conjugate (MDC), macrophage mannose receptor 1 modulators, MAdCAM inhibitors, MAP kinase modulators, MAP3K2 gene inhibitors, MAPKAPK5 inhibitors, matrix metalloprotease inhibitors, MCL1 gene inhibitors, MEK protein kinase inhibitors, MEK-1 protein kinase inhibitors, MEK-2 protein kinase inhibitors, membrane copper amine oxidase inhibitors, metalloprotease-2 inhibitors, metalloprotease-9 inhibitors, methylprednisolone, midkine ligand inhibitors, mitochondrial 10 kDa heat shock protein stimulators, mTOR complex 1 inhibitors, mTOR inhibitors, NAD ADP ribosyltransferase stimulators, NAMPT gene inhibitors, NF kappa B inhibitor stimulators, NFAT gene inhibitors, NFE2L2 gene stimulators, nicotinic acetylcholine receptor antagonists, NK cell receptor modulators, NKG2 A B activating NK receptor antagonists, NKG2 D activating NK receptor antagonists, nuclear erythroid 2-related factor 2 stimulators, nuclear factor kappa B inhibitors, nuclear factor kappa B modulators, nuclear factor kappa B p105 inhibitors, opioid growth factor receptor agonists, opioid receptor delta antagonists, osteoclast differentiation factor antagonists, osteoclast differentiation factor ligand inhibitors, oxidoreductase inhibitors, P2X7 purinoceptor agonists, p38 MAP kinase alpha inhibitors, p38 MAP kinase inhibitors, PDE 4 inhibitors, PDE 5 inhibitors, PDGF receptor agonists, PDGF receptor antagonists, PDGF-B ligand inhibitors, PERK gene inhibitors, phosphoinositide-3 kinase delta inhibitors, phosphoinositide-3 kinase gamma inhibitors, phospholipase A2 inhibitors, platelet activating factor receptor antagonists, PPAR gamma agonists, programmed cell death protein 1 modulators, prostaglandin D synthase stimulators, protein arginine deiminase inhibitors, protein tyrosine kinase inhibitors, protease-activated receptor-2 antagonist, PurH purine biosynthesis protein inhibitors, rho associated protein kinase 2 inhibitors, seprase inhibitors, signal transducer CD24 modulators, signal transduction inhibitors, sodium glucose transporter-2 inhibitors, sphingosine 1 phosphate phosphatase modulators, STAT3 gene inhibitors, serum amyloid A protein modulator, superoxide dismutase stimulators, SYK family tyrosine kinase inhibitors, Syk tyrosine kinase inhibitors, syndecan-1 inhibitors, T cell receptor antagonists, T cell receptor modulators, T cell surface glycoprotein CD28 inhibitors, T cell surface glycoprotein CD28 stimulators, TAK1 binding protein modulators, talin modulators, T-cell differentiation antigen CD6 inhibitors, T-cell surface glycoprotein CD8 inhibitors, tenascin modulators, TGF beta agonists, thymulin agonists, TLR-2 antagonists, TLR-4 antagonists, TLR-9 antagonists, TNF alpha ligand inhibitors, TNF alpha ligand modulators, TNF antagonists, TNF gene inhibitors, TNF receptor modulators, TNFSF11 gene inhibitors, transcription factor p65 inhibitors, transcription factor RelB inhibitors, transferrin modulators, transthyretin modulator, tumor necrosis factor 13C receptor antagonists, tumor necrosis factor 15 ligand inhibitors, tumor necrosis factor ligand 13 inhibitors, tumor necrosis factor ligand inhibitors, type I IL-1 receptor antagonists, type I TNF receptor antagonists, type II TNF receptor modulators, unspecified GPCR agonists, VEGF receptor antagonists, VEGF-2 receptor antagonists, VEGF-2 receptor modulators, VEGF-B ligand inhibitors, X-linked inhibitor of apoptosis protein inhibitors, and zap70 tyrosine kinase inhibitors.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from 99mTc labelled annexin V-128, abatacept, abatacept biosimilar, ABBV-257, ABT-122, ABT-494, acalabrutinib, aceclofenac, actarit, AdMSCs, MS-392, adalimumab, adalimumab biosimilar, adalimumab follow-on biologic, AK-106, ALX-0061, Amilo-5MER, aminopterin, AMT-101, anakinra, anakinra biosimilar, anakinra follow-on biologic, annexuzlimab, ARG-301, ARQ-250, ASLAN-003, ASP-5094, AT-132, AZD-9567, baricitinib, BI-655064, bimekizumab, BiP (rheumatoid arthritis), BLHP-006, blisibimod, BMS-986104, BMS-986142, ABBV-105, BTT-1023, canakinumab, Cartistem, CCX-354, CD24-IgFc, celecoxib, cerdulatinib, certolizumab pegol, CF-101, CFZ-533, CHR-5154, cibinetide, ciclosporin, clazakizumab, CNTO-6785, corticotropin, CR-6086, CreaVax-RA, CWG-92, CWG-940, Cx-611, DE-098, DEN-181, deflazacort, Rheumavax, denosumab, diacerein, diclofenac, DWJ-1421, E-6011, eicosapentaenoic acid monoglycerides, etanercept, etanercept biosimilar, etanercept follow-on biologic, etodolac, etoricoxib, filgotinib, fosdagrocorat, GLPG-3970, gerilimzumab, ginsenoside C-K, givinostat, GLPG-4399, goat polyclonal antibodies, golimumab, GS-5745, GS-9876, GSK-3196165, HHT-109, HM-71224, HMPL-523, HST-003, hyaluronate sodium, (S)-hydroxychloroquine, IB-RA (injectable, rheumatoid arthritis), IB-RA (oral, rheumatoid arthritis), IcanoMAB, ICP-022, iguratimod, IMD-2560, imidazole salicylate, infliximab, infliximab biobetter, infliximab biosimilar, CT-P13, INSIX RA, interferon gamma follow-on biologic, interleukin-2 (injectable), interleukin-2 follow-on biologic, INV-103, IR-501, itolizumab, JNJ-40346527, Ka Shu Ning, KB-312, KD-025, ketoprofen+omeprazole, KINE-101, LB-600, leflunomide, lenzilumab, LLDT-8, LNK-01001, LNP-1955, lumiracoxib, LY-3090106, masitinib, mavrilimumab, MBS-2320, MEDI-5117, meloxicam, methotrexate, MGD-010, misoprostol+diclofenac, MM-A01-01, monalizumab, MORAb-022, MPC-300-IV, MRC-375, nabumetone, namilumab, naproxen+esomeprazole, naproxen+esomeprazole strontium, NIP-046, ocaratuzumab, ofatumumab, OHR-118, olokizumab, OM-89, once-daily naproxen (oral controlled release, pain), ONO-4059, Oralgam, ozoralizumab, PAR-2 inhibitors, peficitinib, pelubiprofen, PF-06687234, piperidone hydrochloridum, piroxicam, prednisolone, prednisone, Procell, Prosorba, PRT-2607, PRTX-100, PRX-167700, QBSAU, rabeximod, RCT-18, recombinant human CD22 monoclonal antibody (iv infusion), Lonn Ryonn Pharma/SinoMab Bioscience (Shenzhen), RA-Curcusome, recombinant human interleukin-1 receptor antagonist (rheumatoid arthritis), recombinant human interleukin-2 recombinant TNF receptor 2-Fc fusion protein mutant, RG-6125, RhuDex, rifabutin+clarithromycin+clofazimine, rituximab, rituximab biosimilar, Toritz, rituximab follow-on biologic, RPI-78, SAN-300, sarilumab, SBI-087, seliciclib, SHR-0302, sirukumab, spebrutinib, SR-047, SSS-07, KDDF-201110-06, Syn-1002, T-5224, TAB-08, tacrolimus, TAK-020, TAK-079, tarenflurbil (transdermal spraygel, skin disease/rheumatoid arthritis), technetium Tc 99m tilmanocept, technetium[99Tc]methylenediphosphonate, tenoxicam, Debio-0512, tocilizumab, tofacitinib, tofacitinib citrate, TQG-2813, Trichuris suis ova, umbilical cord-derived mesenchymal stem cells (iv, RA/liver disease), ustekinumab, VAY-736, VB-201, WF-10, XmAb-5871, YH-1713, YHB-1411-2, YRA-1909, and ZM-008, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one, two, three, or four additional therapeutic agents selected from:

-   -   14-3-3 protein eta inhibitors, including but not limited to         anti-AGX-020 mAbs (rheumatoid arthritis) and Augurex;     -   5-Lipoxygenase inhibitors, including but not limited to         darbufelone, tebufelone, ZD-2138, etalocib, PGV-20229, L-708780,         T-0757, T-0799, ZM-216800, L-699333, BU-4601A, and SKF-104351;     -   5-Lipoxygenase/Cyclooxygenase inhibitors, including but not         limited to tenoxicam, licofelone, tenidap, tepoxalin, flobufen,         SKF-86002, WY-28342, and CI-986;     -   5-Lipoxygenase/PPAR gamma agonists, including but not limited to         etalocib;     -   Abl tyrosine kinase inhibitors/Bcr protein inhibitors/Kit         tyrosine kinase inhibitors/PDGF receptor antagonists/Signal         transduction inhibitors, including but not limited to imatinib;     -   ACTH receptor agonists/Adrenocorticotrophic hormone         ligands/Opioid growth factor receptor agonists, including but         not limited to FAR-404 and metenkefalin acetate+tridecactide         acetate;     -   adenosine A1 receptor antagonist, including but not limited to         CP-25;     -   adenosine A3 receptor agonists, including but not limited to         CF-101 (piclidenoson);     -   adenosine deaminase inhibitors, cladribine, pentostatin, and         FR-221647;     -   ADP ribosyl cyclase-1 inhibitors, including but not limited to         daratumumab;     -   ADP ribosyl cyclase-1 modulators/syndecan-1 inhibitors,         including but not limited to indatuximab ravtansine;     -   ADP ribosylation factor 6 inhibitors, including but not limited         to NAV-2729;     -   adrenocorticotrophic hormone ligands, including but not limited         to corticotropin and Mallinckrodt;     -   aggrecanase-2/TNF gene inhibitors, including but not limited to         GIBH-R-001-2;     -   albumin modulators, including but not limited to ONS-1210;     -   albumin modulators/IL-6 antagonists, including but not limited         to ALX-0061 (vobarilizumab);     -   albumin modulators/TNF alpha ligand inhibitors, including but         not limited to HOT-3010;     -   AP1 transcription factor/nuclear factor kappa B inhibitors,         including but not limited to tarenflurbil and SP-100030;     -   anti-TNF steroid antibody-drug conjugates (anti-TNF-GRM),         including but not limited to ABBV-3373 and ABBV-154;     -   basigin inhibitors/branched amino acid aminotransferase         1/metalloprotease-9 inhibitors/metalloprotease-2 inhibitors,         including but not limited to ERG-240;     -   BET inhibitors, including but not limited to GSK-3358699;     -   bispecific anti-CD86/IL-10, including but not limited to         APVO-210;     -   bispecific humanized monoclonal antibody targeted against BAFF         and IL-17A, including but not limited to tibulizumab;     -   bispecific antibody-peptide conjugate (BAFF/ICOSL), including         but not limited to AMG-570;     -   B-lymphocyte antigen CD19 inhibitors, including but not limited         to MDX-1342;     -   B-lymphocyte antigen CD19 inhibitors/immunoglobulin gamma Fc         receptor IIB antagonists, including but not limited to         XmAb-5871;     -   B-lymphocyte antigen CD20 inhibitors, including but not limited         to ocrelizumab, ofatumumab, rituximab, ABP-798, Maball, Mabtas,         Reditux, Zytux, veltuzumab, ocaratuzumab, BLX-301, IDEC-102,         ABP-798, GP-2013, MK-8808, HLX-01, CT-P10, TL-011, PF-05280586,         IBPM-OO1RX, IBI-301, AME-133v, BCD-020, BT-D004, SAIT-101, and         JHL-1101;     -   B-lymphocyte antigen CD20 modulators, including but not limited         to SBI-087, TRU-015, DXL-625, and MabionCD20;     -   B-lymphocyte cell adhesion molecule inhibitor, including but not         limited to SM-06;     -   B-lymphocyte stimulator ligand inhibitors, including but not         limited to belimumab, RCT-18, blisibimod, tabalumab, and         briobacept;     -   B-lymphocyte stimulator ligand/Tumor necrosis factor ligand 13         inhibitors, including but not limited to atacicept;     -   bradykinin receptor modulators/histone deacetylase         inhibitors/P2X7 purinoceptor agonists, including but not limited         to givinostat;     -   BRAF gene/MEK protein kinase/PERK gene inhibitors, including but         not limited to binimetinib;     -   Bromodomain containing protein inhibitors, including but not         limited to RVX-297, ZEN-003694     -   Btk tyrosine kinase inhibitors, including but not limited to         AC-0058, acalabrutinib, HM-71224, spebrutinib, BMS-986142,         TAK-020, tirabrutinib (ONO-4059), TAS-5315, ABBV-105, GDC-0834,         EBI-1459, BMS-986195, evobrutinib, fenebrutinib, SIMM-016, and         YZJ-3058;     -   Btk tyrosine kinase inhibitors/Syk tyrosine kinase         inhibitors/VEGF-2 receptor antagonists, including but not         limited to CG-026806;     -   Btk tyrosine kinase inhibitors/IL-6 antagonists, including but         not limited to RN-486;     -   Btk tyrosine kinase/Jak1 tyrosine kinase inhibitors, including         but not limited to upadacitinib+ABBV-105;     -   Btk tyrosine kinase/Jak3 tyrosine kinase inhibitors, including         but not limited to AC-0025;     -   cadherin-11 antagonists, including but not limited to RG-6125;     -   calcineurin inhibitors, including but not limited to         ciclosporin;     -   calcineurin inhibitors/opioid receptor delta antagonists,         including but not limited to HS-378;     -   calcium channel inhibitors, including but not limited to         RP-3128;     -   calreticulin inhibitor, including but not limited to ALB-001 and         ZYBK-2;     -   carbonic anhydrase/cyclooxygenase 2 inhibitors, including but         not limited to polmacoxib;     -   cathepsin K inhibitors, including but not limited to CRA-013783         and VEL-0230;     -   cathepsin K/cathepsin S inhibitors, including but not limited to         AM-3876 and NPI-2019;     -   cathepsin S inhibitors, including but not limited to MIV-247 and         RWJ-445380;     -   CCR1 chemokine antagonists, including but not limited to BX-471,         BMS-817399, BI-638683, CCX-354, MLN-3701, MLN-3897, CP-481715,         and PS-375179;     -   CCR2 chemokine antagonists, including but not limited to MK-0812         and AZD-6942;     -   CCR3 gene modulators/eotaxin 2 ligand inhibitors, including but         not limited to CM-102;     -   CCR5 chemokine antagonists, including but not limited to         OHR-118, NIBR-6465, AZD-5672, and AZD-8566;     -   CD29 modulators/interleukin-10 ligands, including but not         limited to PF-06687234;     -   CD3 modulators, including but not limited to otelixizumab;     -   CD39/CD73 agonists, including but not limited to AAV5-CD39/CD73         (rheumatoid arthritis), and Arthrogen;     -   CCR5 chemokine antagonists/CD4 agonists/HIV-1 gpl20 protein         inhibitors, including but not limited to maraviroc;     -   CD4 antagonists, including but not limited to zanolimumab,         MTRX-1011A, BW-4162W94, EP-1645, clenoliximab, and         DerG-PG275Cit;     -   CD40 ligand inhibitors, including but not limited to         dapirolizumab pegol, and TNX-1500;     -   CD40 ligand receptor antagonists, including but not limited to         BI-655064, anti-CD40-XTEN, teneliximab, VIB-4920, and iscalimab;     -   CD40 ligand receptor modulators/immunoglobulin G1 modulators,         including but not limited to CFZ-533;     -   CD52 antagonists/clusterin stimulators, including but not         limited to alemtuzumab;     -   bispecific CD32B/CD79B antibody, including but not limited to         PRV-3279 (MGD-010);     -   CD80 antagonists, including but not limited to abatacept         biobetter;     -   CD80 antagonists/T cell surface glycoprotein CD28 inhibitors,         including but not limited to RhuDex;     -   CD80 antagonists/CD86 antagonists, including but not limited to         XENP-9523 and ASP-2408;     -   CD86 antagonists, including but not limited to abatacept         biosuperior;     -   CD86 antagonists/cytotoxic T-lymphocyte protein-4 modulators,         including but not limited to ES-210;     -   CD95 antagonists, including but not limited to DE-098 and         CS-9507;     -   Cell adhesion molecule inhibitors, including but not limited to         alicaforsen, NPC-17923, TK-280, and PD-144795;     -   Chemokine receptor antagonists, including but not limited to         PF-06835375;     -   Complement C5 factor inhibitors, including but not limited to         eculizumab,     -   Complement C5 factor inhibitors/IL-1 antagonists, including but         not limited to antisense oligonucleotides (rheumatoid arthritis)         and Leiden University Medical Center Complement Factor         stimulators, including but not limited to CM-101;     -   C-reactive protein inhibitors, including but not limited to         ISIS-353512;     -   C-reactive protein inhibitors/cyclooxygenase 2         inhibitors/Nuclear factor kappa B inhibitors/immunoglobulin M         antagonists/IL-2 receptor antagonists/PGE2 antagonists:         IB-RACSF-1 antagonists, including but not limited to masitinib,         FPA-008, JNJ-27301937, JNJ-40346527, PLX-5622, CT-1578,         PD-360324, and JNJ-28312141;     -   CSF-1 antagonists/Fyn tyrosine kinase inhibitors/Kit tyrosine         kinase inhibitors/Lyn tyrosine kinase inhibitors/NK cell         receptor modulators/PDGF receptor antagonists, including but not         limited to masitinib;     -   CXC10 chemokine ligand inhibitors, including but not limited to         946414-98-8 and BMS-936557;     -   CXCR4 chemokine antagonists, including but not limited to         plerixafor;     -   CDK-2/7/9 inhibitors/MCL1 gene inhibitors, including but not         limited to seliciclib;     -   CDK-1/2/5/7/9 inhibitors, including but not limited to BP-14;     -   Chaperonin modulator, including but not limited to IRL-201805;     -   cyclooxygenase 2 inhibitors, including but not limited to         celecoxib, etoricoxib, meloxicam, and lumiracoxib;     -   cyclooxygenase 2/oxidoreductase inhibitors, including but not         limited to etodolac;     -   cyclooxygenase 2 modulators, including but not limited to         DRGT-46;     -   cyclooxygenase inhibitors, including but not limited to         aceclofenac, diclofenac, naproxcinod, naproxen etemesil,         nabumetone, Aleve, pelubiprofen, LY-210073, NS-398, bromfenac,         L-746483, LY-255283, ibuprofen, flurbiprofen, SC-57666, and         bermoprofen;     -   cyclooxygenase inhibitors/H+K+ATPase inhibitors, including but         not limited to naproxen+esomeprazole strontium;     -   cyclooxygenase inhibitors/PGE1 agonists, including but not         limited to misoprostol+diclofenac;     -   cyclooxygenase inhibitors/oxidoreductase inhibitors, including         but not limited to imidazole salicylate;     -   cytosolic phospholipase A2 inhibitors/phospholipase A2         inhibitors, including but not limited to AVX-002;     -   cytotoxic T-lymphocyte protein-4 stimulators/T cell surface         glycoprotein CD28 inhibitors, including but not limited to         abatacept, BMS-188667, and belatacept;     -   deoxyribonuclease gamma stimulator, including but not limited to         NTR-441;     -   DHFR inhibitors, including but not limited to MPI-2505, Jylamvo,         and ZeNEO-Methotrexate;     -   DHFR inhibitors/folate antagonists/transferrin modulators,         including but not limited to methotrexate;     -   diamine acetyltransferase inhibitors, including but not limited         to diminazene aceturate;     -   dihydroorotate dehydrogenase inhibitors, including but not         limited to ASLAN-003, HWA-486, and ABR-224050;     -   dihydroorotate dehydrogenase/protein tyrosine kinase inhibitors,         including but not limited to leflunomide;     -   DYRK-1 alpha protein kinase inhibitor, including but not limited         to VRN-02;     -   elongation factor 2 inhibitors/interleukin-2 ligands/NAD ADP         ribosyltransferase stimulators, including but not limited to         denileukin diftitox;     -   enolase 1 inhibitor, including but not limited to HuL-001;     -   EP4 prostanoid receptor antagonists, including but not limited         to CR-6086;     -   erythropoietin receptor agonists, including but not limited to         cibinetide;     -   Fas ligands, including but not limited to AP-300;     -   FGF-2 ligand inhibitors, including but not limited to RBM-007;     -   FK506 binding protein-12 modulators/mTOR inhibitors, including         but not limited to temsirolimus;     -   folate antagonists/transferrin modulators/DHFR inhibitors,         including but not limited to MBP-Y003;     -   folate receptor modulators, including but not limited to         technetium (99mTc) etarfolatide;     -   fractalkine ligand inhibitors, including but not limited to         E-6011;     -   Fyn tyrosine kinase inhibitors/GABA A receptor         modulators/cyclooxygenase 2 inhibitors/dihydroorotate         dehydrogenase inhibitors, including but not limited to         laflunimus;     -   glucocorticoid agonists, including but not limited to         prednisone, prednisolone, and fosdagrocorat;     -   glucocorticoid antagonists, including but not limited to         REC-200;     -   glucocorticoid induced leucine zipper stimulators, including but         not limited to ART-GO1;     -   GM-CSF ligand inhibitors, including but not limited to         namilumab, gimsilumab (MORAb-022), and TJM-2;     -   GM-CSF receptor antagonists, including but not limited to         mavrilimumab;     -   GM-CSF receptor modulators, including but not limited to         GSK-3196165 and otilimab;     -   growth regulated protein alpha ligand inhibitors/AP1         transcription factor inhibitors/TL-6 antagonists/interleukin-1         beta ligand inhibitors/cathepsin K inhibitors/NFAT gene         inhibitors, including but not limited to T-5224;     -   H+K+ATPase inhibitors, including but not limited to         naproxen+esomeprazole, ketoprofen+omeprazole, KEO-25001,         HC-1004, and PN-40020;     -   histamine H4 receptor antagonists, including but not limited to         toreforant and GD-48;     -   histone deacetylase inhibitors, including but not limited to         CHR-5154 (GSK-3117391) and NIPEP-CARE;     -   histone deacetylase-6 inhibitors, including but not limited to         CKD-506;     -   HLA class II antigen DQ-2 alpha modulators, including but not         limited to NexVax2;     -   HLA class II antigen inhibitors, including but not limited to         HLA-DR1/DR4 inhibitors (rheumatoid arthritis) and Provid;     -   HLA class II antigen modulators, including but not limited to         recombinant T-cell receptor ligand (rheumatoid arthritis) and         Artielle;     -   Hsp 70 family inhibitors, including but not limited to         gusperimus trihydrochloride;     -   hypoxia inducible factor-1 inhibitors/VEGF receptor antagonists,         including but not limited to 2-methoxyestradiol;     -   IFNB gene stimulators, including but not limited to ART-102;     -   I-kappa B kinase beta inhibitors, including but not limited to         IMD-2560;     -   I-kappa B kinase beta inhibitors/Nuclear factor kappa B         inhibitors, including but not limited to IMD-0560;     -   I-kappa B kinase inhibitors/NFE2L2 gene stimulators/Nuclear         factor kappa B inhibitors/STAT3 gene inhibitors, including but         not limited to bardoxolone methyl;     -   IL-1 antagonists, including but not limited to recombinant human         interleukin-1 receptor antagonist (rheumatoid arthritis),         Shanghai Fudan-Zhangjiang Bio-Pharmaceutical;     -   IL-1 antagonists/interleukin-1 beta ligand inhibitors, including         but not limited to rilonacept;     -   IL-10 agonists, including but not limited to peg-ilodecakin;     -   IL-11 agonists/PDGF receptor agonists, including but not limited         to oprelvekin;     -   IL-12 antagonists/IL-23 antagonists, including but not limited         to ustekinumab and briakinumab;     -   IL-15 antagonists, including but not limited to AMG-714;     -   IL-17 antagonists, including but not limited to ixekizumab and         secukinumab;     -   IL-17 receptor modulators, including but not limited to         CNTO-6785;     -   IL-2 receptor agonists, including but not limited to         interleukin-2 follow-on biologic (IL-2), Anteluke, and         Interking;     -   IL-2/IL-21/IL-15 antagonists, including but not limited to         BNZ-132-2;     -   IL-21 antagonists, including but not limited to NN-8828;     -   TL-4 agonists, including but not limited to SER-130-AMI;     -   TL-6 antagonists, including but not limited to BCD-089,         olokizumab, clazakizumab, sirukumab, SA-237, FB-704A, OP-R003,         peptide IL-6 antagonist, MEDI-5117, AMG-220, FM-101, BLX-1025,         esonarimod, TA-383, and sarilumab;     -   IL-6 antagonists/interleukin-1 beta ligand inhibitors/TNF alpha         ligand inhibitors, including but not limited to K-832;     -   IL-6 antagonists/insulin sensitizers/interleukin-1 beta ligand         inhibitors, including but not limited to BLX-1002;     -   IL-6 receptor antagonists/modulators, including but not limited         to tocilizumab, HS-628, and LusiNEX;     -   IL-6 receptor modulators, including but not limited to BAT-1806         and RO-4877533;     -   immunoglobulin antagonists, including but not limited to         iguratimod;     -   immunoglobulin G1 agonists, including but not limited to BX-2922         and HF-1020;     -   immunoglobulin G1 agonists/interleukin-1 beta ligand inhibitors,         including but not limited to canakinumab;     -   immunoglobulin G1 agonists/TNF alpha ligand inhibitors,         including but not limited to STI-002;     -   immunoglobulin G1 antagonists/TNF alpha ligand inhibitors,         including but not limited to YHB-1411-2;     -   immunoglobulin G1 modulators/GM-CSF ligand         inhibitors/immunoglobulin kappa modulators, including but not         limited to lenzilumab;     -   immunoglobulin G2 antagonists/NF kappa B inhibitor         stimulators/osteoclast differentiation factor         antagonists/osteoclast differentiation factor ligand         inhibitors/TNFSF11 gene inhibitors, including but not limited to         denosumab;     -   immunoglobulin gamma Fc receptor II modulators, including but         not limited to MGD-010;     -   inducible nitric oxide synthase inhibitors/cyclooxygenase 2         inhibitors/MAP kinase modulators/nuclear factor kappa B         inhibitors, including but not limited to SKLB-023;     -   inosine monophosphate dehydrogenase inhibitors, including but         not limited to mizoribine;     -   insulin sensitizers/nuclear factor kappa B         inhibitors/interleukin ligand inhibitors, including but not         limited to HE-3286;     -   integrin alpha-1/beta-1 antagonists, including but not limited         to SAN-300;     -   integrin alpha-4/beta-1 antagonists/cell adhesion molecule         inhibitors, including but not limited to natalizumab;     -   integrin alpha-9 antagonist, including but not limited to         ASP-5094;     -   integrin antagonists, including but not limited to PEG-HM-3 and         CY-9652;     -   interferon beta ligands, including but not limited to         recombinant interferon beta-la;     -   interferon beta ligands/IL-6 antagonists, including but not         limited to TA-383;     -   interferon gamma ligands, including but not limited to Li Zhu         Yin De Fu and Clongamma;     -   interleukin 17A ligand inhibitors/tumor necrosis factor ligand         inhibitors, including but not limited to ABT-122 and ABBV-257;     -   interleukin 17F ligand inhibitors, including but not limited to         bimekizumab;     -   interleukin 18 ligand inhibitors, including but not limited to         tadekinig alfa;     -   interleukin 23A inhibitors, including but not limited to         guselkumab;     -   interleukin ligands/IL-1 antagonists, including but not limited         to IBPB-007-IL;     -   interleukin receptor 17A antagonists, including but not limited         to brodalumab;     -   interleukin-1 beta ligand inhibitors, including but not limited         to gevokizumab, LY-2189102, CDP-484, and AR-100;     -   interleukin-1 beta ligand inhibitors/TNF alpha ligand         inhibitors, including but not limited to PMI-001;     -   interleukin-1 beta ligands/TNF alpha ligand modulators,         including but not limited to PUR-0110;     -   interleukin-2 ligands, including but not limited to recombinant         interleukin-2 and CUG-252;     -   IL-2 modulators, including but not limited to AMG-592;     -   interleukin-4 ligands/tenascin modulator, including but not         limited to Tetravil;     -   interleukin-6 ligand inhibitors, including but not limited to         gerilimzumab and PF-4236921;     -   IRAK-4 protein kinase inhibitor, including but not limited to         BAY-1830839, BAY-1834845, PF-06650833, and KT-474;     -   Itk tyrosine kinase inhibitors, including but not limited to         JTE-051;     -   Itk tyrosine kinase inhibitors/Jak3 tyrosine kinase inhibitors,         including but not limited to ARN-4079;     -   JAK tyrosine kinase inhibitors, including but not limited to         deuterated tofacitinib analog, SD-900, and WXSH-0150;     -   JAK tyrosine kinase inhibitors/Syk tyrosine kinase inhibitors,         including but not limited to cerdulatinib and CVXL-0074;     -   Jak1 tyrosine kinase inhibitors, including but not limited to         ABT-494 (upadacitinib), ruxolitinib, filgotinib, itacitinib,         NIP-585, YJC-50018, GLPG-0555, MRK-12, and SHR-0302;     -   Jak1/3 tyrosine kinase inhibitors, including but not limited to         tofacitinib, tofacitinib citrate, peficitinib, CKD-374, and         CS-944X;     -   JAK 1/3 inhibitor/ROCK1/2 inhibitor: CPL-409116     -   Jak1/2 tyrosine kinase inhibitors, including but not limited to         baricitinib, ruxolitinib, LW-104, and TLL-018;     -   Jak2 tyrosine kinase inhibitors/CSF-1 antagonists, including but         not limited to CT-1578;     -   JAK3 gene inhibitors, including but not limited to PF-06651600;     -   Jak3 tyrosine kinase inhibitors, including but not limited to         decernotinib, DNX-04042, MTF-003, and PS-020613;     -   Jun N terminal kinase inhibitors, including but not limited to         IQ-1 S;     -   KCNA voltage-gated potassium channel-3 modulators, including but         not limited to MRAD-P1;     -   Kelch like ECH associated protein 1 modulators/Nuclear erythroid         2-related factor 2 stimulators, including but not limited to         dimethyl fumarate;     -   LanC like protein 2 modulators, including but not limited to         BT-11 and BT-104;     -   LDL receptor related protein-1 stimulator, including but not         limited to SP-16;     -   leukotriene BLT receptor antagonists/complement C5 factor         inhibitors, including but not limited to nomacopan;     -   LITAF gene inhibitors/JAK3 gene inhibitors/MAP3K2 gene         inhibitors/TNF antagonists, including but not limited to GBL-5b;     -   Lymphocyte function antigen-3 receptor antagonists, including         but not limited to alefacept;     -   Macrophage mannose receptor 1 modulators, including but not         limited to technetium Tc 99m tilmanocept;     -   MAdCAM inhibitors/immunoglobulin G2 modulators, including but         not limited to PF-547659;     -   MAPKAPK5 inhibitors/matrix metalloprotease inhibitors, including         but not limited to GLPG-0259;     -   MEK protein kinase inhibitors, including but not limited to         AD-GL0001;     -   membrane copper amine oxidase inhibitors, including but not         limited to BTT-1023, PRX-167700, and vepalimomab;     -   metalloprotease-9 inhibitors, including but not limited to         GS-5745;     -   microbiome modulator, including but not limited to EDP-1815;     -   midkine ligand inhibitors, including but not limited to CAB-102;     -   mitochondrial 10 kDa heat shock protein stimulators, including         but not limited to INV-103;     -   mTOR inhibitors, including but not limited to everolimus;     -   NAMPT gene inhibitors, including but not limited to ART-DO1;     -   Nicotinic acetylcholine receptor antagonists, including but not         limited to RPI-78 and RPI-MN;     -   NKG2 A B activating NK receptor antagonists, including but not         limited to monalizumab;     -   NKG2 D activating NK receptor antagonists, including but not         limited to NNC-0142-002;     -   nuclear factor kappa B inhibitors, including but not limited to         dehydroxymethylepoxyquinomicin, MP-42, VGX-1027, SP-650003,         MG-132, SIM-916, VGX-350, VGX-300, GIT-027, MLN-1145, and         NVP-IKK-005;     -   nuclear factor kappa B modulators/nuclear factor kappa B p105         inhibitors/transcription factor RelB inhibitors/transcription         factor p65 inhibitors, including but not limited to REM-1086;     -   osteoclast differentiation factor antagonists, including but not         limited to cyclic peptidomimetics (rheumatoid         arthritis/osteoporosis), University of Michigan;     -   p38 MAP kinase alpha inhibitors, including but not limited to         VX-745, BMS-582949, and BMS-751324;     -   p38 MAP kinase inhibitors, including but not limited to BCT-197,         losmapimod, and ARRY-797;     -   PDE 4 inhibitors, including but not limited to apremilast;     -   PDE 5 inhibitors, including but not limited to PDE5 inhibitors         (rheumatoid arthritis), University of Rochester;     -   PDGF-B ligand inhibitors/VEGF receptor antagonists, including         but not limited to SL-1026;     -   phosphoinositide-3 kinase delta inhibitors, including but not         limited to CT-732, INK-007, and GNE-293;     -   phosphoinositide-3 kinase delta/gamma inhibitors, including but         not limited to duvelisib and RP-6503;     -   phospholipase A2 inhibitors, including but not limited to         AK-106, varespladib methyl, Ro-31-4493, BM-162353, Ro-23-9358,         and YM-26734;     -   platelet activating factor receptor antagonists, including but         not limited to piperidone hydrochloridum;     -   PPAR gamma agonists, including but not limited to rosiglitazone         XR;     -   PPAR gamma agonists/insulin sensitizers, including but not         limited to rosiglitazone;     -   programmed cell death protein 1 modulators, including but not         limited to INSIX RA;     -   prostaglandin D synthase stimulators, including but not limited         to HF-0220;     -   protein tyrosine kinase inhibitors, including but not limited to         tairuimide;     -   PurH purine biosynthesis protein inhibitors/inosine         monophosphate dehydrogenase inhibitors, including but not         limited to mycophenolate mofetil;     -   Rev protein modulators, including but not limited to ABX-464;     -   RIP-1 kinase inhibitors, including but not limited to         GSK-2982772 and VRN-04;     -   IL-17 antagonist/rho associated protein kinase 2 inhibitor,         including but not limited to KD-025;     -   signal transducer CD24 modulators, including but not limited to         CD24-IgFc;     -   sodium glucose transporter-2 inhibitors/PPAR gamma         agonists/insulin sensitizers, including but not limited to         THR-0921;     -   STAT3 gene inhibitors, including but not limited to         vidofludimus;     -   STAT-3 inhibitors, including but not limited to HL-237;     -   Superoxide dismutase stimulators, including but not limited to         imisopasem manganese;     -   SYK family tyrosine kinase inhibitors/Zap70 tyrosine kinase         inhibitors, including but not limited to MK-8457;     -   Syk tyrosine kinase inhibitors, including but not limited to         fostamatinib, entospletinib, KDDF-201110-06, HMPL-523, AB-8779,         GS-9876, PRT-2607, CG-103065, and SKI-0-703;     -   T cell receptor antagonists, including but not limited to TCR         inhibiting SCHOOL peptides (systemic/topical, rheumatoid         arthritis/dermatitis/scleroderma), SignaBlok and CII modified         peptide (rheumatoid arthritis);     -   T cell receptor modulators/HLA class II antigen modulators,         including but not limited to ARG-301;     -   T cell surface glycoprotein CD28 stimulators, including but not         limited to TAB-08 and theralizumab;     -   TAK1 binding protein modulators, including but not limited to         epigallocatechin 3-gallate;     -   Talin modulators, including but not limited to short-form talin         regulators (rheumatoid arthritis), KayteeBio;     -   T-cell differentiation antigen CD6 inhibitors, including but not         limited to itolizumab;     -   T-cell surface glycoprotein CD8 inhibitors/TGF beta agonists/CD4         antagonists, including but not limited to tregalizumab;     -   thymulin agonists, including but not limited to Syn-1002;     -   TLR-2/TLR-4 antagonists, including but not limited to VB-201;     -   TLR-4 antagonists, including but not limited to NI-O101;     -   TLR-2/4/9 antagonists, including but not limited to P-13;     -   TNF agonists/TNF antagonists/type II TNF receptor modulators,         including but not limited to Lifmior;     -   TNF alpha ligand inhibitors, including but not limited to         Adfrar, FKB-327, Exemptia, Cinnora, Mabura, adalimumab,         infliximab, Flixabi, PF-06438179, hadlima, recombinant humanized         anti-TNF-alpha monoclonal antibody, CMAB-008, CT-P13, GB-242,         golimumab (CNTO-148), ozoralizumab, AT-132, ISIS-104838,         ISU-202, CT-P17, MB-612, Debio-0512, anti-TNF alpha human         monoclonal antibody, UB-721, KN-002, DA-3113, BX-2922,         R-TPR-015, BOW-050, PF-06410293, CKD-760, CHS-1420, GS-071,         ABP-710, BOW-015, HLX-03, BI-695501, MYL-1401A, ABP-501,         BAX-2923, SCH-215596, ABT-D2E7, BAT-1406, XPro-1595, Atsttrin,         SSS-07, golimumab biosimilar, TA-101, BLX-1002, ABX-0401,         TAQ-588, TeHL-1, placulumab, CYT-007-TNFQb, SSR-150106, PassTNF,         Verigen, DOM-0200, DOM-0215, AME-527, anti-TNF-alpha mAb,         GENZ-38167, BLX-1028, CYT-020-TNFQb, CC-1080, CC-1069, LBAL,         GP-2017, Idacio, IBI-303, HS-016, TNF-2, and IA-14069;     -   TNF alpha ligand inhibitors/TNF antagonists/type II TNF receptor         modulators, including but not limited to BAX-2200;     -   TNF alpha ligand inhibitors/Type II TNF receptor modulators,         including but not limited to Eucept, TNF alpha ligand         modulators: MM-A01-01, CDP-571, camobucol, and JNJ-63823539;     -   TNF antagonists, including but not limited to DNX-114, TNF         antagonist+IL-12 antagonist (rheumatoid arthritis), University         of Oxford, BN-006, pegsunercept, ACE-772, onercept, DE-096,         PN-0615, lenercept, ITF-1779, MDL-201112, HD-203, Qiangke, and         TNF a Fc;     -   TNF antagonists/type II TNF receptor modulators, including but         not limited to Altebrel, Intacept, QL-0902, etanercept, Erelzi,         opinercept, YISAIPU, Anbainuo, Benepali, YLB-113, SCB-808,         DA-3853, and SCB-131;     -   TNF antagonists/TNF alpha ligand inhibitors, including but not         limited to certolizumab pegol;     -   TNF receptor modulators, including but not limited to         recombinant TNF receptor 2-Fc fusion protein mutant, T-0001;     -   TNF receptor modulators/TNF alpha ligand inhibitors, including         but not limited to tgAAV-TNFR:Fc;     -   tumor necrosis factor ¹³C receptor antagonists, including but         not limited to VAY-736;     -   tumor necrosis factor 15 ligand inhibitors, including but not         limited to anti-TL1A antibodies (rheumatoid         arthritis/inflammatory bowel disease), NIAMS;     -   tumor necrosis factor ligand inhibitors, including but not         limited to etanercept biosimilar;     -   type I IL-1 receptor antagonists, including but not limited to         anakinra, IL-1 R^(a), anakinra follow-on biologic, and AXXO;     -   type I TNF receptor antagonists, including but not limited to         NM-940 and EN-2001;     -   type II TNF receptor modulators, including but not limited to         LBEC-0101, DMB-3853, DWP-422, and BT-D001;     -   unspecified GPCR agonists, including but not limited to NCP-70X;     -   VEGF receptor antagonists, including but not limited to         NSC-650853;     -   VEGF-2 receptor modulators, including but not limited to VEGFR2         neutralizing antibody (rheumatoid arthritis), University of         Rochester;     -   VEGF-B ligand inhibitors, including but not limited to CSL-346;     -   X-linked inhibitor of apoptosis protein inhibitors, including         but not limited to IAP inhibitors (oral), Pharmascience; and     -   Zap70 tyrosine kinase inhibitors, including but not limited to         CT-5332.

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of a rheumatological condition.

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of rheumatoid arthritis. Non-limiting examples of such agents include disease-modifying antirheumatic drugs (DMARDS), such as hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide; TNF inhibitors (e.g., etanercept, adalimumab, infliximab, golimumab, certolizumab pegol), T cell costimulatory inhibitor, (e.g., abatacept), IL-6 receptor inhibitors (e.g., tocilizumab, sarilumab), anti-CD20 antibody (e.g., rituximab); and JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib); NSAIDs, such as ibuprofen, naproxen, and diclofenac; COX-2 inhibitor, such as celecoxib and etoricoxib; steroids and corticosteroids, such as prednisolone and cortisone; and biological agents known for treatment and/or prophylaxis of such conditions, including for example etanercept (e.g., ENBREL), infliximab (e.g., REMICADE), adalimumab (e.g., HUMIRA), anakinra (e.g., KINARET), abatacept (ORENCIA), rituximab (e.g., RITUXAN), certolizumab (e.g., CIMZIA), golimumab (e.g., SIPONI), and tocilizumab (e.g., ACTEMRA). In some embodiments, a compound of the disclosure is administered with two additional thereapeutic agents useful for the treatment and/or prophylaxis of a rheumatological condition. In some embodiments, agents useful for the treatment and/or prophylaxis of a rheumatological condition include a compound of the disclosure and two additional therapeutic agents, such as methotrexate+leflunomide, methotrexate+sulfasalazine, methotrexate+cyclosporine, methotrexate+hydroxychloroquine and triple therapy treatments hydroxychloroquine+sulfasalazine+methotrexate, hydroxychloroquine+sulfasalazine+leflunomide.

Inflammatory Bowel Disease Combination Therapy

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one or more additional therapeutic agents that treat or ameliorate inflammatory bowel disease (IBD).

The term “inflammatory bowel disease” or “IBD” as used herein is a collective term describing inflammatory disorders of the gastrointestinal tract, the most common forms of which are ulcerative colitis and Crohn's disease. Other forms of IBD that can be treated with the compounds provided herein, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions provided herein include, but are not limited to, diversion colitis, ischemic colitis, infectious colitis, chemical colitis, microscopic colitis (including collagenous colitis and lymphocytic colitis), atypical colitis, pseudomembranous colitis, fulminant colitis, autistic enterocolitis, indeterminate colitis, Behget's disease, gastroduodenal CD, jejunoileitis, ileitis, ileocolitis, Crohn's (granulomatous) colitis, irritable bowel syndrome, mucositis, radiation induced enteritis, short bowel syndrome, celiac disease, stomach ulcers, diverticulitis, pouchitis, proctitis, and chronic diarrhea.

Treating or preventing IBD also includes ameliorating or reducing one or more symptoms of IBD. As used herein, the term “symptoms of IBD” refers to detected symptoms such as abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, and other more serious complications, such as dehydration, anemia and malnutrition. A number of such symptoms are subject to quantitative analysis (e.g. weight loss, fever, anemia, etc.). Some symptoms are readily determined from a blood test (e.g. anemia) or a test that detects the presence of blood (e.g. rectal bleeding). The term “wherein said symptoms are reduced” refers to a qualitative or quantitative reduction in detectable symptoms, including but not limited to a detectable impact on the rate of recovery from disease (e.g. rate of weight gain). The diagnosis is typically determined by way of an endoscopic observation of the mucosa, and pathologic examination of endoscopic biopsy specimens.

The course of IBD varies and is often associated with intermittent periods of disease remission and disease exacerbation. Various methods have been described for characterizing disease activity and severity of IBD as well as response to treatment in subjects having IBD. Treatment according to the present methods and uses is generally applicable to a subject having IBD of any level or degree of disease activity.

The methods and uses provided herein can also be applied at any point in the course of the disease. In some embodiments, the methods and uses are applied to a subject having IBD during a time period of remission (i.e., inactive disease). In some embodiments, the present methods and uses provided herein provide benefit by extending the time period of remission (e.g., extending the period of inactive disease) or by preventing, reducing, or delaying the onset of active disease. In some embodiments, the methods and uses provided herein may be applied to a subject having IBD during a period of active disease. In some embodiments, the methods and uses provided herein provide benefit by reducing the duration of the period of active disease, reducing or ameliorating one or more symptoms of IBD, or treating IBD.

Measures for determining efficacy of treatment of IBD in clinical practice have been described and include, for example, the following: symptom control; fistula closure; extent of corticosteroid therapy required; and improvement in quality of life. Heath-related quality of life (HRQL) can be assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), which is extensively used in clinical practice to assess quality of life in a subject with IBD. (See Guyatt et al. (1989) Gastroenterology 96:804-810.)

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one or more additional therapeutic agents that treat or ameliorate IBD. Non-limiting examples of therapeutic agents that treat or ameliorate IBC include allogeneic bone marrow-derived MSC therapy, AMP activated protein kinase stimulator, aryl hydrocarbon receptor agonist and T cell receptor modulator, ASK1 inhibitors, beta adrenoceptor antagonists, BTK inhibitors, beta-catenin stimulator, beta-glucuronidase inhibitors, bradykinin receptor modulators, calcineurin inhibitors, calcium channel inhibitors, cathepsin S inhibitors, CCR3 chemokine antagonists, CD40 ligand receptor antagonists, chemokine CXC ligand inhibitors, CHST15 gene inhibitors, collagen modulators, CXCR3 chemokine antagonist, CSF-1 antagonists, cyclooxygenase inhibitors, cytochrome P450 3A4 inhibitors, DYRK-1 alpha protein kinase inhibitor, endothelial dysfunction and vascular leakage blocker, enolase 1 inhibitor, eotaxin ligand inhibitors, EP4 prostanoid receptor agonists, erythropoietin receptor agonists, exportin 1 inhibitor, fractalkine ligand inhibitors, free fatty acid receptor 2 antagonists, GATA 3 transcription factor inhibitors, glucagon-like peptide 2 agonists, glucocorticoid agonists, guanylate cyclase receptor agonists, histone deacetylase inhibitors, HLA class II antigen modulators, IL-12 antagonists, IL-13 antagonists, Interleukin-2 ligand, IL-23 antagonists, IL-6 antagonists, IL-6 receptor modulators, interleukin-7 receptor modulators, IL-7 antagonists, IL-8 antagonists, integrin alpha-4/beta-1 antagonists, integrin alpha-4/beta-7 antagonists, integrin alpha-E antagonists, integrin antagonists, integrin beta-7 antagonists, interleukin ligand inhibitors, Interleukin-10 ligand, interleukin receptor 17A antagonists, Interleukin 23A inhibitor, interleukin-1 beta ligands, interleukin-1 beta ligand modulators, IRAK4 inhibitors, JAK tyrosine kinase inhibitors, Jak1 tyrosine kinase inhibitors, Jak3 tyrosine kinase inhibitors, LanC like protein 2 modulators, lipoxygenase modulators, acrophage mannose receptor 1 modulator, MAdCAM inhibitors, matrix metalloprotease inhibitors, melanocortin agonists, metalloprotease-9 inhibitors, NADPH oxidase inhibitor, natriuretic peptide receptor C agonists, NC-301, next-generation intestinal microbiota therapy, neuregulin-4 ligands, NKG2 D activating NK receptor antagonists, Non receptor tyrosine kinase TYK2 antagonist, opioid receptor antagonists, opioid receptor delta antagonists, oxidoreductase inhibitors, P2X7 purinoceptor agonists, PDE 4 inhibitors, phagocytosis stimulating peptide modulators, potassium channel inhibitors, PPAR alpha agonists, PPAR delta agonists, PPAR gamma agonists, protein fimH inhibitors, P-selectin glycoprotein ligand-1 inhibitors, RNA polymerase inhibitors, sphingosine 1 phosphate phosphatase 1 stimulators, sphingosine 1 phosphate phosphatase modulators, sphingosine-1-phosphate receptor-1 agonists, sphingosine-1-phosphate receptor-1 antagonists, sphingosine-1-phosphate receptor-1 modulators, sphingosine-1-phosphate receptor-5 modulators, STAT3 gene inhibitors, stem cell antigen-1 inhibitors, superoxide dismutase modulators, superoxide dismutase stimulators, SYK inhibitors, TGF beta 1 ligand inhibitors, thymulin agonists, TLR antagonists, TNF alpha ligand inhibitors, TNF antagonists, tumor necrosis factor 14 ligand modulators, type II TNF receptor modulators, Tpl 2 inhibitors, X box binding protein 1 stimulator, and Zonulin inhibitors.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, may be combined with one or more additional therapeutic agents selected from ABX-464, adalimumab; ALLO-ASC-CD, AMG-966, AMT-101, anakinra, apremilast; Alequel; ALV-304, AMG-139; amiselimod, anti-CXCR3 mAb, ASD-003, ASP-3291, AX-1505, balsalazide; beclomethasone dipropionate; BI-655130, BMC-321, BMC-322, BMS-986184; BT-051, budesonide; CBX-111, CEQ-508; certolizumab; cibinetide, Clostridium butyricum; ChAdOx2-HAV, CU-06, CUG-252 dexamethasone sodium phosphate, DNVX-078, EB-7020, EM-101, etanercept; ENERGI-F704, ETX-201, golimumab; GS-4997, GS-5718, GS-9876, GS-4875, GS-4059, infliximab; IMS-001, mesalazine, HLD-400, IBI-112, IMM-H013, KB-295, LFS-829, LYC-30937 EC; IONIS-JBIl-2.5Rx, JNJ-64304500, JNJ-66525433, JNJ-4447, mesalamine, MET-642, MVA-HAV, naltrexone; natalizumab; neihulizumab, olsalazine; NOS-1244, NTG-A-009, PH-46-A, propionyl-L-carnitine; PTG-100; remestemcel-L; tacrolimus; teduglutide; tofacitinib; ASP-1002; ustekinumab; vedolizumab; AVX-470; INN-108; SGM-1019; PF-06480605; PF-06651600; PR-600; RBX-8225, R-2187, RG-6287, SER-287; TOP-1288; VBY-129; 99mTc-annexin V-128; bertilimumab; DLX-105; dolcanatide; quetmolimab (E-6011); FFP-104; filgotinib; foralumab; GED-0507-34-Levo; givinostat; GLPG-0974; iberogast; ICP-330, JNJ-40346527; K(D)PT; KAG-308; KHK-4083; KRP-203; larazotide acetate; LY-3074828, midismase; olokizumab; OvaSave; P-28-GST; PF-547659; prednisolone; QBECO; RG-7835; RBX-2660, R07049665, JKB-122; SYGN-313, SB-012; STNM-01; SZN-1326, TJC-0434, Debio-0512; TRK-170; ABT-494; Ampion; BI-655066; carotegast methyl; cobitolimod; elafibranor; etrolizumab; GS-5745; HMPL-004; LP-02, ozanimod; peficitinib; QX-004-N, RHB-104; SEFA-1024, tildrakizumab; TOP-1890, tralokinumab; brodalumab; laquinimod; and plecanatide; or a pharmaceutically acceptable salt of any of the foregoing; or any combination thereof.

In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more agents useful for the treatment and/or prophylaxis of a gastroenterologic condition such as ulcerative colitis (UC) or Crohn's disease (CD). Non-limiting examples of such agents include infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, ustekinumab, natalizumab, mesalamine, diazo-bonded 5-ASA, sulfasalazine, balsalazide, olsalazine, corticosteroids such as budesonide, hydrocortisone, methylprednisolone, and prednisone; immunosuppressants or immunomodulators such as azathioprine and 6-mercaptopurine, cyclosporine, and methotrexate.

VII. Compound Preparation

Some embodiments of the present disclosure are directed to processes and intermediates useful for preparing the compounds provided herein or pharmaceutically acceptable salts thereof.

Compounds described herein can be purified by any of the means known in the art, including chromatographic means, such as high performance liquid chromatography (HPLC), preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. Most typically the disclosed compounds are purified via silica gel and/or alumina chromatography.

During any of the processes for preparation of the compounds provided herein, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis,” 4^(th) ed., Wiley, New York 2006. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

Exemplary chemical entities useful in methods of the embodiments will now be described by reference to illustrative synthetic schemes for their general preparation herein and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Furthermore, one of skill in the art will recognize that the transformations shown in the schemes below may be performed in any order that is compatible with the functionality of the particular pendant groups. Each of the reactions depicted in the general schemes is preferably run at a temperature from about 0° C. to the reflux temperature of the organic solvent used.

The methods of the present disclosure generally provide a specific enantiomer or diastereomer as the desired product, although the stereochemistry of the enantiomer or diastereomer was not determined in all cases. When the stereochemistry of the specific stereocenter in the enantiomer or diastereomer is not determined, the compound is drawn without showing any stereochemistry at that specific stereocenter even though the compound can be substantially enantiomerically or disatereomerically pure.

Representative syntheses of compounds of the present disclosure are described in the schemes below, and the particular examples that follow.

Certain abbreviations and acronyms are used in describing the experimental details. Although a person of ordinary skill in the art will readily recognize and understand most of the abbreviations and acronyms, the below list provides many of the meanings of the abbreviations and acronyms.

List of Abbreviations and Acronyms Abbreviation Meaning Ac acetate AcOH acetic acid ACN acetonitrile AmPhos di-tert-butyl(4-dimethylaminophenyl)phosphine Bn benzyl Bpin (pinacolato)boron B₂Pin₂ bis(pinacolato)diboron Boc tert-butoxycarbonyl Boc₂O di-tert-butyl dicabonate Bu Butyl Burgess reagent methyl N-(triethylammoniumsulfonyl)carbamate Bz benzoyl BzCl benzoyl chloride cataCXium ® A Pd Mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2′-amino-1,1′- G3 biphenyl)]palladium(II) CDI 1,1′-carbonyldiimidazole DBAD di-tert-butyl azodicarboxylate DBU 1,8-Diazabicyclo[5. 4. 0]undec-7-ene DCE 1,2-dichloroethane DCM dichloromethane DEA diethylamine Deoxofluor Bis(2-methoxyethyl)aminosulfur trifluoride DIPEA N,N-diisopropylethylamine DMA dimethylacetamide 4-DMAP 4-dimethylaminopyridine DME dimethoxyethane DMEM Dulbecco's modified Eagle medium DMF dimethylformamide DMF-DMA N,N-Dimethylformamide dimethyl acetal DMSO dimethylsulfoxide dppf 1,1′-Ferrocenediyl-bis(diphenylphosphine) dtbbpy 4,4′-Di-tert-butyl-2,2′-dipyridyl EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride EDCI N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride ES/MS electron spray mass spectrometry Et ethyl HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate HBSS Hank's balanced salt solution HNMR hydrogen nuclear magnetic resonance HT hepatocytes thawing IPA isopropanol JohnPhos (2-Biphenyl)di-tert-butylphosphine KHB Krebs-Henseleit Buffer KOtBu potassium tert-butoxide LC liquid chromatography LCMS liquid chromatography/mass spectrometry LiHMDS Lithium bis(trimethylsilyl)amide MCPBA meta-chloroperbenzoic acid MDCK Madin-Darby canine kidney Me methyl Ms methanesulfonyl m/z mass to charge ratio MS or ms mass spectrum MW microwave NBS N-bromosuccinimide NCS N-chlorosuccinimide NIS N-iodosuccinimide NMP N-methyl-2-pyrrolidone NMR nuclear magnetic resonance PBS Phosphate-buffered saline Pd(AmPhos)₂Cl₂ Bis(di-tert-butyl(4- dimethylaminophenyl)phosphine)dichloropalladium(II) Pd(dppf)Cl₂ [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) Ph phenyl Ph₃P triphenylphosphine PhNTf₂ N-Phenyl-bis(trifluoromethanesulfonimide) Pg Protecting group pin pinacol Piv pivaloyl PMB para-methoxybenzyl PTSA p-Toluenesulfonic acid monohydrate Pyr pyridine RBF round bottom flask RP-HPLC reverse phase high performance liquid chromatography RPM Revolutions per minute RT room temperature SEM [2-(trimethylsilyl)ethoxy]methyl SFC supercritical fluid chromatography STAB Sodium triacetoxyborohydride TiPS Triisopropylsilyl TiPSCl Triisopropylsilyl chloride TLC thin layer chromatography tBuXPhos Pd G3 [(2-Di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2- (2′-amino-1,1′-biphenyl)] palladium(II) methanesulfonate XantPhos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene XPhos Pd G2 Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′- biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) XPhos Pd G3 (2-Dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2- (2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate TBAF Tetrabutylammonium fluoride TBAI Tetrabutylammonium iodide TCFH Chloro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran Tf trifluoromethanesulfonyl Ts 4-toluenesulfonyl δ parts per million referenced to residual solvent peak

General Synthetic Schemes

General Reaction Schemes 1-13 are provided as further embodiments of the present disclosure and illustrate general methods which were used to prepare certain compounds of the present disclosure and which can be used to prepare additional compounds of the present disclosure. Each of the variables (e.g. R¹, R², R³, R⁴) of the compounds disclosed in General Reaction Schemes 1-13 are as defined herein.

The compounds of the present disclosure may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent to a skilled artisan given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers. In general, compounds described herein are typically stable and isolatable at room temperature and pressure.

Typical embodiments of compounds disclosed herein may be synthesized using the general reaction schemes described below. It will be apparent to a skilled artisan given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments disclosed in the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein.

The terms “solvent”, “inert organic solvent”, or “inert solvent” refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, and the like). Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen or argon.

Intermediate 1.1 (where M is —B, —Sn, —Zn, —Si, or —Mg) may be reacted with Intermediate 2 in the presence of a suitable palladium catalyst to deliver intermediate 1.3. Intermediate 1.4 may be reacted in the presence of a metalating reagent (e.g. iPrMgflr, n-BuLi) and di-tertbutyl azodicarboxylate to afford Intermediate 1.6. Intermediate 1.3 may be reacted with intermediate 1.6 at elevated temperatures in the presence of acid (e.g. PTSA) to afford Intermediate 1.7.

Intermediate 1.7 can be reacted in the presence of a suitable base (e.g. LiOH, Me₃SnOH) and heat to produce Intermediate 2.1. Intermediate 2.1 may then be reacted in the presence of a suitable base (e.g. DBU) and heat for produce intermediate 2.2. Alternatively, Intermediate 2.2 may be furnished by reacting Intermediate 1.7 in the presence of a suitable base (e.g. LiOH) and extended heating. Intermediate 2.2 may be reacted in the presence of suitable halogenating reagent (e.g., NBS, NIS, NCS) to produce intermediate 2.3, where X═I, Br, or Cl.

Compounds of formula (Ia) can be assembled by the combination of intermediate 2.1 with a suitable primary or secondary amine 3.1, in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine). If the compound of the formula (Ia) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (Ia) that contains a primary or secondary amine. If the compound of the formula (Ia) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (Ia) that contains a primary or secondary amine.

Compounds of formula (Ib) can be assembled by the combination of intermediate 2.1 with a suitable cyclic secondary amine 4.1, in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine). If the compound of the formula (Ib) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (Ib) that contains a primary or secondary amine. If the compound of the formula (Ib) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (Ib) that contains a primary or secondary amine.

Compounds of the formula (Ic) that contain an (1,3,4)-oxadiazole moiety may be assembled by reacting intermediate 2.1 with an intermediate 5.1 first in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine), and then subsequently in the presence of an oxidant (e.g., Burgess reagent). Alternatively, compounds of the formula (Id) that contain a (1,3,4)-thiadiazole moiety may be assembled by reacting intermediate 2.1 with an intermediate 5.1 first in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine), and then subsequently in the presence of an sulfur reagent (e.g., Lawesson's reagent, P₂S₅). If the compound of the formula (Ic) or (Id) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (Ic) or (Id) that contains a primary or secondary amine. If the compound of the formula (Ic) or (Id) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (Ic) or (Id) that contains a primary or secondary amine.

Compounds of the formula (Le) that contain an (1,2,4)-oxadiazole moiety may be assembled by reacting intermediate 2.1 with an intermediate 6.1 first in the presence of a coupling reagent (e.g., CDI) and heat. If the compound of the formula (Le) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (Ie) that contains a primary or secondary amine. If the compound of the formula (Le) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (Le) that contains a primary or secondary amine.

Compounds of the formula (I.f) that contain an oxazoline moiety may be assembled by reacting intermediate 2.1 with an intermediate 7.1 first in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine), and then subsequently in the presence of an oxidant (e.g., Burgess reagent). Alternatively, compounds of the formula (Ig) that contain an oxazoline moiety may be assembled by reacting intermediate 2.1 with an intermediate 7.2 first in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC, CDI) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine), and then subsequently in the presence of an oxidant (e.g., Burgess reagent). If the compound of the formula (I.f) or (Ig) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (If) or (Ig) that contains a primary or secondary amine. If the compound of the formula (If) or (Ig) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (I.f) or (Ig) that contains a primary or secondary amine.

Compounds of formula (I.h) can be assembled by the combination of intermediate 2.3 with a suitable metallated coupling partner M-Z (where Z is aryl, heteroaryl, alkenyl, and M is —B, —Sn, —Zn, —Si, or —Mg) using a suitable palladium catalyst and a base (e.g., cesium carbonate, potassium phosphate tribasic, sodium carbonate) to deliver compounds of formula (I.h). If the compound of formula (I.h) contains an alkene, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas). If the compound of the formula (I.h) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.h) that contains a primary or secondary amine. If the compound of the formula (I.h) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (I.h) that contains a primary or secondary amine.

Compounds of formula (I.j) can be assembled by the combination of a compound of formula (Ii) (produced via one of the methods elaborated above, such as Scheme 3) with a suitable carboxylic acid 9.1, in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine). Alternatively, compounds of formula (Ik) can be assembled by the combination of compounds of formula (Ii) with a suitable aldehyde 9.2, in the presence of a suitable reducing reagent (e.g., NaBH₄, Na(OAc)₃BH, Na(CN)₃BH). Alternatively, compounds of formula (I.l) can be assembled by the combination of compounds of formula (Ii) with an intermediate 9.3, where X is a leaving group (e.g. —Cl, —Br, —I, OTs, —OMs), in the presence of a base (e.g., N,N-diisopropylethylamine, triethylamine, K₂CO₃, CsCO₃). If the compound of the formula (I.j.), (Ik), or (I.l) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (I.j.), (Ik), or (I.l) that contains a primary or secondary amine. If the compound of the formula (I.j.), (Ik), or (I.l) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (I.j.), (Ik), or (I.l) that contains a primary or secondary amine.

Intermediate 2.3 can be coupled with intermediate 10.1 (where -M is —B, —Sn, or —Zn, and Pg is Boc or Bn) in the presence of a palladium catalyst and a base (e.g., cesium carbonate, potassium phosphate tribasic, sodium carbonate) to produce intermediate 10.2. Intermediate 10.2 may be reacted in the presence of a metal catalyst (e.g., palladium) and H₂ gas to produce Intermediate 10.3. Alternatively, Intermediate 2.3 can be coupled with intermediate 10.4 (where -M is —B or —Zn, and Pg is Boc or Bn) in the presence of a palladium catalyst to produce intermediate 10.3. Alternatively, Intermediate 2.3 can be coupled with intermediate 10.5 (where —X is —Cl, —Br, —I, OMs, —OTs, —OTf, and Pg is Boc or Bn) in the presence of a palladium or nickel catalyst to produce intermediate 10.3. If Pg=Boc, Intermediate 10.3 may be reacted in the presence of acid (e.g., TFA, HCl) to produce a compound of formula (Im). Alternatively, if Pg=Bn, Intermediate 10.3 may be reacted in the presence of a metal catalyst (e.g., palladium) and H₂ gas to produce a compound of formula (Im).

Compounds of formula (In) can be assembled by the combination of a compound of formula (Im) (produced via one of the methods elaborated above, such as Scheme 10) with a suitable carboxylic acid 11.1, in the presence of a suitable peptide coupling reagent (e.g., HATU, TCFH, EDC) and a suitable base (e.g., N,N-diisopropylethylamine, triethylamine). Alternatively, compounds of formula (Io) can be assembled by the combination of compounds of formula (Im) with a suitable aldehyde or ketone 11.2, in the presence of a suitable reducing reagent (e.g., NaBH₄, Na(OAc)₃BH, Na(CN)₃BH). Alternatively, compounds of formula (Ip) can be assembled by the combination of compounds of formula (Im) with an intermediate 10.3, where X is a leaving group (e.g. —Cl, OBr, —I, OTs, —OMs), in the presence of a base (e.g., N,N-diisopropylethylamine, triethylamine, K₂CO₃, CsCO₃). If the compound of the formula (I.n), (Io), or (Ip) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (In), (Jo), or (Ip) that contains a primary or secondary amine. If the compound of the formula (In), (Jo), or (Ip) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (In), (Jo), or (Ip) that contains a primary or secondary amine.

Intermediate 2.3 can be coupled with intermediate 12.1 (where -M is —B, —Sn, or -Zn, and the ketal moiety may or may not be cyclized to form a ring) in the presence of a palladium catalyst and a base (e.g., cesium carbonate, potassium phosphate tribasic, sodium carbonate) to produce intermediate 12.2. Intermediate 12.2 may be reacted in the presence of a metal catalyst (e.g., palladium) and H₂ gas to produce Intermediate 12.3. Alternatively, Intermediate 2.3 can be coupled with intermediate 12.4 (where -M is —B or —Zn, and the ketal moiety may or may not be cyclized to form a ring) in the presence of a palladium catalyst to produce intermediate 12.3. Alternatively, Intermediate 2.3 can be coupled with intermediate 12.5 (where —X is —Cl, —Br, —I, OMs, —OTs, —OTf, and the ketal moiety may or may not be cyclized to form a ring) in the presence of a palladium or nickel catalyst to produce intermediate 12.3. Intermediate 10.3 may be reacted in the presence of acid (e.g., TFA, HCl) to produce a compound of formula (I.q).

Compounds of formula (Ir) can be assembled by the combination of compounds of formula (I.q) with a suitable primary or secondary amine 13.1, in the presence of a suitable reducing reagent (e.g., NaBH₄, Na(OAc)₃BH, Na(CN)₃BH). Compounds of formula (I.s) can be assembled by the combination of compounds of formula (I.q) with a suitable cyclic amine 4.1, in the presence of a suitable reducing reagent (e.g., NaBH₄, Na(OAc)₃BH, Na(CN)₃BH). If the compound of the formula (Ir) or (Is) contains a tert-butylcarbamate functional group, this can be subsequently removed by treatment with acid (e.g., trifluoroacetic acid or hydrochloric acid) to reveal a compound of formula (Ir) or (Is) that contains a primary or secondary amine. If the compound of the formula (Ir) or (Is) contains a benzyl-amine functional group, this can be subsequently removed (e.g., using a metal catalyst and H₂ gas), to reveal a compound of formula (Ir) or (I.s) that contains a primary or secondary amine.

VII. Examples

Exemplary chemical entities of the present disclosure are provided in the specific examples that follow. Those skilled in the art will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Furthermore, one of skill in the art will recognize that the transformations shown in the schemes below may be performed in any order that is compatible with the functionality of the particular pendant groups.

The Examples provided herein describe the synthesis of compounds disclosed herein as well as intermediates used to prepare the compounds. It is to be understood that individual steps described herein may be combined. It is also to be understood that separate batches of a compound may be combined and then carried forth in the next synthetic step.

In the following description of the Examples, specific embodiments are described. These embodiments are described in sufficient detail to enable those skilled in the art to practice certain embodiments of the present disclosure. Other embodiments may be utilized and logical and other changes may be made without departing from the scope of the disclosure. The following description is, therefore, not intended to limit the scope of the present disclosure.

Intermediates

Preparation of Intermediate 1:

3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (I-1): To a vial was added 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (7.77 g, 30.0 mmol), palladium acetate (0.337 g, 1.50 mmol) and tris(4-methoxyphenyl)phosphine (0.617 g, 1.75 mmol) followed by THF (100 mL), water (1.13 mL, 62.5 mmol) and isovaleryl anhydride (5.00 mL, 25.0 mmol). Argon was bubbled through the mixture for 4 min and the reaction mixture was heated to 60° C. for 16 h. The reaction mixture was filtered through celite, eluting with DCM and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-50% EtOAc in hexane) to give the title compound. ES/MS: 218.2 (M+H⁺). H NMR (400 MHz, Methanol-d₄) δ 9.39 (s, 1H), 8.52 (s, 1H), 7.98 (s, 1H), 2.97 (d, J=6.8 Hz, 2H), 2.66 (s, 3H), 2.37-2.23 (m, 1H), 1.04 (dd, J=6.7, 0.8 Hz, 6H).

Preparation of Intermediate I-2:

di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (1-2): To a solution of methyl 5-bromo-3-methyl-thiophene-2-carboxylate (3.90 g, 16.6 mmol) in THE (50 mL) cooled to −40° C. was added isopropylmagnesium bromide in 2-MeTHF (2.90 mol/L, 8.01 mL, 23.2 mmol) dropwise and the solution was stirred for 30 min at −40° C. di-tert-butylazodicarboxylate (4.58 g, 19.9 mmol) was then added as a solution in THE (50 mL) dropwise and the reaction was stirred for 15 min at −40° C. The reaction was quenched by the addition of saturated aqueous ammonium chloride and the mixture was extracted with DCM (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-50% EtOAc in hexane) to give the title compound. ES/MS: 387.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d₄) δ 6.62 (s, 1H), 3.82 (s, 3H), 2.46 (s, 3H), 1.60-1.51 (m, 18H).

Preparation of Intermediate I-3:

methyl 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-3): To a solution of di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (I-2) (4.63 g, 12.0 mmol) and p-Toluenesulfonic Acid, monohydrate (12.4 g, 71.9 mmol) in a 500 mL round-bottomed flask in 2-MeTHF (140 mL) was added 3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (I-1) (2.86 g, 13.2 mmol) and the reaction mixture was heated to 90° C. for 16 h with a reflux condenser. The reaction mixture was concentrated in vacuo, taken up in EtOAc and washed with sat. aq. sodium bicarbonate. The layers were separated, the aqueous layer was extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the title compound. ES/MS: 369.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d₄) δ 8.66 (s, 1H), 8.46 (s, 1H), 7.58 (t, J=1.4 Hz, 1H), 3.85 (s, 3H), 3.41-3.34 (m, 1H), 2.88 (s, 3H), 2.69 (s, 3H), 1.40 (d, J=7.1 Hz, 6H).

Preparation of Intermediate I-4:

4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (I-4): To a solution of methyl 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-3) (52.3 mg, 0.14 mmol) in DCE (1.00 mL) was added trimethyltin hydroxide (0.257 g, 0.00142 mol) and the reaction mixture was heated to 120° C. for 16 h. The reaction mixture was concentrated under reduced pressure and purified by column chromatography (0-100% EtOAc in hexane) to give the title compound. ES/MS: 355.1 (M+H⁺).

Preparation of Intermediate I-5:

4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-5): To a solution of methyl 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-3) (2.62 g, 7.11 mmol) in methanol (75 mL) and water (7.5 mL) was added potassium hydroxide (1.60 g, 28.4 mmol) and the reaction mixture was heated to 100° C. for 24 h. The reaction mixture was concentrated under reduced pressure then diluted with hydrochloric acid (1.00 mol/L, 42.7 mL, 42.7 mmol) and water and the precipitate was collected by filtration and air-dried for 1 h to give the crude title product. ES/MS: 311.2 (M+H⁺).

Preparation of Intermediate I-6:

2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-6): To a solution of 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-5) (2.21 g, 7.12 mmol) in THE (57 mL) cooled to 0° C. was added N-bromosuccinimide (1.27 g, 7.12 mmol) slowly and the reaction mixture was allowed to slowly warm to room temperature and stirred for 16 h. The reaction was diluted with DCM and quenched by the addition of 10% aqueous thiosulfate and the layers separated. The aqueous layer was extracted with DCM (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the title compound. ES/MS: 391.1 (M+H⁺). ¹H NMR (400 MHz, Methanol-d₄) δ 8.63 (s, 1H), 8.47 (s, 1H), 7.59 (s, 1H), 3.31-3.23 (m, 2H), 2.69 (s, 3H), 2.48 (s, 3H), 1.40 (dd, J=7.1, 1.0 Hz, 6H).

Preparation of Intermediate I-7:

tert-butyl 4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate: 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-6) (92.7 mg, 0.24 mmol) in acetonitrile (2.0 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (0.103 g, 0.33 mmol), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (0.0253 g, 0.036 mmol) and 1.0 M potassium acetate/1.5 M sodium carbonate in water (0.60 mL, 0.60 mmol/0.89 mmol) and the reaction mixture was heated to 120° C. in a microwave for 30 min. The reaction mixture was dried over sodium sulfate, filtered through celite, eluting with DCM and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the title compound. ES/MS: 492.2 (M+H⁺).

tert-butyl 4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate: To a solution of tert-butyl 4-[4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (37.4 mg, 0.0761 mmol) in ethanol (2 mL) and ethyl acetate (1 mL) was added acetic acid (0.1 mL). Nitrogen was bubbled through the solution for 4 min then palladium on carbon 10 wt. % (10.0%, 16.2 mg, 0.0152 mmol) was added and the reaction mixture was stirred for 48 h. The reaction mixture was degassed with argon, diluted with EtOAc, and filtered through celite, eluting with EtOAc and the filtrate was concentrated under reduced pressure to give the crude product which was used directly in the next step. ES/MS: 494.2 (M+H⁺).

4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (I-7): To a solution of tert-butyl 4-[4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl]piperidine-1-carboxylate (37.0 mg, 0.0749 mmol) in DCM (2.0 mL) was added 4.0 N HCl in dioxane (4.00 mol/L, 0.187 mL, 0.749 mmol) and the reaction mixture was stirred for 16 h at room temperature. The reaction mixture was concentrated under reduced pressure to give the title compound as an HCl salt which was used directly in subsequent reactions. ES/MS: 394.2 (M+H⁺).

Preparation of Intermediate I-8:

di-tert-butyl 1-(5-(methoxycarbonyl)thiophen-2-yl)hydrazine-1,2-dicarboxylate (I-8): The reaction was performed analogously to that of I-2 starting from methyl 5-bromothiophene-2-carboxylate to give the title compound. ES/MS: 373.2 (M+H⁺).

Preparation of Intermediate I-9:

methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-9): The reaction was performed analogously to that of I-3 starting I-8 to give the title compound. ES/MS: 355.1 (M+H⁺)

Preparation of Intermediate 1-10:

4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (I-10): To a solution of methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-9) in acetonitrile (1.00 mL) and water (0.10 mL) was added lithium hydroxide monohydrate (0.0152 g, 0.362 mmol) and the reaction mixture was stirred for 16 h at 100° C. The reaction mixture was concentrated in vacuo and then diluted with hydrochloric acid (1.00 mol/L, 1.18 mL, 1.18 mmol) and water and the precipitate was collected by filtration to give the title compound which was used directly in the next step. ES/MS: 341.2 (M+H⁺).

Preparation of Intermediate 1-12:

4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-11): To a solution of 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (I-10) (181 mg, 0.611 mmol) in DMA (7 mL) was added DBU (0.263 mL, 1.76 mmol), and the resulting reaction mixture was stirred at 150° C. for 2 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (30 mL) and extracted with brine (2×20 mL). The aqueous layers were combined and extracted with EtOAc (30 mL). The combined organic layer was dried over Na₂SO₄, concentrated under reduced pressure, and purified by flash column chromatography. ES/MS: 297.1 (M+H⁺).

2-bromo-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-12): To an ice-cooled, stirred solution of I-11 (121 mg, 0.41 mmol) in acetonitrile (24 mL) and methanol (40 mL) was added NBS (73 mg, 0.41 mmol) dissolved in acetonitrile (10 mL) dropwise until LCMS showed completion of reaction. The reaction mixture was diluted with EtOAc (50 mL) and the resultant mixture was extracted with aq. sodium thiosulfate solution (30 mL). The organic layer was then successively washed with water (2×30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and evaporated under reduced pressure to yield I-12. ES/MS: 375.1 (M⁺)

Preparation of Intermediate 1-13:

7,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (I-13): To a 500 mL RBF was added 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (10 g, 44.2 mmol), Bis(pinacolato)diboron (14.6 g, 57.5 mmol), [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (2.62 g, 3.54 mmol), and potassium propionate (14.9 g, 133 mmol). The mixture was dissolved in 1,4-dioxane (140 mL), and nitrogen was bubbled through the reaction mixture for 5 minutes. The mixture was heated at 100° C. for 1 hour under nitrogen. The mixture was cooled to rt, filtered through celite, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (eluent: EtOAc/hexanes) to provide the product I-13. ES/MS: 274.2 (M+H⁺).

Preparation of Intermediate 1-14:

3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (I-14): To a vial was added 7,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (I-13) (1 g, 3.66 mmol), palladium acetate (0.043 g, 0.193 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (dppf) (0.142 g, 0.26 mmol) followed by THE (15 mL), water (0.5 mL, 27.8 mmol), sodium carbonate (0.194 g, 1.83 mmol) and isovaleric anhydride (1.00 mL, 5.0 mmol). Argon was bubbled through the mixture for 4 min and the reaction mixture was heated to 60° C. for 16 h. The reaction mixture was filtered through celite, eluting with DCM and the filtrate was concentrate under reduced pressure. The crude residue was purified by column chromatography (0-50% EtOAc in hexane) to give the title compound. ES/MS: 232.3 (M+H⁺).

Preparation of Intermediate I-15:

tert-butyl 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (1-15): To a solution of 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-6) (1.0 g, 2.57 mmol) in THE (15 mL) was added N,N-dimethylpyridin-4-amine (DMAP) (0.408 g, 3.34 mmol), and tert-butoxycarbonyl tert-butyl carbonate (673 mg, 3.08 mmol). The mixture was stirred at rt for 60 minutes. The mixture was concentrated under reduced pressure. The crude residue product was purified by flash chromatography (eluent: EtOAc/hexanes) to provide the product. ES/MS: 489.1 (M⁺).

Preparation of Intermediate I-16:

tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (1-16): Prepared analogously to I-25, 1-6, 1-5, and 1-3, substituting 3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (I-1) with 3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (1-14). ES/MS: 503.2 (M⁺).

Preparation of Intermediate I-16:

tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (1-16): To a solution of tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (1-34) (10.2 g, 24 mmol) in ACN (250 mL) and methanol (100) cooled to 0° C. was added N-bromosuccinimide (4.28 g, 24 mmol) dissolved in ACN (50 mL) dropwise and the reaction mixture was monitored by LCMS for reaction completion (1-34 is prepared as disclosed herein). The reaction mixture was concentrated under reduced pressure, then was diluted with EtOAc (300 mL) and washed with 50% aqueous thiosulfate (100 mL), water (50 mL), and brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the title compound 1-16. ES/MS: 503.2 (M⁺). ¹H NMR (400 MHz, Chloroform-d) δ 8.37 (s, 1H), 8.34 (s, 1H), 2.89 (hept, J=7.1 Hz, 1H), 2.67 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H), 1.33 (s, 9H), 1.24 (d, J=7.2 Hz, 3H), 1.18 (d, J=7.1 Hz, 3H).

Preparation of Intermediate I-17:

di-tert-butyl 1-(4-(difluoromethyl)thiophen-2-yl)hydrazine-1,2-dicarboxylate (1-17): Prepared analogously to 1-2, substituting methyl 5-bromo-3-methyl-thiophene-2-carboxylate with 2-bromo-4-(difluoromethyl)thiophene. ES/MS: 387.1 (M+23)

Preparation of Intermediate I-18:

2-bromo-3-(difluoromethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (1-18): Prepared analogously to 1-6, 1-5, and 1-3, substituting di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (1-2) with di-tert-butyl 1-(4-(difluoromethyl)thiophen-2-yl)hydrazine-1,2-dicarboxylate (1-17). ES/MS: 425.1 (M⁺).

Preparation of Intermediate I-19:

tert-butyl 2-bromo-3-(difluoromethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (1-19): Prepared analogously to 1-15, substituting 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (1-6) with 2-bromo-3-(difluoromethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (1-18). ES/MS: 525.1 (M⁺).

Preparation of Intermediate I-20:

tert-butyl 6-iodo-2-azaspiro[3.3]heptane-2-carboxylate (1-20): To a solution of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (1.5 g, 7.03 mmol) in toluene (50 mL) was added triphenylphosphine (2.61 g, 10.5 mmol), molecular iodine (1.79 g, 7.03 mmol) and imidazole (958 mg, 14.1 mmol). The mixture was stirred at reflux for 2-16 hours. The mixture was concentrated under reduced pressure. The crude residue product was purified by flash chromatography (eluent: EtOAc/hexanes) to provide the product. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-21:

tert-butyl exo-3-iodo-8-azabicyclo[3.2.1]octane-8-carboxylate (1-20): Prepared analogously to 1-20, substituting of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl endo-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate. ES/MS: 282.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-22:

tert-butyl endo-8-iodo-3-azabicyclo[3.2.1]octane-3-carboxylate (1-22): Prepared analogously to 1-20, substituting of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl exo-8-hydroxy-3-azabicyclo[3.2.1]octane-3-carboxylate. ES/MS: 282.1 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-23:

tert-butyl 6-iodo-3-azabicyclo[3.1.1]heptane-3-carboxylate (1-23): Prepared analogously to 1-20, substituting of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-24:

tert-butyl (1S,4S,5S)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-24): Prepared analogously to I-20, substituting of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl (1S,4S,5R)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-25:

tert-butyl (3aR,6aS)-5-iodohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (I-25): Prepared analogously to I-20, substituting of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl (3aR,6aS)-5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate.

Preparation of Intermediate I-26:

tert-butyl 7-iodo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (I-26): Prepared analogously to I-20, substituting of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 7-hydroxy-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate. ES/MS: 353.6 (M+H⁺).

Preparation of Intermediate I-27:

tert-butyl (1R,4R)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-27): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl (1R,4R)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl)

Preparation of Intermediate I-28:

tert-butyl 2-iodo-6-azaspiro[3.4]octane-6-carboxylate (I-28): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 2-hydroxy-6-azaspiro[3.4]octane-6-carboxylate. ES/MS: 282.1 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-29:

tert-butyl (1S,4S,5R)-5-iodo-2-azabicyclo[2.2.2]octane-2-carboxylate (I-29): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl (1S,4S,5S)-5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate. ES/MS: 282.0 (M+H⁺) (mass minus tert-butyl)

Preparation of Intermediate I-30:

tert-butyl 2-iodo-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate (1-30): Prepared analogously to 1-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 2-hydroxy-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate. ES/MS: 298.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-31:

tert-butyl (1S,4S,5R)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (1-31): Prepared analogously to 1-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl (1S,4S,5S)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl). ¹H NMR (400 MHz, Chloroform-d) δ 4.20 (s, 1H), 4.08 (ddd, 1H), 3.29 (dd, 1H), 3.06 (d, 1H), 2.90-2.84 (m, 1H), 2.59-2.47 (m, 1H), 2.26 (dt, 1H), 2.10 (d, 1H), 1.78 (dd, 1H), 1.46 (d, 9H).

Preparation of Intermediates I-31 and I-24:

tert-butyl (1S,4S)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate: A solution of tert-butyl (1S,4S)-5-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate (10 g, 47.3 mmol) in methanol (100 mL) was cooled to 0° C. Sodium borohydride (1.8 g, 47.3 mmol) was slowly added to the reaction, which was then stirred for 30 minutes and checked for completion. The reaction was quenched with saturated ammonium chloride and further diluted with water and ethyl acetate. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated to provide the product as a mixture of diastereomers, which was used in the next step without further purification. ES/MS: 213.8 (M+H⁺).

tert-butyl (1S,4S,5R)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-31) and tert-butyl (1S,4S,5S)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-24): To a solution of tert-butyl (1S,4S)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (mixture of diastereomers) (10 g, 46.9 mmol, mixture of isomers) in toluene (250 mL) was added triphenylphosphine (14 g, 56.3 mmol), molecular iodine (14 g, 56.3 mmol) and imidazole (6.4 g, 93.8 mmol). The mixture was concentrated under reduced pressure and the crude residue was purified by silica flash chromatography (eluent: EtOAc/hexanes) to provide the two products, with I-31 (major product) eluting first and I-24 (minor product) eluting second.

tert-butyl (1S,4S,5R)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-31): ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl). ¹H NMR (400 MHz, Chloroform-d) δ 4.20 (s, 1H), 4.08 (ddd, 1H), 3.29 (dd, 1H), 3.06 (d, 1H), 2.90-2.84 (m, 1H), 2.59-2.47 (m, 1H), 2.26 (dt, 1H), 2.10 (d, 1H), 1.78 (dd, 1H), 1.46 (d, 9H).

tert-butyl (1S,4S,5S)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-21): ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl). ¹H NMR (400 MHz, Chloroform-d) δ 4.32 (dd, 1H), 4.04 (s, 1H), 3.66 (d, 1H), 3.41 (d, 1H), 2.71 (s, 1H), 2.45 (ddd, 1H), 2.07 (s, 1H), 1.74 (d, 1H), 1.57 (d, 1H), 1.49 (s, 9H).

Preparation of Intermediate I-32:

methyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-32): To a solution of di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (I-2) (5.69 g, 14.7 mmol) and p-Toluenesulfonic Acid, monohydrate (20.1 g, 51.9 mmol) in a 500 mL round-bottomed flask were added 1-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-methylbutan-1-one (I-14) (10 g, 43.2 mmol) and 2-butanol (220 mL). The reaction mixture was heated to 100° C. and stirred for 24 h with a reflux condenser. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and water (200 mL) was added. The mixture was allowed to sit at 0° C. for 30 minutes and filtered and then the filter cake was washed with water (4×25 mL) and further dried overnight in a lyophillizer to furnish the product I-32 as a PTSA salt. ES/MS: 383.1 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 9.16 (s, 1H), 9.01 (s, 1H), 7.77-7.69 (m, 2H), 7.24 (d, J=7.9 Hz, 2H), 3.86 (s, 3H), 3.12 (dt, J=14.2, 7.0 Hz, 1H), 2.88 (s, 3H), 2.70 (s, 3H), 2.41 (s, 3H), 2.39 (s, 3H), 1.32 (d, J=7.1 Hz, 3H), 1.26 (d, J=7.1 Hz, 3H).

Preparation of Intermediate I-33:

5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (I-33): To a solution of methyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2-carboxylate (PTSA salt) (I-32) (10.7 g, 19.3 mmol) in ethanol (200 mL) and water (50 mL) was added potassium hydroxide (6.5 g, 116 mmol) and the reaction mixture was heated to 90° C. for 24 h. The reaction mixture was concentrated under reduced pressure, diluted with hydrochloric acid (1.00 mol/L, 154 mL, 154 mmol), and then cooled to 0° C. for 30 minutes. The reaction mixture was then filtered and the filter cake was collected by filtration, washed with water (2×40 mL), and air-dried for 1 h to give the title product. The material was further dried overnight in a lyophillizer to complete the drying process. ES/MS: 325.2 (M+H⁺). ¹H NMR (400 MHz, Chloroform-d) δ 8.43-8.39 (m, 1H), 8.36 (s, 1H), 6.50 (d, J=1.5 Hz, 1H), 3.03-2.91 (m, 1H), 2.64 (s, 3H), 2.54 (s, 3H), 2.22 (s, 3H), 1.27 (d, J=7.5 Hz, 6H).

Preparation of Intermediate I-34:

tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-34): To a solution of 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (I-33) (11.8 g, 36.5 mmol) in THE (180 mL) was added N,N-dimethylpyridin-4-amine (DMAP) (6.24 g, 51.1 mmol), and di-tert-butyl dicarbonate (Boc Anhydride) (10.4 g, 47.4 mmol). The mixture was stirred at rt overnight. The mixture was concentrated under reduced pressure. The crude residue product was purified by flash chromatography (eluent: EtOAc/hexanes) to provide the product. ES/MS: 425.2 (M+H⁺). ¹H NMR (400 MHz, Chloroform-d) δ 8.37 (s, 1H), 8.33 (s, 1H), 6.69 (d, J=1.2 Hz, 1H), 2.86 (hept, J=7.1 Hz, 1H), 2.67 (s, 3H), 2.53 (s, 3H), 2.17 (s, 3H), 1.31 (s, 9H), 1.25 (d, J=7.1 Hz, 3H), 1.21 (d, J=7.1 Hz, 3H).

Preparation of Intermediate I-35:

methyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-35): Prepared analogously to I-3, substituting di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (I-2) with di-tert-butyl 1-(5-(methoxycarbonyl)thiophen-2-yl)hydrazine-1,2-dicarboxylate (I-8), and substituting 3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (I-1) with 3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (I-14). ES/MS: 369.2 (M+H⁺).

Preparation of Intermediate I-36:

5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (I-36): To a solution of methyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole-2-carboxylate (5 g, 13.6 mmol) (I-35) in ethanol (80 mL) was added potassium hydroxide (1M aqueous, 67.9 mL, 67.9 mmol) and the reaction mixture was stirred for 16 h at 60° C. The reaction mixture was concentrated in vacuo then diluted with hydrochloric acid (1.00 mol/L, 82 mL, 82 mmol) and cooled to 0° C. The reaction mixture was then filtered and the filter cake provided the title compound which was used directly in the next step. ES/MS: 355.1 (M+H⁺).

Preparation of Intermediate I-37:

5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole (I-37): Prepared analogously to I-11, substituting 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (I-10) with 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (I-36). ES/MS: 311.1 (M+H⁺).

Preparation of Intermediate I-38:

tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-38): Prepared analogously to I-34, substituting 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (I-33) with 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole (I-37). ES/MS: 411.2 (M+H⁺).

Preparation of Intermediate I-39:

tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-39): Prepared analogously to I-16, substituting solution of tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-34) with tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-38). ES/MS: 489.1 (M^(+l).)

Preparation of Intermediate I-40:

tert-butyl5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-2-(3-(methoxycarbonyl)cyclobutyl)-3-methyl-61-thieno[2,3-b]pyrrole-6-carboxylate: To a dried vial was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxyloate (I-16) (120 mg, 0.238 mmol), methyl 3-iodocyclobutane-1-carboxylate (143 mg, 0.596 mmol), tetrabutyl ammonium iodide (TBAI) (105 mg, 1.43 mmol), Ni(dtbbpy)(Hz0)₄C12 (11.2 mg, 0.024 mmol), and zinc dust (93 mg, 1.43 mmol). Dry DMA (1 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70 C for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes) to afford the product. ES/MS: 537.2 (M⁺).

3-(5-(7,8-dim ethyl-[11,2,4]triazolo1[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H1-thieno[2,3-b]pyrrol-2-yl)cyclobutane-1-carboxylic acid (1-40): To a vial was added tert-butyl 5-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-2-(3-(methoxycarbonyl)cyclobutyl)-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (128 mg, 0.23 mmol), and the material was dissolved in MeOH (1 mL), and potassium carbonate (sat. aq., 0.25 mL) was added. The mixture was stirred at 50° C. overnight. The mixture was concentrated under reduced pressure, and the mixture was acidified with 2N HCL. The mixture was filtered, and the precipitate was washed with water, and dried in a lyophilizer to afford the product as a mixture of cis-/trans-isomers. ES/MS: 423.2 (M+H⁺).

Preparation of Intermediate I-41:

4-(tert-butyl) 3-methyl (R)-morpholine-3,4-dicarboxylate: To a 50 mL RBF was added (3R)-4-tert-butoxycarbonylmorpholine-3-carboxylic acid (250 mg, 1.08 mmol), potassium carbonate (448 mg, 3.24 mmol) and DMF (10 mL). Iodomethane (0.68 mL, 2.7 mmol) was added, and the reaction was stirred at rt overnight. The mixture was diluted with water (20 mL) and EtOAc (100 mL), and the layers were separated. The organic layer was washed once with water (20 mL), and the organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude material was purified by silica chromatography (eluent: EtOAc/hexanes) to afford the product. ES/MS: 268.2 (M+23).

tert-butyl (R)-3-(hydrazinecarbonyl)morpholine-4-carboxylate (1-41): To a 10 mL vial was added 4-(tert-butyl) 3-methyl (R)-morpholine-3,4-dicarboxylate (260 mg, 1.08 mmol) and isopropanol (2 mL). Hydrazine hydrate (0.16 mL, 3.18 mmol) was added, and the reaction was stirred at 50° C. for 16 h. The mixture was diluted with EtOAc (50 mL), and the organic layer was washed with water (2×15 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the product. ES/MS: 268.1 (M+23).

Preparation of Intermediate I-42:

tert-butyl (S)-3-(hydrazinecarbonyl)morpholine-4-carboxylate (1-42): Prepared analogously to 1-41, substituting (3R)-4-tert-butoxycarbonylmorpholine-3-carboxylic acid with (3S)-4-tert-butoxycarbonylmorpholine-3-carboxylic acid.

Preparation of Intermediate I-43:

tert-butyl 3-ethynylmorpholine-4-carboxylate (I-43): To a 50 mL RBF was added tert-butyl 3-formylmorpholine-4-carboxylate (400 mg, 1.86 mmol), potassium carbonate (1.03 mg, 7.43 mmol), dimethyl (1-Diazo-2-oxopropyl)phosphonate (500 mg, 2.6 mmol) and MeOH (15 mL). The reaction was stirred at rt overnight. The mixture was concentrated under reduced pressure, the crude residue was diluted with EtOAc (50 mL) and water (10 mL), and the layers were separated. The organic layer was washed once with water (10 mL), and the organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude material was purified by silica chromatography (eluent: EtOAc/hexanes) to afford the product. ES/MS: 156.1 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-44:

2-(3-iodocyclobutyl)isoindoline-1,3-dione (I-44): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with 2-(3-hydroxycyclobutyl)isoindoline-1,3-dione. ES/MS: 327.98 (M+H⁺).

Preparation of Intermediate I-45:

5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline-8-carbonitrile (I-45): Prepared analogously to I-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with 5-bromoquinoline-8-carbonitrile. ES/MS: 281.2 (M+H⁺).

Preparation of Intermediate I-46:

8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline-5-carbonitrile (I-46): Prepared analogously to I-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with 8-bromoquinoxaline-5-carbonitrile. ES/MS: 200.1 (M+H⁺) (mass of boronic ester).

Preparation of Intermediate I-47:

8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine (I-47): Prepared analogously to I-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with 6-bromo-8-methylimidazo[1,2-a]pyridine. ES/MS: 259.2 (M+H⁺).

Preparation of Intermediate I-48:

7-methyl-6-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (1-48): Prepared analogously to 1-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with 6-bromo-7-methyl-[1,2,4]triazolo[1,5-a]pyridine. ES/MS: 260.2 (M+H⁺).

Preparation of Intermediate I-49:

5-bromo-2-hydrazineylidene-3-methyl-1,2-dihydropyridine: To a stirred solution of 2,5-dibromo-3-methylpyridine (10 g, 40 mmol) in ethanol (100 mL) was added hydrazine hydrate (20 mL, 400 mmol) at rt. After completion of addition, the reaction mixture was heated to 110° C. and stirred for 48 hours. After 48h, the reaction mixture was cooled to rt, and the suspension was filtered. The precipitate was washed with ethanol (20 mL) and dried under reduced pressure to obtain the product.

6-bromo-8-methyltetrazolo[1,5-a]pyridine (1-49): To a stirred solution of 5-bromo-2-hydrazineylidene-3-methyl-1,2-dihydropyridine (4 g, 19.8 mmol) in AcOH:H₂O (3:1) (100 mL) was added aqueous NaNO₂ (4.0 g dissolved in 10 mL water) dropwise at 0° C. over a period of 30 min. The reaction mixture was stirred at 0° C. for 2 hours. The progress of reaction was monitored by TLC. After completion of the reaction, EtOAc and water was added to reaction mixture and stirred for additional 20 min. The layers were separated, and the aqueous layer was extracted with EtOAc (3×100 mL). The combined organic layers were washed with sat. aq. Na₂CO₃ (500 mL) solution followed by brine (300 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The obtained crude residue was triturated sequentially with diethyl ether and n-pentane to obtain the product. ES/MS: 213.1 (M⁺).

Preparation of Intermediate I-50:

8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)tetrazolo[1,5-a]pyridine (1-50): Prepared analogously to 1-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with 6-bromo-8-methyltetrazolo[1,5-a]pyridine (1-49). ES/MS: 276.2 (M+H⁺).

Preparation of Intermediate I-51:

8-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (1-51): Prepared analogously to 1-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with 6-bromo-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine. ES/MS: 276.2 (M+H⁺).

Preparation of Intermediate I-52:

tert-butyl 5-(7,8-dimethyl-1[1,2,4]triazolo11,5-alpyridin-6-yl)-2-(3-(1,3-dioxoisoindolin-2-yl)cyclobutyl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate: To a dried vial was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (300 mg, 0.596 mmol), 2-(3-iodocyclobutyl)isoindoline-1,3-dione (I-44) (390 mg, 1.19 mmol), tetrabutylammonium iodide (TBAI) (264 mg, 3.58 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (28 mg, 0.06 mmol), and zinc dust (232 mg, 3.58 mmol). Dry DMA (3 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes) to afford the product.

2-((3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)carbamoyl)benzoic acid: To a vial was added tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(3-(1,3-dioxoisoindolin-2-yl)cyclobutyl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (300 mg, 0.48 mmol), and the material was dissolved in MeOH (2 mL) and potassium carbonate (sat. aq., 1 mL) was added. The mixture was stirred at 55° C. overnight. Solid LiGH (100 mg) was added, and the mixture was stirred at 70° C. for 24 hr. The mixture was carefully acidified with concentrated HCl, and the mixture was diluted with EtOAc (100 mL) and water (15 mL). The layers were separated, and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the product. ES/MS: 542.2 (M+H⁺).

3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutan-1-amine (I-52): To a 10 mL vial was added 2-((3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)carbamoyl)benzoic acid (200 mg, 0.369 mmol) and ethanol (3 mL). Hydrazine hydrate (0.22 mL, 4.43 mmol) was added, and the reaction was stirred at 80° C. for 36 h. TFA (1 mL) was added slowly, and the crude mixture was concentrated under reduced pressure. The crude residue was dissolved in acetonitrile and water, and was filtered through an acrodisc and purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the product as a mixture of cis-/trans-isomers. ES/MS: 394.2 (M+23).

Preparation of Intermediate I-53:

5-ethyl 2-methyl 4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2,5-dicarboxylate: To a solution of di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (I-2) (32.2 g, 83 mmol) and p-toluenesulfonic acid, monohydrate (66.1 g, 348 mmol) in a 500 mL round-bottomed flask in 2-butanol (140 mL) was added ethyl 4-methyl-2-oxo-pentanoate (prepared as described in Org. Preparations and Procedures International vol. 21, issue 4, p. 501, 1989) (11 g, 69.5 mmol) and the reaction mixture was heated to 90° C. for 16 h with a reflux condenser. The reaction mixture was concentrated under reduced pressure, and then taken up in EtOAc and water. The layers were separated, the aqueous layer was extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude oil was used for the next step without further purification. ES/MS: 310.0 (M+H⁺).

4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2,5-dicarboxylic acid: To a solution of 5-ethyl 2-methyl 4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2,5-dicarboxylate (21 g, 67.9 mmol) in ethanol (150 mL) was added potassium hydroxide (339 mL, 1M aq.) and the reaction mixture was heated to 100° C. for 24 h. The reaction mixture was concentrated under reduced pressure, then diluted with hydrochloric acid (339 mL, 1M aq.), and poured onto a brine solution. The product was extracted from the aqueous phase with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude oil was used for the next step without further purification. ES/MS: 268.0 (M+H⁺).

4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole: To a solution of 4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2,5-dicarboxylic acid (18.1 g, 67.7 mmol) in DMA (120 mL) was added DBU (30.3 mL, 203 mmol), and the resulting reaction mixture was stirred at 150° C. for 2 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (30 mL) and extracted with brine (2×20 mL). The aqueous layers were combined and extracted with EtOAc (30 mL). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The crude residue product was purified by flash chromatography (eluent: EtOAc/hexanes) to provide the product. ES/MS: 180.1 (M+H⁺).

tert-butyl 4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate: To a solution of 4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole. (12.1 g, 67.5 mmol) in THE (150 mL) was added N,N-dimethylpyridin-4-amine (DMAP) (2.0 g, 16.9 mmol), triethylamine (9.41 mL, 67.5 mmol), and tert-butoxycarbonyl tert-butyl carbonate (15.5 g, 70.9 mmol). The mixture was stirred at rt for 16h. The mixture was concentrated under reduced pressure. The crude residue product was purified by flash chromatography (eluent: EtOAc/hexanes) to provide the product. ¹H NMR (400 MHz, Chloroform-d) δ 7.00 (s, 1H), 6.57 (s, 1H), 3.14 (pd, J=6.8, 1.0 Hz, 1H), 2.43 (s, 3H), 1.67 (s, 9H), 1.32 (d, J=6.8 Hz, 6H).

tert-butyl 2-bromo-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-53): To a solution of tert-butyl 4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (7.02 g, 25.1 mmol) in acetonitrile (70.1 mL) at 0° C. was added NBS (4.47 g, 25.1 mmol) dissolved in acetonitrile (10 mL) dropwise until LCMS showed completion of reaction. The reaction mixture was diluted with EtOAc (150 mL) and the resultant mixture was extracted with aq. sodium thiosulfate solution (30 mL). The organic layer was then successively washed with water (2×30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and evaporated under reduced pressure and the crude residue was purified by column chromatography (eluent: EtOAc in hexane) to give the product. ES/MS: 302.0 (M⁺) (mass minus tert-butyl). ¹H NMR (400 MHz, DMSO-d₆) δ 7.18 (s, 1H), 3.21-2.97 (m, 1H), 2.32 (s, 3H), 1.59 (s, 9H), 1.24 (d, J=6.8 Hz, 6H).

Preparation of Intermediate I-54:

tert-butyl 2-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate: To tert-butyl 2-bromo-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-53) (4.1 g, 11.4 mmol) in 10:1 dioxane (100 ml) and water (10 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (4.6 g, 14.8 mmol), XPhos Pd G3 (859 mg, 1.1 mmol) and cesium carbonate (11.1 g, 34.2 mmol). The reaction mixture was degassed with argon, and heated to 110° C. for 2 hours. The reaction mixture was diluted with EtOAc (150 mL) and the resultant mixture was extracted with aq. sodium thiosulfate solution (30 mL). The organic layer was then washed with water (2×30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The crude residue was purified by column chromatography (eluent: EtOAc in hexane) to give the product. ES/MS: 461.2 (M+H⁺).

tert-butyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate: To a solution of tert-butyl 2-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (4.2 g, 9.12 mmol) in ethyl acetate (25 mL) was added palladium on carbon 10 wt. % (10.0%, 970 mg, 9.12 mmol) and the reaction mixture was stirred at room temp for 24 h under an atmosphere of hydrogen. The reaction mixture was subsequently degassed with argon, diluted with EtOAc, and filtered through celite, and rinsed with EtOAc. The filtrate was concentrated under reduced pressure to give the product which was used directly in the next step without further purification. ES/MS: 463.3 (M+H⁺).

tert-butyl 4-(4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate (I-54): To tert-butyl 2-(1-tert-butoxycarbonyl-4-piperidyl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (4.2 g, 9.1 mmol) in a 1:1:1 mixture of EtOH/THF/water (50 mL) was added LiGH (1.4 g, 54.7 mmol) and the reaction mixture was stirred for 16 h at 80° C. The reaction mixture was diluted with EtOAc (150 mL) and the organic layer was then successively washed with water (2×50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and evaporated under reduced pressure to provide the product. ES/MS: 363.3 (M+H⁺).

Preparation of Intermediate I-55:

tert-butyl 2-((1S,4R,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-5-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate: To a dried vial was added tert-butyl 4-(4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate (I-53) (250 mg, 0.7 mmol), tert-butyl (1S,4S,5R)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-31) (451 mg, 1.4 mmol), tetrabutylammonium iodide (TBAI) (309 mg, 0.837 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (32.8 mg, 0.07 mmol), and zinc dust (272 mg, 4.19 mmol). Dry DMA (2.5 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes) to provide the product.

tert-butyl (1S,4R,5R)-5-(4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-55): To a solution of tert-butyl 2-((1S,4R,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-5-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (320 mg, 0.67 mmol) in THF (1 mL) and MeOH (2 mL) was added LiGH monohydrate (100 mg, 2.38 mmol) (dissolved in 1 mL water) and the reaction mixture was stirred for 6 h at 90° C. The reaction mixture was diluted with EtOAc (50 mL) and the organic layer was then successively washed with water (15 mL) and brine (5 mL), dried over MgSO₄, filtered, and evaporated under reduced pressure to provide the product. ES/MS: 375.2 (M+H⁺).

Preparation of Intermediate I-56:

(1S,4S)-spiro[bicyclo[2.2.1]heptane-2,2′-[1,3]dioxolan]-5-ol: To a solution of (1S,4S)-spiro[bicyclo[2.2.1]heptane-2,2′-[1,3]dioxolan]-5-one (1.0 g, 5.95 mmol) in methanol (20 mL) cooled to 0° C. was added sodium borohydride (0.22 g, 5.95 mmol). The mixture was slowly warmed to rt over a period of 2 hours. The mixture was quenched with sat. ammonium chloride and the reaction was diluted in ethyl acetate. The layers were separated, and the organic phase was washed with water, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude residue product was purified by flash chromatography (eluent: EtOAc/hexanes) to provide the product.

(1S,4S)-5-iodospiro[bicyclo[2.2.1]heptane-2,2′-[1,3]dioxolane](I-56): To a solution of (1S,4S)-spiro[bicyclo[2.2.1]heptane-2,2′-[1,3]dioxolan]-5-ol (0.9 g, 5.3 mmol) in toluene (50 mL) was added triphenylphosphine (1.57 g, 6.35 mmol), molecular iodine (1.61 g, 6.35 mmol) and imidazole (720 mg, 10.6 mmol). The mixture was stirred at reflux for 16 hours. The mixture was concentrated under reduced pressure. The crude residue product was purified by flash chromatography (eluent: EtOAc/hexanes) to provide the product.

Preparation of Intermediate I-57:

tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-((1S,4S)-5-oxobicyclo[2.2.1]heptan-2-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-57): To a dried vial was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (700 mg, 1.39 mmol), (1S,4S)-5-iodospiro[bicyclo[2.2.1]heptane-2,2′-[1,3]dioxolane](I-56) (545 mg, 1.95 mmol), tetrabutylammonium iodide (TBAI) (514 mg, 1.39 mmol), Ni(dtbbpy)(H20)₄Cl₂ (53.6 mg, 0.114 mmol), and zinc dust (452 mg, 6.95 mmol). Dry DMA (6 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in DCM (5 mL), cooled to 0° C., and then TFA (1.0 mL) was added dropwise. The mixture was stirred at 0° C. for 3h. LCMS indicated removal of Intermediate I-56, and the mixture was diluted with EtOAc (60 mL) and sat. sodium bicarbonate (6 mL). The layers were separated, and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the product. ES/MS: 533.3 (M+H⁺).

Preparation of Intermediate I-58:

Methyl 5-[tert-butoxycarbonyl-(tert-butoxycarbonylamino)amino]thiophene-3-carboxylate (I-58): Prepared analogously to I-2, substituting methyl 5-bromo-3-methyl-thiophene-2-carboxylate with methyl 5-bromothiophene-3-carboxylate. ES/MS: 373.1 (M+H⁺).

Preparation of Intermediate I-59:

methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-3-carboxylate (1-59): Prepared analogously to 1-3, substituting di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (1-2) with methyl 5-[tert-butoxycarbonyl-(tert-butoxycarbonylamino)amino]thiophene-3-carboxylate (I-58). ES/MS: 355.2 (M+H⁺).

Preparation of Intermediate I-60:

6-(tert-butyl) 3-methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-3,6-dicarboxylate (1-60): Prepared analogously to 1-15, substituting 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (1-6) with methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-3-carboxylate (1-59). ES/MS: 455.3 (M+H⁺).

Preparation of Intermediate I-61:

tert-butyl3-(hydroxymethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (1-61): To a solution of 6-(tert-butyl) 3-methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-3,6-dicarboxylate (I-60) (5.3 g, 11.7 mmol) in THE (50 mL) cooled to 0° C. was added lithium aluminum hydride (1M in THF) (11.7 ml, 11.7 mmol) and the reaction mixture was stirred. Another three additions of 3 ml LiAlH₄ were then added. The reaction mixture was quenched with sat. NH₄Cl and diluted with EtOAc. The layers were separated, the aqueous layer was extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The material was carried forward to the next step without further purification. ES/MS: 427.4 (M+H⁺). Preparation of Intermediate I-62:

tert-butyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(((triisopropylsilyl)oxy)methyl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-62): To a solution of tert-butyl 3-(hydroxymethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-61) (5.0 g, 11.7 mmol) in DMF (40 mL) was added imidazole (1.6 g, 23.3 mmol), DMAP (1.4 g, 11.7 mmol) and triisopropylsilyl chloride (3.7 mL, 17.5 mmol). The reaction mixture was stirred overnight. The reaction mixture was quenched with water and diluted with EtOAc. The layers were separated, the aqueous layer was extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the product. ES/MS: 583.9 (M+H⁺).

Preparation of Intermediate I-63:

tert-butyl 2-bromo-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(((triisopropylsilyl)oxy)methyl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-63): Prepared analogously to I-16, substituting solution of tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-34) with tert-butyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(((triisopropylsilyl)oxy)methyl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-62). ES/MS: 662.2 (M⁺).

Preparation of Intermediate I-64:

tert-butyl (1S,4R)-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-64): To a solution of tert-butyl (1S,4R)-6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate (1.00 g, 4.73 mmol) in methanol (20.0 mL) in a 250 mL round-bottomed flask at 0° C. was added sodium borohydride (0.18 g, 4.73 mmol). The resulting mixture was warmed to room temperature and stirred for 1 hour. The reaction mixture was then quenched with saturated aqueous ammonium chloride (5 mL), diluted with water (10 mL) and EtOAc (10 mL), and extracted with EtOAc (2×20 mL). The combined organic layer was dried over MgSO₄, vacuum filtered, and concentrated under reduced pressure to yield the crude product. The crude material was used directly in subsequent reactions without the need for further purification. ES/MS: 158.2 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-65:

tert-butyl (1S,4R)-6-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-65): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with I-64. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-66:

tert-butyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]morpholine-4-carboxylate (I-66): Prepared analogously to I-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with tert-butyl 2-(4-bromophenyl)morpholine-4-carboxylate. ES/MS: 334.2 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-67:

tert-butyl 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]piperidine-1-carboxylate (I-67): Prepared analogously to I-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with tert-butyl 4-(5-bromopyrimidin-2-yl)piperidine-1-carboxylate. ES/MS: 334.2 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-68:

tert-butyl (1S,4R)-2-hydroxy-7-azabicyclo[2.2.1]heptane-7-carboxylate (I-68): Prepared analogously to I-CJS3, substituting tert-butyl (1S,4R)-6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate with tert-butyl (1S,4R)-2-oxo-7-azabicyclo[2.2.1]heptane-7-carboxylate. ES/MS: 158.2 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-69:

tert-butyl (1S,4R)-2-iodo-7-azabicyclo[2.2.1]heptane-7-carboxylate (I-69): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with I-68. ES/MS: 268.1 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate 1-70:

tert-butyl (1R,4R,5R)-5-iodo-2-azabicyclo[2.2.2]octane-2-carboxylate (I-70): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl (1R,4R,5S)-5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate 1-71:

di-tert-butyl 1-(4-ethyl-5-(methoxycarbonyl)thiophen-2-yl)hydrazine-1,2-dicarboxylate (I-71): Prepared analogously to I-2, substituting methyl 5-bromo-3-methyl-thiophene-2-carboxylate with methyl 5-bromo-3-ethylthiophene-2-carboxylate.

Preparation of Intermediate 1-72:

2-bromo-3-ethyl-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-72): Prepared analogously to I-6, I-5, and I-3, substituting di-tert-butyl 1-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)hydrazine-1,2-dicarboxylate (I-2) with di-tert-butyl 1-(4-ethyl-5-(methoxycarbonyl)thiophen-2-yl)hydrazine-1,2-dicarboxylate (I-71). ES/MS: 402.1 (M^(+l).)

Preparation of Intermediate I-73:

tert-butyl 2-bromo-3-ethyl-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)thieno[2,3-b]pyrrole-6-carboxylate (I-73): Prepared analogously to I-15, substituting 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-6) with 2-bromo-3-ethyl-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-72). ES/MS: 503.2 (M^(+l).)

Preparation of Intermediate I-74:

tert-butyl 2-(2-ethoxycarbonylcyclopropyl)-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)thieno[2,3-b]pyrrole-6-carboxylate: To a solution of tert-butyl 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)thieno[2,3-b]pyrrole-6-carboxylate (I-15) (350 mg, 0.72 mmol) in 10:1 toluene and water (4 mL) was added ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropanecarboxylate (275 mg, 1.2 mmol), cataCXium® A Pd G3 (52.1 mg, 0.072 mmol) and cesium carbonate (699 mg, 2.2 mmol). The reaction mixture was heated to 100° C. for 16 hours under N₂. The reaction mixture was dried over sodium sulfate, filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the product. ES/MS: 523.3 (M+H⁺).

2-[4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl]cyclopropanecarboxylic acid (I-74): To a solution of tert-butyl 2-(2-ethoxycarbonylcyclopropyl)-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)thieno[2,3-b]pyrrole-6-carboxylate (350 mg, 0.67 mmol) in 1:1:1 THF/EtOH/water (6 mL) was added lithium hydroxide monohydrate (80.2 mg, 0.52 mmol) and the reaction mixture was stirred for 4 h at 90° C. The reaction mixture was concentrated in vacuo then diluted with hydrochloric acid (1.00 mol/L, 1.18 mL, 1.18 mmol) and water and the precipitate was then collected by filtration to give the product. ES/MS: 395.2 (M+H⁺).

Preparation of Intermediate I-75:

tert-butyl 2-(1-benzyloxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate: To a solution of tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (800 mg, 1.60 mmol) in 10:1 doxanes and water (13 mL) was added benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (709 mg, 2.07 mmol), Xphos Pd G3 (125 mg, 0.16 mmol) and cesium carbonate (1553 mg, 4.77 mmol). The reaction mixture was heated to 110° C. for 3 hours under N₂. The reaction mixture was dried over sodium sulfate, filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the product. ES/MS: 640.4 (M+H⁺).

tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(4-piperidyl)thieno[2,3-b]pyrrole-6-carboxylate (I-75): To a solution of tert-butyl 2-(1-benzyloxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (1 g, 1.56 mmol) was added ethanol (20 mL). Nitrogen was bubbled through the solution for 4 min then palladium on carbon (10 wt. %, 166 mg, 1.56 mmol) was added and the reaction mixture was stirred for 24 h under an atmosphere of hydrogen. The reaction mixture was degassed with argon, diluted with EtOAc, and filtered through celite, eluted with EtOAc, and the filtrate was concentrated under reduced pressure to give the crude product which was used directly in the next step without further purification. ES/MS: 508.3 (M+H⁺).

Preparation of Intermediate I-76:

tert-butyl 9-iodo-1-oxa-4-azaspiro[5.5]undecane-4-carboxylate (I-76): To a solution of tert-butyl 9-oxo-1-oxa-4-azaspiro[5.5]undecane-4-carboxylate (0.5 g, 1.86 mmol) in MeOH (10 mL) at 0° C. was added NaBH₄ (70.2 mg, 1.86 mmol). The resulting mixture was stirred at room temperature for 30 min. The reaction mixture was then quenched slowly with 5 mL sat. aq. NH₄Cl and diluted with water (20 mL) and EtOAc (20 mL). The aqueous layer was then extracted with EtOAc (2×20 mL). The organic layers were combined, dried over MgSO₄, filtered, concentrated, then dried on the hi-vac. The crude oil was then dissolved in toluene (25 mL), and to this mixture was added triphenylphosphine (0.55 g, 2.21 mmol), molecular iodine (0.56 g, 2.21 mmol) and imidazole (0.25 g, 3.69 mmol). The mixture was stirred at reflux overnight. The mixture was concentrated under reduced pressure. The crude product was purified by flash chromatography (eluent: hexane/EtOAc) to provide the product. ES/MS: 326.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-77:

6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine: To a solution of 5-bromo-3,4-dimethyl-pyridin-2-amine (2.0 g, 9.95 mmol) in 1,4-dioxane (69 mL) was added ethoxycarbonyl isothiocyanate (1.30 g, 1.17 mL, 9.95 mmol) dropwise at room temperature. After stirring for 19 hr, the solvent was evaporated under reduced pressure. The residue product was dissolved in a 1:1 mixture of MeOH and EtOH (IMS grade) (128 mL) and hydroxylamine hydrochloride (3.46 g, 49.7 mmol) was added and the reaction mixture was heated to 60° C., followed by addition of DIPEA (5.2 mL, 29.8 mmol). The reaction was then heated at 60° C. for 4 hr before allowing the reaction mixture to cool down to room temperature. The resultant precipitate was collected by filtration, washed with MeOH and dried to afford the product. ES/MS: 241.0 (M^(+l).)

6-bromo-2-chloro-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine: To a suspension of copper(II) chloride (1.25 g, 9.33 mmol) and tert-buty nitrite (1.11 mL, 9.33 mmol) in dry MeCN (30 mL) at 70° C. was added 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine (1.50, 6.22 mmol). After stirring at 70° C. for 4 hr, the reaction mixture was poured onto 5 N aq. HCl (20 mL) and extracted with EtOAc (4×20 mL). The combined organic phase was dried over Na₂SO₄, filtered and concentrated to dryness under reduced pressure. The crude product was purified by flash chromatography (eluent: EtOAc/hexane) to afford the product. ES/MS: 262.0 (M⁺). ¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1H), 2.62 (s, 3H), 2.49 (s, 3H).

2-chloro-7,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (I-77): A solution of 6-bromo-2-chloro-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.76 g, 2.9 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.11 g, 4.35 mmol), Pd(dppf)Cl₂ (215 mg, 0.29 mmol) and potassium propionate (1.14 g, 10.2 mmol) in 1,4-dioxane (5 mL) was degassed with argon for 3 minutes and stirred at 90° C. for 2 hr. The reaction mixture was allowed to cool down to room temperature, filtered over a celite pad and concentrated to dryness. The residue product was purified by flash chromatography (eluent: EtOAc:hexane) to afford the product. ES/MS: 308.1 (M+H⁺). H NMR (400 MHz, CDCl₃) δ 8.68 (s, 1H), 2.56 (d, J=12.8 Hz, 6H), 1.38 (d, J=1.5 Hz, 12H).

Preparation of Intermediate I-78:

4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexanone (I-78): To a dried vial was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (160 mg, 0.32 mmol), 8-iodo-1,4-dioxaspiro[4.5]decane (170 mg, 0.64 mmol), tetrabutylammonium iodide (TBAI) (141 mg, 0.38 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (18 mg, 0.038 mmol), and zinc dust (124 mg, 1.91 mmol). Dry DMA (1 mL) was added, and the mixture was degassed for 1 min with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). (ES/MS: 565.2 [M+H⁺]). To a solution of the purified ketal intermediate in THE (1 mL) and MeOH (1 mL), LiGH (excess) was added and the resulting reaction mixture stirred at 80° C. for 3 hr. The reaction mixture was diluted with EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (5 mL), dried over MgSO₄, filtered, and concentrated. The material obtained was dissolved in DCM (1 mL) and treated with 4M HCl in dioxane (2 mL) and 3 drops of water. The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with EtOAc (10 mL), washed with sat. aq. NaHCO₃ (10 mL), brine (5 mL), dried over Na₂SO₄, filtered and concentrated. The crude product was purified to provide the product. ES/MS: 421.0 (M+H⁺).

Preparation of Intermediate I-79:

6-bromo-2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (I-79): To a stirred solution of 2-amino-5-bromopyridine (10 g, 53.5 mmol) in N,N-dimethylformamide (24 mL) was added 1,1-dimethoxy-N,N-dimethylethan-1-amine (23.4 mL, 0.16 mol). The reaction mixture was heated to 130° C. overnight. After cooling to room temperature, the volatiles were removed under reduced pressure to afford the intermediate imine product. To an ice-cooled, stirred solution of the intermediate imine product in methanol (80 mL) and pyridine (8.7 mL) was added hydroxylamine-O-sulfonic acid (9.07 g, 80.2 mmol). The reaction mixture was allowed to warm to room temperature and was stirred overnight. The volatiles were removed under reduced pressure, and the residue was partitioned between aqueous sodium bicarbonate solution (50 mL) and ethyl acetate (50 mL). The aqueous layer was further extracted with ethyl acetate (3×50 mL), and the combined organic layers were washed sequentially with water (100 mL) and brine (100 mL), dried over magnesium sulfate, and concentrated in vacuo to provide the product. ES/MS: 226.2 (M^(+l).)

Preparation of Intermediate I-80:

2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (1-80): Prepared analogously to 1-13, substituting 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine with 6-bromo-2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (1-79). ES/MS: 192.1 (M+H⁺) (mass of boronic acid). ¹H NMR (400 MHz, CDCl₃) δ 8.72 (t, J=0.9 Hz, 1H), 7.55 (p, J=1.1 Hz, 1H), 2.66-2.57 (m, 6H), 1.38 (s, 12H).

Preparation of Intermediate I-81:

1-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-methyl-butan-1-one (I-81): Prepared analogously to 1-14, substituting 7,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine with 2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (1-80). ES/MS: 232.2 (M+H⁺). ¹H NMR (400 MHz, CDCl₃) δ 8.99 (d, J=1.7 Hz, 1H), 2.82 (d, J=6.9 Hz, 2H), 2.66 (d, J=3.3 Hz, 6H), 2.33 (dh, J=13.3, 6.7 Hz, 1H), 1.04 (d, J=6.7 Hz, 6H).

Preparation of Intermediate I-82:

Methyl 5-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-82): Prepared analogously to I-3, substituting 3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one with 1-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-methyl-butan-1-one (I-81). ES/MS: 383.2 (M+H⁺).

Preparation of Intermediate I-83:

5-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (I-83): Prepared analogously to I-5, substituting methyl 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylate with methyl 5-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-2-carboxylate (I-82). ES/MS: 325.2 (M+H⁺).

Preparation of Intermediate I-84:

2-bromo-5-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (I-84): Prepared analogously to I-6, substituting 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-5) with 5-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (I-83). ES/MS: 405.1 (M+2H⁺).

Preparation of Intermediate I-85:

tert-butyl 2-bromo-5-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-85): Prepared analogously to I-15, substituting 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole with 2-bromo-5-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (I-84). ES/MS: 504.2 (M+). ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, J=1.6 Hz, 1H), 7.25-7.19 (m, 1H), 2.96 (hept, J=7.1 Hz, 1H), 2.66 (d, J=3.5 Hz, 6H), 2.47 (s, 3H), 1.36 (s, 9H), 1.24 (d, J=7.1 Hz, 6H).

Preparation of Intermediate I-86:

Methyl 4-iodocyclohexanecarboxylate (I-86): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with methyl 4-hydroxycyclohexanecarboxylate. ¹H NMR (400 MHz, CDCl3) δ 4.64 (t, J=4.5 Hz, 1H), 3.68 (s, 3H), 2.41 (tt, J=9.9, 4.0 Hz, 1H), 2.16-2.05 (m, 2H), 2.05-1.86 (m, 2H), 1.86-1.61 (m, 4H).

Preparation of Intermediate I-87:

Tert-butyl 3-iodo-8-azaspiro[4.5]decane-8-carboxylate (I-87): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 3-hydroxy-8-azaspiro[4.5]decane-8-carboxylate. ES/MS: 310.0 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-88:

Tert-butyl 2-iodo-6-azaspiro[3.5]nonane-6-carboxylate (I-88): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. ES/MS: 296.1 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-89:

Tert-butyl 2-iodo-5-azaspiro[3.4]octane-5-carboxylate (I-89): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 2-hydroxy-5-azaspiro[3.4]octane-5-carboxylate. ES/MS: 282.1 (M+H⁺) (mass minus tert-butyl).

Preparation of Intermediate I-90:

Tert-butyl 5-iodo-2-azaspiro[3.3]heptane-2-carboxylate (I-90): Prepared analogously to I-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 7-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate. ES/MS: 268.0 (M+H⁺) (mass minus tert-butyl). ¹H NMR (400 MHz, CDCl3) δ 4.59-4.48 (m, 1H), 4.22 (dd, J=9.0, 1.0 Hz, 1H), 3.96 (dd, J=9.1, 1.0 Hz, 1H), 3.78 (dd, J=9.2, 1.0 Hz, 1H), 3.72 (dd, J=9.2, 1.0 Hz, 1H), 2.59-2.37 (m, 2H), 2.32-2.17 (m, 2H), 1.46 (s, 9H).

Preparation of Intermediate I-91:

tert-butyl (1R,4R,5R)-5-iodo-2-azabicyclo[2.2.2]octane-2-carboxylate (1-91): Prepared analogously to 1-20, substituting tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl (1R,4R,5S)-5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate.

Preparation of Intermediate I-92:

tert-butyl (6-iodospiro[3.3]heptan-2-yl)carbamate (1-92): Prepared analogously to 1-76, substituting tert-butyl 9-oxo-1-oxa-4-azaspiro[5.5]undecane-4-carboxylate with tert-butyl (6-oxospiro[3.3]heptan-2-yl)carbamate. ES/MS: 282.0 (M+H⁺) (mass minus tert-butyl).

Final Procedures Procedure 1, Example 1

4-isopropyl-N-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole-2-carboxamide (Example 1): To a solution of 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (1-10) (20.0 mg, 0.0588 mmol) in DCM (0.75 mL) was added tert-butyl 4-(methylamino)piperidine-1-carboxylate (0.0439 mL, 0.206 mmol), HATU (26.8 mg, 0.0705 mmol) and N,N-diisopropylethylamine (0.0512 mL, 0.294 mmol) and the reaction mixture was heated to 60° C. and stirred for 30 min. Trifluoroacetic acid (0.250 mL, 3.27 mmol) was added and the reaction mixture was stirred at room temperature for 10 min. The reaction mixture was concentrated under reduced pressure and the crude residue was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250 ×21.2 mm) to give the title compound Example 1. ES/MS: 437.3 (M+H⁺). H NMR (400 MHz, DMSO-d6) δ 11.74 (s, 1H), 8.81-8.74 (m, 1H), 8.53 (s, 1H), 8.25-8.02 (m, 2H), 7.65-7.52 (m, 2H), 4.59-4.46 (m, 2H), 3.14 (s, 3H), 3.21-2.97 (m, 4H), 2.62 (s, 3H), 2.06-1.82 (m, 4H), 1.37 (d, J=6.9 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 1 and are shown below in Table 1. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 1 and are noted in the last column of Table 1—“Changes to Procedure 1: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 1 were replaced with the different reagents/starting materials noted below.

TABLE 1 Changes to Procedure 1: Different Reagents/ Ex- ES/MS Starting ample Structure m/z ¹H-NMR Materials 2

409.2 ¹H NMR (400 MHz, DMSO-d6) δ 11.78 (s, 1H), 8.84 (s, 2H), 8.80-8.76 (m, 1H), 8.53 (s, 1H), 7.65 (s, 1H), 7.59-7.53 (m, 1H), 3.98-3.87 (m, 4H), 3.29-3.19 (m, 4H), 3.19-3.07 (m, 1H), 2.62 (s, 3H), 1.37 (d, J = 6.9 Hz, 6H). tert-butyl piperazine- 1-carboxylate 3

423.2 ¹H NMR (400 MHz, DMSO-d6) δ 11.76 (s, 1H), 8.78 (s, 1H), 8.76-8.68 (m, 2H), 8.53 (s, 1H), 7.65 (s, 1H), 7.61-7.53 (m, 1H), 5.02-4.83 (m, 1H), 3.53-3.20 (m, 4H), 3.25 (s, 3H), 3.20-3.08 (m, 1H), 2.62 (s, 3H), 2.30-2.18 (m, 1H), 2.16-2.02 (m, 1H), 1.37 (d, J = 6.8 Hz, 6H). tert-butyl (3S)- 3- (methylamino) pyrrolidine-1- carboxylate 4

392.2 ¹H NMR (400 MHz, DMSO-d6) δ 11.76 (s, 1H), 8.78 (s, 1H), 8.76-8.68 (m, 2H), 8.53 (s, 1H), 7.65 (s, 1H), 7.60-7.54 (m, 1H), 4.94 (p, J = 8.2 Hz, 1H), 3.45- 3.36 (m, 2H), 3.25 (s, 3H), 3.31- 3.09 (m, 3H), 2.62 (s, 3H), 2.31- 2.17 (m, 1H), 2.17-2.01 (m, 1H), 1.37 (d, J = 6.8 Hz, 6H). tert-butyl (3R)- 3- (methylamino) pyrrolidine-1- carboxylate 5

481.3 ¹H NMR (400 MHz, DMSO-d6) δ 11.75 (s, 1H), 9.09 (s, 1H), 8.78 (d, J = 1.5 Hz, 1H), 8.53 (s, 1H), 7.61 (s, 1H), 7.58-7.55 (m, 1H), 5.51-5.26 (m, 1H), 4.61- 4.46 (m, 1H), 3.75 (t, J = 5.1 Hz, 2H), 3.65-3.57 (m, 2H), 3.22- 3.08 (m, 8H), 2.62 (s, 3H), 2.24- 2.10 (m, 2H), 1.95-1.85 (m, 2H), 1.37 (d, J = 6.9 Hz, 6H). 2-[4- (methylamino)- 1-piperidyl] ethanol

Procedure 2, Example 6

tert-butyl 4-((5-bromothiophen-2-yl)sulfonyl)piperazine-1-carboxylate: To a solution of 5-bromothiophene-2-sulfonyl chloride (1.00 g, 3.82 mmol) in THE (15.0 mL) cooled to 0° C. was added tert-butyl piperazine-1-carboxylate (0.783 g, 4.21 mmol) as a solution in THE (5 mL) and the reaction was stirred at 0° C. for 30 min. The reaction was quenched by the addition of water and the mixture was extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-50% EtOAc in hexane) to give the title compound. ES/MS: 435.0 (M+Na⁺).

di-tert-butyl 1-(5-((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)thiophen-2-yl)hydrazine-1,2-dicarboxylate: To a solution of tert-butyl 4-[(5-bromo-2-thienyl)sulfonyl]piperazine-1-carboxylate (0.823 g, 2.00 mmol) in THE (6 mL) cooled to −40° C. was added isopropylmagnesium bromide in 2-MeTHF (2.90 mol/L, 0.841 mL, 2.44 mmol) dropwise and the solution was stirred for 30 min at −40° C. di-tert-butylazodicarboxylate (0.507 g, 2.20 mmol) was then added as a solution in THE (6 mL) dropwise and the reaction was stirred for 30 min at −40° C. The reaction was quenched by the addition of saturated aqueous ammonium chloride and the mixture was extracted with DCM (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated in vacuo. The crude residue was purified by column chromatography (0-50% EtOAc in hexane) to give the title compound. ES/MS: 585.3 (M+Na⁺). ¹H NMR (400 MHz, Chloroform-d) δ 7.34-7.30 (m, 1H), 6.80-6.76 (m, 1H), 3.61-3.49 (m, 4H), 3.11-3.00 (m, 4H), 1.61-1.42 (m, 27H).

4-Isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperazin-1-ylsulfonyl)-6H-thieno[2,3-b]pyrrole (Example 6): To a solution of methyl 5-[tert-butoxycarbonyl-(tert-butoxycarbonylamino)amino]thiophene-2-carboxylate (200 mg, 0.537 mmol) and p-toluenesulfonic acid, monohydrate (0.555 g, 3.22 mmol) in ethanol (12 mL) was added 3-methyl-1-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)butan-1-one (I-1) (0.175 g, 0.806 mmol) and the reaction mixture was heated to 130° C. in a microwave for 30 min. The reaction mixture was concentrated in vacuo, taken up in EtOAc and washed with sat. aq. sodium bicarbonate. The layers were separated, the organic layer was dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 6. ES/MS: 445.2 (M+H⁺). ¹H NMR (400 MHz, DMSO-d6) δ 12.03 (s, 1H), 8.87-8.81 (m, 1H), 8.55 (s, 1H), 8.54-8.47 (m, 2H), 7.89 (s, 1H), 7.61-7.54 (m, 1H), 3.42-3.12 (m, 9H), 2.63 (s, 3H), 1.38 (d, J=6.9 Hz, 6H).

Procedure 3, Example 7

N-(1-(2-hydroxyethyl)piperidin-4-yl)-4-isopropyl-N,3-dimethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxamide (Example 7): To a solution of 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-2-carboxylic acid (44.0 mg, 0.124 mmol) in DCM (0.75 mL) was added 2-[4-(methylamino)-1-piperidyl]ethanol (21.6 mg, 0.137 mmol), HATU (56.6 mg, 0.149 mmol) and N,N-Diisopropylethylamine (0.108 mL, 0.621 mmol) and the reaction mixture was stirred for 30 min. Trifluoroacetic acid (0.250 mL, 3.27 mmol) was added and the reaction mixture was stirred for 10 min at room temperature. The reaction mixture was concentrated under reduced pressure and the crude residue was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 7. ES/MS: 495.3 (M+H⁺). H NMR (400 MHz, DMSO-d6) δ 11.62 (s, 1H), 9.06 (s, 1H), 8.77 (s, 1H), 8.53 (s, 1H), 7.52 (t, J=1.5 Hz, 1H), 5.46-5.30 (m, 1H), 4.43-4.28 (m, 1H), 3.77-3.69 (m, 2H), 3.62-3.52 (m, 2H), 3.26-3.04 (m, 5H), 2.89 (s, 3H), 2.62 (s, 3H), 2.43 (s, 3H), 2.24-2.07 (m, 2H), 1.94-1.81 (m, 2H), 1.33 (d, J=7.1 Hz, 6H).

Procedure 4, Example 8

4-Isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole (Example 8): To a solution of 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (I-7) (32.0 mg, 0.075 mmol) in DCM (0.5 mL) was added trifluoroacetic acid (0.1 mL), and the reaction mixture was stirred for 10 min at room temperature. The reaction mixture was concentrated under reduced pressure, and the crude residue was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 8. ES/MS: 394.3 (M+H⁺). ¹H NMR (400 MHz, DMSO-d6) δ 11.40 (s, 1H), 8.68 (s, 1H), 8.60-8.52 (m, 1H), 8.52 (s, 1H), 8.30-8.13 (m, 1H), 7.49 (s, 1H), 3.28-3.14 (m, 3H), 3.14-3.00 (m, 2H), 2.63-2.60 (m, 4H), 2.41 (s, 3H), 2.00 (d, J=13.6 Hz, 2H), 1.82-1.65 (m, 2H), 1.32 (d, J=7.1 Hz, 6H).

Procedure 5, Example 9

2-(4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)piperidin-1-yl)acetamide (Example 9): To a solution of 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (I-7) (70 mg, 0.163 mmol) in 1,2-dichloroethane (2 mL) was added 2-bromoacetamide (27 mg, 0.195 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.097 mL, 0.65 mmol). The mixture was stirred overnight at rt. To the mixture was added 0.5 mL DMSO and 0.1 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.1 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 9. ES/MS: 451.3 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 10.95 (s, 1H), 8.60 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 3.99 (s, 2H), 3.74 (d, J=12.1 Hz, 2H), 3.52-3.35 (m, 1H), 3.31-3.10 (m, 3H), 2.69 (s, 3H), 2.50 (s, 3H), 2.23 (d, J=14.4 Hz, 2H), 2.08 (q, J=12.8, 12.4 Hz, 2H), 1.40 (d, J=7.1 Hz, 6H).

Procedure 6, Example 10

2-(dimethylamino)-1-(4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)piperidin-1-yl)ethan-1-one (Example 10): To a solution of 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (I-7) (15 mg, 0.035 mmol) in 1,2-dichloroethane (1 mL) was added 2-(dimethylamino)acetyl chloride (6 mg, 0.042 mmol) and triethylamine (0.02 mL, 0.14 mmol). The mixture was stirred 2 hr at rt. To the mixture was added 0.1 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.1 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 10. ES/MS: 479.3 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 4.68 (d, J=13.5 Hz, 2H), 4.42-4.17 (m, 3H), 3.79 (d, J=13.5 Hz, 2H), 3.31-3.26 (m, 1H), 3.00 (s, 3H), 2.97 (s, 3H), 2.91 (t, J=13.8 Hz, 1H), 2.68 (s, 3H), 2.49 (s, 3H), 2.12-1.97 (m, 2H), 1.80-1.52 (m, 2H), 1.41 (d, J=7.3 Hz, 6H).

Procedure 7, Example 11

2-(dimethylamino)-1-(4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)piperidin-1-yl)ethan-1-one (Example 11): To a dram vial with 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (I-7) (12 mg, 0.028 mmol) in 1,2-dichloroethane (1 mL) was added 3-methyloxetane-3-carbaldehyde (6 mg, 0.056 mmol), N,N-diisopropylethylamine (0.01 mL, 0.056 mmol), and acetic acid (1 drop). The mixture was stirred 2 hr at rt. To the mixture was subsequently added sodium triacaetoxyborohydride (STAB) (18 mg, 0.084 mmol), and the mixture was stirred overnight at rt. To the mixture was added 0.1 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.1 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 11. ES/MS: 478.3 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.46 (s, 1H), 7.57 (s, 1H), 4.65 (d, J=6.2 Hz, 2H), 4.44 (d, J=6.2 Hz, 2H), 3.58-3.38 (m, 7H), 3.30-3.24 (m, 1H), 2.68 (s, 3H), 2.50 (s, 3H), 2.23 (d, J=14.6 Hz, 2H), 2.09-1.95 (m, 2H), 1.61 (s, 3H), 1.40 (d, J=7.1 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 7 and are shown below in Table 2. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 7 and are noted in the last column of Table 2—“Changes to Procedure 7: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 7 were replaced with the different reagents/starting materials noted below.

TABLE 2 Changes to Procedure 7: Different Reagents/ Ex- ES/MS Starting ample Structure m/z ¹H-NMR Materials 8

526.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.46 (s, 1H), 7.57 (s, 1H), 3.81-3.58 (m, 3H), 3.57-3.38 (m, 4H), 3.30 (s, 5H), 2.68 (s, 3H), 2.59-2.48 (m, 4H), 2.47-2.35 (m, 2H), 2.30 (d, J = 14.3 Hz, 2H), 2.09- 1.94 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H). 1,1- dioxothian- 4-one

Procedure 8, Example 13

2-(4-(4-isopropyl-3-methyl-5-(8-methyl-1[1,2,4]triazolo11,5-alpyridin-6-yl)-6H1-thieno[2,3-b]pyrrol-2-yl)piperidin-1-yl)ethan-1-ol (Example 13): To a dram vial with 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1, 5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (I-7) (20 ing, 0.047 minol) in 1,2-dichloroethane (0.5 mL) was added 2-[tert-butyl(dimethyl)silyl]oxyacetaldehyde (18 ing, 0.093 minol), N,N-diisopropylethyl amine (0.02 mL, 0.093 minol), and acetic acid (1 drop). The mixture was stirred 2 hr at rt. To the mixture was subsequently added sodium triacaetoxyborohydride (STAB) (30 mg, 0.14 mmol), and the mixture was stirred overnight at rt. The crude mixture was purified directly by silica chromatography (eluent EtOAc/hexanes). The product was subsequently dissolved in acetonitrile (1 mL), and TFA (0.25 mL) was added. The reaction was heated at 40° C. for 3 hr. Water (0.15 mL) was added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 13. ES/MS: 438.3 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 3.94 (t, J=5.3 Hz, 2H), 3.76 (d, J=12.3 Hz, 2H), 3.62-3.37 (m, 4H), 3.29-3.18 (m, 2H), 2.69 (s, 3H), 2.50 (s, 3H), 2.24 (d, J=14.2 Hz, 2H), 2.14-1.95 (m, 2H), 1.41 (d, J=7.1 Hz, 6H).

Procedure 9, Example 14

(S)-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(1-prolylpiperidin-4-yl)-6H-thieno[2,3-b]pyrrole (Example 14): To a dram vial with 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (I-7) (15 mg, 0.035 mmol) in 1,2-dichloroethane (1 mL) was added (2S)-1-tert-butoxycarbonylpyrrolidine-2-carboxylic acid (10 mg, 0.045 mmol), 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (17 mg, 0.45 mmol), N,N-diisopropylethylamine (0.03 mL, 0.14 mmol). The mixture was stirred 5 hr at rt. To the mixture was added TFA (0.25 mL), and the mixture was stirred 2 hr at rt. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL) and water (0.15 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 14. ES/MS: 491.3 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 4.79-4.55 (m, 2H), 3.99 (d, J=13.3 Hz, 1H), 3.47-3.36 (m, 2H), 2.94 (t, J=13.1 Hz, 1H), 2.68 (s, 3H), 2.65-2.51 (m, 1H), 2.49 (s, 3H), 2.20-1.88 (m, 5H), 1.76-1.51 (m, 2H), 1.41 (d, J=7.1 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 9 and are shown below in Table 3. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 9 and are noted in the last column of Table 3—“Changes to Procedure 9: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 9 were replaced with the different reagents/starting materials noted below.

TABLE 3 Changes to Procedure 9: Different Ex- Reagents/ am- ES/MS Starting ple Structure m/z ¹H-NMR Materials 15

491.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 4.71 (dd, J = 30.4, 9.7 Hz, 2H), 3.99 (d, J = 14.1 Hz, 1H), 3.48-3.38 (m, 2H), 2.94 (t, J = 12.7 Hz, 1H), 2.68 (s, 3H), 2.64-2.52 (m, 1H), 2.49 (s, 3H), 2.22-1.86 (m, 5H), 1.79-1.51 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). (2R)-1-tert- butoxy- carbonyl- pyrrolidine- 2- carboxylic acid 16

477.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (d, J = 1.5 Hz, 1H), 8.46 (s, 1H), 7.58 (d, J = 1.6 Hz, 1H), 4.69 (d, J = 13.6 Hz, 1H), 4.42-4.20 (m, 6H), 4.11 (q, J = 8.1 Hz, 1H), 3.71 (t, J = 11.3 Hz, 1H), 3.31-3.22 (m, 1H), 2.88 (t, J = 12.9 Hz, 1H), 2.68 (s, 3H), 2.48 (s, 3H), 2.04 (d, J = 13.3 Hz, 2H), 1.60 (q, J = 12.5 Hz, 2H), 1.41 (d, J = 7.1 Hz, 6H). 1-tert- butoxy- carbonyl- azetidine- 3- carboxylic acid 17

492.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (d, J = 1.3 Hz, 1H), 8.46 (s, 1H), 7.58 (d, J = 1.6 Hz, 1H), 3.69 (d, J = 9.2 Hz, 1H), 3.64-3.39 (m, 4H), 3.31 (d, J = 9.9 Hz, 1H), 3.12 (s, 3H), 3.02-2.98 (m, 4H), 2.69 (s, 3H), 2.50 (s, 3H), 2.11 (d, J = 13.3 Hz, 2H), 1.84 (dd, J = 53.9, 13.4 Hz, 2H), 1.41 (d, J = 7.1 Hz, 6H). 1-methyl- azetidine- 3- carboxylic acid 18

505.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 4.74-4.48 (m, 2H), 3.95-3.69 (m, 2H), 3.40 (d, J = 12.3 Hz, 1H), 3.30-3.20 (m, 1H), 2.98 (s, 2H), 2.94 (s, 3H), 2.74-2.58 (m, 4H), 2.49 (s, 3H), 2.27 (s, 1H), 2.07 (d, J = 15.3 Hz, 5H), 1.80-1.51 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). (2R)-1- methyl- pyrrolidine- 2-carboxylic acid hydrochloride 19

505.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 4.72-4.49 (m, 2H), 3.95-3.68 (m, 2H), 3.42-3.38 (m, 1H), 3.29- 3.21 (m, 1H), 2.98 (s, 2H), 2.94 (s, 3H), 2.74-2.60 (m, 4H), 2.49 (s, 3H), 2.41-2.18 (m, 1H), 2.18-1.96 (m, 5H), 1.79-1.51 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). (2S)-1- methyl- pyrrolidine- 2- carboxylic acid

Procedure 10, Example 20

4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(6-(piperazin-1-yl)pyridin-3-yl)-6H-thieno[2,3-b]pyrrole (Example 20): To a vial was added 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole (I-6) (40 mg, 0.10 mmol), tert-butyl 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]piperazine-1-carboxylate (80 mg, 0.21 mmol), and [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (11 mg, 0.015 mmol). Dimethoxyethane (0.5 mL) and sodium carbonate (2M aq, 0.1 mL, 0.21 mmol) were added, and the mixture was degassed with argon for 30 seconds. The vial was sealed, and the mixture was heated at 120° C. for 20 minutes in a microwave. The crude mixture was purified directly by silica chromatography (eluent EtOAc/hexanes). The product was subsequently dissolved in acetonitrile (1 mL), and TFA (0.25 mL) was added. The reaction was heated at 40° C. for 3 hr. Water (0.15 mL) was added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 20. ES/MS: 472.3 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.64 (s, 1H), 8.48 (s, 1H), 8.29 (d, J=2.4 Hz, 1H), 7.77 (dd, J=8.8, 2.5 Hz, 1H), 7.62 (s, 1H), 7.04 (d, J=8.8 Hz, 1H), 3.96-3.84 (m, 4H), 3.41-3.37 (m, 4H), 3.27 (s, 1H), 2.70 (s, 3H), 2.51 (s, 3H), 1.44 (d, J=7.1 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 10 and are shown below in Table 4. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 10 and are noted in the last column of Table 4—“Changes to Procedure 10: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 10 were replaced with the different reagents/starting materials noted below.

TABLE 4 Changes to Procedure 10: Different Ex- ES/ Reagents/ am- MS Starting ple Structure m/z ¹H-NM Materials 21

443.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.66 (d, J = 1.5 Hz, 1H), 8.65- 8.62 (m, 1H), 8.49 (s, 1H), 7.85 (d, J = 2.1 Hz, 1H), 7.62 (t, J = 1.4 Hz, 1H), 4.53 (s, 2H), 3.71 (t, J = 6.4 Hz, 2H), 3.41-3.36 (m, 1H), 3.31-3.27 (m, 2H), 2.70 (s, 3H), 2.58 (s, 3H), 1.44 (d, J = 7.1 Hz, 6H). tert-butyl 3- (4,4,5,5- tetramethyl- 1,3,2- dioxaborolan-2- yl)-7,8-dihydro- 5H-1,6- naphthyridine- 6- carboxylate 22

522.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.65 (s, 1H), 8.48 (s, 1H), 7.69 (s, 1H), 7.67-7.60 (m, 2H), 7.44 (dd, J = 8.3, 1.7 Hz, 1H), 4.76 (s, 1H), 4.31 (s, 1H), 3.47-3.35 (m, 1H), 3.11 (s, 1H), 2.71 (s, 3H), 2.55 (s, 3H), 2.13-1.77 (m, 6H), 1.45 (d, J = 7.2 Hz, 6H). tert-butyl (1R,3S,4S)- 3-[5-(4,4,5,5- tetramethyl- 1,3,2- dioxaborolan- 2-yl)-1H- benzimidazol- 2-yl]-2- azabicyclo [2.2.1]heptane- 2-carboxylate 23

471.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.63 (s, 1H), 8.47 (s, 1H), 7.62 (t, J = 1.4 Hz, 1H), 7.42 (d, J = 8.6 Hz, 2H), 7.12 (d, J = 8.6 Hz, 2H), 3.56-3.48 (m, 4H), 3.45-3.39 (m, 4H), 3.39-3.34 (m, 1H), 2.70 (s, 3H), 2.52 (s, 3H), 1.44 (d, J = 7.1Hz, 6H). tert-butyl 4-[4- (4,4,5,5- tetramethyl- 1,3,2- dioxaborolan- 2-yl)phenyl] piperazine-1- carboxylate

The following Examples were made in an analogous fashion according to the referenced procedure and are shown in Table 5a below. To prepare the below Examples, different reagents/starting materials were used than some of those described in the referenced procedure and are noted in the last column of Table 5a—“Changes to Referenced Procedure: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of the referenced procedure were replaced with the different reagents/starting materials noted below.

TABLE 5a Changes to Referenced Procedure: Ex- ES/MS Pro- Different Reagents/ ample Structure m/z ¹H-NMR cedure Starting Materials 24

434.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 7.62-7.51 (m, 1H), 3.94 (s, 2H), 3.81 (s, 2H), 3.31-3.24 (m, 1H), 3.02 (t, J = 12.0 Hz, 1H), 2.68 (s, 3H), 2.44 (s, 3H), 2.19 (d, J = 13.3 Hz, 2H), 2.08- 1.93 (m, 2H), 1.83-1.71 (m, 2H), 1.55-1.42 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H). 4 tert-butyl 7-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-2- azaspiro[3.5]non-6- ene-2-carboxylate 25

491.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 4.25 (d, J = 10.5 Hz, 1H), 4.14 (s, 2H), 4.08 (d, J = 10.7 Hz, 1H), 3.99 (d, J = 10.8 Hz, 1H), 3.89 (d, J = 10.8 Hz, 1H), 3.32-3.25 (m, 1H), 3.02 (t, J = 12.1 Hz, 1H), 2.68 (s, 3H), 2.44 (s, 3H), 2.27 (d, J = 13.0 Hz, 1H), 2.15 (d, J = 13.4 Hz, 1H), 2.06-1.91 (m, 2H), 1.79 (d, J = 12.2 Hz, 2H), 1.62- 1.43 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H). 5 Example 24 26

437.2 ¹H NMR (400 MHz, MeOD) δ 8.65-8.59 (m, 1H), 8.47 (s, 1H), 7.63 (t, J = 1.4 Hz, 1H), 6.97 (s, 1H), 4.01 (s, 2H), 3.75 (d, J = 12.0 Hz, 2H), 3.31-3.14 (m, 4H), 2.68 (s, 3H), 2.35 (d, J = 14.4 Hz, 2H), 2.21- 2.10 (m, 2H), 1.41 (d, J = 6.9 Hz, 6H). 4, 5 I-12 27

465.2 ¹H NMR (400 MHz, Chloroform-d) δ 8.51 (s, 1H), 8.49 (s, 1H), 8.20 (s, 1H), 7.47 (s, 1H), 3.83 (s, 2H), 3.70 (d, 2H), 3.33-3.20 (m, 1H), 2.89 (d, 3H), 2.73 (d, 3H), 2.48 (s, 3H), 2.25-2.19 (m, 4H), 1.38 (d, 6H). 5 2-bromopropanamide 28

465.2 ¹H NMR (400 MHz, Chloroform-d) δ 8.49 (dd, 1H), 8.47 (s, 1H), 8.43 (s, 1H), 8.13 (s, 1H), 7.46 (t, 1H), 5.75 (s, 1H), 4.21 (q, 1H), 3.81-3.61 (m, 2H), 3.42 (t, 1H), 3.27 (p, 1H), 3.11 (s, 1H), 2.72 (t, 3H), 2.47 (s, 3H), 2.24 (d, 4H), 1.67 (d, 3H), 1.38 (d, 6H). 5 2-bromo-N-methyl- acetamide 29

463.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.67-7.51 (m, 1H), 4.54 (d, J = 10.7 Hz, 1H), 4.33-4.20 (m, 2H), 4.19-4.02 (m, 3H), 3.93-3.74 (m, 1H), 3.30-3.25 (m, 1H), 2.91 (s, 1H), 2.77 (s, 1H), 2.68 (s, 3H), 2.55-2.35 (m, 5H), 1.39 (d, J = 7.1 Hz, 6H). 5 Example 58 30

493.2 ¹H NMR (400 MHz, Acetonitrile-d₃) δ 9.43 (s, 1H), 8.57 (dd, 1H), 8.37 (s, 1H), 7.50 (t, 1H), 6.82 (s, 1H), 6.39 (s, 1H), 4.50 (tt, 1H), 4.29-4.13 (m, 4H), 4.13 (s, 2H), 3.59 (s, 2H), 3.30 (p, 1H), 2.66 (d, 3H), 2.48 (s, 3H), 2.43-2.24 (m, 4H), 1.37 (d, 6H). 5 Example 59 31

477.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.43 (s, 1H), 4.53 (d, J = 10.6 Hz, 1H), 4.29 (t, J = 12.3 Hz, 2H), 4.12 (d, J = 11.1 Hz, 1H), 4.09 (s, 2H), 3.93- 3.73 (m, 1H), 3.02 (p, J = 7.1 Hz, 1H), 2.90 (d, J = 11.5 Hz, 1H), 2.78 (d, J = 12.2 Hz, 1H), 2.64 (s, 3H), 2.53-2.38 (m, 2H), 2.37 (s, 3H), 2.27 (s, 3H), 1.24 (dd, J = 24.6, 6.1 Hz, 6H). 5 Example 60 32

506.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.34 (s, 1H), 8.56 (dd, 1H), 8.39 (s, 1H), 7.51 (t, 1H), 3.81 (d, 2H), 3.49-3.40 (m, 4H), 3.29 (dt, 1H), 3.22 (t, 6H), 3.02- 2.90 (m, 2H), 2.65 (t, 3H), 2.46 (s, 3H), 1.61 (qd, 2H), 1.36 (d, 6H). 6 tert-butyl 4- chlorocarbonylpiperazine- 1-carboxylate 33

480.2 ¹H NMR (400 MHz, Acetonitrile-d₃) δ 9.39 (s, 1H), 8.56 (s, 1H), 8.35 (s, 1H), 7.49 (t, 1H), 4.60-4.44 (m, 1H), 4.31 (d, 2H), 4.25-4.02 (m, 3H), 3.99-3.93 (m, 1H), 3.64 (s, 2H), 3.62-3.47 (m, 2H), 3.30 (p, 1H), 2.65 (t, 3H), 2.48 (s, 3H), 1.37 (d, 6H). 8 Example 59 34

505.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 4.67 (d, J = 13.6 Hz, 2H), 4.53- 4.27 (m, 2H), 3.79 (d, J = 13.0 Hz, 4H), 3.23-3.09 (m, 3H), 2.89 (t, J = 12.8 Hz, 1H), 2.68 (s, 3H), 2.49 (s, 3H), 2.10 (dd, J = 39.1, 24.1 Hz, 6H), 1.81-1.52 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). 9 2-pyrrolidin-1-ylacetic acid 35

507.2 ¹H NMR (400 MHz, Chloroform-d) δ 8.58 (s, 1H), 8.55-8.45 (m, 2H), 8.25 (s, 1H), 7.48 (d, 1H), 4.64 (s, 1H), 4.54 (dd, 1H), 4.15-4.02 (m, 3H), 3.98- 3.77 (m, 2H), 3.62 (t, 1H), 3.42-3.17 (m, 4H), 2.72 (s, 3H), 2.47 (d, 3H), 2.18-1.95 (m, 2H), 1.60 (dt, 1H), 1.39 (d, 6H). 9 (3R)-4-tert- butoxycarbonylmorpholine- 3-carboxylic acid 36

507.2 ¹H NMR (400 MHz, Chloroform-d) δ 8.55-8.47 (m, 3H), 8.22 (s, 1H), 7.48 (d, 1H), 4.69-4.46 (m, 2H), 4.13 (d, 2H), 4.06 (d, 2H), 3.95-3.75 (m, 2H), 3.62 (t, 1H), 3.41-3.32 (m, 1H), 3.32-3.16 (m, 3H), 2.73 (s, 3H), 2.47 (d, 4H), 2.21-1.93 (m, 2H), 1.68-1.51 (m, 1H), 1.39 (d, 6H). 9 (3S)-4-tert- butoxycarbonylmorpholine- 3-carboxylic acid 37

531.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 4.38 (dt, J = 14.6, 7.8 Hz, 1H), 4.18-4.03 (m, 1H), 4.02-3.83 (m, 2H), 3.77 (q, J = 9.7 Hz, 1H), 3.46-3.37 (m, 2H), 3.09-2.95 (m, 1H), 2.68 (s, 3H), 2.58-2.47 (m, 1H), 2.45 (s, 3H), 2.21- 1.90 (m, 8H), 1.77 (t, J = 13.3 Hz, 2H), 1.63-1.42 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H). 9 (2S)-1-tert- butoxycarbonylpyrrolidine- 2-carboxylic acid; Example 24 38

531.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 7.58 (d, J = 1.8 Hz, 1H), 4.38 (dt, J = 14.6, 8.0 Hz, 1H), 4.16-4.03 (m, 1H), 4.03-3.83 (m, 2H), 3.77 (q, J = 9.7 Hz, 1H), 3.46-3.37 (m, 2H), 3.03 (s, 1H), 2.68 (s, 3H), 2.58-2.47 (m, 1H), 2.45 (d, J = 1.1 Hz, 3H), 2.16-1.94 (m, 8H), 1.77 (t, J = 13.3 Hz, 2H), 1.48 (q, J = 16.0, 14.4 Hz, 2H), 1.40 (d, J = 7.1 Hz, 6H). 9 (2R)-1-tert- butoxycarbonylpyrrolidine- 2-carboxylic acid; Example 24 39

527.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 5.11 (t, J = 8.8 Hz, 1H), 5.03 (t, J = 8.9 Hz, 1H), 4.95-4.89 (m, 1H), 4.67 (d, J = 13.5 Hz, 1H), 3.97-3.74 (m, 4H), 3.41-3.37 (m, 1H), 2.96 (t, J = 13.0 Hz, 1H), 2.68 (s, 3H), 2.66-2.54 (m, 1H), 2.49 (s, 3H), 2.07 (d, J = 13.3 Hz, 2H), 1.81- 1.54 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). 9 (2R)-1-tert- butoxycarbonyl-4,4- difluoro-pyrrolidine-2- carboxylic acid 40

503.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 5.11 (t, J = 8.8 Hz, 1H), 5.03 (t, J = 8.9 Hz, 1H), 4.95-4.89 (m, 1H), 4.67 (d, J = 13.5 Hz, 1H), 3.97-3.74 (m, 4H), 3.41-3.37 (m, 1H), 2.96 (t, J = 13.0 Hz, 1H), 2.68 (s, 3H), 2.66-2.54 (m, 1H), 2.49 (s, 3H), 2.07 (d, J = 13.3 Hz, 2H), 1.81- 1.54 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). 9 2-tert-butoxycarbonyl-2- azabicyclo[2.1.1]hexane- 1-carboxylic acid 41

521.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 4.82-4.66 (m, 2H), 4.43-4.11 (m, 2H), 3.50 (s, 2H), 3.40-3.37 (m, 2H), 3.16-3.11 (m, 3H), 2.68 (s, 3H), 2.55-2.45 (m, 4H), 2.07 (d, J = 15.2 Hz, 2H), 1.73-1.52 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). 9 2-tert-butoxycarbonyl-2- azabicyclo[2.1.1]hexane- 1-carboxylic acid 42

509.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 5.48 (dd, J = 51.6, 12.9 Hz, 1H), 4.67 (d, J = 13.6 Hz, 1H), 3.87 (t, J = 14.9 Hz, 2H), 3.62-3.40 (m, 3H), 3.31-3.28 (m, 1H), 3.06-2.76 (m, 2H), 2.68 (s, 3H), 2.50 (s, 3H), 2.47-2.23 (m, 2H), 2.08 (d, J = 14.7 Hz, 2H), 1.78-1.53 (m, 2H), 1.41 (d, J = 4.2 Hz, 6H). 9 (2R,4R)-1-tert- butoxycarbonyl-4- fluoro-pyrrolidine-2- carboxylic acid 43

509.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.45 (s, 1H), 7.58 (s, 1H), 5.60-5.45 (m, 1H), 4.67 (d, J = 13.7 Hz, 1H), 3.99 (d, J = 14.5 Hz, 1H), 3.85-3.44 (m, 5H), 3.33-3.25 (m, 1H), 2.95 (d, J = 12.2 Hz, 2H), 2.68 (s, 3H), 2.50 (s, 3H), 2.41-2.03 (m, 3H), 1.61 (d, J = 15.4 Hz, 3H), 1.41 (d, J = 7.1 Hz, 6H). 9 (2R,4S)-1-tert- butoxycarbonyl-4- fluoro-pyrrolidine-2- carboxylic acid 44

521.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 4.80-4.60 (m, 2H), 4.20 (d, J = 14.4 Hz, 1H), 3.88 (d, J = 13.8 Hz, 1H), 3.68 (d, J = 12.3 Hz, 1H), 3.46-3.36 (m, 6H), 2.95 (t, J = 12.9 Hz, 1H), 2.85-2.70 (m, 1H), 2.68 (s, 3H), 2.49 (s, 3H), 2.23-2.01 (m, 4H), 1.66 (dd, J = 24.1, 12.6 Hz, 2H), 1.41 (d, J = 7.1 Hz, 6H). 9 (2R,4R)-1-tert- butoxycarbonyl-4- methoxy-pyrrolidine- 2-carboxylic acid 45

521.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (d, J = 1.1 Hz, 1H), 7.57 (s, 1H), 4.85-4.78 (m, 1H), 4.67 (d, J = 13.2 Hz, 1H), 4.26 (d, J = 13.5 Hz, 1H), 3.97 (d, J = 13.8 Hz, 1H), 3.63-3.51 (m, 1H), 3.44- 3.38 (m, 5H), 3.31-3.25 (m, 1H), 3.00-2.88 (m, 1H), 2.83-2.72 (m, 1H), 2.68 (s, 3H), 2.49 (s, 3H), 2.22-1.93 (m, 4H), 1.79-1.52 (m, 2H), 1.41 (d, J = 7.4 Hz, 6H). 9 (2R,4S)-1-tert- butoxycarbonyl-4- methoxy-pyrrolidine- 2-carboxylic acid 46

507.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.34 (s, 1H), 8.55 (s, 1H), 8.35 (s, 1H), 7.49 (d, 1H), 4.85-4.74 (m, 1H), 4.61 (d, 1H), 4.13-3.82 (m, 3H), 3.54-3.40 (m, 1H), 3.40-3.18 (m, 4H), 2.83 (td, 1H), 2.65 (s, 3H), 2.47 (s, 3H), 1.74-1.44 (m, 2H), 1.36 (d, 6H). 9 (2R)-4-tert- butoxycarbonylmorpholine- 2-carboxylic acid 47

507.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.34 (s, 1H), 8.55 (s, 1H), 8.35 (s, 1H), 7.48 (s, 1H), 4.85-4.74 (m, 1H), 4.61 (d, 1H), 4.12-3.81 (m, 3H), 3.52-3.42 (m, 1H), 3.41-3.13 (m, 6H), 2.90-2.76 (m, 2H), 2.65 (s, 3H), 2.47 (s, 3H), 1.73-1.43 (m, 2H), 1.36 (d, 6H). 9 (2S)-4-tert- butoxycarbonylmorpholine- 2-carboxylic acid 48

521.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.36 (s, 1H), 8.58-8.51 (m, 1H), 8.36 (s, 1H), 7.50 (t, 1H), 4.61 (d, 1H), 4.44 (ddd, 1H), 4.26-4.13 (m, 1H), 4.07 (d, 1H), 3.96-3.78 (m, 1H), 3.68-3.48 (m, 2H), 3.43-3.17 (m, 4H), 2.89 (s, 2H), 2.83 (s, 2H), 2.65 (d, 3H), 2.48 (s, 3H), 1.37 (d, 6H). 9 (3R)-4- methylmorpholine-3- carboxylic acid 49

521.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.36 (s, 1H), 8.55 (d, 1H), 8.35 (s, 1H), 7.49 (t, 1H), 4.62 (d, 1H), 4.44 (ddd, 1H), 4.25-4.13 (m, 1H), 4.07 (d, 1H), 3.96- 3.78 (m, 2H), 3.69-3.48 (m, 2H), 3.42-3.18 (m, 3H), 2.89 (s, 2H), 2.83 (s, 1H), 2.65 (t, 3H), 2.47 (s, 3H), 1.37 (d, 6H). 9 (3S)-4- methylmorpholine-3- carboxylic acid 50

521.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.35 (s, 1H), 8.55 (dd, 1H), 8.34 (s, 1H), 7.48 (t, 1H), 4.59 (d, 1H), 4.11 (q, 2H), 3.98 (s, 5H), 3.67 (d, 1H), 3.39-3.18 (m, 2H), 2.85 (t, 1H), 2.65 (d, 3H), 2.47 (s, 3H), 1.76- 1.48 (m, 2H), 1.37 (d, 6H). 9 2-morpholinoacetic acid 51

521.1 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.34 (s, 1H), 8.55 (dd, 1H), 8.34 (s, 1H), 7.48 (t, 1H), 4.34 (s, 2H), 4.23-4.03 (m, 2H), 4.01-3.75 (m, 2H), 3.47-3.33 (m, 2H), 3.29 (p, 1H), 3.11 (s, 2H), 2.65 (t, 3H), 2.47 (s, 3H), 2.09-1.99 (m, 2H), 1.73 (s, 3H), 1.57 (q, 2H), 1.36 (d, 6H). 9 4-tert-butoxycarbonyl- 3-methyl-morpholine- 3-carboxylic acid 52

533.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.42 (s, 1H), 4.51 (s, 1H), 4.33-4.16 (m, 5H), 4.06 (dd, J = 20.2, 10.2 Hz, 2H), 3.88-3.71 (m, 2H), 3.71-3.56 (m, 1H), 3.41-3.36 (m, 1H), 3.03 (p, J = 7.0 Hz, 1H), 2.85-2.71 (m, 2H), 2.64 (s, 3H), 2.43-2.34 (m, 5H), 2.27 (s, 3H), 1.33-1.18 (m, 6H). 9 (3R)-4-tert- butoxycarbonylmorpholine- 3-carboxylic acid; Example 60 53

519.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 4.51 (s, 1H), 4.35-4.15 (m, 5H), 4.12-3.94 (m, 2H), 3.90-3.70 (m, 2H), 3.70-3.55 (m, 1H), 3.40-3.37 (m, 1H), 3.30-3.23 (m, 1H), 2.84-2.72 (m, 2H), 2.68 (s, 3H), 2.45-2.33 (m, 5H), 1.39 (d, J = 7.1 Hz, 6H). 9 (3R)-4-tert- butoxycarbonylmorpholine- 3-carboxylic acid; Example 58 54

535.4 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.36 (s, 1H), 8.56 (dd, 1H), 8.39 (s, 1H), 7.52 (q, 1H), 4.71 (ddd, 1H), 4.56 (d, 1H), 4.23 (dt, 1H), 4.07-3.94 (m, 1H), 3.73-3.63 (m, 2H), 3.63-3.42 (m, 1H), 3.40-3.23 (m, 3H), 2.82 (td, 1H), 2.65 (t, 3H), 2.47 (s, 3H), 1.55 (d, 4H), 1.43 (d, 3H), 1.37 (d, 6H). 9 5,5-dimethylmorpholine- 3-carboxylic acid; hydrochloride 55

519.3 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.35 (s, 1H), 8.56 (dd, 1H), 8.38 (s, 1H), 7.51 (t, 1H), 4.81 (d, 1H), 4.20 (t, 2H), 3.43-3.37 (m, 4H), 3.36-3.23 (m, 1H), 2.67-2.65 (m, 3H), 2.47 (s, 3H), 2.01 (t, 2H), 1.67- 1.53 (m, 2H), 1.37 (d, 6H). 9 5-tert-butoxycarbonyl- 2-oxa-5-azabicyclo [2.2.1]heptane- 4-carboxylic acid 56

521.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.44 (s, 1H), 4.77-4.55 (m, 2H), 4.28 (dd, J = 12.7, 3.7 Hz, 1H), 4.06 (t, J = 14.0 Hz, 2H), 3.88-3.75 (m, 1H), 3.75-3.57 (m, 1H), 3.44-3.35 (m, 4H), 3.05 (h, J = 7.1 Hz, 1H), 2.90 (t, J = 13.0 Hz, 1H), 2.68-2.58 (m, 3H), 2.47 (s, 3H), 2.27 (s, 3H), 2.19-1.99 (m, 2H), 1.79-1.45 (m, 2H), 1.26 (dd, J = 28.8, 7.2 Hz, 6H). 12, 9 tert-butyl 4- iodopiperidine-1- carboxylate; I-16; (3R)-4-tert- butoxycarbonylmorpholine- 3-carboxylic acid 57

493.2 ¹H NMR (400 MHz, Acetonitrile-d₃) δ 9.41 (s, 1H), 8.57 (dd, 1H), 8.39 (s, 1H), 7.55 (t, 1H), 6.94 (d, 1H), 4.66-4.42 (m, 1H), 4.20 (dt, 1H), 4.03 (d, 1H), 3.90 (d, 1H), 3.80 (td, 1H), 3.59 (ddd, 1H), 3.41 (d, 1H), 3.29 (q, 2H), 3.17 (dq, 2H), 2.82 (d, 1H), 2.66 (t, 3H), 2.23-2.04 (m, 2H), 1.82-1.52 (m, 2H), 1.37 (dd, 6H). 4, 9 I-12; (3R)-4-tert- butoxycarbonylmorpholine- 3-carboxylic acid

Procedure 11, Example 58

tert-butyl 6-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)-2-azaspiro[3.3]heptane-2-carboxylate: To dried vial was added tert-butyl 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-15) (200 mg, 0.409 mmol), tert-butyl 6-iodo-2-azaspiro[3.3]heptane-2-carboxylate (I-20) (198 mg, 0.613 mmol), tetrabutylammonium iodide (TBAI) (37.7 mg, 0.102 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (23.2 mg, 0.049 mmol), zinc dust (133 mg, 2.04 mmol), and 4 Angstrom molecular sieves (100 mg). Dry DMA (1.5 mL) and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in MeOH (1.5 mL) and potassium carbonate (sat. aq., 0.25 mL) was added. The mixture was stirred at 40° C. overnight. LCMS indicated removal of the Boc group, and the mixture was diluted with EtOAc (30 mL) and water (5 mL). The layers were separated, and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the product. ES/MS: 506.3 (M+H⁺)

4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(2-azaspiro[3.3]heptan-6-yl)-6H-thieno[2,3-b]pyrrole (Example 58): To a vial with tert-butyl 6-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)-2-azaspiro[3.3]heptane-2-carboxylate 90 mg, 0.178 mmol) was added 1,4-dioxane (0.25 mL) and methanol (0.25 mL). HCl (4M in dioxane, 0.55 mL, 2.22 mmol) was added, and the mixture was stirred for 3 hours at rt. LCMS indicated reaction completion, and the volatiles were evaporated under reduced pressure. The mixture was dissolved in acetonitrile (1 mL), water (0.5 mL) and trifluoroacetic acid (0.1 mL), and the crude material was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250 ×21.2 mm) to give the title compound Example 58.ES/MS: 406.2 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.47 (s, 1H), 7.63-7.39 (m, 1H), 4.27 (s, 2H), 4.07 (s, 2H), 3.89-3.76 (m, 1H), 3.32-3.21 (m, 1H), 2.86-2.76 (m, 2H), 2.69 (s, 3H), 2.48-2.34 (m, 5H), 1.39 (d, J=7.1 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 11 and are shown below in Table 6. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 11 and are noted in the last column of Table 6—“Changes to Procedure 11: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 11 were replaced with the different reagents/starting materials noted below.

TABLE 6 Changes to Procedure 11: Different Ex- ES/ Reagents/ am- MS Starting ple Structure m/z ¹H-NMR Materials 59

436.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.41 (s, 1H), 8.56 (dd, 1H), 8.37 (s, 1H), 7.50 (t, 1H), 4.50 (tt, 1H), 4.13 (d, 4H), 3.65 (s, 2H), 3.30 (p, 1H), 2.65 (t, 3H), 2.47 (s, 3H), 2.41- 2.19 (m, 4H), 1.36 (d, 6H). I-26 60

420.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.42 (s, 1H), 4.27 (s, 2H), 4.07 (s, 2H), 3.84 (p, J = 8.8 Hz, 1H), 3.06-2.92 (m, 1H), 2.89-2.76 (m, 2H), 2.64 (s, 3H), 2.46-2.37 (m, 2H), 2.37 (s, 3H), 2.27 (s, 3H), 1.25 (dd, J = 25.8, 7.1 Hz, 6H). I-16 61

420.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (dd, J = 1.6, 0.8 Hz, 1H), 8.47 (s, 1H), 7.63-7.56 (m, 1H), 4.13-3.99 (m, 4H), 3.60 (ddd, J = 17.4, 9.8, 7.3 Hz, 1H), 3.29 (q, J = 7.2 Hz, 1H), 2.68 (t, J = 0.9 Hz, 3H), 2.54 (dd, J = 13.2, 7.5 Hz, 1H), 2.45 (s, 3H), 2.23 (ddd, J = 11.7, 10.3, 4.0 Hz, 2H), 2.17-2.04 (m, 1H), 1.98 (dd, J = 13.2, 10.1 Hz, 1H), 1.82-1.67 (m, 1H), 1.40 (d, J = 7.1 Hz, 6H). tert-butyl 6- iodo-2- azaspiro[3.4] octane-2- carboxylate

Procedure 12, Example 62

tert-butyl 3-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate: To dried vial was added tert-butyl 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-15) (95 mg, 0.194 mmol), tert-butyl 6-iodo-2-azaspiro[3.3]heptane-2-carboxylate (I-21) (98 mg, 0.291 mmol), tetrabutylammonium iodide (TBAI) (18 mg, 0.0485 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (11 mg, 0.023 mmol), zinc dust (63 mg, 0.97 mmol), and 4 Angstrom molecular sieves (100 mg). Dry DMA (1.0 mL) and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in MeOH (1.5 mL) and potassium carbonate (sat. aq., 0.25 mL) was added. The mixture was stirred at 40° C. overnight. LCMS indicated removal of the Boc group, and the mixture was diluted with EtOAc (30 mL) and water (5 mL). The layers were separated, and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the product. ES/MS: 520.3 (M+H⁺).

2-(8-azabicyclo[3.2.1]octan-3-yl)-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole: To a vial with tert-butyl 3-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (50 mg, 0.096 mmol) was added 1,4-dioxane (0.25 mL) and methanol (0.25 mL). HCl (4M in dioxane, 0.55 mL, 2.22 mmol) was added, and the mixture was stirred for 3 hours at rt. LCMS indicated reaction completion, and the volatiles were evaporated under reduced pressure. The material was carried forward as an HCl salt. ES/MS: 420.3 (M+H⁺).

2-(3-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide (Example 62): To a solution of 2-(8-azabicyclo[3.2.1]octan-3-yl)-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole hydrochloride (50 mg, 0.132 mmol) in 1,2-dichloroethane (1 mL) was added 2-bromoacetamide (18 mg, 0.132 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.066 mL, 0.44 mmol). The mixture was stirred overnight at rt. To the mixture was added 0.2 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.2 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 62. ES/MS: 477.3 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 8.60 (d, J=1.4 Hz, 1H), 8.46 (s, 1H), 7.58 (t, J=1.4 Hz, 1H), 4.15 (s, 2H), 3.89 (s, 2H), 3.83-3.66 (m, 1H), 3.30-3.25 (m, 1H), 2.69 (s, 3H), 2.51 (s, 3H), 2.45-2.09 (m, 8H), 1.40 (d, J=7.1 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 12 and are shown below in Table 7. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 12 and are noted in the last column of Table 7—“Changes to Procedure 12: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 12 were replaced with the different reagents/starting materials noted below.

TABLE 7 Changes to Procedure 12: Different Ex- ES/ Reagents/ am- MS Starting ple Structure m/z ¹H-NMR Materials 63

477.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (d, J = 1.5 Hz, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 3.98 (s, 2H), 3.76-3.64 (m, 3H), 3.54-3.47 (m, 2H), 3.31-3.27 (m, 1H), 2.73-2.64 (m, 5H), 2.53 (s, 3H), 2.46-2.32 (m, 2H), 2.06- 1.86 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H). I-22 64

423.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.46 (s, 1H), 7.57 (s, 1H), 4.78-4.38 (m, 2H), 4.35-4.12 (m, 4H), 3.39-3.36 (m, 1H), 3.29-3.22 (m, 1H), 2.69 (t, J = 0.9 Hz, 3H), 2.45 (s, 3H), 1.39 (d, J = 7.1 Hz, 6H). tert-butyl 3- iodo- azetidine- 1- carboxylate 65

463.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 4.11-3.95 (m, 2H), 3.68 (s, 2H), 3.64-3.56 (m, 3H), 3.44-3.36 (m, 1H), 3.17-2.81 (m, 4H), 2.69 (s, 3H), 2.46 (s, 3H), 1.44-1.35 (m, 6H). I-23 66

463.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (dd, J = 1.7, 0.9 Hz, 1H), 8.46 (s, 1H), 7.57 (t, J = 1.4 Hz, 1H), 4.35- 3.91 (m, 3H), 3.86-3.52 (m, 2H), 3.31- 3.26 (m, 1H), 3.23-3.04 (m, 1H), 2.82- 2.72 (m, 1H), 2.72-2.58 (m, 4H), 2.50 (d, J = 4.3 Hz, 3H), 2.39-1.88 (m, 3H), 1.40 (d, J = 7.1 Hz, 6H). I-24 67

465.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 3.99 (s, 2H), 3.74 (d, J = 12.1 Hz, 2H), 3.47-3.36 (m, 1H), 3.26 (d, J = 12.8 Hz, 2H), 3.12-3.00 (m, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 2.26-2.18 (m, 2H), 2.17-2.00 (m, 2H), 1.26 (dd, J = 28.9, 7.2 Hz, 6H). tert-butyl 4- iodo- piperidine- 1- carboxylate; I-16

Procedure 13, Example 68

tert-butyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)-3-(difluoromethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate: To dried vial was added tert-butyl 2-bromo-3-(difluoromethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (1-19) (54 mg, 0.103 mmol), tert-butyl 4-(p-tolylsulfonyloxy)piperidine-1-carboxylate (73 mg, 0.205 mmol), potassium iodide (26 mg, 0.154 mmol), NiBr2 DME (5 mg, 0.015 mmol), manganese dust (28 mg, 0.51 mmol), 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine (dtbbpy) (4.1 mg, 0.015 mmol), and 4-ethylpyridine (11 mg, 0.103 mmol). Dry DMA (0.5 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 80° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes).

3-(difluoromethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole (Example 68): The purified material from above was dissolved in 1,4-dioxane (0.1 mL) and methanol (0.2 mL). HCl (4M in dioxane, 0.2 mL, 0.8 mmol) was added, and the mixture was stirred for 3 hours at rt. LCMS indicated reaction completion, and the volatiles were evaporated under reduced pressure. The mixture was dissolved in acetonitrile (1 mL), water (0.5 mL) and trifluoroacetic acid (0.1 mL), and the crude material was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 68. ES/MS: 430.2 (M+H⁺). ¹NMR (400 MHz, Methanol-d4) δ 8.67 (s, 1H), 8.48 (s, 1H), 7.59 (s, 1H), 7.21 (t, J=54.4 Hz, 1H), 3.79-3.64 (m, 1H), 3.57-3.37 (m, 3H), 3.30-3.11 (m, 2H), 2.69 (s, 3H), 2.28 (d, J=14.2 Hz, 2H), 2.02-1.80 (m, 2H), 1.29 (d, J=7.2 Hz, 6H).

Procedure 14, Example 69 and Example 69a

tert-butyl (3aR,6aS)-5-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)hexahydrocyclopenta [c]pyrrole-2(1H)-carboxylate: To dried vial was added tert-butyl 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-15) (150 mg, 0.306 mmol), tert-butyl (3aR,6aS)-5-iodohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (I-25) (155 mg, 0.46 mmol), tetrabutylammonium iodide (TBAI) (28.3 mg, 0.077 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (17.3 mg, 0.037 mmol), and zinc dust (100 mg, 1.53 mmol). Dry DMA (1.5 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in MeOH (1 mL) and potassium carbonate (sat. aq., 0.5 mL) was added. The mixture was stirred at 40° C. overnight. LCMS indicated removal of the Boc group, and the mixture was diluted with EtOAc (30 mL) and water (5 mL). The layers were separated, and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the product as a mixture of diastereomers (stereochemistry arbitrarily assigned), which was carried forward.

tert-butyl (3aR,6aS)-5-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-((3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-yl)-6H-thieno[2,3-b]pyrrole (Example 69 and Example 69a): To a vial with tert-butyl (3aR,6aS)-5-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (70 mg, 0.135 mmol) was added dichloromethane (1 mL) and trifluoroacetic acid (0.2 mL). The mixture was stirred for 3 hours at rt. LCMS indicated reaction completion, and the volatiles were evaporated under reduced pressure. The mixture was dissolved in acetonitrile (1 mL) and water (0.5 mL), and the crude material was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give two isomers (stereochemistry arbitrarily assigned), with the first eluting product Example 69 and the second eluting product Example 69a.

Example 69

ES/MS: 420.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 10.88 (s, 1H), 8.59 (d, J=1.7 Hz, 1H), 8.45 (s, 1H), 7.58 (t, J=1.4 Hz, 1H), 3.73 (td, J=11.6, 5.9 Hz, 2H), 3.66 (dd, J=11.1, 7.4 Hz, 2H), 3.15-2.97 (m, 5H), 2.68 (t, J=0.9 Hz, 3H), 2.49 (s, 3H), 2.07 (dd, J=13.3, 6.4 Hz, 2H), 1.94 (td, J=12.8, 7.0 Hz, 2H), 1.41 (d, J=7.1 Hz, 6H).

Procedure 15, Example 70

2-((3aR,6aS)-5-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)hexahydrocyclopenta [c]pyrrol-2(1H)-yl)acetamide (Example (70): To a solution of 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-((3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-yl)-6H-thieno[2,3-b]pyrrole trifluoroacetic acid (Example 69) (20 mg, 0.0386 mmol) in 1,2-dichloroethane (6 mL) was added 2-bromoacetamide (8 mg, 0.058 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.023 mL, 0.16 mmol). The mixture was stirred overnight at rt. To the mixture was added 0.2 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.2 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 70.,ES/MS: 477.3 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.59 (dd, J=1.6, 0.8 Hz, 1H), 8.47 (s, 1H), 7.59 (t, J=1.4 Hz, 1H), 4.15 (s, 2H), 4.02 (s, 2H), 3.10 (s, 2H), 2.93 (t, J=9.9 Hz, 2H), 2.68 (t, J=0.9 Hz, 3H), 2.51 (s, 3H), 2.05 (dd, J=13.2, 6.0 Hz, 2H), 1.41 (d, J=7.1 Hz, 6H).

Procedure 16, Example 71

2-((3aR,6aS)-5-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)hexahydrocyclopenta [c]pyrrol-2(1H)-yl)acetamide (Example 71): To a solution of 4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-((3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-yl)-6H-thieno[2,3-b]pyrrole trifluoroacetic acid (Example 69a) (10 mg, 0.019 mmol) in 1,2-dichloroethane (3 mL) was added 2-bromoacetamide (4 mg, 0.029 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.012 mL, 0.08 mmol). The mixture was stirred overnight at rt. To the mixture was added 0.1 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.2 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 71. ES/MS: 477.3 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.60 (dd, J=1.7, 0.8 Hz, 1H), 8.49 (s, 1H), 7.63-7.57 (m, 1H), 4.05 (t, J=22.5 Hz, 3H), 3.73 (d, J=11.6 Hz, 2H), 3.32-3.24 (m, 3H), 3.13 (s, 1H), 3.06 (s, 1H), 2.69 (t, J=0.9 Hz, 3H), 2.46 (s, 5H), 1.63 (q, J=12.1 Hz, 2H), 1.40 (d, J=7.1 Hz, 6H).

Procedure 17, Example 72

tert-butyl (1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate: To a dried vial was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (500 mg, 0.993 mmol), tert-butyl (1S,4S,5R)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-31) (481 mg, 1.49 mmol), tetrabutylammonium iodide (TBAI) (440 mg, 1.19 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (46.7 mg, 0.099 mmol), and zinc dust (387 mg, 5.96 mmol). Dry DMA (5 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in MeOH (3 mL) and potassium carbonate (sat. aq., 1.5 mL) was added. The mixture was stirred at 50° C. overnight. The mixture was diluted with EtOAc (60 mL) and water (6 mL). The layers were separated, and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the title product. ES/MS: 520.3 (M+H⁺).

2-((1S,4R,5R)-2-azabicyclo[2.2.1]heptan-5-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (Example 72): To a vial with tert-butyl (1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate (350 mg, 0.673 mmol) was added methanol (3 mL). HCl (4M in dioxane, 2.02 mL, 8.08 mmol) was added, and the mixture was stirred for 16 hours at rt. The volatiles were then evaporated under reduced pressure and the residue was triturated with acetonitrile (2 mL) and dried under reduced pressure to afford the desired compound as an HCl salt. The mixture was dissolved in acetonitrile (2 mL), water (1.5 mL) and trifluoroacetic acid (0.5 mL), and the crude material was filtered through an acrodisc and purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 72 as a trifluoroacetate salt. ES/MS: 420.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.44 (s, 1H), 4.22 (s, 1H), 3.61-3.44 (m, 1H), 3.28-3.25 (m, 2H), 3.06 (p, J=7.1 Hz, 1H), 2.79 (s, 1H), 2.64 (s, 3H), 2.53-2.39 (m, 4H), 2.31-2.25 (m, 4H), 2.02-1.91 (m, 1H), 1.82 (d, J=11.8 Hz, 1H), 1.30 (d, J=7.5 Hz, 3H), 1.23 (d, J=7.0 Hz, 3H).

The following Examples were made in an analogous fashion according to Procedure 17 and are shown below in Table 8. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 17 and are noted in the last column of Table 8—“Changes to Procedure 17: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 17 were replaced with the different reagents/starting materials noted below.

TABLE 8 Changes to Procedure 17: Different Ex- ES/ Reagents/ am- MS Starting ple Structure m/z ¹H-NMR Materials 73

408.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.42 (s, 1H), 3.61-3.37 (m, 3H), 3.21 (t, J = 13.0 Hz, 2H), 3.07 (p, J = 6.9 Hz, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 2.21 (d, J = 14.3 Hz, 2H), 1.91 (q, J = 12.8, 11.8 Hz, 2H), 1.26 (dd, J = 29.4, 7.3 Hz, 6H). tert-butyl 4-iodo- piperidine- 1- carboxylate 74

420.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.43 (s, 1H), 4.22 (s, 1H), 3.59-3.47 (m, 1H), 3.26 (d, J = 4.7 Hz, 2H), 3.06 (p, J = 7.2 Hz, 1H), 2.79 (s, 1H), 2.64 (s, 3H), 2.50-2.33 (m, 4H), 2.33-2.21 (m, 4H), 2.02-1.94 (m, 1H), 1.82 (d, J = 11.9 Hz, 1H), 1.30 (d, J = 7.1 Hz, 3H), 1.23 (d, J = 7.1 Hz, 3H). I-27 75

434.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.50 (s, 1H), 3.99 (p, J = 8.8 Hz, 1H), 3.38 (t, J = 7.2 Hz, 2H), 3.25 (s, 2H), 3.03 (hept, J = 7.1 Hz, 1H), 2.65 (s, 3H), 2.56 (tt, J = 7.7, 2.4 Hz, 2H), 2.39 (s, 3H), 2.30 (d, J = 8.9 Hz, 7H), 1.34-1.07 (m, 6H). I-28 76

450.3 ¹H NMR (400 MHz, MeOD) δ 8.59 (d, J = 4.2 Hz, 1H), 8.48 (d, J = 2.5 Hz, 1H), 4.00- 3.79 (m, 2H), 3.72-3.57 (m, 1H), 3.43 (s, 2H), 3.28-3.15 (m, 2H), 3.11-2.96 (m, 1H), 2.84- 2.71 (m, 2H), 2.65 (s, 3H), 2.39 (s, 3H), 2.33- 2.20 (m, 5H), 1.41-1.08 (m, 6H). I-30

Procedure 18, Example 77

tert-butyl 2-(3-(tert-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate: To tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (200 mg, 0.40 mmol) in 10:1 toluene and water (13 mL) was added tert-butyl 6-(trifluoro-boraneyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate, potassium salt (193 mg, 0.64 mmol), cataCXium® A Pd G3 (28.9 mg, 0.040 mmol) and cesium carbonate (388 mg, 1.2 mmol). The reaction mixture was heated to 100° C. for 16 hours under N₂. The reaction mixture was dried over sodium sulfate, filtered through celite, eluted with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (0-100% EtOAc in hexane) to give the title product. ES/MS: 620.4 (M+H⁺).

2-(3-azabicyclo[4.1.0]heptan-6-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (Example 77): tert-butyl 2-(3-tert-butoxycarbonyl-3-azabicyclo[4.1.0]heptan-6-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate) (230 mg, 0.37 mmol) was added to a vial with acetonitrile and trifluoroacetic acid (1:1 mixture, 5 mL) and the reaction mixture was stirred at 80° C. until reaction completion. The reaction mixture was concentrated under reduced pressure, and the crude material was dissolved in acetonitrile (1 mL), water (0.5 mL) and trifluoroacetic acid (0.1 mL), and the crude material was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250 ×21.2 mm) to give the title compound Example 77 as a trifluoroacetate salt. ES/MS: 420.3 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.47 (s, 1H), 3.83 (dd, J=13.5, 7.4 Hz, 1H), 3.24 (dd, J=12.9, 5.5 Hz, 1H), 3.11-2.91 (m, 3H), 2.65 (s, 3H), 2.54 (s, 3H), 2.39 (tp, J=15.0, 5.2 Hz, 3H), 2.27 (s, 3H), 1.71 (d, J=7.5 Hz, 1H), 1.44-1.36 (m, 1H), 1.32-1.20 (m, 7H).

Procedure 19, Example 78

tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-1-oxa-8-azaspiro[4.5]dec-3-ene-8-carboxylate: To a solution of tert-butyl 3-oxo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate (1.00 g, 3.92 mmol) in anhydrous THE (26 mL) was added LiHMDS (983 mg, 5.88 mmol) dropwise at −78° C. under nitrogen. After 20 min, a solution of N-phenyl trifluoromethanesulfonimide (1.82 g, 5.09 mmol) in THE (5 mL) was added and the reaction was allowed to gradually warm to 0° C. and stirred for 3 h. The reaction was quenched with saturated aqueous NaHCO₃ (10 mL) and the resultant mixture was concentrated under reduced pressure. The residue was purified by flash chromatography using EtOAc/Hexane as eluent to afford the title product. ¹H NMR (400 MHz, CDCl3) δ 5.76 (t, J=2.2 Hz, 1H), 4.66 (d, J=2.1 Hz, 2H), 3.77 (dt, J=9.1, 4.4 Hz, 2H), 3.27 (ddd, J=13.9, 8.5, 5.6 Hz, 2H), 1.76-1.63 (m, 4H), 1.48 (s, 9H).

tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-oxa-8-azaspiro[4.5]dec-3-ene-8-carboxylate: To a 50 mL RBF was added tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-1-oxa-8-azaspiro[4.5]dec-3-ene-8-carboxylate (0.78 g, 2.02 mmol), bis(pinacolato)diboron (0.62 g, 2.42 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.15 g, 0.20 mmol), and potassium propionate (0.68 g, 6.06 mmol). The mixture was dissolved in 1,4-dioxane (10 mL), and nitrogen was bubbled through the reaction mixture for 3 minutes. The mixture was heated at 80° C. for 3 hours under nitrogen. The mixture was cooled to rt, filtered through celite, and concentrated under reduced pressure. The crude residue product was purified by silica gel chromatography (eluent: EtOAc/hexanes) to provide the title product. ES/MS: 388.3 [M+23]. ¹H NMR (400 MHz, CDCl3) δ 6.40 (t, J=2.4 Hz, 1H), 4.77 (d, J=2.4 Hz, 2H), 3.73 (m, 2H), 3.31 (ddd, J=13.6, 10.0, 3.7 Hz, 2H), 1.72-1.55 (m, 4H), 1.48 (s, 9H), 1.29 (d, J=10.1 Hz, 12H).

3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-8-azaspiro[4.5]decane (Example 78): To a MW vial was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (0.100 g, 0.20 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-oxa-8-azaspiro[4.5]dec-3-ene-8-carboxylate (0.87 g, 0.24 mmol), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (0.014 g, 0.02 mmol), and 1.0 M potassium acetate/1.5 M sodium carbonate (0.5 mL). The mixture was dissolved in acetonitrile (3 mL), and nitrogen was bubbled through the reaction mixture for 3 minutes. The mixture was heated at 140° C. for 45 minutes in a MW. The mixture was cooled to rt, diluted with EtOAc, filtered through celite, washed with excess EtOAc, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (eluent: EtOAc/hexanes) to provide the alkene intermediate: tert-butyl 3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-8-azaspiro[4.5]dec-3-ene-8-carboxylate. This material was dissolved in EtOH (4 mL) and one spatula of palladium on carbon (10%) was added and the resulting mixture was stirred for two days under hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated to dryness. The residue was then dissolved in DCM (2 mL) and treated with TFA (0.3 mL). The mixture was stirred for 1 hour at rt and the volatiles were evaporated under reduced pressure. Acetonitrile (0.5 mL) and water (0.2 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the product Example 78 as a trifluoroacetate salt. ES/MS: 464.2 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.49 (s, 1H), 4.26 (t, J=7.9 Hz, 1H), 4.07 (p, J=8.5 Hz, 1H), 3.79 (t, J=8.8 Hz, 1H), 3.33-3.26 (m, 4H), 3.05 (hept, J=7.1 Hz, 1H), 2.65 (s, 3H), 2.48-2.38 (m, 4H), 2.28 (s, 3H), 2.13-1.84 (m, 5H), 1.40-1.12 (m, 6H).

Procedure 20, Example 79

2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)acetamide (Example 79): To a solution of 2-((1S,4R,5R)-2-azabicyclo[2.2.1]heptan-5-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (HCl salt) (Example 72) (460 mg, 1.01 mmol) in 1,2-dichloroethane (18 mL) was added 2-bromoacetamide (167 mg, 1.21 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.6 mL, 4 mmol). The mixture was stirred overnight at rt. To the mixture was added 1 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (5 mL) and water (5 mL) were added and the mixture was mildly-heated. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 79 as a trifluoroacetate salt. ES/MS: 477.3 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.46 (s, 1H), 4.34-3.96 (m, 3H), 3.76 (dd, J=25.5, 11.6 Hz, 1H), 3.67-3.48 (m, 1H), 3.22-2.97 (m, 2H), 2.84-2.71 (m, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.41-2.20 (m, 4H), 2.12 (d, J=12.1 Hz, 1H), 2.09-1.91 (m, 2H), 1.30 (d, J=7.0 Hz, 3H), 1.23 (d, J=7.2 Hz, 3H).

The following Examples were made in an analogous fashion according to Procedure 20 and are shown below in Table 9. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 20 and are noted in the last column of Table 9—“Changes to Procedure 20: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 20 were replaced with the different reagents/starting materials noted below.

TABLE 9 Changes to Procedure 20: Different Ex- ES/ Reagents/ am- MS Starting ple Structure m/z ¹H-NMR Materials 80

521.3 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.52 (s, 1H), 4.26 (t, J = 7.9 Hz, 1H), 4.08 (p, J = 8.5 Hz, 1H), 3.98 (s, 2H), 3.79 (t, J = 8.8 Hz, 1H), 3.57 (d, J = 11.9 Hz, 2H), 3.34 (s, 2H), 3.05 (hept, J = 7.0 Hz, 1H), 2.65 (s, 3H), 2.46 (s, 3H), 2.45- 2.36 (m, 1H), 2.28 (s, 3H), 2.21-1.91 (m, 5H), 1.39- Example 78 1.16 (m, 6H). 81

490.9 ¹H NMR (400 MHz, Methanol- d4) δ 10.76 (s, 1H), 8.57 (s, 1H), 8.43 (s, 1H), 4.47- 4.26 (m, 1H), 4.12 (d, 1H), 4.04 (s, 1H), 3.96 (d, 1H), 3.89 (d, 1H), 3.73 (d, 1H), 3.65-3.40 (m, 1H), 3.16-3.12 (m, 1H), 3.06 (p, 1H), 2.95 (d, 1H), 2.81 (d, 1H), 2- bromo- propanamide 2.74 (s, 1H), 2.64 (s, 3H), 2.52-2.44 (m, 3H), 2.36 (t, 1H), 2.26 (s, 3H), 2.12- 1.91 (m, 2H), 1.75-1.53 (m, 3H), 1.26 (dd, 6H). 82

490.8 ¹H NMR (400 MHz, Methanol- d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.46 (s, 1H), 8.20 (s, 1H), 4.28 (s, 1H), 4.16 (s, 1H), 4.10 (d, 1H), 3.99 (q, 1H), 3.83-3.67 (m, 1H), 3.62 (s, 1H), 3.55 (t, 1H), 3.20-3.12 (m, 1H), 3.06 (p, 1H), 2.85 (d, 3H), 2.82-2.71 2-bromo- N-methyl- acetamide (m, 1H), 2.48 (s, 3H), 2.27 (s, 3H), 2.24 (s, 1H), 2.11 (d, 1H), 2.06-1.96 (m, 1H), 1.26 (dd, 6H). 83

526.2 ¹H NMR (400 MHz, Methanol- d4) δ 10.77 (s, 1H), 8.59 (s, 1H), 8.47 (s, 1H), 4.39- 4.26 (m, 1H), 3.87-3.75 (m, 1H), 3.74-3.61 (m, 5H), 3.59-3.50 (m, 1H), 3.15 (s, 3H), 3.06 (p, 1H), 2.89- 2.76 (m, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 2-bromoethyl methyl sulfone 2.20 (d, 1H), 2.08-1.95 (m, 1H), 1.26 (dd, 6H). 84

477.2 ¹H NMR (400 MHz, Methanol- d₄) δ 8.57 (s, 1H), 8.43 (s, 1H), 4.33-3.91 (m, 3H), 3.76 (dd, J = 24.1, 11.6 Hz, 1H), 3.68-3.45 (m, 1H), 3.23-2.96 (m, 2H), 2.78 (d, J = 17.5 Hz, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.41-2.20 (m, 4H), 2.16-1.92 (m, 3H), Example 74 1.30 (d, J = 7.3 Hz, 3H), 1.22 (d, J = 7.1 Hz, 3H).

Procedure 21: Example 85 and Example 86

2-(2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-6-azaspiro[3.4]octan-6-yl)acetamide (Example 85 and Example 86): 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(6-azaspiro[3.4]octan-2-yl)-6H-thieno[2,3-b]pyrrole (Example 75) was separated by chiral SFC (AD-H4.6×100 mm with 35% EtOH-NH₃ co-solvent) to give two distinct stereoisomers. These isomers were separately reacted according to the conditions in Procedure 20 to afford the two diastereomers, which were arbitrarily assigned as Isomer 1 (Example 85) and Isomer 2 (Example 86):

Isomer 1: 2-(2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-6-azaspiro[3.4]octan-6-yl)acetamide (Example 85). ES/MS: 491.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.50 (s, 1H), 4.18-3.69 (m, 5H), 3.32-3.09 (m, 2H), 3.03 (hept, J=7.1 Hz, 1H), 2.78-2.19 (m, 15H), 1.31-1.15 (m, 6H).

Isomer 2: 2-(2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-6-azaspiro[3.4]octan-6-yl)acetamide (Example 86). ES/MS: 491.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.50 (s, 1H), 4.18-3.69 (m, 5H), 3.32-3.09 (m, 2H), 3.03 (hept, J=7.1 Hz, 1H), 2.78-2.19 (m, 15H), 1.31-1.15 (m, 6H).

Procedure 22: Example 87 and Example 88

2-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-8-azaspiro[4.5]decan-8-yl)acetamide (Example 87 and Example 88): 3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-8-azaspiro[4.5]decane (Example 78) was separated by chiral SFC (IG 4.6×100 mm 5mic with 40% IPA-NH₃ co-solvent) to give two distinct stereoisomers. These isomers were separately reacted according to the conditions in Procedure 20 to afford the two enantiomers, which were arbitrarily assigned as Isomer 1 (Example 87) and Isomer 2 (Example 88):

Isomer 1: 2-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-8-azaspiro[4.5]decan-8-yl)acetamide (Example 87). ES/MS: 521.2 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.49 (d, J=7.1 Hz, 1H), 4.26 (t, J=8.0 Hz, 1H), 4.15-3.93 (m, 3H), 3.82 (dt, J=17.5, 8.7 Hz, 1H), 3.57 (d, J=11.8 Hz, 2H), 3.38 (d, J=11.6 Hz, 2H), 3.05 (hept, J=7.1 Hz, 1H), 2.65 (s, 3H), 2.46 (s, 4H), 2.28 (s, 3H), 2.21-1.87 (m, 5H), 1.38-1.15 (m, 6H).

Isomer 2: 2-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-8-azaspiro[4.5]decan-8-yl)acetamide (Example 88). ES/MS: 521.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.49 (d, J=7.1 Hz, 1H), 4.26 (t, J=8.0 Hz, 1H), 4.15-3.93 (m, 3H), 3.82 (dt, J=17.5, 8.7 Hz, 1H), 3.57 (d, J=11.8 Hz, 2H), 3.38 (d, J=11.6 Hz, 2H), 3.05 (hept, J=7.1 Hz, 1H), 2.65 (s, 3H), 2.46 (s, 4H), 2.28 (s, 3H), 2.21-1.87 (m, 5H), 1.38-1.15 (m, 6H).

Procedure 23: Example 89 and Example 90

2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-5-oxa-8-azaspiro[3.5]nonane (Example 88 and Example 90): 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-5-oxa-8-azaspiro[3.5]nonane (Example 76) as a mixture of 2 stereoisomers was separated by chiral SFC (IG 4.6×100 mm 5mic with 35% IPA-NH3 co-solvent) to give two distinct diastereomers, which were arbitrarily assigned as Isomer 1 (Example 89) and Isomer 2 (Example 90).

Isomer 1: 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-5-oxa-8-azaspiro[3.5]nonane (Example 89). ES/MS: 450.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.48 (d, J=1.1 Hz, 1H), 3.88 (dd, J=6.0, 4.0 Hz, 2H), 3.64 (p, J=9.0 Hz, 1H), 3.43 (s, 2H), 3.26-3.15 (m, 2H), 3.03 (hept, J=7.2 Hz, 1H), 2.88-2.71 (m, 2H), 2.65 (s, 3H), 2.40 (s, 3H), 2.26 (d, J=17.1 Hz, 5H), 1.35-1.14 (m, 6H).

Isomer 2: 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-5-oxa-8-azaspiro[3.5]nonane (Example 90). ES/MS: 450.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.57 (s, 1H), 8.43 (s, 1H), 4.08 (p, J=8.6 Hz, 1H), 4.00-3.90 (m, 2H), 3.29-3.12 (m, 4H), 3.03 (hept, J=7.0 Hz, 1H), 2.84-2.70 (m, 2H), 2.64 (s, 3H), 2.44-2.20 (m, 8H), 1.35-1.18 (m, 6H).

The following Examples were made in an analogous fashion according to the referenced procedure and are shown below in Table 10. To prepare the below Examples, different reagents/starting materials were used than some of those described in the referenced procedure and are noted in the last column of Table 10—“Changes to Referenced Procedure: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of the referenced procedure were replaced with the different reagents/starting materials noted below.

TABLE 10 Changes to Referenced Procedure: Different Ex- ES/ Pro- Reagents/ am- MS ce- Starting ple Structure m/z ¹H-NMR dure Materials 91

491.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.42 (s, 1H), 4.14 (s, 2H), 3.89 (s, 2H), 3.80-3.63 (m, 1H), 3.06 (p, J = 7.0 Hz, 1H), 2.64 (s, 3H), 2.49 (s, 3H), 2.42-2.28 (m, 6H), 2.27 (s, 3H), 2.18 (d, 12 I-16 J = 14.5 Hz, 2H), 1.26 (dd, J = 29.3, 7.2 Hz, 6H). 92

521.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.42 (s, 1H), 4.68 (dd, J = 24.7, 12.1 Hz, 2H), 4.39-4.22 (m, 1H), 4.06 (t, J = 14.0 Hz, 2H), 3.80 (d, J = 8.5 Hz, 1H), 3.75-3.55 (m, 1H), 3.44-3.35 (m, 4H), 3.06 (p, J = 7.0 Hz, 1H), 2.90 (t, J = 13.1  9 Example 73; (3S)-4-tert- butoxy- carbonyl- morpholine- 3-carboxylic acid Hz, 1H), 2.64 (s, 3H), 2.47 (s, 3H), 2.27 (s, 3H), 2.19-2.00 (m, 2H), 1.73-1.49 (m, 2H), 1.30 (d, J = 7.7 Hz, 3H), 1.22 (d, J = 7.1 Hz, 3H). 93

477.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.50 (s, 1H), 4.10 (s, 1H), 3.91 (s, 1H), 3.03 (p, J = 7.1 Hz, 2H), 2.65 (s, 3H), 2.55 (s, 4H), 2.27 (s, 3H), 1.76 (d, J = 7.8 Hz, 1H), 1.43 (s, 1H), 1.29 (d, J = 6.9 Hz, 15 Example 77 4H), 1.23 (d, J = 7.1 Hz, 3H). 94

561.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.50 (s, 1H), 4.69-4.62 (m, 1H), 3.96 (d, J = 13.5 Hz, 1H), 3.89-3.82 (m, 2H), 3.35 (s, 2H), 3.29-3.13 (m, 4H), 3.05 (hept, J = 7.2 Hz, 1H), 2.82 (td, J = 13.0, 2.7 Hz, 1H), 2.64 (s, 3H), 2.57-2.31 (m, 7H), 2.28 (s, 3H), 2.02 (t, J = 13.0 Hz, 2H), 1.57  9 Example 73; cis-8-tert- butoxy- carbonyl- 5-oxa-8- azaspiro[3.5] nonane- 2-carboxylic acid (ddt, J = 16.2, 12.5, 6.1 Hz, 2H), 1.40-1.14 (m, 6H). 95

491.3 ¹H NMR (400 MHz, MeOD) δ 10.79 (s, 1H), 8.61 (s, 1H), 8.49 (s, 1H), 4.26-4.10 (m, 2H), 3.95 (d, J = 12.2 Hz, 1H), 3.83 (dd, J = 22.2, 11.0 Hz, 2H), 3.63 (s, 1H), 3.19 (d, J = 12.3 Hz, 1H), 3.07 (p, J = 7.1 Hz, 1H), 2.74 (s, 1H), 2.65 (s, 3H), 2.46 (s, 3H), 2.29 (s, 3H), 2.10 (td, J = 46.6, 44.7, 21.2 14, 15 I-16; I-29 Hz, 6H), 1.70 (d, J = 17.4 Hz, 1H), 1.30 (d, J = 6.8 Hz, 3H), 1.23 (d, J = 7.1 Hz, 3H). 96

491.3 ¹H NMR (400 MHz, MeOD) δ 8.61 (d, J = 9.7 Hz, 1H), 8.49 (s, 1H), 4.34-4.01 (m, 3H), 3.74-3.55 (m, 3H), 3.40 (d, J = 12.5 Hz, 1H), 3.07 (p, J = 7.0 Hz, 2H), 2.65 (s, 3H), 2.46 (s, 3H), 2.28 (s, 5H), 2.03 (d, J = 59.2 Hz, 5H), 1.30 (d, J = 7.1 Hz, 3H), 1.23 (d, J = 7.2 Hz, 3H). 14, 16 I-16; I-29 97

463.2 ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.55 (s, 1H), 6.99 (s, 1H), 4.21-3.97 (m, 3H), 3.69 (d, J = 11.4 Hz, 1H), 3.40 (t, J = 6.8 Hz, 1H), 3.20 (dd, J = 11.6, 3.5 Hz, 1H), 2.88 (d, J = 13.2 Hz, 1H), 2.77 12 I-31; I-39 (h, J = 7.6, 6.9 Hz, 1H), 2.65 (s, 3H), 2.57 (dd, J = 14.8, 8.8 Hz, 1H), 2.32 (s, 3H), 2.23 (d, J = 14.6 Hz, 1H), 2.12 (s, 1H), 1.32 (d, J = 6.9 Hz, 6H). 98

505.2 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.52 (s, 1H), 4.79-4.62 (m, 2H), 4.03-3.95 (m, 1H), 3.58-3.35 (m, 4H), 3.06 (hept, J = 7.1 Hz, 1H), 2.93 (tt, J = 13.0, 3.2 Hz, 1H), 2.72-2.37 (m, 7H), 2.29 (s, 3H), 2.20-1.91 (m, 5H), 1.78-1.51 (m,  9 Example 73; (2R)-1-tert- butoxy- carbonyl- pyrrolidine- 2-carboxylic acid 2H), 1.41-1.16 (m, 6H). 99

505.2 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.52 (s, 1H), 4.79-4.62 (m, 2H), 4.03-3.95 (m, 1H), 3.58-3.35 (m, 4H), 3.06 (hept, J = 7.1 Hz, 1H), 2.93 (tt, J = 13.0, 3.2 Hz, 1H), 2.72-2.37 (m, 7H), 2.29 (s, 3H), 2.20-1.91 (m, 5H), 1.78-1.51  9 Example 73; (2S)-1-tert- butoxy- carbonyl- pyrrolidine- 2-carboxylic acid (m, 2H), 1.41-1.16 (m, 6H).

Procedure 24: Example 100 and Example 101

2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)propanamide (Example 100 and Example 101): 2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)propanamide (Example 95) as a mixture of 2 stereoisomers was separated by chiral SFC (AD-H4.6×100 mm column with 35% MeOH-DEA cosolvent) to give two distinct diastereomers, which were arbitrarily assigned as Isomer 1 (Example 100) and Isomer 2 (Example 101).

Isomer 1: 2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)propanamide (Example 100). ES/MS: 491.9 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.57 (s, 1H), 8.43 (s, 1H), 4.31 (s, 1H), 4.13 (d, 1H), 4.04 (s, 1H), 3.89 (q, 1H), 3.74 (dd, 1H), 3.58 (dt, 1H), 3.47 (d, 1H), 3.06 (p, 1H), 2.95 (d, 1H), 2.78 (d, 1H), 2.64 (s, 3H), 2.48 (d, 3H), 2.38 (d, 1H), 2.26 (s, 3H), 2.04 (d, 2H), 1.60 (dd, 3H), 1.26 (dd, 6H).

Isomer 2: 2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)propanamide (Example 101). ES/MS: 491.2 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 4.41 (d, 1H), 4.10-3.87 (m, 1H), 3.72 (d, 1H), 3.64-3.52 (m, 1H), 3.20-2.98 (m, 2H), 2.79 (s, 1H), 2.64 (s, 3H), 2.49 (d, 3H), 2.34 (d, 1H), 2.26 (s, 3H), 2.11-1.94 (m, 2H), 1.68 (dd, 3H), 1.26 (dd, 6H).

Procedure 25: Example 102 and Example 103

2-[6-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-3-azabicyclo[4.1.0]heptan-3-yl]acetamide (Example 102 and Example 103): 2-[6-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-3-azabicyclo[4.1.0]heptan-3-yl]acetamide (Example 89) as a mixture of 2 stereoisomers was separated by chiral SFC (AD-H column with 35% IPA-NH₃ cosolvent) to give two enantiomers, which were arbitrarily assigned as Isomer 1 (Example 102) and Isomer 2 (Example 103).

Isomer 1: 2-[6-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-3-azabicyclo[4.1.0]heptan-3-yl]acetamide (Example 102) ES/MS: 477.2 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.50 (s, 1H), 4.00 (d, J=60.9 Hz, 4H), 3.03 (p, J=7.1 Hz, 2H), 2.65 (s, 3H), 2.55 (s, 6H), 2.27 (s, 3H), 1.77 (s, 1H), 1.50-1.10 (m, 1OH).

Isomer 2: 2-[6-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-3-azabicyclo[4.1.0]heptan-3-yl]acetamide (Example 103). ES/MS: 477.2 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 8.46-8.41 (m, 1H), 8.12 (dd, J=8.6, 1.5 Hz, 1H), 7.82 (t, J=7.8 Hz, 1H), 7.74-7.67 (m, 2H), 7.62 (dd, J=8.0, 1.5 Hz, 1H), 7.57 (d, J=9.0 Hz, 2H), 7.23 (dd, J=7.6, 1.7 Hz, 1H), 7.06-6.97 (m, 2H), 4.76 (t, J=5.0 Hz, 2H), 4.69 (s, 2H), 3.84 (t, J=4.9 Hz, 2H), 3.32 (s, 3H), 2.17 (d, J=1.0 Hz, 3H).

TABLE 11 Changes to Procedure: Exam- ES/MS Proce- Different Reagents/ ple Structure m/z ¹H-NMR dure Starting Materials 104

561.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.55 (s, 1H), 8.42 (s, 1H), 5.12 (d, J = 17.8 Hz, 1H), 4.68-4.35 (m, 2H), 4.33-4.04 (m, 4H), 3.67 (d, J = 62.6 Hz, 3H), 3.04 (p, J = 7.1 Hz, 1H), 2.86 (d, J = 5.6 Hz, 2H), 2.62 (s, 3H), 2.45 (s, 3H), 2.25 (s, 8H), 1.80-1.49 (m, 3H), 1.24 (dd, J = 28.8, 7.2 Hz, 6H).  9 Example 73; (3R,8aS)-3,4,6,7,8,8a- hexahydro-1H- pyrrolo[2,1- c][1,4]oxazine-3- carboxylic acid; DCM solvent 105

573.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.46 (s, 1H), 4.62 (td, J = 12.6, 12.1, 9.5 Hz, 2H), 4.43- 4.14 (m, 2H), 4.13-3.93 (m, 2H), 3.93-3.74 (m, 2H), 3.52 (dt, J = 12.3, 9.4 Hz, 1H), 3.03 (q, J = 7.0 Hz, 2H), 2.85 (dd, J = 15.8, 12.3 Hz, 1H), 2.62 (s, 3H), 2.45 (d, J = 2.0 Hz, 3H), 2.26 (s, 4H), 2.20-1.93 (m, 5H), 1.85-1.49 (m, 4H), 1.24 (dd, J = 27.8, 7.4 Hz, 6H).  9 Example 73: 3-oxa-6- azatricyclo[6.1.1.01,6] decane-4-carboxylic acid; DCM solvent 106

507.2 ¹H NMR (400 MHz, Methaol-d4) δ 8.57 (s, 1H), 8.45 (s, 1H), 5.07 (d, J = 8.7 Hz, 2H), 4.81 (d, J = 8.6 Hz, 2H), 3.41 (ddt, J = 12.0, 7.6, 3.8 Hz, 1H), 3.04 (p, J = 7.1 Hz, 1H), 2.62 (s, 3H), 2.47 (s, 3H), 2.26 (s, 3H), 2.10 (d, J = 13.8 Hz, 2H), 1.73 (d, J = 12.5 Hz, 2H), 1.24 (dd, J = 28.1, 7.0 Hz, 6H).  9 Example 73; 3-(tert- butoxycarbonylamino) oxetane-3-carboxylic acid; DCM solvent 107

533.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.44 (s, 1H), 4.90 (d, J = 10.8 Hz, 1H), 4.78-3.93 (m, 5H), 3.41 (d, J = 13.0 Hz, 2H), 3.04 (p, J = 7.1 Hz, 1H), 2.93 (s, 1H), 2.82 (d, J = 11.5 Hz, 1H), 2.62 (s, 3H), 2.45 (s, 3H), 2.34 (s, 2H), 2.26 (s, 3H), 2.07 (d, J = 11.8 Hz, 2H), 1.66-1.54 (m, 2H), 1.31-1.17 (m, 6H).  9 Example 73; 5-tert- butoxycarbonyl-2- oxa-5- azabicyclo[2.2.1]heptane- 4-carboxylic acid; DCM solvent 108

547.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.46 (s, 1H), 4.63 (d, J = 10.9 Hz, 1H), 4.52 (s, 2H), 4.14 (d, J = 3.1 Hz, 2H), 3.64 (d, J = 12.4 Hz, 1H), 3.40 (s, 2H), 3.23-2.92 (m, 3H), 2.83-2.67 (m, 1H), 2.64 (s, 3H), 2.47 (s, 4H), 2.27 (s, 4H), 2.16-2.04 (m, 2H), 2.03-1.85 (m, 1H), 1.69-1.48 (m, 2H), 1.26 (dd, J = 28.4, 7.2 Hz, 6H).  9 Example 73; 2-oxa- 5- azabicyclo[2.2.2]octane- 4-carboxylic acid; hydrochloride; DCM solvent 109

521.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 4.79 (ddd, J = 13.0, 6.3, 3.3 Hz, 1H), 4.74- 4.61 (m, 1H), 4.23-3.89 (m, 3H), 3.49 (dd, J = 13.1, 6.4 Hz, 2H), 3.44-3.36 (m, 2H), 3.28 (d, J = 12.1 Hz, 2H), 3.06 (p, J = 7.1 Hz, 1H), 2.95-2.83 (m, 1H), 2.64 (s, 3H), 2.47 (s, 3H), 2.27 (s, 3H), 2.06 (d, J = 13.1 Hz, 2H), 1.78-1.51 (m, 2H), 1.26 (dd, J = 28.9, 7.3 Hz, 6H).  9 Example 73; (2S)-4- tert-butoxycarbonyl- morpholine-2-carboxylic acid; DCM solvent 110

521.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.45 (s, 1H), 4.77 (ddd, J = 13.1, 6.6, 3.5 Hz, 1H), 4.69- 4.60 (m, 1H), 4.18-3.91 (m, 3H), 3.47 (dd, J = 13.1, 6.4 Hz, 1H), 3.40-3.33 (m, 2H), 3.28-3.20 (m, 2H), 3.04 (p, J = 7.1 Hz, 1H), 2.85 (dd, J = 13.3, 10.7 Hz, 1H), 2.62 (s, 3H), 2.45 (s, 3H), 2.26 (s, 3H), 2.04 (d, J = 13.2 Hz, 2H), 1.61 (dddd, J = 45.2, 20.8, 12.7, 6.2 Hz, 2H), 1.24 (dd, 6H).  9 Example 73; (2R)-4- tert-butoxycarbonyl- morpholine-2-carboxylic acid; DCM solvent 111

484.3 ¹H NMR (400 MHz, Chloroform-d) δ 9.57 (d, J = 11.7 Hz, 1H), 9.10 (d, J = 11.4 Hz, 1H), 8.48 (d, J = 6.4 Hz, 2H), 8.39 (s, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.3 Hz, 2H), 3.58 (d, J = 12.3 Hz, 2H), 3.07 (tt, J = 10.4, 5.5 Hz, 3H), 2.84 (tt, J = 10.9, 5.4 Hz, 1H), 2.64 (s, 3H), 2.54 (s, 3H), 2.29 (s, 3H), 2.13 (t, J = 10.7 Hz, 4H), 1.25 (s, 6H). 10 Example 73; tert- butyl 4-[4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl]piperidine- 1-carboxylate 112

420.2 ¹H NMR (400 MHz, Chloroform-d) δ 9.50 (s, 1H), 8.47 (s, 1H), 8.43 (s, 2H), 3.95 (s, 2H), 3.18 (d, J = 58.8 Hz, 2H), 2.99 (p, J = 7.1 Hz, 1H), 2.82 (s, 1H), 2.62 (s, 3H), 2.46 (s, 3H), 2.24 (s, 3H), 2.03 (dd, J = 90.8, 11.6 Hz, 3H), 1.22 (s, 6H). 17 Example 73; I-65 113

541.3 ¹H NMR (400 MHz, Chloroform-d) δ 8.50 (s, 1H), 8.49 (s, 1H), 8.12 (s, 1H), 8.03 (s, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 3.84 (s, 2H), 3.75 (d, J = 11.8 Hz, 2H), 3.20 (t, J = 12.3 Hz, 3H), 3.08 (p, J = 7.1 Hz, 1H), 2.85 (t, J = 12.0 Hz, 2H), 2.66 (s, 3H), 2.54 (s, 3H), 2.30 (s, 4H), 2.15 (d, J = 14.6 Hz, 2H), 2.01 (s, 1H), 1.26 (s, 6H). 20 Example 111 114

477.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.79 (s, 1H), 8.59 (t, J = 3.5 Hz, 1H), 8.48 (s, 1H), 4.19-3.79 (m, 4H), 3.54 (d, J = 11.0 Hz, 1H), 3.19-3.12 (m, 1H), 3.03 (p, J = 7.1 Hz, 1H), 2.86 (s, 1H), 2.62 (s, 3H), 2.54 (s, 3H), 2.48 (t, J = 10.8 Hz, 1H), 2.25 (d, J = 2.8 Hz, 3H), 2.21-1.92 (m, 3H), 1.75 (ddt, J = 50.1, 19.6, 6.7 Hz, 1H), 1.43-1.08 (m, 6H). 20 Example 112 115

486.2 ¹H NMR (400 MHz, Methanol-d₄) δ 8.64 (s, 1H), 8.49 (s, 1H), 7.64-7.26 (m, 4H), 4.82 (dd, J = 11.2, 2.5 Hz, 1H), 4.27 (ddd, J = 13.1, 3.9, 1.3 Hz, 1H), 4.03 (ddd, J = 13.1, 11.7, 3.0 Hz, 1H), 3.51 (d, J = 11.8 Hz, 1H), 3.46-3.34 (m, 2H), 3.23-3.01 (m, 2H), 2.64 (s, 3H), 2.51 (s, 3H), 2.29 (s, 3H), 1.27 (dd, J = 32.0, 7.0 Hz, 6H). 10 Example 73; I-66 116

547.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.62 (s, 1H), 8.53 (s, 1H), 7.63 (s, 1H), 4.59 (d, J = 12.9 Hz, 2H), 3.74 (s, 5H), 3.18-2.97 (m, 2H), 2.78 (s, 5H), 2.69 (s, 3H), 2.50 (d, J = 2.5 Hz, 3H), 2.15-1.95 (m, 2H), 1.67 (d, J = 12.9 Hz, 2H), 1.41 (d, J = 7.1 Hz, 6H), 1.16 (s, 2H), 0.99 (s, 2H).  9 1- morpholinocyclopropane- carboxylic acid 117

509.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (d, J = 8.1 Hz, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 5.54 (dd, J = 51.8, 12.7 Hz, 2H), 4.99 (dt, J = 28.7, 8.9 Hz, 2H), 4.67 (d, J = 12.8 Hz, 2H), 3.99 (d, J = 13.2 Hz, 2H), 3.83-3.46 (m, 3H), 3.10-2.88 (m, 3H), 2.68 (d, J = 1.0 Hz, 3H), 2.50 (d, J = 3.1 Hz, 3H), 2.34-1.96 (m, 3H), 1.88-1.52 (m, 1H), 1.41 (d, J = 7.1 Hz, 6H).  9 (2S,4R)-1-tert- butoxycarbonyl-4- fluoro-pyrrolidine-2- carboxylic acid 118

509.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (d, J = 8.1 Hz, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 5.54 (dd, J = 51.8, 12.7 Hz, 2H), 4.99 (dt, J = 28.7, 8.9 Hz, 2H), 4.75 (m, 2H), 4.67 (d, J = 12.8 Hz, 2H), 3.99 (d, J = 13.2 Hz, 2H), 3.83-3.46 (m, 3H), 3.10-2.88 (m, 3H), 2.68 (d, J = 1.0 Hz, 3H), 2.50 (d, J = 3.1 Hz, 4H), 2.34-1.96 (m, 3H), 1.88-1.52 (m, 2H), 1.41 (d, J = 7.1 Hz, 6H)  9 (2S,4S)-1-tert- butoxycarbonyl-4- fluoro-pyrrolidine-2- carboxylic acid 119

516.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 4.85-4.74 (m, 1H), 4.43 (s, 1H), 3.34 (s, 4H), 3.07 (h, J = 7.1 Hz, 1H), 2.83 (d, J = 25.4 Hz, 1H), 2.64 (d, J = 5.0 Hz, 1H), 2.48 (d, J = 4.5 Hz, 3H), 2.37 (d, J = 12.4 Hz, 1H), 2.27 (s, 3H), 2.22-1.88 (m, 1H), 1.36-1.09 (m, 7H).  7 Example 72; 2- (bromomethyl)-5- methyl-1,3,4- oxadiazole 120

529.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 4.34-4.24 (m, 2H), 3.73-3.40 (m, 2H), 3.29- 2.97 (m, 2H), 2.89 (s, 1H), 2.65 (s, 3H), 2.59 (d, J = 3.1 Hz, 3H), 2.51 (d, J = 19.8 Hz, 1H), 2.42 (s, 3H), 2.32 (s, 2H), 2.27 (s, 3H), 2.02 (dd, J = 15.3, 5.3 Hz, 1H), 1.26 (dd, J = 28.1, 7.1 Hz, 7H).  7 Example 72; 3,5- dimethylisoxazole-4- carbaldehyde 121

477.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.50 (s, 1H), 7.55 (s, 1H), 4.38-3.92 (m, 3H), 3.84-3.41 (m, 2H), 3.13 (dd, J = 36.1, 12.1 Hz, 1H), 2.77 (d, J = 17.1 Hz, 1H), 2.63 (d, J = 15.4 Hz, 7H), 2.50 (d, J = 4.3 Hz, 3H), 2.40-1.86 (m, 4H), 1.40 (d, J = 7.1 Hz, 7H). 12 I-85; I-31 122

477.3 ¹H NMR (400 MHz, MeOD) δ 8.61-8.54 (m, 1H), 8.47 (s, 1H), 7.58 (t, J = 1.5 Hz, 1H), 4.44-3.92 (m, 6H), 3.72-3.44 (m, 1H), 3.31-3.23 (m, 1H), 2.68 (d, J = 0.9 Hz, 3H), 2.45 (s, 3H), 2.38-1.48 (m, 6H), 1.40 (d, J = 7.1 Hz, 6H).  5 Example 61 123

434.3 ¹H NMR (400 MHz, MeOD) δ 8.64-8.54 (m, 1H), 8.47 (s, 1H), 7.59 (t, J = 1.4 Hz, 1H), 3.95 (p, J = 9.0 Hz, 1H), 3.31-3.26 (m, 1H), 3.26-3.20 (m, 2H), 3.16-3.09 (m, 2H), 2.68 (s, 3H), 2.50 (td, J = 9.0, 2.6 Hz, 2H), 2.39 (s, 3H), 2.02 (td, J = 9.6, 3.3 Hz, 6H), 1.89-1.82 (m, 2H), 1.39 (d, J = 7.1 Hz, 6H). 17 I-15; tert-butyl 2-iodo- 7- azaspiro[3.5]nonane- 7-carboxylate 124

491.3 ¹H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.45 (s, 1H), 7.57 (s, 1H), 3.95 (s, 3H), 3.59 (d, J = 11.5 Hz, 1H), 3.50 (d, J = 1.7 Hz, 1H), 3.30-2.96 (m, 3H), 2.68 (s, 3H), 2.60 (s, 1H), 2.39 (s, 4H), 2.33-1.85 (m, 6H), 1.39 (d, J = 7.1 Hz, 6H).  5 Example 123 125

420.3 ¹H NMR (400 MHz, MeOD) δ 8.63-8.54 (m, 1H), 8.47 (s, 1H), 7.63-7.56 (m, 1H), 3.97 (p, J = 8.9 Hz, 1H), 3.38 (t, J = 7.2 Hz, 2H), 3.31-3.22 (m, 3H), 2.68 (t, J = 0.9 Hz, 3H), 2.56 (ddt, J = 11.3, 8.2, 1.9 Hz, 2H), 2.40 (s, 3H), 2.34-2.22 (m, 4H), 1.39 (d, J = 7.1 Hz, 6H). 17, 21 1-15; I-28 126

477.3 ¹H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 4.07 (d, J = 5.4 Hz, 2H), 3.96 (p, J = 8.9 Hz, 1H), 3.88-3.66 (m, 2H), 3.27 (q, J = 7.1 Hz, 3H), 2.89-2.53 (m, 5H), 2.51-2.10 (m, 7H), 1.39 (d, J = 7.1 Hz, 6H). 21 Example 125 127

380.2 ¹H NMR (400 MHz, MeOD) δ 8.60 (dd, J = 1.6, 0.8 Hz, 1H), 8.46 (s, 1H), 7.58 (p, J = 1.2 Hz, 1H), 4.03 (tt, J = 10.7, 7.6 Hz, 1H), 3.75 (dd, J = 11.6, 7.9 Hz, 1H), 3.61 (ddd, J = 11.4, 8.5, 2.8 Hz, 1H), 3.42 (td, J = 11.1, 7.0 Hz, 1H), 3.32-3.25 (m, 1H), 3.12 (t, J = 11.1 Hz, 1H), 2.68 (t, J = 0.9 Hz, 3H), 2.58-2.47 (m, 4H), 2.12 (dtd, J = 13.0, 10.6, 8.5 Hz, 1H), 1.49-1.32 (m, 6H). 17 I-15; tert-butyl 3- iodopyrrolidine-1- carboxylate 128

437.3 ¹H NMR (400 MHz, MeOD) δ 8.63-8.55 (m, 1H), 8.47 (s, 1H), 7.58 (t, J = 1.3 Hz, 1H), 4.20 (s, 2H), 4.12-3.39 (m, 4H), 3.31-3.24 (m, 1H), 3.23-3.06 (m, 1H), 2.78-2.44 (m, 7H), 2.40-2.04 (m, 1H), 1.40 (d, J = 7.1 Hz, 6H). 20 Example 127 129

448.3 ¹H NMR (400 MHz, MeOD) δ 8.65-8.54 (m, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 3.68 (ddd, J = 17.6, 10.2, 7.3 Hz, 1H), 3.31-3.14 (m, 5H), 2.68 (t, J = 0.9 Hz, 3H), 2.45 (s, 3H), 2.20 (dd, J = 13.5, 7.9 Hz, 2H), 1.98-1.51 (m, 8H), 1.40 (d, J = 7.1 Hz, 6H). 17 I-15; I-87 130

420.2 ¹H NMR (400 MHz, MeOD) δ 8.58 (dd, J = 1.7, 0.8 Hz, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 3.97 (d, J = 6.3 Hz, 2H), 3.80-3.49 (m, 3H), 3.30-3.07 (m, 3H), 2.68 (t, J = 0.9 Hz, 3H), 2.45 (d, J = 2.7 Hz, 3H), 2.38-1.69 (m, 10H), 1.40 (d, J = 7.1 Hz, 6H). 17, 21 1-15, I-28 131

408.2 ¹H NMR (400 MHz, MeOD) δ 8.52 (dd, J = 1.6, 0.8 Hz, 1H), 7.60 (t, J = 1.4 Hz, 1H), 3.55-3.34 (m, 3H), 3.31-3.15 (m, 3H), 2.65 (t, J = 0.9 Hz, 3H), 2.62 (s, 3H), 2.49 (s, 3H), 2.23-2.14 (m, 2H), 1.90 (qd, J = 13.4, 4.0 Hz, 2H), 1.40 (d, J = 7.1 Hz, 6H). 17 I-85; tert-butyl 4- iodopiperidine-1- carboxylate 132

477.4 ¹H NMR (400 MHz, MeOD) δ 8.59 (d, J = 1.6 Hz, 1H), 8.45 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 4.27-3.65 (m, 6H), 3.28 (q, J = 7.1 Hz, 2H), 2.89-2.60 (m, 5H), 2.40 (s, 7H), 1.39 (d, J = 7.1 Hz, 6H). 21 Example 130 133

505.2 ¹H NMR (400 MHz, MeOD) δ 8.58 (dd, J = 1.7, 0.8 Hz, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 3.97 (d, J = 6.3 Hz, 2H), 3.80-3.49 (m, 3H), 3.30-3.07 (m, 3H), 2.68 (t, J = 0.9 Hz, 3H), 2.45 (d, J = 2.7 Hz, 3H), 2.38-1.69 (m, 10H), 1.40 (d, J = 7.1 Hz, 6H). 20 Example 129 134

465.3 ¹H NMR (400 MHz, MeOD) δ 8.57 (dd, J = 1.7, 0.8 Hz, 1H), 7.68 (d, J = 1.4 Hz, 1H), 4.00 (s, 2H), 3.73 (d, J = 12.0 Hz, 2H), 3.51-3.13 (m, 4H), 2.66 (d, J = 6.0 Hz, 6H), 2.49 (s, 3H), 2.28-1.96 (m, 4H), 1.40 (d, J = 7.1 Hz, 6H). 20 Example 131 135

521.3 ¹H NMR (400 MHz, MeOD) δ 8.55 (d, J = 1.6 Hz, 1H), 7.66 (t, J = 1.4 Hz, 1H), 4.77-4.60 (m, 2H), 4.26 (dt, J = 13.0, 4.6 Hz, 1H), 4.11-3.99 (m, 2H), 3.88- 3.56 (m, 2H), 3.46-3.20 (m, 5H), 2.87 (td, J = 13.3, 6.2 Hz, 1H), 2.65 (d, J = 6.3 Hz, 6H), 2.48 (s, 3H), 2.27-1.90 (m, 2H), 1.81-1.45 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H).  9 Example 131; (3R)-4- tert-butoxycarbonyl- morpholine-3-carboxylic acid 136

521.3 ¹H NMR (400 MHz, MeOD) δ 8.55 (d, J = 1.6 Hz, 1H), 7.66 (t, J = 1.4 Hz, 1H), 4.77-4.60 (m, 2H), 4.26 (dt, J = 13.0, 4.6 Hz, 1H), 4.11-3.99 (m, 2H), 3.88- 3.56 (m, 2H), 3.46-3.20 (m, 5H), 2.87 (td, J = 13.3, 6.2 Hz, 1H), 2.65 (d, J = 6.3 Hz, 6H), 2.48 (s, 3H), 2.27-1.90 (m, 2H), 1.81-1.45 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H).  9 Example 131; (3S)-4- tert-butoxycarbonyl- morpholine-3-carboxylic acid 137

434.3 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.47 (s, 1H), 7.59 (t, J = 1.4 Hz, 1H), 3.97 (p, J = 9.2 Hz, 1H), 3.36 (s, 1H), 3.31-3.25 (m, 1H), 3.13 (s, 3H), 2.69 (s, 3H), 2.60-2.50 (m, 2H), 2.39 (s, 3H), 2.11-1.93 (m, 2H), 1.79 (d, J = 2.9 Hz, 4H), 1.39 (d, J = 7.1 Hz, 6H). 17 I-15; I-88 138

420.2 ¹H NMR (400 MHz, MeOD) δ 8.60 (dd, J = 1.7, 0.9 Hz, 1H), 8.47 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 4.14 (p, J = 8.9 Hz, 1H), 3.40 (t, J = 7.4 Hz, 2H), 3.31-3.19 (m, 1H), 3.00-2.89 (m, 2H), 2.69 (s, 3H), 2.55-2.45 (m, 2H), 2.42 (d, J = 5.2 Hz, 3H), 2.20-2.01 (m, 4H), 1.39 (d, J = 7.1 Hz, 6H). 17 I-15; I-89 139

511.2 ¹H NMR (400 MHz, MeOD) δ 10.75 (s, 1H), 8.50 (s, 1H), 4.23-3.97 (m, 3H), 3.83-3.69 (m, 1H), 3.67- 3.44 (m, 1H), 3.22-3.15 (m, 1H), 3.06 (dq, J = 14.2, 6.6 Hz, 1H), 2.59 (s, 5H), 2.48 (d, J = 4.1 Hz, 3H), 2.25 (s, 4H), 2.13-1.96 (m, 2H), 1.30-1.19 (m, 6H). 29, 20 I-77; I-55 140

477.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (dd, J = 1.7, 0.9 Hz, 1H), 8.47 (s, 1H), 7.64-7.54 (m, 1H), 4.35 (s, 1H), 4.09 (h, J = 7.9, 7.5 Hz, 2H), 3.86 (s, 1H), 3.31- 3.21 (m, 1H), 3.22-3.04 (m, 2H), 2.69 (t, J = 0.9 Hz, 3H), 2.59-2.21 (m, 8H), 2.11 (q, J = 7.8 Hz, 2H), 1.40 (d, J = 7.1 Hz, 6H). 20 Example 138 141

491.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (dd, J = 1.7, 0.8 Hz, 1H), 8.47 (s, 1H), 7.59 (t, J = 1.4 Hz, 1H), 3.98 (t, J = 10.5 Hz, 4H), 3.44 (d, J = 11.9 Hz, 1H), 3.31- 3.23 (m, 1H), 3.19-3.05 (m, 1H), 3.00 (d, J = 12.0 Hz, 1H), 2.83 (t, J = 10.1 Hz, 1H), 2.72-2.65 (m, 3H), 2.40 (s, 3H), 2.20-1.56 (m, 7H), 1.40 (d, J = 7.1 Hz, 6H). 21 Example 137 142

491.3 1H NMR (400 MHz, MeOD) δ 8.61-8.55 (m, 1H), 8.46 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 4.10-3.78 (m, 4H), 3.61 (t, J = 11.3 Hz, 1H), 3.46 (d, J = 11.4 Hz, 1H), 3.34-3.21 (m, 1H), 3.09 (d, J = 11.3 Hz, 1H), 2.96 (d, J = 11.9 Hz, 1H), 2.68 (s, 3H), 2.56 (s, 1H), 2.40 (s, 3H), 2.24 (t, J = 13.0 Hz, 2H), 2.03 (q, J = 7.9 Hz, 3H), 1.71 (d, J = 12.2 Hz, 1H), 1.39 (d, J = 7.1 Hz, 6H). 21 Example 137 143

547.4 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.51 (s, 1H), 4.84 (dd, J = 9.5, 5.1 Hz, 1H), 4.69-4.56 (m, 2H), 4.40 (ddd, J = 6.9, 4.7, 1.8 Hz, 1H), 4.19-4.06 (m, 1H), 3.86 (dddd, J = 17.4, 14.6, 9.5, 4.3 Hz, 2H), 3.39 (dt, J = 12.1, 3.4 Hz, 2H), 3.05 (hept, J = 7.1 Hz, 1H), 2.93 (t, J = 12.8 Hz, 1H), 2.79 (dddd, J = 17.2, 14.8, 9.4, 5.3 Hz, 1H), 2.70-2.54 (m, 4H), 2.52- 2.35 (m, 4H), 2.28 (s, 4H), 2.15-1.96 (m, 2H), 1.76- 1.57 (m, 2H), 1.46-1.14 (m, 6H).  9 Example 73; (3aS,5S,6aS)-4-tert- butoxycarbonyl- 2,3,3a,5,6,6a- hexahydrofuro[3,2- b]pyrrole-5-carboxylic acid 144

478.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.48 (d, J = 2.7 Hz, 1H), 4.01-3.91 (m, 2H), 3.33 (dt, J = 3.3, 1.7 Hz, 1H), 3.25-3.17 (m, 2H), 3.11-2.97 (m, 3H), 2.68-2.62 (m, 3H), 2.44 (d, J = 2.8 Hz, 3H), 2.31- 2.14 (m, 4H), 2.06 (d, J = 13.4 Hz, 1H), 1.87-1.67 (m, 4H), 1.64-1.50 (m, 2H), 1.39-1.15 (m, 6H). 17 I-76 145

463.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.47 (s, 1H), 7.58 (s, 1H), 4.31-3.90 (m, 3H), 3.84-3.66 (m, 1H), 3.66-3.43 (m, 1H), 3.32-3.24 (m, 1H), 3.21-3.02 (m, 1H), 2.85-2.73 (m, 1H), 2.73-2.57 (m, 4H), 2.56-2.45 (m, 3H), 2.30 (dd, J = 38.9, 12.2 Hz, 1H), 2.16-1.93 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H). 12 I-27 146

533.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 4.65-4.37 (m, 2H), 4.28 (dd, J = 12.7, 3.7 Hz, 1H), 4.08 (d, J = 12.8 Hz, 1H), 3.86-3.58 (m, 3H), 3.58-3.43 (m, 1H), 3.43-3.34 (m, 2H), 3.06 (p, J = 7.1 Hz, 1H), 2.75 (s, 1H), 2.65 (s, 3H), 2.52-2.43 (m, 3H), 2.42-2.24 (m, 4H), 2.13 (dd, J = 34.3, 10.5 Hz, 1H), 2.06-1.73 (m, 2H), 1.30 (d, J = 7.3 Hz, 3H), 1.23 (d, J = 7.0 Hz, 3H).  9 Example 72; (3R)-4- tert-butoxycarbonyl- morpholine-3-carboxylic acid 147

535.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 5.63-5.37 (m, 1H), 4.82-4.38 (m, 2H), 3.85 (t, J = 15.7 Hz, 1H), 3.64-3.43 (m, 4H), 3.06 (p, J = 7.0 Hz, 1H), 3.00-2.68 (m, 2H), 2.65 (s, 3H), 2.51- 2.46 (m, 3H), 2.46-2.33 (m, 2H), 2.28 (s, 3H), 2.14 (dd, J = 24.0, 10.5 Hz, 1H), 2.04-1.74 (m, 2H), 1.30 (d, J = 7.5 Hz, 3H), 1.23 (d, J = 7.0 Hz, 3H).  9 Example 72; (2R,4R)- 1-tert-butoxycarbonyl- 4-fluoro-pyrrolidine- 2-carboxylic acid 148

535.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.48 (s, 1H), 5.67-5.42 (m, 1H), 5.00-4.90 (m, 1H), 4.84- 4.71 (m, 1H), 4.60 (d, J = 38.7 Hz, 1H), 3.82-3.61 (m, 2H), 3.61-3.46 (m, 2H), 3.06 (p, J = 7.1 Hz, 1H), 3.01-2.86 (m, 1H), 2.75 (s, 1H), 2.65 (s, 3H), 2.51- 2.30 (m, 5H), 2.28 (s, 3H), 2.14 (dd, J = 24.9, 10.7 Hz, 1H), 2.04-1.72 (m, 2H), 1.30 (d, J = 7.4 Hz, 3H), 1.23 (d, J = 7.1 Hz, 3H).  9 Example 72; (2R,4S)- 1-tert-butoxycarbonyl- 4-fluoro-pyrrolidine- 2-carboxylic acid 149

535.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 5.63-5.37 (m, 1H), 4.82-4.38 (m, 2H), 3.85 (t, J = 15.7 Hz, 1H), 3.64-3.43 (m, 4H), 3.06 (p, J = 7.0 Hz, 1H), 3.00-2.68 (m, 2H), 2.65 (s, 3H), 2.51- 2.46 (m, 3H), 2.46-2.33 (m, 2H), 2.28 (s, 3H), 2.14 (dd, J = 24.0, 10.5 Hz, 1H), 2.04-1.74 (m, 2H), 1.30 (d, J = 7.5 Hz, 3H), 1.23 (d, J = 7.0 Hz, 3H).  9 Example 72; (2S,4S)- 1-tert-butoxycarbonyl- 4-fluoro-pyrrolidine- 2-carboxylic acid 150

535.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.48 (s, 1H), 5.67-5.42 (m, 1H), 5.00-4.90 (m, 1H), 4.84- 4.71 (m, 1H), 4.60 (d, J = 38.7 Hz, 1H), 3.82-3.61 (m, 2H), 3.61-3.46 (m, 2H), 3.06 (p, J = 7.1 Hz, 1H), 3.01-2.86 (m, 1H), 2.75 (s, 1H), 2.65 (s, 3H), 2.51- 2.30 (m, 5H), 2.28 (s, 3H), 2.14 (dd, J = 24.9, 10.7 Hz, 1H), 2.04-1.72 (m, 2H), 1.30 (d, J = 7.4 Hz, 3H), 1.23 (d, J = 7.1 Hz, 3H).  9 Example 72; (2S,4R)- 1-tert-butoxycarbonyl- 4-fluoro-pyrrolidine- 2-carboxylic acid 151

491.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.50 (d, J = 1.0 Hz, 1H), 4.08-3.60 (m, 5H), 3.57-3.35 (m, 1H), 3.27 (q, J = 9.9, 7.5 Hz, 4H), 3.10-2.92 (m, 1H), 2.86-2.67 (m, 2H), 2.65 (s, 3H), 2.56-2.38 (m, 5H), 2.38 (s, 3H), 2.29 (s, 3H), 1.28 (d, J = 7.1 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H).  1 I-40; tert-butyl piperazine-1- carboxylate 152

517.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.42 (s, 1H), 4.38 (d, J = 14.5 Hz, 2H), 3.80-3.67 (m, 1H), 3.60-3.45 (m, 3H), 3.13-2.76 (m, 3H), 2.64 (s, 3H), 2.54-2.42 (m, 3H), 2.30-2.21 (m, 4H), 2.14-1.95 (m, 2H), 1.30 (d, J = 8.0 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H). 20 3-(chloromethyl)-1,4- dihydro-1,2,4-triazol- 5-one 153

592.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.48 (s, 1H), 4.39-4.09 (m, 3H), 4.09-3.87 (m, 3H), 3.12- 2.99 (m, 3H), 2.72-2.55 (m, 4H), 2.47 (s, 3H), 2.38- 2.25 (m, 4H), 2.10 (d, J = 11.2 Hz, 1H), 1.93-1.58 (m, 4H), 1.26 (dd, J = 21.8, 10.1 Hz, 6H). 20 2-(1- methylsulfonylazetidin- 3- ylidene)acetontrile; solvent: acetonitrile 154

588.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.42 (s, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.58-7.47 (m, 2H), 4.49 (d, J = 12.5 Hz, 1H), 4.30-4.12 (m, 2H), 3.67- 3.38 (m, 2H), 3.31-3.18 (m, 1H), 3.12-2.92 (m, 1H), 2.89-2.73 (m, 1H), 2.64 (s, 3H), 2.58-2.47 (m, 1H), 2.45 (s, 3H), 2.30-2.21 (m, 4H), 2.09-1.87 (m, 2H), 1.29 (d, J = 7.3 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H).  7 Example 72; 4- bromobenzaldehyde 155

553.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.43 (s, 1H), 4.33-3.94 (m, 3H), 3.87-3.68 (m, 1H), 3.68- 3.52 (m, 1H), 3.46 (s, 6H), 3.23-3.14 (m, 1H), 3.07 (td, J = 14.2, 13.2, 6.1 Hz, 1H), 2.77 (d, J = 17.9 Hz, 1H), 2.68-2.56 (m, 4H), 2.48 (d, J = 1.8 Hz, 3H), 2.39-2.09 (m, 5H), 2.09-1.88 (m, 1H), 1.30 (d, J = 7.2 Hz, 3H), 1.23 (d, J = 7.1 Hz, 3H). 20 2-chloro-N- (dimethyl(oxo)- sulfaneylidene)acetamide 156

542.2 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.36 (s, 1H), 8.55 (dd, 1H), 8.36 (s, 1H), 7.50 (t, 1H), 3.79 (d, 1H), 3.51 (dd, 4H), 3.35-3.25 (m, 5H), 3.20 (tt, 1H), 3.04 (td, 2H), 2.65 (t, 3H), 2.46 (s, 3H), 1.69 (qd, 2H), 1.36 (d, 6H).  6 tert-butyl 4- chlorosulfonylpiperazine- 1-carboxylate 157

556.3 ¹H NMR (400 MHz, Acetontrile-d3) δ 9.36 (s, 1H), 8.56 (dd, 1H), 8.40 (s, 1H), 7.52 (q, 1H), 3.84-3.72 (m, 4H), 3.51 (d, 2H), 3.29 (dt, 3H), 3.19 (tt, 1H), 3.03 (td, 3H), 2.84 (s, 3H), 2.65 (d, 3H), 2.46 (s, 3H), 1.68 (qd, 2H), 1.36 (d, 6H).  6 4-methylpiperazine-1- sulfonyl chloride 158

535.3 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.34 (s, 1H), 8.55 (s, 1H), 8.37 (s, 1H), 7.50 (t, 1H), 4.63-4.51 (m, 2H), 4.47 (dd, 0H), 4.10-3.96 (m, 1H), 3.95-3.84 (m, 1H), 3.84-3.67 (m, 1H), 3.37-3.20 (m, 3H), 3.07 (d, 1H), 2.84 (t, 1H), 2.65 (d, 3H), 2.47 (s, 3H), 1.78-1.63 (m, 0H), 1.62-1.46 (m, 1H), 1.39-1.33 (m, 9H), 1.30 (s, 3H).  9 (3R)-4-tert- butoxycarbonyl-6,6- dimethyl-morpholine- 3-carboxylic acid 159

535.3 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.34 (s, 1H), 8.55 (d, 1H), 8.36 (s, 1H), 7.49 (t, 1H), 4.63-4.44 (m, 2H), 4.05 (dt, 1H), 3.95-3.84 (m, 1H), 3.83-3.66 (m, 1H), 3.29 (ddd, 3H), 3.07 (d, 1H), 2.84 (t, 2H), 2.47 (s, 3H), 1.40-1.32 (m, 11H), 1.30 (s, 3H).  9 (3S)-4-tert- butoxycarbonyl-6,6- dimethyl-morpholine- 3-carboxylic acid 160

481.1 ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.44 (s, 1H), 8.57 (dd, 1H), 8.36 (s, 1H), 7.49 (q, 1H), 6.75 (s, 1H), 6.29 (s, 1H), 4.62 (s, 2H), 3.87 (s, 2H), 3.73-3.57 (m, 0H), 3.54-3.43 (m, 0H), 3.42 (s, 3H), 3.32 (p, 1H), 2.65 (t, 3H), 2.23-2.08 (m, 3H), 1.33 (d, 6H). 20 Example 259 161

465.2 ¹H NMR (400 MHz, Acetonitrile-d₃) δ 9.39 (s, 1H), 8.56 (dd, 1H), 8.37 (s, 1H), 7.50 (p, 1H), 6.69 (s, 1H), 6.31 (s, 1H), 4.00-3.83 (m, 2H), 3.63-3.34 (m, 3H), 3.28 (h, 1H), 3.07 (s, 22H), 2.65 (t, 3H), 2.45 (s, 3H), 2.25-2.01 (m, 2H), 1.36 (d, 6H). 12 tert-butyl 4- iodoazepane-1- carboxylate 162

487.2 ¹H NMR (400 MHz, Methanol-d₄) δ 11.23 (s, 1H), 8.68 (dd, 1H), 8.48 (s, 1H), 7.59 (t, 1H), 7.21 (t, 1H), 4.00 (s, 2H), 3.75 (d, 3H), 3.48-3.37 (m, 1H), 3.30 (d, 3H), 2.69 (t, 3H), 2.31 (d, 2H), 2.18 (d, 1H), 2.09 (d, 1H), 1.29 (d, 6H).  5 Example 68; 163

505.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 4.40 (d, 1H), 4.31 (d, 1H), 4.19 (d, 1H), 3.85- 3.70 (m, 1H), 3.60 (dt, 1H), 3.21 (dd, 1H), 3.11-3.05 (m, 2H), 3.04 (s, 5H), 2.77 (d, 1H), 2.65 (s, 3H), 2.49 (d, 3H), 2.27 (s, 3H), 2.20-1.94 (m, 2H), 1.26 (dd, 6H). 20 2-Bromo-N,N- dimethylacetamide 164

540.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 4.27 (d, 1H), 3.74-3.58 (m, 1H), 3.50 (ddd, 2H), 3.26-3.18 (m, 1H), 3.12-3.00 (m, 4H), 2.80 (d, 1H), 2.65 (s, 3H), 2.49 (s, 1H), 2.48 (s, 2H), 2.27 (s, 5H), 2.13 (d, 1H), 2.07-1.89 (m, 1H), 1.26 (dd, 6H). 20 1-bromo-3- methylsulfonyl- propane 165

459.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.56 (s, 1H), 8.42 (s, 1H), 4.49 (q, 2H), 4.27 (s, 1H), 3.56 (t, 2H), 3.50 (d, 1H), 3.42 (d, 1H), 3.06 (p, 1H), 2.84 (s, 1H), 2.64 (s, 3H), 2.56 (d, 1H), 2.48 (s, 3H), 2.32 (d, 1H), 2.26 (s, 3H), 2.12 (d, 1H), 2.04 (d, 1H), 1.26 (dd, 6H). 20 Bromoacetonitrile 166

473.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 4.32 (d, 1H), 3.68 (s, 3H), 3.59-3.47 (m, 2H), 3.09-3.00 (m, 3H), 2.82 (d, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.26 (s, 3H), 2.21-1.91 (m, 1H), 1.26 (dd, 6H). 20 3-Bromopropionitrile 167

476.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.77 (s, 1H), 8.59 (s, 1H), 8.47 (s, 1H), 4.97 (dt, 2H), 4.75 (dd, 1H), 4.71 (s, 1H), 4.51 (s, 1H), 4.11 (s, 1H), 3.70 (d, 1H), 3.56 (t, 1H), 3.06 (p, 2H), 2.82 (s, 1H), 2.65 (s, 3H), 2.61-2.52 (m, 1H), 2.48 (s, 3H), 2.27 (s, 3H), 2.16- 1.96 (m, 2H), 1.37-1.14 (m, 6H).  7 Example 72, 3- Oxetanone 3-Oxetanone 168

552.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.77 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 4.47 (d, 1H), 3.70-3.58 (m, 2H), 3.58-3.47 (m, 1H), 3.41 (t, 1H), 3.27 (d, 4H), 3.07 (p, 1H), 2.90-2.68 (m, 1H), 2.65 (s, 3H), 2.58 (d, 1H), 2.51 (s, 2H), 2.48 (s, 1H), 2.42 (d, 1H), 2.27 (s, 4H), 2.12-1.89 (m, 2H), 1.26 (dd, 6H).  7 Example 72, 1,1- dioxothian-4-one 169

564.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.59 (s, 1H), 8.46 (s, 1H), 4.27 (d, 4H), 4.10 (s, 1H), 3.91 (p, 1H), 3.64-3.46 (m, 2H), 3.12-2.97 (m, 2H), 2.92-2.74 (m, 3H), 2.64 (s, 4H), 2.62-2.54 (m, 1H), 2.48 (d, 3H), 2.27 (s, 3H), 2.16-1.89 (m, 2H), 1.26 (dd, 6H).  7 Example 72, 2- thiaspiro[3.3]heptan- 6-one 2,2-dioxide 170

527.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.44 (s, 1H), 7.72 (dd, 1H), 6.88 (d, 1H), 6.73 (d, 1H), 4.46 (d, 1H), 4.35 (s, 1H), 4.29 (s, 1H), 3.60 (s, 2H), 3.06 (p, 1H), 2.83 (s, 1H), 2.64 (s, 3H), 2.49 (s, 3H), 2.33 (d, 1H), 2.27 (s, 3H), 2.08-1.96 (m, 1H), 1.26 (dd, 6H).  7 Example 72, 2- Pyridone-6- carboxaldehyde 171

527.3 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.58 (s, 1H), 8.44 (s, 1H), 7.93-7.81 (m, 1H), 7.62 (dd, 1H), 6.58-6.43 (m, 1H), 4.42-4.29 (m, 1H), 4.24 (d, 1H), 3.72 (t, 1H), 3.62 (d, 1H), 3.55 (dd, 1H), 3.23 (d, 1H), 3.06 (h, 1H), 2.83 (s, 1H), 2.64 (s, 3H), 2.52 (s, 1H), 2.46 (s, 2H), 2.27 (s, 3H), 2.07-1.94 (m, 1H), 1.34-1.16 (m, 6H).  7 Example 72, 2- Hydroxy-pyridine-3- carbaldehyde 172

577.3 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 7.96-7.90 (m, 2H), 7.88 (t, 1H), 6.61 (t, 1H), 4.42-4.31 (m, 1H), 4.25 (t, 2H), 3.75-3.59 (m, 1H), 3.57-3.48 (m, 1H), 3.06 (p, 1H), 2.81 (d, 1H), 2.64 (s, 3H), 2.55-2.48 (m, 2H), 2.46 (s, 2H), 2.39-2.31 (m, 1H), 2.27 (s, 4H), 2.02 (t, 1H), 1.34-1.17 (m, 6H).  7 Example 72, 1- (difluoromethyl)-2- oxo-pyridine-3- carbaldehyde 173

508.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.57 (s, 1H), 8.43 (s, 1H), 4.84-4.71 (m, 1H), 4.27 (d, 1H), 4.12-3.99 (m, 1H), 3.91 (t, 1H), 3.71 (d, 1H), 3.55-3.46 (m, 1H), 3.22-3.13 (m, 1H), 3.06 (p, 1H), 2.81 (d, 2H), 2.64 (s, 3H), 2.49 (d, 3H), 2.42- 2.29 (m, 1H), 2.26 (s, 3H), 2.03 (d, 1H), 1.26 (dd, 6H).  7 Example 72, 3- fluorooxetane-3- carbaldehyde 174

501.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 8.04 (s, 1H), 4.73-4.60 (m, 1H), 4.51 (d, 1H), 4.41-4.16 (m, 1H), 3.79-3.60 (m, 1H), 3.54 (dd, 2H), 3.06 (p, 1H), 2.88-2.75 (m, 1H), 2.64 (s, 3H), 2.53 (s, 1H), 2.46 (s, 2H), 2.27 (s, 4H), 2.08-1.94 (m, 1H), 1.26 (d, 6H).  7 Example 72, 1H- triazole-4- carbaldehyde 175

515.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 8.15 (s, 1H), 4.71-4.53 (m, 1H), 4.46 (d, 1H), 4.35 (s, 1H), 4.18 (s, 3H), 3.73 (s, 1H), 3.59-3.48 (m, 2H), 3.06 (p, 1H), 2.82 (d, 1H), 2.64 (s, 3H), 2.52 (s, 1H), 2.46 (s, 2H), 2.27 (s, 4H), 2.07-1.93 (m, 1H), 1.35-1.16 (m 6H).  7 Example 72, 1- methyltriazole-4- carbaldehyde 176

501.3 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.60 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 4.69-4.30 (m, 2H), 3.76 (dq, 2H), 3.59-3.45 (m, 1H), 3.25 (q, 2H), 3.06 (p, 1H), 2.83 (s, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.26 (s, 3H), 2.09-1.93 (m, 1H), 1.26 (dd, 6H).  7 Example 72, 4H- 1,2,4-triazole-3- carbaldehyde 177

527.3 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 7.59 (d, 1H), 6.73 (s, 1H), 6.54 (d, 1H), 4.43 (d, 1H), 4.24 (d, 2H), 3.58 (dt, 2H), 3.28-3.13 (m, 1H), 3.06 (p, 1H), 2.83 (d, 1H), 2.64 (s, 3H), 2.47 (s, 2H), 2.30 (s, 1H), 2.27 (s, 1H), 2.01 (dd, 1H), 1.26 (dd, 6H).  7 Example 72, 2-oxo- 1H-pyridine-4- carbaldehyde 178

527.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.59 (s, 1H), 8.46 (s, 1H), 7.80-7.70 (m, 2H), 6.64 (d, 1H), 4.34 (d, 1H), 4.23 (s, 1H), 4.10 (d, 1H), 3.61- 3.40 (m, 2H), 3.29-3.12 (m, 1H), 3.06 (p, 1H), 2.81 (d, 1H), 2.65 (s, 3H), 2.53 (s, 1H), 2.46 (s, 2H), 2.27 (s, 5H), 2.10-1.97 (m, 1H), 1.35-1.14 (m, 6H).  7 Example 72, 6-oxo- 1H-pyridine-3- carbaldehyde 179

534.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.58 (s, 1H), 8.44 (s, 1H), 4.25 (d, 1H), 4.21-4.07 (m, 2H), 3.78 (dd, 1H), 3.68-3.52 (m, 1H), 3.24- 3.13 (m, 1H), 3.06 (p, 1H), 2.78 (d, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 2.14 (d, 1H), 2.03 (d, 1H), 1.58 (s, 9H), 1.38-1.13 (m, 6H). 20 tert-butyl 2- bromoacetate 180

527.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 4.42-4.15 (m, 1H), 3.81- 3.66 (m, 2H), 3.55 (d, 2H), 3.25 (d, 1H), 3.15 (s, 1H), 3.06 (p, 1H), 2.82 (d, 1H), 2.64 (s, 3H), 2.49 (d, 3H), 2.26 (s, 3H), 2.18 (d, 1H), 2.10-1.93 (m, 1H), 1.26 (dd, 6H). 20 Ethenesulfonamide; THF solvent 181

555.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.44 (s, 1H), 4.35 (d, 1H), 3.71 (d, 3H), 3.63-3.45 (m, 1H), 3.28 (t, 1H), 3.14 (d, 1H), 3.06 (p, 1H), 2.96 (s, 6H), 2.81 (d, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.33-2.23 (m, 4H), 2.19 (d, 1H), 2.03 (d, 1H), 1.26 (dd, 6H). 20 N,N-dimethylethene- sulfonamide; THF solvent 182

541.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.44 (s, 1H), 4.35 (d, 1H), 3.71 (d, 3H), 3.56 (s, 2H), 3.31-3.19 (m, 1H), 3.15 (s, 1H), 3.06 (p, 1H), 2.89-2.76 (m, 4H), 2.64 (s, 3H), 2.48 (s, 2H), 2.27 (s, 3H), 2.18 (d, 1H), 2.11-1.97 (m, 1H), 1.26 (dd, 6H). 20 N- methylethenesulfonamide; THF solvent 183

477.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.83 (s, 1H), 8.60 (d, 1H), 8.47 (d, 1H), 4.21 (d, 2H), 4.03 (q, 1H), 3.97-3.83 (m, 2H), 3.61 (d, 1H), 3.11-2.96 (m, 3H), 2.65 (s, 3H), 2.62-2.51 (m, 1H), 2.48 (s, 3H), 2.28 (s, 4H), 2.14 (d, 1H), 2.09-2.00 (m, 1H) 1.36-1.17 (m, 6H). 20 Example 275 184

517.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.50 (s, 1H), 4.22 (d, 1H), 4.10-3.94 (m, 2H), 3.76 (dd, 1H), 3.67-3.48 (m, 1H), 3.23-3.12 (m, 1H), 3.05 (h, 1H), 2.77 (tt, 2H), 2.70-2.61 (m, 4H), 2.48 (s, 3H), 2.28 (s, 3H), 2.06 (dd, 2H), 1.33-1.15 (m, 6H), 0.80 (ddd, 2H), 0.63-0.50 (m, 2H). 20 2-bromo-N- cyclopropyl-acetamide 185

519.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.51 (s, 1H), 8.22 (d, 1H), 4.21 (d, 1H), 4.11-4.05 (m, 1H), 4.03-3.93 (m, 1H), 3.76 (dd, 1H), 3.66-3.50 (m, 1H), 3.20-3.11 (m, 1H), 3.06 (p, 1H), 2.77 (d, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.28 (s, 3H), 2.16- 1.95 (m, 2H), 1.34-1.17 (m, 12H). 20 2-bromo-N-isopropyl- acetamide 186

505.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.77 (s, 1H), 8.61 (s, 1H), 8.51 (s, 1H), 8.30 (s, 1H), 4.22 (d, 1H), 4.13-3.97 (m, 2H), 3.73 (d, 1H), 3.65-3.51 (m, 1H), 3.22-3.13 (m, 1H), 3.06 (p, 1H), 2.77 (d, 1H), 2.65 (d, 3H), 2.48 (s, 3H), 2.28 (s, 3H), 2.15-1.97 (m, 2H), 1.36-1.22 (m, 6H), 1.20 (t, 3H). 20 2-bromo-N-ethyl- acetamide 187

434.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.46 (s, 1H), 3.92-3.75 (m, 1H), 3.71 (q, J = 8.1 Hz, 1H), 3.02 (p, J = 7.1 Hz, 1H), 2.75-2.59 (m, 5H), 2.51 (ddd, J = 12.5, 7.9, 4.9 Hz, 1H), 2.41 (td, J = 7.7, 4.0 Hz, 1H), 2.36 (s, 3H), 2.34-2.10 (m, 7H), 1.28 (d, J = 7.0 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H). 17 I-92 188

546.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.45 (d, J = 2.3 Hz, 1H), 4.87-4.83 (m, 4H), 4.77-4.64 (m, 4H), 4.54 (p, J = 7.4 Hz, 2H), 3.83 (p, J = 8.7 Hz, 1H), 3.69 (p, J = 8.5 Hz, 1H), 3.01 (p, J = 7.1 Hz, 1H), 2.64 (s, 4H), 2.58-2.44 (m, 2H), 2.35 (s, 3H), 2.35- 2.18 (m, 8H), 1.27 (d, J = 7.1 Hz, 5H), 1.21 (d, J = 6.9 Hz, 3H).  7 Example 187; oxetan- 3-one 189

420.3 ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.46 (s, 1H), 7.58 (s, 1H), 5.24 (s, 3H), 3.78 (s, 3H), 3.69 (s, 5H), 3.61 (d, J = 12.6 Hz, 7H), 2.69 (s, 3H), 2.48 (s, 3H, 2.25-2.09 (m, 6H), 1.40 (dt, J = 7.2, 2.4 Hz, 6H). 11 I-91 190

477.3 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.49 (s, 1H), 7.63-7.57 (m, 1H), 4.33-4.00 (m, 3H), 3.66 (d, J = 15.9 Hz, 3H), 2.69 (t, J = 0.9 Hz, 3H), 2.56 (t, J = 11.9 Hz, 1H), 2.47 (s, 3H), 2.44-1.88 (m, 8H), 1.40 (dd, J = 7.1, 1.9 Hz, 6H). 14, 15 I-91 191

477.3 ¹H NMR (400 MHz, MeOD) δ 8.61 (dd, J = 1.7, 0.8 Hz, 1H), 8.47 (s, 1H), 7.62-7.57 (m, 1H), 4.25-4.08 (m, 3H), 3.98-3.75 (m, 3H), 3.63 (s, 1H), 3.18 (d, J = 12.1 Hz, 1H), 2.74 (d, J = 10.8 Hz, 1H), 2.69 (t, J = 0.9 Hz, 3H), 2.48 (s, 3H), 2.29-1.93 (m, 6H), 1.70 (d, J = 16.7 Hz, 1H), 1.41 (dd, J = 7.2, 1.2 Hz, 6H). 14, 16 I-91 192

463.3 ¹H NMR (400 MHz, MeOD) δ 8.63-8.58 (m, 1H), 8.48 (s, 1H), 7.60 (t, J = 1.4 Hz, 1H), 3.86 (s, 1H), 3.74 (s, 1H), 3.23 (t, J = 5.3 Hz, 2H), 2.69 (s, 3H), 2.63 (d, J = 7.2 Hz, 1H), 2.53 (s, 3H), 2.36 (t, J = 7.3 Hz, 1H), 1.41 (t, J = 6.8 Hz, 6H).  1 I-74; tert-butyl piperazine-1- carboxylate 193

392.2 ¹H NMR (400 MHz, MeOD) δ 8.63-8.58 (m, 1H), 8.46 (s, 1H), 7.60-7.55 (m, 1H), 3.82-3.69 (m, 3H), 3.57 (d, J = 11.7 Hz, 1H), 3.47 (d, J = 11.3 Hz, 2H), 2.69 (t, J = 0.9 Hz, 3H), 2.57 (s, 3H), 2.18 (dt, J = 8.5, 4.3 Hz, 1H), 1.40 (d, J = 7.1 Hz, 6H), 1.29-1.19 (m, 2H). 18 I-15; potassium (3- (tert-butoxycarobnyl)- 3- azabicyclo[3.1.0]hexan- 1-yl)trifluoroborate 194

406.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (d, J = 1.4 Hz, 1H), 8.48 (s, 1H), 7.59-7.57 (m, 1H), 3.68-3.49 (m, 4H), 3.28 (d, J = 7.1 Hz, 2H), 3.20-3.10 (m, 2H), 3.01 (ddd, J = 13.7, 8.4, 5.0 Hz, 2H), 2.69 (s, 3H), 2.57 (s, 3H), 2.49 (dq, J = 14.7, 6.7 Hz, 2H), 2.13 (dd, J = 14.3, 6.9 Hz, 2H), 1.79 (q, J = 7.0 Hz, 2H), 1.40 (dd, J = 7.1, 1.5 Hz, 7H), 1.21 (t, J = 5.8 Hz, 1H). 18 I-15; potassium (3- (tert-butoxycarbonyl)- 3- azabicyclo[4.1.0]heptan- 1-yl)trifluoroborate 195

406.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (dd, J = 1.7, 0.8 Hz, 1H), 8.47 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 3.83 (dd, J = 13.5, 7.3 Hz, 1H), 3.31-3.18 (m, 3H), 3.00- 2.93 (m, 1H), 2.68 (t, J = 0.9 Hz, 3H), 2.56 (s, 3H), 2.38 (dtd, J = 24.9, 15.1, 5.3 Hz, 3H), 1.74-1.67 (m, 1H), 1.40 (dd, J = 7.1, 2.0 Hz, 6H), 1.23 (t, J = 5.6 Hz, 1H). 18 I-15; potassium (3- (tert-butoxycarbonyl)- 3- azabicyclo[4.1.0]heptan- 6-yl)trifluoroborate 196

463.3 ¹H NMR (400 MHz, MeOD) δ 8.59 (dd, J = 1.7, 0.8 Hz, 1H), 8.47 (s, 1H), 7.60-7.55 (m, 1H), 3.97 (s, 4H), 3.27 (q, J = 7.0 Hz, 2H), 2.68 (t, J = 0.9 Hz, 3H), 2.56 (s, 3H), 2.22 (s, 1H), 1.85 (q, J = 8.0, 7.2 Hz, 1H), 1.39 (dd, J = 7.1, 1.6 Hz, 6H), 1.32 (d, J = 6.6 Hz, 1H). 17 Example 194 197

449.3 ¹H NMR (400 MHz, MeOD) δ 8.62 (d, J = 1.7 Hz, 1H), 8.52 (s, 1H), 7.61 (t, J = 1.4 Hz, 1H), 4.17 (s, 2H), 3.28 (q, J = 7.1 Hz, 4H), 2.69 (s, 3H), 2.58 (s, 3H), 2.24 (dt, J = 8.7, 4.2 Hz, 1H), 1.51 (t, J = 5.5 Hz, 1H), 1.40 (dd, J = 7.2, 1.1 Hz, 7H). 17 Example 193 198

428.2 ¹H NMR (400 MHz, MeOD) δ 8.63 (s, 1H), 8.48 (s, 1H), 7.58 (t, J = 1.4 Hz, 1H), 4.15-4.04 (m, 2H), 3.86 (d, J = 12.6 Hz, 1H), 3.77 (dd, J = 12.5, 4.8 Hz, 1H), 3.01 (dd, J = 11.0, 5.3 Hz, 1H), 2.69 (s, 3H), 2.53 (s, 3H), 1.40 (dd, J = 7.2, 2.1 Hz, 6H). 18 I-15; potassium (3- (tert-butoxycarbonyl)- 6,6-difluoro-3- azabicyclo[3.1.0]hexan- 1-yl)trifluoroborate 199

463.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (dd, J = 1.7, 0.8 Hz, 1H), 8.47 (s, 1H), 7.58 (t, J = 1.3 Hz, 1H), 4.00 (d, J = 63.3 Hz, 4H), 3.28 (q, J = 7.1 Hz, 2H), 2.69 (s, 3H), 2.56 (s, 3H), 2.51 (s, 2H), 1.80-1.73 (m, 1H), 1.40 (dd, J = 7.1, 4.2 Hz, 7H), 1.34 (s, 1H). 17 Example 195 200

485.2 ¹H NMR (400 MHz, MeOD) δ 8.66-8.61 (m, 1H), 8.49 (s, 1H), 7.62-7.57 (m, 1H), 4.22 (d, J = 12.0 Hz, 2H), 4.17 (s, 2H), 4.00 (d, J = 14.5 Hz, 2H), 3.31- 3.26 (m, 1H), 3.09 (ddd, J = 10.7, 6.1, 2.0 Hz, 1H), 2.69 (s, 3H), 2.51 (s, 3H), 1.40 (dd, J = 7.2, 1.8 Hz, 6H). 17 Example 198 201

392.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (dd, J = 1.7, 0.8 Hz, 1H), 8.45 (s, 1H), 7.59-7.54 (m, 1H), 3.69-3.55 (m, 4H), 3.28 (q, J = 7.1 Hz, 2H), 2.68 (t, J = 0.9 Hz, 3H), 2.53 (s, 3H), 2.22-2.17 (m, 3H), 1.40 (d, J = 7.1 Hz, 6H). 18 I-15; tert-butyl (1S,5R)-6-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-3- azabicyclo[3.1.0]hexane- 3-carboxylate 202

449.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (dd, J = 1.6, 0.9 Hz, 1H), 8.48 (s, 1H), 7.61-7.56 (m, 1H), 4.12 (s, 2H), 3.30-3.25 (m, 1H), 2.68 (t, J = 0.9 Hz, 3H), 2.54 (s, 3H), 2.47 (s, 1H), 2.25 (s, 2H), 1.40 (d, J = 7.1 Hz, 6H). 17 Example 201 203

479.3 ¹H NMR (400 MHz, MeOD) δ 8.64-8.59 (m, 1H), 8.55 (s, 1H), 7.66-7.60 (m, 1H), 3.92 (s, 2H), 3.65 (d, J = 12.0 Hz, 2H), 3.31-3.25 (m, 1H), 3.12-2.99 (m, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.69 (s, 3H), 2.43 (s, 3H), 2.11-2.03 (m, 2H), 1.78-1.53 (m, 5H), 1.40 (d, J = 7.1 Hz, 6H). 17 Example 276 204

442.3 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.48 (s, 1H), 7.59 (t, J = 1.4 Hz, 1H), 3.85 (dd, J = 14.1, 8.8 Hz, 1H), 3.41 (dd, J = 13.9, 3.5 Hz, 2H), 3.32-3.20 (m, 4H), 3.06 (d, J = 8.9 Hz, 1H), 2.69 (s, 3H), 2.60 (d, J = 15.7 Hz, 1H), 2.51 (s, 3H), 2.48-2.29 (m, 3H), 1.40 (d, J = 7.1 Hz, 6H). 18 I-15; potassium (3- (tert-butoxycarbonyl)- 7,7-difluoro-3- azabicyclo[3.1.0]heptan- 6-yl)trifluoroborate 205

499.3 ¹H NMR (400 MHz, MeOD) δ 8.63 (d, J = 1.6 Hz, 1H), 8.48 (s, 1H), 7.60-7.58 (m, 1H), 4.06 (s, 3H), 3.51 (s, 1H), 3.32-3.24 (m, 2H), 3.12 (s, 1H), 2.75 (s, 1H), 2.69 (s, 3H), 2.52 (s, 3H), 1.40 (d, J = 7.1 Hz, 6H). 17 Example 204 206

465.2 ¹H NMR (400 MHz, MeOD) δ 8.68-8.63 (m, 1H), 8.53 (s, 1H), 7.63 (t, J = 1.4 Hz, 1H), 4.00 (s, 2H), 3.74 (d, J = 12.0 Hz, 2H), 3.44-3.35 (m, 2H), 3.31- 3.23 (m, 2H), 2.94 (q, J = 7.5 Hz, 2H), 2.69 (s, 3H), 2.27-2.09 (m, 4H), 1.36 (d, J = 7.2 Hz, 6H), 1.27 (t, J = 7.4 Hz, 3H). 17 Example 277 207

521.3 ¹H NMR (400 MHz, MeOD) δ 8.63 (d, J = 1.5 Hz, 1H), 8.50 (s, 1H), 7.61 (t, J = 1.4 Hz, 1H), 4.69 (ddd, J = 27.4, 10.9, 3.6 Hz, 2H), 4.27 (dt, J = 13.0, 4.2 Hz, 1H), 4.12-4.01 (m, 2H), 3.84-3.76 (m, 1H), 3.66 (ddd, J = 37.9, 12.7, 10.7 Hz, 1H), 3.44-3.35 (m, 4H), 3.01-2.89 (m, 3H), 2.69 (s, 3H), 2.15-2.00 (m, 2H), 1.83-1.58 (m, 2H), 1.36 (d, J = 7.1 Hz, 6H), 1.28 (t, J = 7.4 Hz, 3H).  9 Example 277; (3S)-4- tert-butoxycarbonyl- morpholine-3-carboxylic acid 208

521.3 ¹H NMR (400 MHz, MeOD) δ 8.65-8.60 (m, 1H), 8.49 (s, 1H), 7.60 (t, J = 1.4 Hz, 1H), 4.76-4.62 (m, 2H), 4.28 (dd, J = 12.8, 4.1 Hz, 1H), 4.11-4.01 (m, 2H), 3.80 (dt, J = 12.2, 5.9 Hz, 1H), 3.38 (t, J = 5.3 Hz, 3H), 2.99-2.84 (m, 3H), 2.68 (t, J = 0.9 Hz, 3H), 2.05 (d, J = 16.5 Hz, 2H), 1.89-1.52 (m, 3H), 1.36 (d, J = 7.1 Hz, 6H), 1.28 (t, J = 7.4 Hz, 3H).  9 Example 277; (3R)-4- tert-butoxycarbonyl- morpholine-3-carboxylic acid 209

420.2 ¹H NMR (400 MHz, MeOD) δ 10.90 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 7.57 (t, J = 1.4 Hz, 1H), 3.45-3.35 (m, 2H), 3.29 (d, J = 7.5 Hz, 3H), 3.22-3.09 (m, 3H), 2.68 (s, 3H), 2.55 (s, 3H), 2.25 (dd, J = 8.7, 5.9 Hz, 1H), 2.14-2.03 (m, 2H), 1.87-1.75 (m, 2H), 1.70 (d, J = 14.7 Hz, 1H), 1.48 (d, J = 14.9 Hz, 1H), 1.41 (d, J = 7.1 Hz, 6H), 1.16 (dd, J = 8.9, 5.1 Hz, 1H), 0.97 (t, J = 5.4 Hz, 1H). 18 I-15; potassium (6- (tert-butoxycarbonyl)- 6-azaspiro[2.5.]octan- 1-yl)trifluoroborate 210

465.2 ¹H NMR (400 MHz, MeOD) δ 8.62-8.57 (m, 1H), 8.50 (s, 1H), 7.60 (t, J = 1.4 Hz, 1H), 3.92 (s, 2H), 3.65 (d, J = 12.1 Hz, 2H), 3.32-3.26 (m, 1H), 3.05 (t, J = 12.5 Hz, 2H), 2.81 (d, J = 7.1 Hz, 2H), 2.69 (s, 3H), 2.45 (s, 3H), 2.06 (d, J = 14.4 Hz, 2H), 1.74- 1.59 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H). 17 Example 278 211

477.2 ¹H NMR (400 MHz, MeOD) δ 8.62-8.57 (m, 1H), 8.48 (s, 1H), 7.58 (t, J = 1.5 Hz, 1H), 4.02 (d, J = 15.7 Hz, 2H), 3.65 (dd, J = 38.1, 11.6 Hz, 2H), 3.25-3.12 (m, 1H), 2.69 (s, 3H), 2.62 (s, 1H), 2.52 (s, 3H), 2.26 (t, J = 7.6 Hz, 1H), 2.07 (d, J = 9.3 Hz, 1H), 1.69 (d, J = 14.9 Hz, 1H), 1.49 (d, J = 14.5 Hz, 1H), 1.41 (d, J = 7.1 Hz, 6H), 1.27 (d, J = 15.0 Hz, 1H), 1.20-1.12 (m, 1H), 0.98 (d, J = 5.6 Hz, 1H). 17 Example 209 212

519.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.47 (s, 1H), 4.42 (q, J = 8.0, 7.3 Hz, 2H), 3.99-3.77 (m, 2H), 3.63 (s, 1H), 3.13-2.98 (m, 7H), 2.86 (dd, J = 8.5, 6.6 Hz, 1H), 2.65 (s, 3H), 2.47 (d, J = 2.3 Hz, 3H), 2.29 (s, 5H), 2.14-1.95 (m, 4H), 1.73 (t, J = 16.2 Hz, 1H), 1.37-1.18 (m, 6H). 14, 15 I-16; I-19; 2-bromo- N,N-dimethyl- acetamide 213

519.4 ¹H NMR (400 MHz, MeOD) δ 8.62 (d, J = 10.0 Hz, 1H), 8.52 (d, J = 2.7 Hz, 1H), 4.48 (dd, J = 34.6, 16.0 Hz, 1H), 4.29 (dd, J = 16.0, 4.7 Hz, 1H), 4.11 (d, J = 13.4 Hz, 1H), 3.66 (dd, J = 20.2, 13.0 Hz, 3H), 3.54- 3.41 (m, 1H), 3.10-3.00 (m, 7H), 2.65 (s, 3H), 2.46 (s, 3H), 2.42-2.33 (m, 2H), 2.29 (s, 3H), 2.15 (d, J = 16.4 Hz, 2H), 2.09-1.94 (m, 3H), 1.26 (dd, J = 28.1, 7.2 Hz, 6H). 14, 16 I-16; I-29; 2-bromo- N,N-dimethyl- acetamide 214

540.2 ¹H NMR (400 MHz, MeOD) δ 8.60 (d, J = 16.1 Hz, 1H), 8.49 (s, 1H), 3.86-3.66 (m, 6H), 3.43 (d, J = 12.6 Hz, 1H), 3.16 (s, 3H), 3.07 (p, J = 7.1 Hz, 1H), 2.65 (s, 3H), 2.46 (s, 3H), 2.27 (d, J = 5.8 Hz, 3H), 2.22-2.12 (m, 3H), 1.24 (ddd, J = 26.6, 17.4, 7.1 Hz, 6H). 14, 15 I-16; I-29; 1-bromo- 2-methylsulfonyl- ethane 215

529.3 ¹H NMR (400 MHz, MeOD) δ 10.78 (s, 1H), 8.58 (s, 1H), 8.43 (s, 1H), 8.18 (s, 1H), 4.71-4.55 (m, 3H), 4.19 (s, 3H), 3.90 (s, 1H), 3.76-3.61 (m, 3H), 3.53 (s, 1H), 3.12-2.91 (m, 3H), 2.65 (s, 3H), 2.46 (d, J = 20.4 Hz, 4H), 2.28 (s, 3H), 2.07 (ddd, J = 47.9, 32.3, 11.8 Hz, 6H), 1.82 (d, J = 13.3 Hz, 1H), 1.26 (d, J = 28.5 Hz, 6H). 14; 8 I-16; I-29; 1- methyltriazole-4- carbaldehyde 216

529.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (d, J = 11.3 Hz, 1H), 8.46 (s, 1H), 8.17 (d, J = 7.5 Hz, 1H), 4.69-4.57 (m, 2H), 4.17 (s, 3H), 3.75-3.65 (m, 2H), 3.58 (d, J = 14.0 Hz, 1H), 3.41 (d, J = 12.4 Hz, 1H), 3.07 (s, 1H), 2.65 (s, 3H), 2.47 (s, 3H), 2.43 (s, 1H), 2.27 (s, 3H), 2.16 (d, J = 14.9 Hz, 2H), 1.36-1.16 (m, 6H). 14, 8 I-16; I-29; 1- methyltriazole-4- carbaldehyde 217

526.2 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.54 (s, 1H), 3.75 (dd, J = 8.6, 5.0 Hz, 2H), 3.68 (d, J = 8.2 Hz, 2H), 3.14 (s, 3H), 3.04 (h, J = 7.1 Hz, 2H), 2.65 (s, 3H), 2.60-2.41 (m, 6H), 2.28 (s, 3H), 1.83-1.72 (m, 1H), 1.45 (dd, J = 9.6, 4.9 Hz, 1H), 1.34-1.18 (m, 7H). 17 Example 77; 1- bromo-2- methylsulfonyl-ethane 218

512.3 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.50 (s, 1H), 7.02-6.97 (m, 1H), 4.35 (s, 1H), 3.73 (d, J = 33.2 Hz, 5H), 3.15 (s, 3H), 2.93 (s, 1H), 2.89-2.73 (m, 1H), 2.65 (s, 3H), 2.31 (s, 3H), 2.25-2.16 (m, 2H), 1.32 (d, J = 6.9 Hz, 6H). 15 Example 220; 1- bromo-2- methylsulfonyl-ethane 219

394.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.50 (s, 1H), 6.96 (d, J = 1.0 Hz, 1H), 3.55-3.49 (m, 2H), 3.26-3.14 (m, 3H), 2.76 (p, J = 6.9 Hz, 1H), 2.65 (t, J = 0.7 Hz, 3H), 2.31 (s, 5H), 2.05-1.92 (m, 2H), 1.31 (d, J = 6.9 Hz, 6H). 17 I-39; tert-butyl 4- iodopiperidine-1- carboxylate 220

406.2 ¹H NMR (400 MHz, MeOD) δ 8.57 (s, 1H), 8.46 (s, 1H), 6.97 (d, J = 1.1 Hz, 1H), 4.23 (s, 1H), 3.39 (dd, J = 8.7, 5.1 Hz, 1H), 3.24 (qd, J = 10.9, 2.4 Hz, 3H), 2.89 (s, 1H), 2.76 (dq, J = 13.8, 6.8 Hz, 2H), 2.65 (s, 3H), 2.37 (ddd, J = 14.8, 8.8, 2.6 Hz, 1H), 2.30 (s, 3H), 2.23-2.11 (m, 2H), 1.81 (d, J = 11.5 Hz, 1H), 1.31 (d, J = 6.9 Hz, 6H). 17 I-39 221

451.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.50 (s, 1H), 6.97 (s, 1H), 4.00 (s, 2H), 3.76 (d, J = 12.1 Hz, 2H), 3.24 (q, J = 11.9, 11.3 Hz, 3H), 2.76 (hept, J = 7.0 Hz, 1H), 2.65 (t, J = 0.8 Hz, 3H), 2.36 (d, J = 14.4 Hz, 2H), 2.31 (s, 3H), 2.22-2.07 (m, 2H), 1.31 (d, J = 6.9 Hz, 6H). 20 Example 219 222

484.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.80 (s, 1H), 8.63 (s, 1H), 8.47 (s, 1H), 7.46-7.33 (m, 3H), 7.24 (d, J = 7.5 Hz, 1H), 3.53 (d, J = 12.7 Hz, 2H), 3.22- 3.07 (m, 3H), 3.03-2.94 (m, 1H), 2.64 (s, 3H), 2.51 (s, 3H), 2.30 (s, 3H), 2.15 (d, J = 14.4 Hz, 2H), 2.06- 1.89 (m, 2H), 1.35-1.21 (m, 6H). 10 I-16:; tert-butyl 4-[3- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)phenyl]piperidine- 1-carboxylate 223

541.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.66 (s, 1H), 8.54 (s, 1H), 7.49-7.30 (m, 3H), 7.25 (d, J = 7.3 Hz, 1H), 4.00 (s, 2H), 3.75 (d, J = 12.1 Hz, 2H), 3.30-3.20 (m, 2H), 3.10 (p, J = 7.1 Hz, 1H), 2.97 (d, J = 9.1 Hz, 1H), 2.64 (s, 3H), 2.52 (s, 3H), 2.31 (s, 3H), 2.17 (dd, J = 8.6, 3.2 Hz, 4H), 1.37-1.20 (m, 6H). 20 Example 222 224

486.2 ¹H NMR (400 MHz, Methanol-d4) δ 11.00 (s, 1H), 8.86 (s, 2H), 8.65 (s, 1H), 8.47 (s, 1H), 3.53 (dt, J = 13.0, 3.8 Hz, 2H), 3.29-3.26 (m, 1H), 3.21 (td, J = 12.6, 3.2 Hz, 2H), 3.12 (p, J = 7.1 Hz, 1H), 2.64 (s, 3H), 2.56 (s, 3H), 2.37-2.31 (m, 2H), 2.29 (s, 3H), 2.17 (dtd, J = 14.7, 11.7, 4.0 Hz, 2H), 1.28 (dd, J = 32.2, 7.1 Hz, 6H). 10 I-16; I-67 225

420.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.48 (d, J = 3.9 Hz, 1H), 4.34 (d, J = 4.3 Hz, 1H), 4.31- 4.24 (m, 1H), 3.77 (dd, J = 9.3, 5.8 Hz, 1H), 3.04 (p, J = 7.1 Hz, 1H), 2.63 (s, 3H), 2.56-2.49 (m, 1H), 2.46 (s, 3H), 2.25 (s, 3H), 2.17-2.01 (m, 4H), 1.95-1.86 (m, 1H), 1.24 (dd, J = 27.0, 7.1 Hz, 6H). 17 I-69 226

543.2 ¹H NMR (400 MHz, Methanol-d4) δ 11.01 (s, 1H), 8.86 (s, 2H), 8.65 (s, 1H), 8.47 (s, 1H), 4.01 (s, 2H), 3.79 (d, J = 12.3 Hz, 2H), 3.66-3.39 (m, 2H), 3.31- 3.21 (m, 2H), 3.12 (p, J = 7.1 Hz, 1H), 2.65 (s, 3H), 2.57 (s, 3H), 2.40 (d, J = 13.3 Hz, 2H), 2.29 (s, 4H), 1.28 (dd, J = 32.2, 7.1 Hz, 6H). 20 Example 225 227

477.3 ¹H NMR (400 MHz, Methanol-d4) δ 10.84 (s, 1H), 8.57 (s, 1H), 8.45 (s, 1H), 4.29 (d, J = 23.4 Hz, 2H), 3.96 (q, J = 15.0, 11.7 Hz, 2H), 3.05 (p, J = 7.1 Hz, 1H), 2.63 (s, 3H), 2.60-2.52 (m, 1H), 2.45 (s, 3H), 2.25 (s, 3H), 2.22-2.11 (m, 4H), 2.12-2.00 (m, 1H), 1.85-1.63 (m, 2H), 1.38-1.16 (m, 6H). 20 Example 225 228

420.2 ¹H NMR (400 MHz, MeOD) δ 8.62-8.51 (m, 1H), 8.45 (s, 1H), 4.26-3.99 (m, 4H), 3.92 (d, J = 9.1 Hz, 1H), 3.11 (dq, J = 14.2, 6.8 Hz, 1H), 2.65 (s, 3H), 2.57 (s, 3H), 2.40 (d, J = 9.8 Hz, 3H), 2.29-2.25 (m, 3H), 2.15-2.01 (m, 1H), 1.43-1.17 (m, 6H). 17 I-90 229

464.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.46 (s, 1H), 4.30 (d, J = 17.1 Hz, 1H), 3.99-3.78 (m, 2H), 3.71-3.50 (m, 2H), 3.48-3.37 (m, 1H), 3.30-3.17 (m, 1H), 3.17-2.96 (m, 2H), 2.78 (d, J = 20.8 Hz, 1H), 2.69-2.62 (m, 3H), 2.62-2.53 (m, 1H), 2.48 (d, J = 5.4 Hz, 3H), 2.41-2.22 (m, 4H), 2.18-1.90 (m, 2H), 1.30 (d, J = 7.3 Hz, 3H), 1.23 (d, J = 7.1 Hz, 3H).  8 Example 72 230

472.2 ¹H NMR (400 MHz, Methanol-d4) δ 9.05 (dd, J = 4.3, 1.7 Hz, 1H), 8.36-8.26 (m, 2H), 7.73 (d, J = 7.5 Hz, 1H), 7.66 (dd, J = 8.6, 4.2 Hz, 1H), 4.00 (s, 2H), 3.75 (d, J = 12.1 Hz, 2H), 3.52-3.38 (m, 1H), 3.31-3.24 (m, 2H), 3.04 (p, J = 7.1 Hz, 1H), 2.51 (s, 3H), 2.24 (d, J = 14.3 Hz, 2H), 2.10 (dd, J = 26.9, 13.8 Hz, 2H), 1.35-1.17 (m, 6H). 20 Example 247 231

473.3 ¹H NMR (400 MHz, Methanol-d4) δ 9.07-9.02 (m, 2H), 8.36 (d, J = 7.7 Hz, 1H), 7.91 (d, J = 7.7 Hz, 1H), 4.00 (s, 2H), 3.75 (d, J = 12.2 Hz, 2H), 3.48-3.37 (m, 1H), 3.30-3.18 (m, 3H), 2.53 (s, 3H), 2.24 (d, J = 14.3 Hz, 2H), 2.10 (q, J = 14.1, 13.2 Hz, 2H), 1.39 (d, J = 7.1 Hz, 6H). 20 Example 248 232

450.2 ¹H NMR (400 MHz, MeOD) δ 8.38 (dd, J = 5.1, 1.4 Hz, 1H), 8.17 (dd, J = 8.0, 1.4 Hz, 1H), 7.50 (s, 1H), 7.31 (dd, J = 7.9, 5.1 Hz, 1H), 4.00 (s, 4H), 3.74 (d, J = 12.1 Hz, 2H), 3.42 (s, 1H), 3.33-3.18 (m, 11H), 2.49 (s, 3H), 2.22 (d, J = 14.2 Hz, 2H), 2.09 (td, J = 13.2, 7.3 Hz, 2H), 1.34 (d, J = 7.2 Hz, 6H). 20 Example 249 233

540.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.45 (s, 1H), 3.78 (d, J = 30.5 Hz, 7H), 3.17 (s, 3H), 3.08 (p, J = 7.1 Hz, 1H), 2.65 (s, 3H), 2.46 (s, 3H), 2.28 (s, 3H), 1.26 (dd, J = 29.7, 6.9 Hz, 6H). 14, 16 I-16; I-29; 1-bromo- 2-methylsulfonyl- ethane 234

441.2 ¹H NMR (400 MHz, MeOD) δ 7.52 (d, J = 2.9 Hz, 1H), 7.47 (dd, J = 2.5, 1.2 Hz, 1H), 3.99 (s, 2H), 3.72 (d, J = 12.2 Hz, 2H), 3.65 (s, 3H), 3.41 (d, J = 12.1 Hz, 1H), 3.32-3.14 (m, 5H), 2.46 (s, 3H), 2.24-2.16 (m, 5H), 2.07 (dd, J = 18.1, 7.8 Hz, 2H), 1.35 (d, J = 7.2 Hz, 6H). 20 Example 250 235

451.3 ¹H NMR (400 MHz, MeOD) δ 8.70 (s, 1H), 8.46 (s, 1H), 7.74-7.69 (m, 1H), 3.99 (s, 2H), 3.74 (d, J = 12.1 Hz, 2H), 3.42 (t, J = 12.4 Hz, 2H), 3.30-3.22 (m, 2H), 3.08 (h, J = 7.1 Hz, 1H), 2.48 (s, 3H), 2.37 (d, J = 1.0 Hz, 3H), 2.23 (d, J = 14.4 Hz, 2H), 2.09 (q, J = 12.8 Hz, 2H), 1.28 (d, J = 7.2 Hz, 6H). 29, 20 I-48 236

452.3 ¹H NMR (400 MHz, MeOD) δ 11.07 (s, 1H), 8.86 (dd, J = 1.5, 0.8 Hz, 1H), 7.69 (p, J = 1.2 Hz, 1H), 4.00 (s, 2H), 3.74 (d, J = 12.1 Hz, 2H), 3.41 (dd, J = 23.9, 11.9 Hz, 2H), 3.34-3.23 (m, 15H), 2.79 (t, J = 1.0 Hz, 3H), 2.50 (s, 3H), 2.22 (d, J = 14.4 Hz, 2H), 2.11 (d, J = 12.6 Hz, 1H), 2.05 (d, J = 13.2 Hz, 1H), 1.43 (d, J = 7.1 Hz, 6H). 20 Example 251 237

450.3 ¹H NMR (400 MHz, MeOD) δ 8.64 (dd, J = 1.6, 0.8 Hz, 1H), 8.30 (d, J = 2.2 Hz, 1H), 8.10 (d, J = 2.1 Hz, 1H), 7.83 (t, J = 1.3 Hz, 1H), 4.00 (s, 2H), 3.74 (d, J = 12.1 Hz, 2H), 3.45 (d, J = 12.1 Hz, 2H), 3.34-3.16 (m, 35H), 2.72 (t, J = 0.9 Hz, 3H), 2.50 (s, 3H), 2.22 (d, J = 14.4 Hz, 2H), 2.08 (q, J = 12.8 Hz, 3H), 1.42 (d, J = 7.1 Hz, 6H). 20 Example 252

Procedure 26: Example 238 and Example 239

(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)(piperazin-1-yl)methanone (Example 238 and Example 240): (3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)(piperazin-1-yl)methanone (Example 151) as a mixture of 2 stereoisomers was separated by chiral SFC (CCO-F2 column with 25% MeOH cosolvent) to give two isomers, the cis-/trans-stereochemistry of which was arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: (3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)(piperazin-1-yl)methanone (Example 238): ES/MS: 491.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.62 (s, 1H), 8.53 (s, 1H), 4.00 (t, J=8.4 Hz, 1H), 3.94-3.83 (m, 2H), 3.76-3.66 (m, 2H), 3.49 (dq, J=9.3, 4.7 Hz, 1H), 3.31-3.22 (m, 4H), 3.02 (dq, J=14.6, 7.3 Hz, 1H), 2.79 (ddd, J=13.0, 6.8, 3.4 Hz, 2H), 2.65 (s, 3H), 2.57-2.44 (m, 2H), 2.36 (s, 3H), 2.30 (s, 3H), 1.34-1.21 (m, 6H).

Isomer 2: (3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)(piperazin-1-yl)methanone (Example 239): ES/MS: 491.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.47 (s, 1H), 3.97-3.72 (m, 5H), 3.42 (p, J=9.0 Hz, 1H), 3.29-3.22 (m, 4H), 3.03 (p, J=7.1 Hz, 1H), 2.70 (qd, J=8.1, 2.5 Hz, 2H), 2.65 (s, 3H), 2.45-2.33 (m, 4H), 2.28 (s, 3H), 1.32-1.17 (m, 6H).

Procedure 27: Example 240 and Example 241

(R)-3-(5-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)-1,3,4-oxadiazol-2-yl)morpholine: To a solution of 3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutane-1-carboxylic acid (I-40) (75 mg, 0.177 mmol) in THE (1.0 mL) was added tert-butyl (R)-3-(hydrazinecarbonyl)morpholine-4-carboxylate (I-41) (56.6 mg, 0.231 mmol), 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (80.9 mg, 0.213 mmol) and N,N-diisopropylethylamine (0.06 mL, 0.36 mmol) and the reaction mixture was stirred at rt overnight. Subsequently, Burgess reagent (127 mg, 0.532 mmol) was added to the reaction mixture. The mixture was stirred for 2 hours at 60° C. TFA (1 mL) was added, and the reaction was heated at 45° C. for 2 hr. The reaction mixture was concentrated under reduced pressure, and acetonitrile and water were added. The mixture was filtered through an acrodisc, and was purified by RP-HPLC (eluent: water/MeCN*0.1% TFA) to yield the products as two separable trans- and cis-isomers, the stereochemistry of which were arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: Example 240. ES/MS: 532.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.45 (s, 1H), 5.05 (dd, J=8.8, 3.7 Hz, 1H), 4.43 (dd, J=12.8, 3.7 Hz, 1H), 4.28 (p, J=8.6 Hz, 1H), 4.18-4.00 (m, 2H), 3.99-3.76 (m, 2H), 3.65-3.54 (m, 1H), 3.53-3.40 (m, 1H), 3.04 (p, J=7.0 Hz, 1H), 2.92 (tt, J=8.6, 4.0 Hz, 2H), 2.76 (q, J=10.3, 9.7 Hz, 2H), 2.65 (s, 3H), 2.39 (s, 3H), 2.29 (s, 3H), 1.29 (d, J=7.1 Hz, 3H), 1.22 (d, J=7.0 Hz, 3H).

Isomer 2: Example 241. ES/MS: 532.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.43 (s, 1H), 5.02 (dd, J=8.8, 3.7 Hz, 1H), 4.40 (dd, J=12.8, 3.7 Hz, 1H), 4.17-3.98 (m, 3H), 3.96-3.72 (m, 2H), 3.61-3.38 (m, 2H), 3.09-2.88 (m, 3H), 2.64 (s, 3H), 2.57 (d, J=10.5 Hz, 2H), 2.43 (s, 3H), 2.28 (s, 3H), 1.29 (d, J=7.2 Hz, 3H), 1.22 (d, J=7.0 Hz, 3H).

The following Examples were made in an analogous fashion according to Procedure 27 and are shown below in Table 12. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 27 and are noted in the last column of Table 12—“Changes to Procedure 27: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 27 were replaced with the different reagents/starting materials noted below.

TABLE 12 Changes to Procedure 27: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 242

532.3 ¹H NMR (400 MHz, Methanol- d4) δ 8.58 (s, 1H), 8.43 (s, 1H), 5.04 (dd, J = 8.7, 3.7 Hz, 1H), 4.43 (dd, J = 12.8, 3.7 Hz, 1H), 4.28 (t, J = 8.5 Hz, 1H), 4.16-4.01 (m, 2H), 4.00-3.79 (m, 2H), 3.63-3.39 (m, 2H), 3.04 (p, J = 7.2 Hz, 1H), 2.98-2.87 (m, 2H), 2.76 (q, J = 10.2, 9.7 Hz, 2H), 2.65 (s, 3H), 2.39 (s, 3H), 2.28 (s, 3H), 1.29 (d, J = 7.3 Hz, 3H), 1.24-1.20 (m, 3H). I-42 243

532.3 ¹H NMR (400 MHz, Methanol- d4) δ 8.58 (s, 1H), 8.45 (s, 1H), 5.02 (dd, J = 8.8, 3.7 Hz, 1H), 4.41 (dd, J = 12.8, 3.7 Hz, 1H), 4.16-3.96 (m, 3H), 3.96-3.73 (m, 2H), 3.64-3.41 (m, 2H), 3.09-2.86 (m, 3H), 2.65 (s, 3H), 2.61-2.49 (m, 2H), 2.43 (s, 3H), 2.28 (s, 3H), 1.29 (d, J = 7.1 Hz, 3H), 1.22 (d, J = 7.3 Hz, 3H). I-42

Procedure 28: Example 244 and Example 245

3-(1-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutyl)-1H-1,2,3-triazol-4-yl)morpholine: To a solution of 3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclobutan-1-amine; trifluoroacetate (I-52) (65 mg, 0.165 mmol) in MeOH (2.0 mL) was added potassium carbonate (70 mg, 0.50 mmol), 1H-imidazole-1-sulfonyl azide; sulfate (68 mg, 0.25 mmol), cupric sulfate; pentahydrate (7 mg, 0.025 mmol) and the reaction mixture was stirred at rt for 2 hr. Subsequently, acetic acid (0.05 mL, 0.8 mmol) was added to the reaction mixture. To the reaction was added THE (1 mL), tert-butyl 3-ethynylmorpholine-4-carboxylate (I-43) (53 mg, 0.25 mmol), and copper (26.5 mg, 0.417 mmol). The mixture was stirred at rt for 1 hour. The crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in ACN (1 mL), and TFA (0.5 mL) was added, and the reaction was heated at 35° C. for 1 hr. Water (0.5 mL) was added and the mixture was filtered through an acrodisc, and was purified by RP-IPLC (eluent: water/MeCN*0.1% TFA) to yield the products as two separable trans- and cis-isomers, the stereochemistry of which were arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: Example 244. ES/MS: 531.3 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.44 (s, 1H), 8.31 (s, 1H), 5.39 (p, J=7.1 Hz, 1H), 4.76 (dd, J=9.8, 3.7 Hz, 1H), 4.38-4.19 (m, 2H), 4.13 (d, J=13.0 Hz, 1H), 4.01 (dd, J=12.8, 9.9 Hz, 1H), 3.90 (dt, J=13.1, 6.7 Hz, 1H), 3.43 (dd, J=6.8, 3.1 Hz, 2H), 3.21-2.96 (m, 3H), 2.88 (dt, J=13.5, 7.7 Hz, 2H), 2.65 (s, 3H), 2.40 (s, 3H), 2.29 (s, 3H), 1.30 (d, J=7.2 Hz, 3H), 1.23 (d, J=7.0 Hz, 3H).

Isomer 2: Example 245. ES/MS: 531.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.43 (s, 1H), 8.23 (s, 1H), 5.17 (q, J=8.2 Hz, 1H), 4.74 (dd, J=9.9, 3.6 Hz, 1H), 4.25 (dd, J=12.7, 3.7 Hz, 1H), 4.12 (d, J=12.9 Hz, 1H), 3.99 (dd, J=12.8, 10.0 Hz, 1H), 3.89 (p, J=6.3 Hz, 2H), 3.46-3.39 (m, 2H), 3.14 (d, J=10.2 Hz, 2H), 3.05 (p, J=7.1 Hz, 1H), 2.73 (q, J=10.2 Hz, 2H), 2.65 (s, 3H), 2.45 (s, 3H), 2.28 (s, 3H), 1.30 (d, J=7.3 Hz, 3H), 1.23 (d, J=7.1 Hz, 3H).

Procedure 29: Example 246

tert-butyl 4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate: A solution of tert-butyl 4-(4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate (I-54) (75 mg, 0.207 mmol) in ACN (4 mL) was cooled to 0° C., and N-bromosuccinimide (35 mg, 0.197 mmol) (dissolved in 1 mL ACN) was added dropwise. After completion of addition, LCMS indicated reaction completion. The mixture was quickly concentrated under reduced pressure. The crude residue was dissolved in DME (1 mL) and this solution was added to a MW vial containing 8-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (I-51) (114 mg, 0.414 mmol), XPhos Pd G3 (26 mg, 0.031 mmol) and cesium carbonate (202 mg, 0.621 mmol). Water (0.2 mL) was added, and the mixture was degassed with argon for 30 seconds. The vial was sealed, and the mixture was heated at 120° C. for 15 minutes in a microwave. The crude mixture was purified directly by silica chromatography (eluent EtOAc/hexanes). ES/MS: 510.2 (M+H⁺).

4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-methyl-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole (Example 246): To a vial with tert-butyl 4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate (60 mg, 0.118 mmol) was added acetonitrile (0.5 mL) and TFA (0.5 mL). The reaction was stirred at rt for 2 hr. Water (0.5 mL) was added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 246. ES/MS: 410.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.41 (s, 1H), 8.36 (d, J=1.3 Hz, 1H), 7.13 (d, J=1.4 Hz, 1H), 4.12 (s, 3H), 3.57-3.48 (m, 2H), 3.48-3.35 (m, 2H), 3.27-3.12 (m, 2H), 2.50 (s, 3H), 2.20 (d, J=14.2 Hz, 2H), 1.90 (qd, J=13.2, 3.9 Hz, 2H), 1.42 (d, J=7.1 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 29 and are shown below in Table 13. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 29 and are noted in the last column of Table 13—“Changes to Procedure 29: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 29 were replaced with the different reagents/starting materials noted below.

TABLE 13 Changes to Procedure 29: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 247

415.2 ¹H NMR (400 MHz, Methanol-d4) δ 9.05 (dd, J = 4.3, 1.7 Hz, 1H), 8.35-8.27 (m, 2H), 7.73 (d, J = 7.5 Hz, 1H), 7.66 (dd, J = 8.6, 4.3 Hz, 1H), 3.58-3.38 (m, 3H), 3.28-3.17 (m, 2H), 3.04 (hept, J = 7.1 Hz, 1H), 2.51 (s, 3H), 2.28-2.15 (m, 2H), 1.92 (qd, J = 13.3, 4.0 Hz, 2H), 1.38-1.17 (m, 6H). I-45 248

416.2 ¹H NMR (400 MHz, Methanol-d4) δ 9.09-9.01 (m, 2H), 8.35 (d, J = 7.7 Hz, 1H), 8.06-7.79 (m, 1H), 3.58-3.38 (m, 3H), 3.28-3.13 (m, 3H), 2.53 (s, 3H), 2.22 (d, J = 14.3 Hz, 2H), 1.92 (qd, J = 13.3, 4.0 Hz, 2H), 1.39 (d, J = 7.1 Hz, 6H). I-46 249

393.4 ¹H NMR (400 MHz, MeOD) δ 8.32 (dd, J = 4.9, 1.5 Hz, 1H), 8.02 (dd, J = 7.9, 1.5 Hz, 1H), 7.42 (s, 1H), 7.20 (dd, J = 7.9, 4.9 Hz, 1H), 3.96 (s, 3H), 3.53 (s, 1H), 3.51-3.37 (m, 4H), 3.24-3.14 (m, 3H), 2.49 (s, 3H), 2.20 (d, J = 14.3 Hz, 3H), 1.89 (dd, J = 13.7, 9.9 Hz, 3H), 1.33 (d, J = 7.1 Hz, 6H). 1-methyl-3- (4,4,5,5- tetramethyl- 1,3,2- dioxaborolan- 2- yl)pyrrolo[2,3- b]pyridine 250

384.2 ¹H NMR (400 MHz, MeOD) δ 7.54-7.45 (m, 2H), 3.65 (s, 3H), 3.50 (d, J = 13.2 Hz, 3H), 3.26-3.14 (m, 4H), 2.46 (s, 3H), 2.19 (s, 5H), 1.90 (ddd, J = 26.2, 12.9, 9.0 Hz, 3H), 1.35 (d, J = 7.2 Hz, 6H). 1,3-dimethyl- 5-(4,4,5,5- tetramethyl- 1,3,2- dioxaborolan- 2-yl)pyridin-2- one 251

395.2 ¹H NMR (400 MHz, MeOD) δ 8.87 (dd, J = 1.5, 0.8 Hz, 1H), 7.69 (t, J = 1.3 Hz, 1H), 3.43 (tt, J = 11.8, 3.6 Hz, 3H), 3.27-3.13 (m, 3H), 2.79 (t, J = 1.0 Hz, 3H), 2.50 (s, 3H), 2.23-2.16 (m, 2H), 1.90 (ddd, J = 26.3, 13.8, 4.2 Hz, 3H), 1.43 (d, J = 7.1 Hz, 6H). I-50 252

393.2 ¹H NMR (400 MHz, MeOD) δ 8.63 (s, 2H), 8.29 (d, J = 2.2 Hz, 1H), 8.09 (d, J = 2.1 Hz, 1H), 7.81 (s, 2H), 3.59 (s, 1H), 3.53 (s, 2H), 3.49-3.38 (m, 4H), 3.22 (t, J = 12.6 Hz, 4H), 2.77-2.70 (m, 4H), 2.50 (s, 3H), 2.20 (d, J = 13.9 Hz, 3H), 1.98-1.86 (m, 4H), 1.42 (d, J = 7.1 Hz, 5H). I-47

Procedure 30: Example 253

N-((1S,4S)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)bicyclo[2.2.1]heptan-2-yl)oxetan-3-amine (Example 253): To a solution of tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-((1S,4S)-5-oxobicyclo[2.2.1]heptan-2-yl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-57) (100 mg, 0.23 mmol) in THE (1 mL) and DMF (1 mL) was added acetic acid (0.02 mL) and then the mixture was stirred at rt for 16 hrs. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in dry MeOH (4 mL). The mixture was cooled to −78° C. and sodium cyanoborohydride was added in one portion (73 mg, 1.16 mmol), stirred at that temperature for 3 hrs, and then allowed to reach rt. The reaction was quenched with water (1 mL) and the reaction was diluted in ethyl acetate. The layers were separated, and the organic phase was washed with water, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude material was dissolved in MeOH (1.5 mL) and lithium hydroxide (20 mg, 8 mmol) was added. The mixture was stirred at 70° C. for 3 hrs. The mixture was subsequently diluted with EtOAc (30 mL) and water (5 mL). The organic phase was separated and concentrated. Acetonitrile (0.5 mL) and water (0.2 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 253 as a trifluoroacetate salt. ES/MS: 490.2 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.49 (s, 1H), 5.06-4.92 (m, 2H), 4.75 (dt, J=8.1, 4.9 Hz, 2H), 4.55 (tt, J=7.0, 5.4 Hz, 1H), 3.67-3.46 (m, 1H), 3.18-2.97 (m, 1H), 2.65 (s, 4H), 2.55-2.37 (m, 4H), 2.33-2.18 (m, 5H), 2.04 (d, J=10.9 Hz, 1H), 1.84 (dt, J=14.7, 4.9 Hz, 1H), 1.57 (d, J=11.1 Hz, 1H), 1.45-1.08 (m, 8H).

The following Examples were made in an analogous fashion according to Procedure 30 and are shown below in Table 14. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 30 and are noted in the last column of Table 14—“Changes to Procedure 30: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 30 were replaced with the different reagents/starting materials noted below.

TABLE 14 Changes to Procedure 30: Different Reagents/ Exam- ES/MS Starting ple Structure m/z ¹H-NMR Materials 254

564.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.49 (d, J = 1.3 Hz, 1H), 4.53 (t, J = 7.5 Hz, 6H), 3.98-3.83 (m, 1H), 3.17 (d, J = 7.3 Hz, 1H), 3.04 (h, J = 7.1 Hz, 1H), 2.74 (s, 1H), 2.64 (s, 3H), 2.54 (s, 1H), 2.43 (d, J = 6.7 Hz, 4H), 2.28 (s, 3H), 2.23-2.10 (m, 1H), 2.04 (d, J = 10.7 Hz, 1H), 1.78 (ddd, J = 14.4, 11.5, 6.3 Hz, 1H), 1.58 (d, J = 11.0 Hz, 1H), 1.50-1.06 (m, 7H), 0.93 (t, J = 6.6 Hz, 1H), 0.69-0.42 (m, 1H). 2-thia-6- azaspiro [3.3] heptane 2,2-dioxide 255

551.3 ¹H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.47 (s, 1H), 3.87-3.65 (m, 5H), 3.58 (s, 2H), 3.30-3.22 (m, 2H), 3.05 (p, J = 7.1 Hz, 1H), 2.69-2.54 (m, 4H), 2.44 (s, 3H), 2.42-2.34 (m, 2H), 2.28 (s, 3H), 2.12 (s, 1H), 2.00 (d, J = 10.6 Hz, 1H), 1.70 (d, J = 13.3 Hz, 1H), 1.55 (d, J = 10.6 Hz, 1H), 1.33-1.26 (m, 6H), 1.23 (d, J = 7.2 Hz, 3H). 1-imino- 1,4- thiazinane 1-oxide 256

552.2 ¹H NMR (400 MHz, MeOD) δ 8.63 (s, 1H), 8.53 (s, 1H), 3.77 (s, 4H), 3.66-3.46 (m, 5H), 3.41-3.33 (m, 1H), 3.05 (hept, J = 7.2 Hz, 1H), 2.78 (s, 1H), 2.65 (s, 3H), 2.45 (s, 4H), 2.38-2.19 (m, 5H), 2.07 (d, J = 10.9 Hz, 1H), 1.86-1.78 (m, 1H), 1.61 (d, J = 10.8 Hz, 1H), 1.50 (d, J = 13.1 Hz, 1H), 1.36-1.16 (m, 6H). 1,4- thiazinane 1,1-dioxide 257

517.4 ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.50 (s, 1H), 4.12-3.89 (m, 2H), 3.79-3.55 (m, 5H), 3.42-3.34 (m, 1H), 3.05 (hept, J = 6.9 Hz, 1H), 2.89 (s, 1H), 2.65 (s, 3H), 2.51-2.41 (m, 4H), 2.39-2.21 (m, 5H), 2.09 (d, J = 11.2 Hz, 1H), 1.89 (dt, J = 14.5, 4.8 Hz, 1H), 1.66-1.49 (m, 2H), 1.35-1.14 (m, 6H). piperazin- 2-one

Procedure 31, Examples 258 and 259

tert-butyl 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(((triisopropylsilyl)oxy)methyl)-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate: To a dried vial was added tert-butyl 2-bromo-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(((triisopropylsilyl)oxy)methyl)-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-63) (170 mg, 0.257 mmol), tert-butyl 4-iodopiperidine-1-carboxylate (95.9 mg, 0.308 mmol), tetrabutylammonium iodide (TBAI) (23.7 mg, 0.064 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (7.3 mg, 0.015 mmol), and zinc dust (83.5 mg, 1.28 mmol). Dry DMA (3 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in MeOH (1 mL) and potassium carbonate (sat. aq., 0.25 mL) was added. The mixture was stirred at 40° C. overnight. The mixture was diluted with EtOAc (60 mL) and water (6 mL). The layers were separated, and the organic layer was washed with brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the product. ES/MS: 766.9 (M+H⁺).

(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrol-3-yl)methanol (Example 258) and 4-isopropyl-3-(methoxymethyl)-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole (Example 259): To a vial with tert-butyl 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(((triisopropylsilyl)oxy)methyl)-6H-thieno[2,3-b]pyrrol-2-yl)piperidine-1-carboxylate (87 mg, 0.131 mmol) was added methanol (0.25 mL). HCl (4M in dioxane, 0.41 mL, 1.63 mmol) was added, and the mixture was stirred for 16 hours at rt. The volatiles were evaporated under reduced pressure. The crude residue was dissolved in acetonitrile (2 mL), water (1.5 mL) and trifluoroacetic acid (0.5 mL), and the crude material was filtered through an acrodisc and purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compounds Example 258 and Example 259 as trifluoroacetate salts.

Example 258: ES/MS: 410.1 (M+H⁺). ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.40 (s, 1H), 8.57 (d, 1H), 8.34 (s, 1H), 7.64 (s, 2H), 7.49 (t, 1H), 4.80 (s, 2H), 3.52 (t, 3H), 3.35 (p, 1H), 3.13 (d, 2H), 2.65 (t, 3H), 1.35 (d, 6H).

Example 259: ES/MS: 424.1 (M+H⁺). ¹H NMR (400 MHz, Acetonitrile-d3) δ 9.44 (s, 1H), 8.57 (dd, 1H), 8.36 (s, 1H), 7.63 (s, 2H), 7.50 (q, 1H), 4.61 (s, 2H), 3.54-3.46 (m, 3H), 3.41 (s, 3H), 3.31 (p, 1H), 3.13 (d, 2H), 2.65 (d, 3H), 2.19-2.10 (m, 2H), 1.33 (d, 6H).

Procedure 32, Example 260

(R)-(4-(3-(hydroxymethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)piperidin-1-yl)(morpholin-3-yl)methanone (Example 260): To a vial with 3-(difluoromethyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(piperidin-4-yl)-6H-thieno[2,3-b]pyrrole (HCl salt) (Example 68) (15 mg, 0.032 mmol) in 1,2-dichloroethane (1 mL) was added ((R)-4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid (9.7 mg, 0.042 mmol), 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (12 mg, 0.32 mmol), and N,N-diisopropylethylamine (0.02 mL, 0.13 mmol). The mixture was stirred for 16 hr at rt. To the mixture was added TFA (0.25 mL), and the mixture was stirred for 2 hr at rt. The crude mixture was concentrated under reduced pressure, and methanol (1 mL) and NaBH₄ (5 mg, 0.13 mmol) were added. The mixture was stirred for 1 hour then quenched with water. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL) and water (0.15 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 260 as a trifluoroacetate salt. ES/MS: 523.1 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 8.61 (dd, 1H), 8.46 (s, 1H), 7.58 (d, 1H), 4.72 (dd, 1H), 4.66 (d, 1H), 4.28 (dd, 1H), 4.06 (t, 2H), 3.88-3.75 (m, 1H), 3.75-3.63 (m, 1H), 3.61-3.47 (m, 1H), 3.43-3.35 (m, 3H), 2.90 (t, 1H), 2.68 (d, 3H), 2.18 (dd, 2H), 1.81-1.55 (m, 2H), 1.41 (d, 6H).

The following Examples were made in an analogous fashion according to Procedure 32 and are shown below in Table 15. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 32 and are noted in the last column of Table 15—“Changes to Procedure 32: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 32 were replaced with the different reagents/starting materials noted below.

TABLE 15 Changes to Procedure 32: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 261

523.1 ¹H NMR (400 MHz, Methanol-d4) δ 8.68-8.53 (m, 1H), 8.46 (s, 1H), 7.58 (t, 1H), 4.76-4.59 (m, 2H), 4.28 (dd, 1H), 4.06 (t, 2H), 3.90-3.76 (m, 1H), 3.76-3.59 (m, 1H), 3.59-3.48 (m, 1H), 3.42-3.35 (m, 2H), 2.90 (t, 1H), 2.68 (t, 3H), 2.18 (dd, 2H), 1.83-1.53 (m, 2H), 1.41 (d, 6H). (S)-4-(tert- butoxy- carbonyl) morpholine- 3-carboxylic acid

Procedure 33: Example 262 and Example 263

2-(4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)azepan-1-yl)acetamide (Example 262 and Example 263): 2-(4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)azepan-1-yl)acetamide (Example 161) as a mixture of 2 stereoisomers was separated by chiral SFC (IA 4.6×100 mm column with 40% MeOH-DEA cosolvent) to give two enantiomers, for which stereochemistry were arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: 2-(4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)azepan-1-yl)acetamide (Example 262): ES/MS: 465.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d₄) δ 8.58 (s, 1H), 8.43 (s, 1H), 7.57 (s, 1H), 3.43-3.37 (m, 1H), 3.31-3.24 (m, 3H), 2.99-2.85 (m, 5H), 2.68 (d, 3H), 2.45 (s, 3H), 2.17-2.04 (m, 1H), 2.03-1.90 (m, 1H), 1.90-1.77 (m, 2H), 1.40 (d, 6H).

Isomer 2: 2-(4-(4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6H-thieno[2,3-b]pyrrol-2-yl)azepan-1-yl)acetamide (Example 263): ES/MS: 465.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d₄) δ 8.58 (s, 1H), 8.44 (s, 1H), 7.57 (s, 1H), 3.44-3.36 (m, 1H), 3.31-3.23 (m, 3H), 3.13-3.00 (m, 5H), 2.68 (s, 3H), 2.45 (s, 3H), 2.22-2.08 (m, 1H), 2.08-1.95 (m, 1H), 1.96-1.76 (m, 2H), 1.40 (d, 6H).

Procedure 34, Example 264

2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)acetic acid (Example 264): To a vial with tert-butyl 2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)acetate (Example 179) (25.5 mg, 0.048 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (1 ml). The mixture was stirred 16 hr at rt. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL) and water (0.15 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 264. ES/MS: 478.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.59 (s, 1H), 8.47 (s, 1H), 4.37-4.09 (m, 3H), 3.76 (d, 1H), 3.59 (d, 1H), 3.22 (d, 1H), 3.06 (p, 1H), 2.79 (s, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 2.15 (d, 1H), 2.09-1.94 (m, 1H), 1.36-1.15 (m, 7H).

Procedure 35, Example 265

2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-1-(3-hydroxyazetidin-1-yl)ethan-1-one (Example 265): To a solution of 2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)acetic acid (Example 264) (13 mg, 0.026 mmol) in DCM (2 mL) was added azetidin-3-ol hydrochloride (5.7 mg, 0.052 mmol), HATU (20 mg, 0.052 mmol) and N,N-diisopropylethylamine (0.019 mL, 0.10 mmol) and the reaction mixture was stirred 4 hours. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL) and water (0.15 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 265 as a trifluoroacetate salt. ES/MS: 533.3 (M+H⁺). H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.57 (s, 1H), 8.43 (s, 1H), 4.73-4.65 (m, 1H), 4.50-4.38 (m, 1H), 4.31 (dd, 1H), 4.17 (s, 1H), 4.12 (d, 1H), 4.04 (d, 1H), 3.88 (d, 1H), 3.82-3.69 (m, 1H), 3.55 (t, 1H), 3.21-3.11 (m, 1H), 3.06 (p, 1H), 2.64 (s, 3H), 2.48 (d, 3H), 2.26 (s, 3H), 2.15 (d, 1H), 2.08-1.94 (m, 1H), 1.26 (dd, 6H).

The following Examples were made in an analogous fashion according to Procedure 35 and are shown below in Table 16. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 35 and are noted in the last column of Table 16—“Changes to Procedure 35: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 35 were replaced with the different reagents/starting materials noted below.

TABLE 16 Changes to Procedure 35: Different ES/ Reagents/ Exam- MS Starting ple Structure m/z ¹H-NMR Materials 266

535.3 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.59 (s, 1H), 8.46 (s, 1H), 4.57-4.42 (m, 1H), 4.31 (dd, 1H), 4.15 (d, 1H), 3.81-3.69 (m, 2H), 3.63-3.53 (m, 1H), 3.52-3.42 (m, 1H), 3.26-3.13 (m, 1H), 3.11-2.99 (m, 3H), 2.77 (d, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 2.12 (d, 1H), 2.07-1.97 (m, 1H), 1.26 (dd, 6H). 2-(methyl- amino) ethanol 267

521.3 ¹H NMR (400 MHz, Methanol-d4) δ 10.76 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 8.34 (d, 1H), 4.32-3.93 (m, 3H), 3.73 (d, 1H), 3.67 (t, 2H), 3.55 (t, 1H), 3.42 (t, 2H), 3.22-3.12 (m, 1H), 3.07 (td, 1H), 2.78 (d, 1H), 2.64 (s, 3H), 2.48 (d, 3H), 2.27 (s, 3H), 2.11 (d, 1H), 2.07-1.95 (m, 1H), 1.26 (dd, 6H). 2-Amino- ethanol 268

517.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 4.37 (d, 1H), 4.25 (d, 1H), 4.19-4.08 (m, 2H), 3.85-3.69 (m, 1H), 3.67-3.52 (m, 1H), 3.23-3.18 (m, 1H), 3.15 (s, 1H), 3.08 (d, 1H), 3.04 (s, 4H), 2.86-2.71 (m, 1H), 2.64 (s, 3H), 2.48 (t, 3H), 2.26 (s, 3H), 2.17 (s, 1H), 2.08-1.92 (m, 2H), 1.26 (dd, 6H). azetidine hydro- chloride 269

547.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.57 (s, 1H), 8.43 (s, 1H), 4.20 (d, 1H), 4.07-3.95 (m, 2H), 3.95-3.84 (m, 1H), 3.75 (dd, 1H), 3.66-3.52 (m, 1H), 3.16 (d, 1H), 3.06 (p, 1H), 2.79 (s, 1H), 2.72 (d, 3H), 2.48 (d, 3H), 2.26 (s, 3H), 2.10 (d, 1H), 2.02 (d, 1H), 1.88 (s, 2H), 1.26 (dd, 6H). cis-3- amino- butanol hydro- chloride 270

547.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.56 (s, 1H), 8.41 (s, 1H), 4.51-4.35 (m, 2H), 4.21 (d, 1H), 4.07-3.88 (m, 1H), 3.83-3.68 (m, 1H), 3.65-3.52 (m, 1H), 3.28 (s, 1H), 3.19-3.11 (m, 1H), 3.11-2.98 (m, 1H), 2.77 (d, 1H), 2.64 (s, 3H), 2.48 (d, 3H), 2.33 (d, 4H), 2.26 (s, 3H), 2.15-1.95 (m, 3H), 1.26 (dd, 6H). trans-3- amino- cyclo- butanol hydro- chloride 271

559.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.56 (s, 1H), 8.41 (s, 1H), 4.20 (d, 1H), 4.11-3.93 (m, 2H), 3.71 (d, 1H), 3.63-3.45 (m, 1H), 3.16 (d, 2H), 3.06 (p, 1H), 2.77 (d, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.26 (s, 3H), 2.21 (s, 6H), 2.06 (d, 1H), 1.26 (dd, 6H). 3-amino- bicyclo [1.1.1] pentan-1-ol 272

535.2 ¹H NMR (400 MHz, Methanol-d4) δ 10.75 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 4.22 (d, 1H), 4.14-3.99 (m, 1H), 3.75 (dd, 1H), 3.59-3.43 (m, 2H), 3.41-3.35 (m, 4H), 3.20-3.13 (m, 1H), 3.13-2.99 (m, 1H), 2.78 (d, 1H), 2.64 (s, 3H), 2.48 (d, 3H), 2.26 (s, 3H), 2.15-1.95 (m, 2H), 1.26 (dd, 6H). 2- Methoxy- ethyl- amine 273

581.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.41 (s, 1H), 4.24 (d, 1H), 4.07 (d, 1H), 3.77 (dd, 1H), 3.56 (q, 2H), 3.50 (d, 1H), 3.22-3.14 (m, 1H), 3.12-3.01 (m, 1H), 2.80 (s, 1H), 2.76 (t, 2H), 2.64 (s, 3H), 2.48 (d, 3H), 2.26 (s, 4H), 2.12 (d, 1H), 2.02 (d, 1H), 1.26 (dd, 6H). (3R)-4- amino-3- fluoro-2- methyl- butan-2-ol 274

533.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.42 (s, 1H), 5.03 (p, 1H), 4.96-4.91 (m, 1H), 4.60 (q, 2H), 4.23 (d, 1H), 4.13-4.02 (m, 1H), 3.75 (dd, 1H), 3.66-3.52 (m, 1H), 3.50 (dd, 1H), 3.22-3.13 (m, 1H), 3.06 (dq, 1H), 2.78 (d, 1H), 2.64 (s, 3H), 2.48 (d, 3H), 2.26 (s, 4H), 2.12 (d, 1H), 2.00 (dd, 1H), 1.26 (dd, 6H). oxetan-3- amine

Procedure 36, Example 275

2-((1S,4R,5S)-2-azabicyclo[2.2.1]heptan-5-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (Example 275): To a dried round bottom flask was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (5 g, 9.9 mmol), tert-butyl (1S,4S,5R)-5-iodo-2-azabicyclo[2.2.1]heptane-2-carboxylate (I-31) (4.5 g, 13.9 mmol), tetrabutylammonium iodide (TBAI) (3.7 g, 9.9 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (280 mg, 0.60 mmol), and zinc dust (3.2 g, 49.7 mmol). Dry DMA (33 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at RT for 16 h. Afterward, the reaction was filtered and diluted with EtOAc, water, and 5% LiCl (aq.). The layers were separated, and the organic layer was washed with water, followed by brine. The organic layer was dried over sodium sulfate and concentrated. The d.r. for the product was observed to be >20:1, favoring the exo-isomer. The crude mixture was purified by silica chromatography (eluent: EtOAc/hexanes). The purified material was dissolved in MeOH (3.7 mL) and HCl (3M methanolic solution, 19 mL). The mixture was stirred at 70° C. overnight. The mixture was concentrated to near dryness. To the mixture was added ACN (33 mL) and the mixture was stirred for 30 minutes and then filtered. The collected residue was identified as Example 72 (major product; exo-isomer); the mother liquor contained a mixture of Example 72 and Example 275 (minor product; endo-isomer), which was purified by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to obtain Example 275 as a TFA salt. ES/MS: 420.2 (M+H⁺). ¹H NMR (400 MHz, Methanol-d4) δ 10.79 (s, 1H), 8.56 (d, 1H), 8.42 (s, 1H), 4.16 (s, 1H), 3.99-3.85 (m, 1H), 3.47-3.36 (m, 1H), 3.07 (d, 2H), 2.99 (s, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.48-2.40 (m, 1H), 2.27 (s, 3H), 2.16 (d, 1H), 1.95 (d, 1H), 1.86 (ddd, 1H), 1.27 (dd, 6H).

Procedure 37, Example 276

tert-butyl 2-[(Z)-2-(1-tert-butoxycarbonyl-4-piperidyl)vinyl]-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)thieno[2,3-b]pyrrole-6-carboxylate: To tert-butyl 2-bromo-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)thieno[2,3-b]pyrrole-6-carboxylate (I-15) (200 mg, 0.41 mmol) in 10:1 dioxane: water (5 mL) was added tert-butyl 4-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl]piperidine-1-carboxylate (165 mg, 0.49 mmol), XPhos Pd G3 (30.7 mg, 0.041 mmol) and cesium carbonate (399 mg, 1.2 mmol). The reaction mixture was heated to 110° C. for 3 hours under N₂. To the reaction was added sodium sulfate, and the mixture was filtered through celite, rinsed with DCM, and the filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (eluent: EtOAc in hexane) to give the product. ES/MS: 620.4 (M+H⁺).

2-(3-azabicyclo[4.1.0]heptan-6-yl)-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrole (Example 276): To a vial with tert-butyl 2-[2-(1-tert-butoxycarbonyl-4-piperidyl)vinyl]-4-isopropyl-3-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)thieno[2,3-b]pyrrole-6-carboxylate (80 mg, 0.129 mmol) was added EtOH (4 mL) and a catalytic amount of palladium on carbon (10% wt) was added, and the resulting mixture was stirred for two days under a hydrogen atmosphere. Upon completion of reaction as judged by LCMS, the reaction mixture was degassed with argon, filtered through celite, and the filtrate was concentrated to dryness. The crude residue was added to a vial with acetonitrile and trifluoroacetic acid (1:1 mixture, 5 mL) and the reaction mixture was stirred at 80° C. for 2 hours. The reaction mixture was concentrated under reduced pressure, and the crude material was dissolved in acetonitrile (1 mL), water (0.5 mL) and trifluoroacetic acid (0.1 mL), and the crude material was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250 ×21.2 mm) to give the title compound Example 276 as a trifluoroacetate salt. ES/MS: 422.4 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.46 (s, 1H), 7.58 (t, J=1.4 Hz, 1H), 3.41 (d, J=12.7 Hz, 2H), 3.32-3.26 (m, 2H), 3.03-2.95 (m, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.69 (s, 3H), 2.43 (s, 3H), 2.05 (d, J=14.2 Hz, 2H), 1.68 (q, J=7.0 Hz, 4H), 1.46 (s, 1H), 1.40 (d, J=7.1 Hz, 6H).

The following Examples were made in an analogous fashion according to Procedure 37 and are shown below in Table 17. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 37 and are noted in the last column of Table 17—“Changes to Procedure 37: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 37 were replaced with the different reagents/starting materials noted below.

TABLE 17 Changes to Procedure 37: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 277

408.3 ¹H NMR (400 MHz, MeOD) δ 8.63 (s, 1H), 8.47 (s, 1H), 7.59 (t, J = 1.4 Hz, 1H), 3.55-3.49 (m, 2H), 3.44-3.36 (m, 2H), 3.27-3.18 (m, 2H), 2.94 (q, J = 7.5 Hz, 2H), 2.69 (s, 3H), 2.19 (d, J = 15.5 Hz, 2H), 1.95 (td, J = 13.2, 12.8, 3.9 Hz, 2H), 1.36 (d, J = 7.1 Hz, 6H), 1.28 (t, J = 7.5 Hz, 3H). I-73; tert- butyl 4- (4,4,5,5- tetramethyl- 1,3,2-dioxa- borolan-2- yl)-3,6- dihydro-2H- pyridine-1- carboxylate 278

408.4 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.48 (s, 1H), 7.59 (t, J = 1.4 Hz, 1H), 3.42 (d, J = 12.7 Hz, 2H), 3.28 (d, J = 7.1 Hz, 1H), 3.03-2.95 (m, 2H), 2.81 (d, J = 7.0 Hz, 2H), 2.69 (s, 3H), 2.45 (s, 3H), 2.04 (d, J = 14.5 Hz, 2H), 1.96 (s, 1H), 1.55-1.44 (m, 2H), 1.40 (d, J = 7.1 Hz, 6H). tert-butyl 4- [(4,4,5,5- tetramethyl- 1,3,2- dioxaborolan- 2- yl)methylene] piperidine-1- carboxylate

Procedure 38, Example 279

[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]-[(3R,6R)-6-methylmorpholin-3-yl]methanone (Example XX): To a dram vial with tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(4-piperidyl)thieno[2,3-b]pyrrole-6-carboxylate (I-75) (50 mg, 0.099 mmol) in 1,2-dichloroethane (1 mL) was added (3R,6R)-4-tert-butoxycarbonyl-6-methyl-morpholine-3-carboxylic acid (29.0 mg, 0.12 mmol), 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (27.8 mg, 0.12 mmol), and N,N-diisopropylethylamine (0.05 mL, 0.3 mmol). The mixture was stirred 1 hr at rt. The crude mixture was added to a vial with acetonitrile and trifluoroacetic acid (1:1 mixture, 5 mL) and the reaction mixture was stirred at 80° C. for 3 hours. The reaction mixture was concentrated under reduced pressure, and the crude material was dissolved in acetonitrile (1 mL), water (0.5 mL) and trifluoroacetic acid (0.1 mL), and the crude material was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 279 as a trifluoroacetate salt. ES/MS: 535.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.48 (s, 1H), 4.64 (t, J=16.6 Hz, 2H), 4.29 (d, J=13.4 Hz, 1H), 4.05 (d, J=14.1 Hz, 1H), 3.87 (s, 1H), 3.64 (t, J=11.6 Hz, 1H), 3.40 (d, J=13.6 Hz, 2H), 3.23 (dd, J=12.6, 2.9 Hz, 1H), 3.07 (h, J=7.2 Hz, 1H), 2.91 (s, 1H), 2.65 (s, 3H), 2.47 (s, 3H), 2.28 (s, 3H), 2.06 (d, J=9.1 Hz, 2H), 1.67 (s, 2H), 1.26 (dt, J=20.3, 7.2 Hz, 1OH).

The following Examples were made in an analogous fashion according to Procedure 38 and are shown below in Table 18. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 38 and are noted in the last column of Table 18—“Changes to Procedure 38: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 38 were replaced with the different reagents/starting materials noted below.

TABLE 18 Changes to Procedure 38: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 280

535.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.47 (d, J = 1.2 Hz, 1H), 4.70-4.64 (m, 1H), 4.64-4.55 (m, 1H), 4.35-4.24 (m, 1H), 4.04 (d, J = 13.8 Hz, 1H), 3.87 (dd, J = 11.1, 5.6 Hz, 1H), 3.79-3.60 (m, 2H), 3.46-3.36 (m, 3H), 3.13-2.84 (m, 4H), 2.65 (s, 3H), 2.47 (s, 3H), 2.28 (s, 3H), 2.19-2.01 (m, 3H), 1.68-1.53 (m, 2H), 1.33-1.20 (m, 9H). (3R,6S)-4- tert-butoxy- carbonyl-6- methyl- morpholine- 3-carboxylic acid 281

535.2 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.48 (d, J = 1.6 Hz, 1H), 4.72 (d, J = 13.3 Hz, 1H), 4.54 (d, J = 9.4 Hz, 1H), 4.35-4.24 (m, 1H), 4.15-4.07 (m, 1H), 3.97-3.74 (m, 2H), 3.40 (ddd, J = 12.4, 10.0, 3.2 Hz, 3H), 3.05 (h, J = 7.1 Hz, 1H), 2.99-2.86 (m, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.28 (s, 3H), 2.10 (q, J = 13.8, 12.3 Hz, 2H), 1.82-1.55 (m, 2H), 1.39 (d, J = 6.3 Hz, 1H), 1.31 (t, J = 7.2 Hz, 5H), 1.23 (d, J = 7.1 Hz, 3H). (3R,6R)-4- tert-butoxy- carbonyl-6- methyl- morpholine- 3-carboxylic acid 282

555.3 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.52 (d, J = 1.6 Hz, 1H), 4.80-4.61 (m, 2H), 3.87 (d, J = 13.6 Hz, 1H), 3.67-3.58 (m, 1H), 3.40 (dd, J = 11.0, 6.7 Hz, 2H), 3.06 (p, J = 7.1 Hz, 1H), 2.92 (dt, J = 13.6, 9.3 Hz, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.46-2.31 (m, 2H), 2.29 (s, 3H), 2.18-2.03 (m, 2H), 1.81-1.55 (m, 2H), 1.27 (dd, J = 27.3, 7.3 Hz, 6H). (2S)-1-tert- butoxy- carbonyl- 4,4- difluoro- piperidine- 2-carboxylic acid 283

589.2 ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.46 (s, 1H), 4.66 (d, J = 13.4 Hz, 1H), 4.50 (ddd, J = 12.9, 9.3, 4.7 Hz, 2H), 4.05 (d, J = 13.6 Hz, 1H), 3.96-3.74 (m, 2H), 3.66 (dt, J = 12.7, 3.1 Hz, 1H), 3.41 (t, J = 12.1 Hz, 3H), 3.06 (p, J = 7.1 Hz, 1H), 2.97-2.86 (m, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.28 (s, 3H), 2.18-2.01 (m, 3H), 1.76-1.54 (m, 3H), 1.26 (dd, J = 28.3, 7.2 Hz, 6H). 6-(trifluoro- methyl) morpholine- 3-carboxylic acid 284

587.3 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.52 (d, J = 2.5 Hz, 1H), 4.67 (d, J = 13.3 Hz, 1H), 4.57-4.45 (m, 1H), 4.01 (t, J = 13.2 Hz, 1H), 3.60 (d, J = 12.9 Hz, 1H), 3.41 (t, J = 12.1 Hz, 2H), 3.17 (td, J = 13.2, 3.3 Hz, 1H), 3.06 (p, J = 7.1 Hz, 1H), 2.98-2.80 (m, 2H), 2.65 (s, 3H), 2.48 (s, 3H), 2.37 (d, J = 13.8 Hz, 1H), 2.29 (s, 3H), 2.19 (d, J = 14.5 Hz, 1H), 2.08 (t, J = 15.6 Hz, 2H), 1.91-1.79 (m, 1H), 1.79-1.55 (m, 3H), 1.27 (dd, J = 27.7, 7.1 Hz, 6H). (2R,4S)-1- tert-butoxy- carbonyl-4- (trifluoro- methyl) piperidine- 2-carboxylic acid 285

589.3 ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.51 (s, 1H), 4.83-4.63 (m, 2H), 4.53-4.34 (m, 2H), 4.29-4.18 (m, 1H), 4.07 (dd, J = 12.8, 10.6 Hz, 1H), 3.89 (d, J = 13.1 Hz, 1H), 3.50 (dd, J = 12.8, 3.6 Hz, 1H), 3.41 (d, J = 16.3 Hz, 3H), 3.06 (p, J = 7.1 Hz, 1H), 2.93 (t, J = 12.4 Hz, 1H), 2.65 (s, 3H), 2.48 (s, 3H), 2.29 (s, 3H), 2.07 (d, J = 13.9 Hz, 2H), 1.74-1.59 (m, 2H), 1.26 (dd, J = 27.6, 7.1 Hz, 6H). (3R,6R)-4- tert-butoxy- carbonyl-6- (trifluoro- methyl) morpholine- 3-carboxylic acid

Procedure 39, Example 286

3-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]piperidin-2-one (Example (286): To a solution of tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(4-piperidyl)thieno[2,3-b]pyrrole-6-carboxylate (I-75) (20 mg, 0.0386 mmol) in ACN (6 mL) was added 3-bromopiperidin-2-one (22.2 mg, 0.13 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.023 mL, 0.16 mmol). The mixture was stirred overnight at 80° C. The crude mixture was added to a vial with acetonitrile and trifluoroacetic acid (1:1 mixture, 5 mL) and the reaction mixture was stirred at 80° C. for 3 hours. The mixture was concentrated under reduced pressure, and the crude residue was dissolved in acetonitrile (1 mL), water (0.5 mL) and trifluoroacetic acid (0.1 mL), and the crude material was purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water, Column: Gemini 5 uM, NX-C18 110 Angstrom, 250×21.2 mm) to give the title compound Example 286 as a trifluoroacetate salt. ES/MS: 505.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.65 (s, 1H), 8.58 (s, 1H), 4.18 (dd, J=11.9, 5.7 Hz, 1H), 3.58-3.34 (m, 7H), 3.23 (q, J=7.2 Hz, 1H), 3.06 (hept, J=7.2 Hz, 1H), 2.67 (d, J=7.7 Hz, 3H), 2.48 (s, 3H), 2.40 (t, J=8.4 Hz, 1H), 2.30 (s, 3H), 2.27-2.22 (m, 2H), 2.12-1.94 (m, 3H), 1.30 (ddt, J=26.3, 20.7, 6.4 Hz, 7H).

The following Examples were made in an analogous fashion according to Procedure 39 and are shown below in Table 19. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 39 and are noted in the last column of Table 19—“Changes to Procedure 39: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 39 were replaced with the different reagents/starting materials noted below.

TABLE 19 Changes to Procedure 39: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 287

491.2 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.48 (s, 1H), 4.30 (t, J = 9.7 Hz, 1H), 4.01 (d, J = 12.1 Hz, 1H), 3.61-3.40 (m, 5H), 3.07 (p, J = 7.1 Hz, 1H), 2.65 (s, 5H), 2.48 (s, 4H), 2.29 (d, J = 10.7 Hz, 5H), 2.07 (dd, J = 25.4, 12.5 Hz, 2H), 1.40-1.16 (m, 7H). 3-bromo- pyrrolidin- 2-one 288

505.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.48 (s, 1H), 4.32 (t, J = 9.4 Hz, 1H), 3.97 (d, J = 12.1 Hz, 1H), 3.60-3.41 (m, 5H), 3.37 (s, 2H), 3.06 (p, J = 7.1 Hz, 1H), 2.95 (s, 3H), 2.65 (s, 3H), 2.54 (d, J = 6.6 Hz, 1H), 2.48 (s, 3H), 2.39 (d, J = 10.0 Hz, 1H), 2.29 (d, J = 10.7 Hz, 5H), 2.15-1.96 (m, 2H), 1.26 (dd, J = 28.3, 7.2 Hz, 6H). 3-bromo- 1-methyl- pyrrolidin- 2-one 289

519.0 ¹H NMR (400 MHz, MeOD) δ 8.57 (s, 1H), 8.43 (s, 1H), 3.87 (d, J = 12.1 Hz, 2H), 3.72 (d, J = 12.4 Hz, 1H), 3.57-3.40 (m, 6H), 3.08 (td, J = 15.9, 14.1, 8.1 Hz, 3H), 2.91 (s, 2H), 2.64 (s, 3H), 2.49 (s, 2H), 2.27 (s, 4H), 2.00 (dd, J = 25.7, 12.9 Hz, 3H), 1.95-1.86 (m, 2H), 1.80 (t, J = 6.8 Hz, 1H), 1.69 (d, J = 5.6 Hz, 1H), 1.35-1.18 (m, 6H). 3-(bromo- methyl)-1- methyl- pyrrolidin- 2-one

Procedure 40, Example 290 and Example 291

3-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]pyrrolidin-2-one (Example 290 and Example 291): 3-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]pyrrolidin-2-one (Example 287) as a mixture of 2 stereoisomers was separated by chiral SFC (AD-H column with 45% EtOH-NH₃ cosolvent) to give two enantiomers, the absolute stereochemistry of which was arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: 3-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]pyrrolidin-2-one (Example 290): ES/MS: 491.3 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.43 (s, 1H), 4.30 (t, J=9.7 Hz, 1H), 4.01 (d, J=12.2 Hz, 1H), 3.59-3.39 (m, 5H), 3.07 (p, J=7.1 Hz, 1H), 2.65 (s, 2H), 2.48 (s, 3H), 2.43 (d, J=11.6 Hz, 1H), 2.27 (s, 4H), 2.13-1.99 (m, 2H), 1.26 (dd, J=29.3, 7.4 Hz, 6H).

Isomer 2: 3-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]pyrrolidin-2-one (Example 291): ES/MS: 491.3 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.44 (s, 1H), 4.30 (t, J=9.7 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.48 (dq, J=28.5, 8.7, 8.2 Hz, 5H), 3.07 (p, J=7.1 Hz, 1H), 2.65 (s, 3H), 2.58 (t, J=7.1 Hz, 1H), 2.48 (s, 4H), 2.27 (s, 4H), 2.14-1.99 (m, 2H), 1.26 (dd, J=28.8, 7.1 Hz, 6H).

Procedure 41, Example 292 and Example 293

9-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-4-azaspiro[5.5]undecane (Example 292 and Example 293): 9-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-4-azaspiro[5.5]undecane (Example 144) as a mixture of 2 stereoisomers was separated by chiral SFC (AD-H4.6×100 mm; EtOH-NH₃ (30%)) to give two diastereomers, the stereochemistry of which were arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: 9-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-4-azaspiro[5.5]undecane (Example 292): ES/MS: 478.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.64 (s, 1H), 8.58 (s, 1H), 4.00-3.91 (m, 2H), 3.24-3.17 (m, 2H), 3.15-2.99 (m, 4H), 2.67-2.63 (m, 3H), 2.43 (s, 3H), 2.30 (s, 3H), 2.24-2.15 (m, 2H), 1.86-1.73 (m, 4H), 1.56 (td, J=13.4, 6.2 Hz, 2H), 1.35-1.18 (m, 6H).

Isomer 2: 9-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-1-oxa-4-azaspiro[5.5]undecane (Example 293): ES/MS: 478.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.44 (s, 1H), 3.97 (dd, J=6.2, 4.1 Hz, 2H), 3.35 (s, 2H), 3.27-2.94 (m, 4H), 2.64 (s, 3H), 2.44 (s, 3H), 2.27 (s, 5H), 2.05 (d, J=13.2 Hz, 2H), 1.72 (td, J=13.3, 3.7 Hz, 2H), 1.65-1.50 (m, 2H), 1.34-1.18 (m, 6H).

Procedure 42, Example 294

3-[(1S,4R)-5-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-2-azabicyclo[2.2.1]heptan-2-yl]thiolane 1,1-dioxide (Example 294): A mixture of Example 72 (HCl salt) (26.0 mg, 0.057 mmol), DBU (34 μL, 0.23 mmol), 2,3-dihydrothiophene 1,1-dioxide (13.5 mg, 0.114 mmol) in MeOH (2 mL) was stirred at 90° C. for two weeks. The volatiles were removed under reduced pressure and the crude product was dissolved in acetonitrile/water/trifluoroacetic acid (2 ml; 5/I/O.2 ratio), and the crude material was filtered through an acrodisc and purified directly by RP-HPLC (0.1% TFA-ACN in 0.1% TFA Water) to give the product as a trifluoroacetate salt. ES/MS: 538.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.46 (s, 1H), 4.49 -3.40 (m, 7H), 3.04 (dp, J=15.7, 7.6 Hz, 1H), 2.83 (s, 2H), 2.65 (s, 3H), 2.49 (s, 4H), 2.34 (s, 2H), 2.27 (s, 3H), 2.11-1.93 (m, 2H), 1.86-1.59 (m, 2H), 1.36-1.18 (m, 6H).

Procedure 43, Example 295

[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]-[8-(2-hydroxyethyl)-5-oxa-8-azaspiro[3.5]nonan-2-yl]methanone (Example 295): A solution of tert-butyl 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-[1-(5-oxa-8-azaspiro[3.5]nonane-2-carbonyl)-4-piperidyl]thieno[2,3-b]pyrrole-6-carboxylate (HCl salt) (produced in an analogous fashion to Example 94, using I-75 as a starting material) (25 mg, 0.036 mmol), 2-bromoethanol (30.5 μL, 0.043 mmol) and DBU (21.4 μL, 0.14 mmol) in CH₃CN (1 mL) was stirred at 80° C. for 1 week. After LCMS showed completion of reaction, the reaction mixture was cooled down to room temperature. TFA (0.2 mL) was added and the reaction was stirred overnight. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL) and water (0.15 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water) to give the product as a trifluoroacetate salt. ES/MS: 605.2 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.47 (s, 1H), 4.66 (d, J=13.2 Hz, 1H), 4.09-3.77 (m, 6H), 3.73-3.13 (m, 7H), 3.05 (p, J=7.1 Hz, 2H), 2.83 (dd, J=14.0, 11.4 Hz, 1H), 2.64 (s, 4H), 2.46 (s, 6H), 2.28 (s, 3H), 2.08-1.93 (m, 2H), 1.58 (dq, J=12.3, 6.5 Hz, 2H), 1.40-1.09 (m, 6H).

Procedure 44, Example 296

[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]-(8-methyl-5-oxa-8-azaspiro[3.5]nonan-2-yl)methanone (Example 296): To a dram vial with [4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]-(5-oxa-8-azaspiro[3.5]nonan-2-yl)methanone (Example 94) (20 mg, 0.036 mmol) in 1,2-dichloroethane (1 mL) was added formaldehyde (3.2 mg, 0.11 mmol) and acetic acid (1 drop). The mixture was stirred 2 hr at rt. To the mixture was subsequently added sodium triacetoxyborohydride (STAB) (23 mg, 0.11 mmol), and the mixture was stirred overnight at rt. To the mixture was added 0.1 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.1 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water) to give the product as a trifluoroacetate salt. ES/MS: 575.3 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.47 (s, 1H), 4.66 (d, J=13.1 Hz, 1H), 3.95 (d, J=13.5 Hz, 2H), 3.79 (d, J=12.0 Hz, 2H), 3.44-3.36 (m, 1H), 3.28-3.01 (m, 6H), 2.97 (s, 3H), 2.83 (dd, J=13.9, 11.3 Hz, 1H), 2.64 (s, 4H), 2.46 (s, 4H), 2.37 (s, 2H), 2.28 (s, 3H), 2.03 (t, J=11.1 Hz, 2H), 1.56 (qd, J=15.2, 6.6 Hz, 2H), 1.36-1.20 (m, 6H).

The following Examples were made in an analogous fashion according to Procedure 44 and are shown below in Table 20. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 44 and are noted in the last column of Table 20—“Changes to Procedure 44: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 44 were replaced with the different reagents/starting materials noted below.

TABLE 20 Changes to Procedure 44: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 297

543.3 1H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.45 (s, 1H), 4.15 (s, 1H), 3.86 (p, J = 6.5 Hz, 1H), 3.68-3.54 (m, 2H), 3.40 (dd, J = 8.3, 5.3 Hz, 2H), 3.12-2.95 (m, 2H), 2.80 (d, J = 16.4 Hz, 1H), 2.64 (s, 3H), 2.62-2.45 (m, 7H), 2.38 (dt, J = 13.8, 6.7 Hz, 2H), 2.27 (s, 4H), 2.14-1.89 (m, 3H), 1.34-1.18 (m, 6H). 6- azaspiro [3.4] octane- 2,5- dione; Example 72; DIPEA

Procedure 45, Example 298

[8-(2,2-difluoroethyl)-5-oxa-8-azaspiro[3.5]nonan-2-yl]-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]methanone (Example 298): A solution of [4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]-1-piperidyl]-(5-oxa-8-azaspiro[3.5]nonan-2-yl)methanone (Example 94) (TFA salt) (15 mg, 0.022 mmol), 2-bromo-1,1-difluoro-ethane (2.5 μL, 0.029 mmol) and DBU (13.3 μL, 0.089 mmol) in 1,2-dichloroethane (1 mL) was stirred overnight at rt. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL), water (0.15 mL) and TFA (0.1 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water) to give the product as a trifluoroacetate salt. ES/MS: 624.3 (M⁺). ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.52 (s, 1H), 4.66 (d, J=13.1 Hz, 1H), 4.16-3.84 (m, 5H), 3.64 (t, J=6.3 Hz, 2H), 3.51-3.40 (m, 2H), 3.33-3.17 (m, 2H), 3.05 (hept, J=7.1 Hz, 1H), 2.83 (dd, J=14.0, 11.4 Hz, 1H), 2.65 (s, 3H), 2.59-2.37 (m, 7H), 2.29 (s, 3H), 2.01 (q, J=14.7 Hz, 2H), 1.80 (p, J=7.1 Hz, 1H), 1.69 (p, J=5.3 Hz, 1H), 1.64-1.50 (m, 2H), 1.35-1.09 (m, 6H).

Procedure 46, Example 299

2-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexyl]-2,6-diazaspiro[3.4]octan-5-one (Example 299): To a dram vial with 4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexanone (I-78) (47 mg, 0.11 mmol) in 1,2-dichloroethane (1 mL) was added 2,6-diazaspiro[3.4]octan-5-one (42 mg, 0.34 mmol) and acetic acid (1 drop). The mixture was stirred 2 hr at rt. To the mixture was subsequently added sodium triacetoxyborohydride (STAB) (71 mg, 0.34 mmol), and the mixture was stirred overnight at rt. To the mixture was added 0.1 mL TFA, and the DCE was subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.1 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water) to give the product as a trifluoroacetate salt. ES/MS: 531.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.49 (s, 1H), 4.27 (d, J=11.5 Hz, 3H), 3.69-3.49 (m, 1H), 3.44-3.33 (m, 3H), 3.29-3.14 (m, 1H), 3.06 (dtd, J=14.4, 7.4, 4.7 Hz, 1H), 2.64 (s, 4H), 2.44 (s, 3H), 2.28 (s, 3H), 2.16 (d, J=14.4 Hz, 1H), 2.10-1.86 (m, 5H), 1.84-1.37 (m, 3H), 1.35-1.17 (m, 6H).

The following Examples were made in an analogous fashion according to Procedure 46 and are shown below in Table 21. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 46 and are noted in the last column of Table 21—“Changes to Procedure 46: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 46 were replaced with the different reagents/starting materials noted below.

TABLE 21 Changes to Procedure 46: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 300

504.3 ¹H NMR (400 MHz, MeOD) δ 8.60 (s, 1H), 8.51 (s, 1H), 4.64-4.37 (m, 4H), 4.32 (t, J = 10.4 Hz, 1H), 3.47 (d, J = 15.3 Hz, 1H), 3.22 (s, 1H), 3.06 (dt, J = 9.0, 5.3 Hz, 2H), 2.98-2.82 (m, 1H), 2.65 (s, 5H), 2.43 (d, J = 1.3 Hz, 3H), 2.28 (s, 3H), 2.15 (d, J = 13.5 Hz, 1H), 2.03-1.89 (m, 2H), 1.78-1.51 (m, 2H), 1.38-1.16 (m, 8H). 1-oxa-6- azaspiro [3.3] heptane 301

552.2 ¹H NMR (400 MHz, MeOD) δ 8.57 (s, 1H), 8.43 (s, 1H), 4.53 (bs, 8H), 3.30 (d, J = 3.5 Hz, 1H), 3.13-2.99 (m, 2H), 2.64 (s, 3H), 2.43 (s, 3H), 2.27 (s, 3H), 2.18 (d, J = 11.6 Hz, 3H), 1.59-1.44 (m, 5H), 1.35-1.11 (m, 6H). 2-thia-6- azaspiro [3.3] heptane 2,2- dioxide 302

494.2 ¹H NMR (400 MHz, MeOD) δ 8.63 (s, 1H), 8.55 (d, J = 1.0 Hz, 1H), 5.73-5.21 (m, 1H), 4.24-3.36 (m, 5H), 3.07 (tdd, J = 14.3, 12.1, 7.7 Hz, 2H), 2.77-1.46 (m, 19H), 1.37-1.15 (m, 6H). (3S)-3- fluoro- pyrrolidine hydro- chloride 303

494.2 ¹H NMR (400 MHz, MeOD) δ 8.63 (s, 1H), 8.55 (d, J = 1.0 Hz, 1H), 5.73-5.21 (m, 1H), 4.24-3.36 (m, 5H), 3.07 (tdd, J = 14.3, 12.1, 7.7 Hz, 2H), 2.77-1.46 (m, 19H), 1.37-1.15 (m, 6H). (3R)-3- fluoro- pyrrolidine hydro- chloride 304

492.3 ¹H NMR (400 MHz, MeOD) δ 8.62 (s, 1H), 8.54 (s, 1H), 4.38-3.95 (m, 4H), 3.57-3.37 (m, 1H), 3.30-3.00 (m, 2H), 2.65 (s, 3H), 2.43 (d, J = 1.7 Hz, 3H), 2.29 (s, 3H), 2.25-1.15 (m, HH), 1.35-1.17 (m, 6H). 3-methyl- azetidin-3- olhydro- chloride

Procedure 47, Example 305 and Example 306

2-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexyl]-2,6-diazaspiro[3.4]octan-5-one (Example 305 and Example 306): 2-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexyl]-2,6-diazaspiro[3.4]octan-5-one (Example 299) as a mixture of 2 stereoisomers was separated by chiral SFC (OD-H 4.6×100 mm; MEOH-DEA (30%)) to give two diastereomers, the stereochemistry of which were arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: 2-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexyl]-2,6-diazaspiro[3.4]octan-5-one (Example 305): ES/MS: 531.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.47 (s, 1H), 4.44-4.31 (m, 2H), 4.28-4.15 (m, 2H), 3.33 (p, J=1.7 Hz, 3H), 3.12-2.98 (m, 2H), 2.61 (d, J=7.0 Hz, 4H), 2.44 (s, 4H), 2.33-2.10 (m, 7H), 1.69-1.36 (m, 4H), 1.34-1.15 (m, 6H).

Isomer 2: 2-[4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexyl]-2,6-diazaspiro[3.4]octan-5-one (Example 306): ES/MS: 531.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.63 (s, 1H), 8.56 (s, 1H), 4.53 (d, J=11.0 Hz, 1H), 4.34-4.20 (m, 3H), 3.66-3.60 (m, 1H), 3.39 (q, J=8.5 Hz, 2H), 3.29-3.18 (m, 1H), 3.05 (hept, J=7.2 Hz, 1H), 2.64 (d, J=9.2 Hz, 4H), 2.54 (t, J=6.8 Hz, 1H), 2.44 (s, 3H), 2.30 (s, 3H), 2.07-1.90 (m, 6H), 1.73 (t, J=13.1 Hz, 2H), 1.38-1.14 (m, 6H).

Procedure 48, Example 307

2-((2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)ethyl)sulfonyl)ethan-1-ol (Example 307): A solution of Example 72 (HCl salt) (15 mg, 0.033 mmol), 2-(2-bromoethylsulfonyl)ethanol (9.3 mg, 0.043 mmol) and DBU (19.6 μL, 0.13 mmol) in acetonitrile (1 mL) was stirred overnight at 80° C. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL), water (0.15 mL) and TFA (0.1 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water) to give the product. ES/MS: 556.2 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.46 (s, 1H), 4.33 (s, 1H), 4.05 (t, J=5.3 Hz, 2H), 3.94-3.59 (m, 5H), 3.57-3.38 (m, 3H), 3.25 (d, J=10.5 Hz, 1H), 3.06 (hept, J=7.3 Hz, 1H), 2.81 (d, J=17.5 Hz, 1H), 2.65 (s, 3H), 2.58-2.14 (m, 9H), 2.06-1.94 (m, 2H), 1.38-1.14 (m, 6H).

Procedure 49, Example 308

2-((1S,4R,5R)-5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)propane-1,3-diol (Example 308): To a dram vial with Example 72 (HCl salt) (20 mg, 0.044 mmol) in 1,2-dichloroethane (1 mL) was added 2,2-dimethyl-1,3-dioxan-5-one (17 mg, 0.13 mmol) and acetic acid (1 drop). The mixture was stirred 2 hr at rt. To the mixture was subsequently added sodium triacetoxyborohydride (STAB) (28 mg, 0.13 mmol), and the mixture was stirred overnight at rt. To the mixture was added 4N HCl in dioxane (5 mL) and stirred overnight at rt. The volatiles were subsequently removed under reduced pressure. Acetonitrile (0.5 mL) and water (0.1 mL) were added, and the mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water) to give the product. ES/MS: 534.3 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.47 (s, 1H), 4.68-4.16 (m, 2H), 4.07-3.84 (m, 3H), 3.71-3.41 (m, 3H), 3.33-3.23 (m, 1H), 3.06 (hept, J=7.0 Hz, 1H), 2.83-2.73 (m, 2H), 2.65 (s, 3H), 2.48 (d, J=5.2 Hz, 3H), 2.39-2.19 (m, 4H), 2.15-1.73 (m, 2H), 1.45-1.15 (m, 6H).

Procedure 50, Example 309

4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexanecarboxylic acid: To a dried vial was added tert-butyl 2-bromo-5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-thieno[2,3-b]pyrrole-6-carboxylate (I-16) (150 mg, 0.30 mmol), methyl 4-iodocyclohexanecarboxylate (I-86) (160 mg, 0.60 mmol), tetrabutylammonium iodide (TBAI) (132 mg, 0.36 mmol), Ni(dtbbpy)(H₂O)₄Cl₂ (17 mg, 0.036 mmol), and zinc dust (116 mg, 1.79 mmol). Dry DMA (1 mL) was added, and the mixture was degassed for 1 minute with argon. The vial was sealed, and the reaction was stirred at 70° C. for 16 h. Afterward, the reaction was cooled, and the crude mixture was purified directly by silica chromatography (eluent: EtOAc/hexanes). (ES/MS: 565.2 [M+H⁺]). To a solution of the purified product in THF (1 mL) and MeOH (1 mL), LiGH (excess) was added and the resulting reaction mixture was stirred at 80° C. for 1 hr. The volatiles were removed under vacuum, and then the reaction was diluted with water (5 mL) and neutralized with 1 N aq. HCl (2 ml). The aqueous layer was extracted with EtOAc (3×10 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated to afford the product. ES/MS: 451.2 (M+H⁺).

(4-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)cyclohexyl)(piperazin-1-yl)methanone (Example 309): To a dram vial with 4-[5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl]cyclohexanecarboxylic acid (35 mg, 0.077 mmol) in DMF (1 mL) was added tert-butyl piperazine-1-carboxylate (19 mg, 0.10 mmol), 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (35.4 mg, 0.093 mmol), andN,N-diisopropylethylamine (20.3 μL, 0.12 mmol). The mixture was stirred at 60° C. for 1 hr. After cooling to room temperature, 4N HCl in dioxane (5 mL) was added and the resulting reaction mixture was stirred for 1 hr at 70° C. The crude mixture was concentrated under reduced pressure, and acetonitrile (0.7 mL), water (0.15 mL) and TFA (0.1 mL) were added. The mixture was filtered through an acrodisc before purification by RP-HPLC (0.1% TFA-ACN in 0.1% TFA-Water) to give the product. ES/MS: 519.3 (M+H⁺). H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 8.45 (s, 1H), 4.04-3.79 (m, 4H), 3.28 (d, J=15.7 Hz, 4H), 3.13-2.98 (m, 2H), 2.86-2.70 (m, 1H), 2.64 (s, 3H), 2.43 (s, 3H), 2.28 (s, 3H), 2.13-2.05 (m, 2H), 1.92 (d, J=12.8 Hz, 2H), 1.79-1.54 (m, 4H), 1.41-1.10 (m, 6H).

The following Examples were made in an analogous fashion according to Procedure 50 and are shown below in Table 22. To prepare the below Examples, different reagents/starting materials were used than some of those described in Procedure 50 and are noted in the last column of Table 22—“Changes to Procedure 50: Different Reagents/Starting Materials”. A person of ordinary skill in the art will readily recognize which reagents/starting materials of Procedure 50 were replaced with the different reagents/starting materials noted below.

TABLE 22 Changes to Procedure 50: Different Reagents/ ES/MS Starting Example Structure m/z ¹H-NMR Materials 310

505.3 ¹H NMR (400 MHz, MeOD) δ 8.58 (dd, J = 1.7, 0.8 Hz, 1H), 8.46 (s, 1H), 7.59 (t, J = 1.4 Hz, 1H), 3.88 (d, J = 17.6 Hz, 4H), 3.31-3.19 (m, 5H), 3.06 (t, J = 11.6 Hz, 1H), 2.79 (t, J = 11.6 Hz, 1H), 2.68 (t, J = 0.9 Hz, 3H), 2.45 (s, 3H), 2.08 (d, J = 12.5 Hz, 2H), 1.98-1.88 (m, 2H), 1.78-1.54 (m, 4H), 1.40 (d, J = 7.1 Hz, 6H). I-15

Procedure 51: Example 311 and Example 312

2-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)pyrrolidin-1-yl)acetamide (Example 311 and Example 312): 2-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)pyrrolidin-1-yl)acetamide (Example 128) as a mixture of 2 stereoisomers was separated by chiral SFC (IA 4.6×100 mm 5mic column; EtOH (30%)) to give two enantiomers, the stereochemistry of which were arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: 2-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)pyrrolidin-1-yl)acetamide (Example 311): ES/MS: 437.3 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.63-8.55 (m, 1H), 8.47 (s, 1H), 7.58 (t, J=1.3 Hz, 1H), 4.20 (s, 2H), 4.12-3.39 (m, 4H), 3.31-3.24 (m, 1H), 3.23-3.06 (m, 1H), 2.78-2.44 (m, 7H), 2.40-2.04 (m, 1H), 1.40 (d, J=7.1 Hz, 6H).

Isomer 2: 2-(3-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)pyrrolidin-1-yl)acetamide (Example 312): ES/MS: 437.3 (M+H⁺). ¹H NMR (400 MHz, MeOD) δ 8.63-8.55 (m, 1H), 8.47 (s, 1H), 7.58 (t, J=1.3 Hz, 1H), 4.20 (s, 2H), 4.12-3.39 (m, 4H), 3.31-3.24 (m, 1H), 3.23-3.06 (m, 1H), 2.78-2.44 (m, 7H), 2.40-2.04 (m, 1H), 1.40 (d, J=7.1 Hz, 6H).

Procedure 52: Example 313 and Example 314

5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(6-(2-(methylsulfonyl)ethyl)-6-azaspiro[3.4]octan-2-yl)-6H-thieno[2,3-b]pyrrole (Example 313 and Example 314): 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(6-azaspiro[3.4]octan-2-yl)-6H-thieno[2,3-b]pyrrole (Example 75) was separated by chiral SFC (AD-H4.6×100 mm column; ETOH-NH₃ (35%)) to give two distinct stereoisomers. These isomers were separately reacted according to the conditions in Procedure 20 to afford the two diastereomers, the absolute stereochemistry of which was arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(6-(2-(methylsulfonyl)ethyl)-6-azaspiro[3.4]octan-2-yl)-6H-thieno[2,3-b]pyrrole (Example 313): ES/MS: 540.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.61 (s, 1H), 8.51 (s, 1H), 4.25-3.37 (m, 9H), 3.15 (s, 3H), 3.03 (p, J=7.1 Hz, 1H), 2.75-2.62 (m, 5H), 2.51-2.14 (m, 10H), 1.38-1.13 (m, 6H).

Isomer 2: 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(6-(2-(methylsulfonyl)ethyl)-6-azaspiro[3.4]octan-2-yl)-6H-thieno[2,3-b]pyrrole (Example 314): ES/MS: 540.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.59 (s, 1H), 8.48 (s, 1H), 4.09-3.60 (m, 9H), 3.13 (s, 3H), 3.03 (p, J=7.1 Hz, 1H), 2.71-2.23 (m, 15H), 1.31-1.14 (m, 6H).

Procedure 53: Example 315 and Example 316

2-(5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azaspiro[3.3]heptan-2-yl)acetamide (Example 315 and Example 316): 5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-2-(2-azaspiro[3.3]heptan-5-yl)-6H-thieno[2,3-b]pyrrole (Example 228) was separated by chiral SFC (AD-H4.6×100 mm column; ETOH-NH₃ (35%)) to give two distinct stereoisomers. These isomers were separately reacted according to the conditions in Procedure 20 to afford the two enantiomers, the absolute stereochemistry of which was arbitrarily assigned as Isomer 1 and Isomer 2.

Isomer 1: 2-(5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azaspiro[3.3]heptan-2-yl)acetamide (Example 315): ES/MS: 477.3 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.69-8.52 (m, 1H), 8.46 (s, 1H), 4.63-3.71 (m, 7H), 3.16-3.08 (m, 1H), 2.79-1.97 (m, 13H), 1.45-1.12 (m, 6H).

Isomer 2: 2-(5-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-3-methyl-6H-thieno[2,3-b]pyrrol-2-yl)-2-azaspiro[3.3]heptan-2-yl)acetamide (Example 316): ES/MS: 477.2 [M+H⁺]. ¹H NMR (400 MHz, MeOD) δ 8.75-8.50 (m, 1H), 8.46 (s, 1H), 4.60-3.75 (m, 7H), 3.16-3.08 (m, 1H), 2.77-1.98 (m, 13H), 1.41-1.07 (m, 6H).

Biological Examples

In the below examples (Examples A-1, B-1), Example A-1, disclosed as Example 15 in WO2018/005586, has the structure:

and Example B-1, disclosed as Example 413 in WO2021/067326, has the structure:

Example B-1 Example A

TLR7/9 Human Peripheral Blood Mononuclear Cell (PBMC) Cell-Based Assay

Human peripheral blood mononuclear cells (PBMCs) consist of lymphocytes, monocytes and dendritic cells that express TLR7, TLR8 and TLR9. These cells respond to TLR7, TLR8 and TLR9 ligand stimulation and produce cytokines and chemokines in vitro and in vivo. Human PBMCs are therefore suitable to be used in a cell-based assay to assess the in vitro potency of a TLR 7, 8, and/or 9 antagonist. The result is expected to be more translatable to the pharmacodynamics response in vivo than cell line-based assays.

Cryopreserved human PBMCs from healthy donors were thawed and resuspended in RPMI-1640 media with L-glutamine (Corning) supplemented with 10% Fetal Bovine Serum (Hyclone) and 1X Penicillin-Streptomycin (Corning). After counting, the cell density was adjusted to 2 million cells/ml and incubated for 1 hour at 37° C., 5% CO₂ for recovery. Following the recovery, the cells were plated by adding 50p per well (100,000 cells) to 384-well cell culture plates (Greiner) containing 250nl of test antagonists in 100% DMSO per well, in a 10 points dose response in quadruplicates. PBMCs were incubated in the presence of test antagonists for one hour at 37° C., 5% CO₂ before being stimulated with a TLR7 or TLR9agonist. GS-986 (Gilead Sciences) was used as the TLR7 agonist at a final concentration of 400 nM. ODN-2216 (InvivoGen) was used as the TLR9 agonist at a final concentration of 3 μM. PBMCs were incubated in the presence of the test antagonist and the TLR7 (or TLR9) agonist for an additional 6 hours at 37° C., 5% CO₂. At the end of the incubation, the cell culture plates were centrifuged at 500 g for 5 min, and the cell culture supernatant was collected. The level of cytokines (IL-6 and IFNa) in the supernatant was measured by electrochemiluminescence immunoassays (Mesoscale Discovery) following manufacturer's recommended protocols. The level of cytokine measured was plotted against the test antagonist concentration and fitted to a sigmoidal function to determine the ECso, which are shown below in Table 11.

TLR8 Human Peripheral Blood Mononuclear Cell (PBMC) Cell-Based Assay

Cryopreserved human PBMCs from healthy donors were thawed and resuspended in RPMI-1640 media with L-glutamine (Corning) supplemented with 10% Fetal Bovine Serum (Hyclone) and 1X Penicillin-Streptomycin (Corning). After counting, the cell density was adjusted to 2 million cells/ml and incubated for 1 hour at 37° C., 5% CO₂ for recovery. Following the recovery, the cells were plated by adding 50p per well (100,000 cells) to 384-well cell culture plates (Greiner) containing 250nl of test antagonists in 100% DMSO per well, in a 10 points dose response in quadruplicates. PBMCs were incubated in the presence of antagonists for one hour at 37° C., 5% CO₂ before being stimulated with TLR8 agonist. Compound A (Gilead Sciences, U.S. Pat. No. 10,285,990) was used as the TLR8 agonist at a final concentration of 800 nM. PBMCs were incubated in the presence of antagonist and the TLR8 agonist for an additional 6 hours at 37° C., 5% CO₂. At the end of the incubation, the cell culture plates were centrifuged at 500 g for 5 min, and the cell culture supernatant was collected. The level of cytokines (TNFa and IL12p40) in the supernatant was measured by electrochemiluminescence immunoassays (Mesoscale Discovery) following manufacturer's recommended protocols. The level of cytokine measured was plotted against the antagonist concentration and fitted to a sigmoidal function to determine the ECso, which are shown below in Table 11. Compound A has the structure:

TABLE 5 Example TLR-7 EC₅₀ (nM) TLR-8 EC₅₀ (nM)  1 0.56 8.93  2 1.04 5.79  3 0.27 9.95  4 0.37 7.45  5 0.50 5.96  6 21.49 84.60  7 0.14 3.71  8 0.08 4.92  9 0.64 17.11  10 0.18 9.29  11 2.47 14.29  12 2.35 17.83  13 1.27 7.11  14 0.21 13.81  15 0.12 13.39  16 1.63 46.14  17 4.93 595.24  18 0.05 10.89  19 0.43 7.76  20 0.28 12.00  21 1.08 1.25  22 1.27 26.11  23 0.56 16.13  24 0.29 8.98  25 0.11 2.95  26 0.68 1.61  27 0.25 8.43  28 1.06 19.70  29 0.94 0.21  30 3.42 257.28  31 3.15 0.05  32 0.05 8.32  33 7.19 45.88  34 0.06 4.45  35 0.10 12.97  36 0.54 20.77  37 0.20 9.95  38 0.22 10.45  39 1.18 125.26  40 0.07 3.14  41 0.35 12.31  42 0.78 25.68  43 0.32 18.96  44 0.37 13.12  45 0.13 15.63  46 0.59 13.04  47 0.24 14.11  48 0.29 19.69  49 1.12 27.91  50 1.76 35.94  51 0.43 19.30  52 2.08 1.12  53 0.27 2.42  54 0.59 19.78  55 0.23 16.61  56 0.24 2.46  57 0.27 15.55  58 0.24 1.74  59 2.97 28.40  60 1.81 0.93  61 0.19 9.09  62 0.19 7.17  63 0.26 27.33  64 3.12 9.48  65 28.07 33.09  66 0.12 0.16  67 0.35 2.08  68 1.57 5.56  69 0.05 4.20  70 0.05 5.95  71 0.45 7.75  72 0.10 0.11  73 0.10 4.16  74 0.05 0.94  76 0.05 0.24  77 0.09 2.89  78 0.42 5.44  79 0.12 0.23  80 2.15 15.23  81 0.19 0.45  82 0.37 0.17  83 0.45 0.61  84 0.13 0.81  85 0.35 0.39  86 2.43 0.98  87 0.87 20.92  88 1.44 23.80  89 0.20 —  90 2.68 6.79  91 0.09 5.41  92 1.94 2.67  93 1.36 18.37  94 0.05 2.30  95 0.70 4.45  96 0.83 6.75  97 0.31 1.09  98 0.05 4.48  99 0.43 5.96 100 0.32 0.71 101 0.32 0.73 102 0.09 23.14 103 0.91 20.44 104 0.10 2.49 105 <0.05 4.17 106 0.34 49.32 107 <0.05 6.79 108 0.20 4.77 109 <0.05 3.45 110 0.09 6.21 111 0.45 6.58 112 0.07 0.50 113 0.54 9.80 114 0.44 2.71 115 0.24 9.38 116 0.39 27.44 117 0.52 16.57 118 0.24 15.16 119 0.34 4.55 120 0.09 1.10 121 <0.05 0.13 122 0.38 1.63 123 0.16 2.15 124 0.30 3.22 125 0.33 1.50 126 0.24 1.74 127 0.21 1.52 128 — — 129 0.27 10.68 130 — — 131 0.12 6.92 132 0.10 0.54 133 0.60 5.06 134 0.74 12.59 135 0.28 26.99 136 0.68 17.88 137 0.73 1.71 138 0.19 0.49 139 0.54 0.29 140 0.91 3.45 141 0.42 10.64 142 2.31 7.47 143 2.57 10.93 144 0.25 2.03 145 0.09 1.86 146 0.90 12.79 147 0.23 16.05 148 0.51 15.93 149 0.72 9.53 150 1.64 14.23 151 0.26 0.99 152 0.42 2.86 153 0.77 23.16 154 0.44 0.85 155 <0.05 0.51 156 <0.05 9.80 157 0.17 29.62 158 0.15 61.84 159 0.94 31.50 160 0.26 6.51 161 0.13 7.29 162 3.41 24.28 163 0.30 0.38 164 0.23 <0.05 165 0.13 0.41 166 1.20 0.48 167 0.09 0.45 168 0.74 0.96 169 0.29 0.07 170 <0.05 0.26 171 <0.05 0.06 172 3.03 0.82 173 0.15 1.06 174 <0.05 0.09 175 <0.05 <0.05 176 0.08 0.12 177 0.50 0.07 178 0.06 0.16 179 1.71 3.53 180 <0.05 0.17 181 0.27 1.23 182 0.07 0.32 183 0.07 2.82 184 1.27 0.34 185 1.89 0.57 186 0.66 0.45 187 0.20 1.09 188 5.64 27.24 189 2.23 30.94 190 3.52 13.80 191 <0.05 8.77 192 273.69 >1000 193 0.20 2.87 194 0.20 9.52 195 0.05 2.12 196 0.72 69.46 197 1.74 29.80 198 5.06 13.83 199 0.47 14.81 200 4.05 331.52 201 <0.05 0.36 202 2.59 2.97 203 4.20 6.23 204 0.50 30.37 205 0.60 229.51 206 0.18 45.11 207 0.19 32.18 208 0.15 34.63 209 0.94 10.68 210 2.32 10.03 211 5.08 30.86 212 0.45 6.78 213 4.05 3.64 214 4.47 3.40 215 <0.05 0.78 216 2.74 5.26 217 1.27 78.62 218 0.45 0.88 219 0.26 3.01 220 0.11 0.64 221 0.99 3.20 222 8.47 79.30 223 15.47 66.49 224 1.24 3.68 225 0.47 6.12 226 4.14 1.00 227 5.07 15.51 228 8.77 76.22 229 0.06 0.35 230 0.81 14.01 231 41.93 83.36 232 0.83 18.81 233 0.16 0.79 234 4.25 10.57 235 10.13 48.76 236 1.94 21.84 237 0.29 69.30 238 0.39 1.44 239 <0.05 1.50 240 4.86 48.36 241 3.51 30.69 242 2.90 37.33 243 1.25 21.40 244 0.14 9.43 245 0.17 3.33 246 0.09 8.94 247 0.20 13.48 248 11.47 106.06 249 0.32 3.02 250 0.34 3.59 251 0.13 8.16 252 0.07 34.18 253 0.10 1.06 254 0.38 3.64 255 1.22 21.36 256 2.31 29.21 257 1.29 7.58 258 0.89 13.55 259 0.15 3.59 260 0.31 27.28 261 0.94 24.30 262 <0.05 4.54 263 1.17 18.56 264 2.52 13.68 265 0.97 0.83 266 1.27 0.33 267 0.47 0.15 268 <0.05 0.24 269 0.30 0.28 270 0.64 0.59 271 0.49 0.12 272 2.13 1.19 273 1.24 1.01 274 1.54 1.23 275 0.40 2.91 276 0.52 2.29 277 0.06 20.10 278 0.17 0.80 279 0.54 13.64 280 1.96 41.17 281 2.17 13.78 282 1.19 19.53 283 2.65 138.69 284 0.32 4.91 285 3.20 128.99 286 0.94 9.39 287 0.43 12.41 288 2.74 22.56 289 0.72 2.33 290 0.65 19.35 291 0.60 22.21 292 0.09 3.91 293 1.67 20.52 294 0.71 2.77 295 0.06 18.55 296 <0.05 8.94 297 <0.05 0.61 298 <0.05 12.22 299 0.10 2.17 300 0.22 1.85 301 0.13 5.66 302 0.10 6.40 303 <0.05 2.77 304 <0.05 1.76 305 0.78 4.44 306 <0.05 0.49 307 0.21 0.25 308 <0.05 1.16 309 0.14 8.07 310 0.25 9.94 311 0.07 2.42 312 0.83 3.28 313 2.51 1.19 314 10.04 1.22 315 28.18 32.43 316 47.27 108.13 A-1 0.26 0.63 B-1 0.30 2.55

Example B Human Hepatic Stability

Each tested compound was incubated in suspensions of cryopreserved hepatocytes at a final concentration of 1 μM. Vials containing cryopreserved hepatocytes were removed from liquid nitrogen and immediately immersed in a 37° C. water bath. The vials were swirled gently until the contents had thawed. They were then immediately emptied into 48 mL of pre-warmed HT medium in a 50 mL conical tube. Cells remaining in the vial were resuspended with 1.0 mL of pre-warmed HT medium and added to the conical tube. The tube was capped and then gently inverted several times to re-suspend the hepatocytes. The cell suspension was centrifuged at 500×g for 10 minutes at room temperature and the supernatant discarded. The cell pellet was loosened by gently swirling the centrifuge tube. Non-supplemented KHB medium was added to obtain the appropriate target cell density.

For incubations, aliquots of hepatocyte suspension (250 mL at a concentration of 2×10⁶ cells/mL) were added to 250 mL of 2 mM of each tested compound in KHB, in duplicate wells in a 24-well plate. Final concentration in the incubations were 1×10⁶ cells/mL and 1 mM of each tested compound. Propranolol, a compound known to be efficiently metabolized by hepatocytes by oxidation and conjugation, was used as a positive control in parallel incubations (1 mM final concentration). A cell-free control was also tested in parallel with the incubations. The incubations were carried out with gentle shaking in a 37° C. incubator under a humid atmosphere of 95% air/5% CO2 (v/v). Aliquots (100 mL) were removed after 0, 1, 3, and 6 hours and added to 200 mL IS/Q. The samples were then placed on a shaker for 10 min followed by centrifugation at 3000×g for 20 min. The supernatant was transferred to a new plate and diluted with 100 μL of water to reduce the organic solvent content and then placed on a shaker for 10 mins. Samples were injected and analyzed using LC-MS/MS. The results are reported in Table 23 below.

TABLE 23 Example Predicted Clearance (L/hr/kg) A-1 0.27 B-1 0.26  56 0.25  67 0.14  79 0.26  84 0.53  91 0.24  97 0.81  98 0.11 175 0.26 183 0.64 221 0.16 229 0.22

Example C Kinetic Solubility at pH 7.4

100-fold dilutions of a 10 mM DMSO stock solution of each compound being tested were prepared in singleton by combining 3 μL of DMSO stock with 297 L of the appropriate media (0.1N HCL (Alfa Aesar part number 35644-K2) and 1X PBS buffer (pH 7.4)) in a Millipore solubility filter plate with 0.45 m polycarbonate filter membrane using Hamilton Starlet liquid handling. The final DMSO Concentration was 1.0% and maximum theoretical compound concentration is 100 M. The filter plate was sealed. Following 24-hour incubation at ambient temperature (21.7-23.8° C.), the samples were vacuum filtered, and the filtrates were collected in a 96 well polypropylene plate for analysis. The collection plate was sealed for analysis.

Filtrates were injected into the nitrogen detector for quantification on Analiza's Automated Discovery Workstation. The results are reported in μg/ml.

The equimolar nitrogen response of the detector was calibrated using standards which span the dynamic range of the instrument from 0.08 to 4500 μg/ml nitrogen. The filtrates were quantified with respect to this calibration curve. The calculated solubility values were corrected for background nitrogen present in the DMSO, and the media used to prepare the samples. The solubility results presented in Table 24 below assumed that the samples were free of nitrogen containing impurities and were stable under the assay conditions.

The 1X PBS buffer (pH 7.4) was prepared by adding 50 mL of phosphate buffered saline solution 10X, PBS (Fisher Bioreagent part number BP399-500) to approximately 450 mL HPLC grade H₂O. The volume of the solution was then adjusted to 500 mL for a total dilution factor of 1:10 and a final PBS concentration of 1X. The pH of the final solution was measured and found to be 7.4.

Each compound tested was analyzed as a trifluoroacetate salt.

TABLE 24 Example pH 7.4 Solubility (μg/mL) A-1 <1 B-1 22  56 26.5  67 16.8  79 21.5  91 2.2  97 22.8  98 24.9 100 23.5 175 21.1 221 1 229 27.7

Example D MATE2-K IC₅₀ Assay

MATE2-K (multidrug and toxin extrusion protein 2) is expressed in the apical membrane in the kidney and mediates the elimination of compounds to urine. MDCK-II cells were maintained in DMEM with low glucose and 10% FBS. Cells passages up to 40 were seeded at 60K±10K cells/well on 96-well, transwell membrane plates approximately 24 hours before transfection. Transport assays were carried out approximately 48 hours after transfection. On assay day, the DMEM was removed, and cells were washed with HBSS. After washing, the cells in each well were pre-incubated with HBSS containing 30 mM NH₄Cl and either vehicle, the compound being tested at 6 concentrations ranging from 0.127 μM to 40 μM, or 100 μM cimetidine as a reference inhibitor. The assay plate was then placed in a 37° C. incubator with orbital shaking at approximately 60 RPM for the pre-incubation time of 15 minutes. The pre-incubation solutions were then removed, and cells washed with HBSS once. 100 μL of incubation buffer was added to each well containing HBSS with 10 μM¹⁴[C]-metformin as the probe substrate and either vehicle control, the compound being tested (at 6 concentrations ranging from 0.127 μM to 40 μM) or reference inhibitors. The assay plate was incubated at 37° C. with orbital shaking at approximately 60 RPM for the incubation time of 5 minutes. At end of the 5-minute incubation, 15 μL of dosing solution was removed from each well containing the compound being tested and measured using LC/MS/MS for dose recovery assessment. The assay wells were then washed four times with ice cold PBS. 60 μL cell extraction solution was added to each well and the plate was incubated at 37° C. with orbital shaking at approximately 60 RPM for the 15 minutes. After this incubation, 30 μL was removed from each well, added to 200 μL scintillation fluid, and counted on a 1450 Microbeta (Perkin-Elmer) to measure the probe substrate uptake. Inhibition potential of the compound being tested was calculated by dividing the transporter-mediated uptake rate in presence of the compound being tested or the reference inhibitor by the transporter-mediated uptake rate in presence of vehicle control and fitted to a sigmoidal function to determine the IC₅₀ values. The results are reported below in Table 25.

TABLE 25 Example MATE2-K IC₅₀ (μM) A-1 0.3 B-1 1.1  56 7.7  67 6.2  79 8.1  82 >14.5  91 7.8 100 9.7

All references, including publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The present disclosure provides reference to various embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the present disclosure. The description is made with the understanding that it is to be considered an exemplification of the claimed subject matter and is not intended to limit the appended claims to the specific embodiments illustrated. 

1-175. (canceled)
 176. A pharmaceutical composition comprising a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
 177. The pharmaceutical composition of claim 176, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 178. The pharmaceutical composition of claim 176, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 179. The pharmaceutical composition of claim 176, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 180. The pharmaceutical composition of claim 176, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 181. The pharmaceutical composition of claim 176, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 182. The pharmaceutical composition of claim 176, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 183. The pharmaceutical composition of claim 176, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 184. The pharmaceutical composition of claim 176, further comprising hydroxychloroquine, or a pharmaceutically acceptable salt thereof.
 185. The pharmaceutical composition of claim 184, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 186. The pharmaceutical composition of claim 184, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 187. The pharmaceutical composition of claim 184, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 188. The pharmaceutical composition of claim 184, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 189. The pharmaceutical composition of claim 184, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 190. The pharmaceutical composition of claim 184, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 191. The pharmaceutical composition of claim 184, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 192. A method of treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.


193. The method of claim 192, wherein the inflammatory condition is systemic lupus erythematosus.
 194. The method of claim 193, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 195. The method of claim 193, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 196. The method of claim 193, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 197. The method of claim 193, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 198. The method of claim 193, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 199. The method of claim 193, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 200. The method of claim 193, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 201. The method of claim 192, wherein the inflammatory condition is cutaneous lupus erythematosus.
 202. The method of claim 201, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 203. The method of claim 201, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 204. The method of claim 201, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 205. The method of claim 201, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 206. The method of claim 201, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 207. The method of claim 201, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 208. The method of claim 201, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 209. The method of claim 192, wherein the inflammatory condition is lupus nephritis.
 210. The method of claim 209, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 211. The method of claim 209, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 212. The method of claim 209, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 213. The method of claim 209, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 214. The method of claim 209, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 215. The method of claim 209, wherein the compound is

or a pharmaceutically acceptable salt thereof.
 216. The method of claim 209, wherein the compound is

or a pharmaceutically acceptable salt thereof. 